"text","relation"
"<e1>Congenital hypothyroidism</e1> due to a new deletion in the <e2>sodium/iodide symporter</e2> protein.","Association"
"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an <e1>inability of the thyroid</e1> to maintain an <e2>iodide</e2> gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism.","Association"
"COS-7 cells transfected with a vector expressing the mutant <e1>del-(439-443)</e1> NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the <e2>ITD</e2> in this patient.","Positive_Correlation"
"OBJECTIVE: <e1>Iodide transport defect</e1> (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an <e2>iodide</e2> gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism.","Association"
"OBJECTIVE: Iodide transport defect (<e1>ITD</e1>) is a rare disorder characterised by an inability of the thyroid to maintain an <e2>iodide</e2> gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism.","Association"
"OBJECTIVE: Iodide transport defect (<e1>ITD</e1>) is a rare disorder characterised by an inability of the thyroid to maintain an <e2>iodide</e2> gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism.","Association"
"OBJECTIVE: Iodide transport defect (<e1>ITD</e1>) is a rare disorder characterised by an inability of the thyroid to maintain an <e2>iodide</e2> gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism.","Association"
"COS-7 cells transfected with a vector expressing the mutant del-(439-443) <e2>NIS</e2> failed to concentrate iodide, suggesting that the mutation was the direct cause of the <e1>ITD</e1> in this patient.","Negative_Correlation"
"COS-7 cells transfected with a vector expressing the mutant del-(439-443) <e2>NIS</e2> failed to concentrate iodide, suggesting that the mutation was the direct cause of the <e1>ITD</e1> in this patient.","Negative_Correlation"
"COS-7 cells transfected with a vector expressing the mutant del-(439-443) <e2>NIS</e2> failed to concentrate iodide, suggesting that the mutation was the direct cause of the <e1>ITD</e1> in this patient.","Negative_Correlation"
"Treatment with iodide partially corrected the <e2>hypothyroidism</e2>; however, long-term substitution therapy with <e1>L-thyroxine</e1> was started.","Negative_Correlation"
"COS-7 cells transfected with a vector expressing the mutant <e2>del-(439-443)</e2> NIS failed to concentrate <e1>iodide</e1>, suggesting that the mutation was the direct cause of the ITD in this patient.","Negative_Correlation"
"COS-7 cells transfected with a vector expressing the mutant <e2>del-(439-443)</e2> NIS failed to concentrate <e1>iodide</e1>, suggesting that the mutation was the direct cause of the ITD in this patient.","Negative_Correlation"
"COS-7 cells transfected with a vector expressing the mutant <e2>del-(439-443)</e2> NIS failed to concentrate <e1>iodide</e1>, suggesting that the mutation was the direct cause of the ITD in this patient.","Negative_Correlation"
"COS-7 cells transfected with a vector expressing the mutant <e2>del-(439-443)</e2> NIS failed to concentrate <e1>iodide</e1>, suggesting that the mutation was the direct cause of the ITD in this patient.","Negative_Correlation"
"When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium/<e1>iodide</e1> symporter (NIS).","Association"
"When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium/<e1>iodide</e1> symporter (NIS).","Association"
"When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium/<e1>iodide</e1> symporter (NIS).","Association"
"When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium/<e1>iodide</e1> symporter (NIS).","Association"
"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an <e2>iodide</e2> gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital <e1>hypothyroidism</e1>.","Negative_Correlation"
"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an <e2>iodide</e2> gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital <e1>hypothyroidism</e1>.","Negative_Correlation"
"CONCLUSION: In conclusion we describe the first Italian case of <e1>congenital hypothyroidism</e1> due to a new deletion in the <e2>NIS</e2> gene.","Association"
"CONCLUSION: In conclusion we describe the first Italian case of <e1>congenital hypothyroidism</e1> due to a new deletion in the <e2>NIS</e2> gene.","Association"
"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving <e1>levodopa</e1>-induced <e2>dyskinesias</e2>.","Positive_Correlation"
"Carrier frequency of mutation 657del5 in the <e1>NBS1</e1> gene in a population of Polish pediatric patients with <e2>sporadic lymphoid malignancies</e2>.","Association"
"Carrier frequency of mutation <e2>657del5</e2> in the NBS1 gene in a population of Polish pediatric patients with <e1>sporadic lymphoid malignancies</e1>.","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, <e2>657del5</e2>, were found in Russian children with sporadic lymphoid <e1>malignancies</e1>, and in Polish adults with non-Hodgkin lymphoma (NHL).","Association"
"In addition, the substitution 643C>T (<e2>R215W</e2>) has also been found in excess among children with <e1>acute lymphoblastic leukemia</e1> (ALL).","Association"
"In addition, the substitution 643C>T (<e2>R215W</e2>) has also been found in excess among children with acute lymphoblastic leukemia (<e1>ALL</e1>).","Association"
"In addition, the substitution 643C>T (<e2>R215W</e2>) has also been found in excess among children with acute lymphoblastic leukemia (<e1>ALL</e1>).","Association"
"In addition, the substitution 643C>T (<e2>R215W</e2>) has also been found in excess among children with acute lymphoblastic leukemia (<e1>ALL</e1>).","Association"
"In addition, the substitution <e2>643C>T</e2> (R215W) has also been found in excess among children with <e1>acute lymphoblastic leukemia</e1> (ALL).","Association"
"In addition, the substitution <e2>643C>T</e2> (R215W) has also been found in excess among children with acute lymphoblastic leukemia (<e1>ALL</e1>).","Association"
"In addition, the substitution <e2>643C>T</e2> (R215W) has also been found in excess among children with acute lymphoblastic leukemia (<e1>ALL</e1>).","Association"
"In addition, the substitution <e2>643C>T</e2> (R215W) has also been found in excess among children with acute lymphoblastic leukemia (<e1>ALL</e1>).","Association"
"The NBS1 mutation <e2>657del5</e2> on one allele was found in 3 of 270 patients with <e1>ALL</e1> and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).","Association"
"The NBS1 mutation <e2>657del5</e2> on one allele was found in 3 of 270 patients with <e1>ALL</e1> and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).","Association"
"The NBS1 mutation <e2>657del5</e2> on one allele was found in 3 of 270 patients with <e1>ALL</e1> and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder <e1>NBS1</e1> mutation, 657del5, were found in Russian children with sporadic lymphoid <e2>malignancies</e2>, and in Polish adults with non-Hodgkin lymphoma (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder <e1>NBS1</e1> mutation, 657del5, were found in Russian children with sporadic lymphoid <e2>malignancies</e2>, and in Polish adults with non-Hodgkin lymphoma (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder <e1>NBS1</e1> mutation, 657del5, were found in Russian children with sporadic lymphoid <e2>malignancies</e2>, and in Polish adults with non-Hodgkin lymphoma (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder <e1>NBS1</e1> mutation, 657del5, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with <e2>non-Hodgkin lymphoma</e2> (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder <e1>NBS1</e1> mutation, 657del5, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with <e2>non-Hodgkin lymphoma</e2> (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder <e1>NBS1</e1> mutation, 657del5, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with <e2>non-Hodgkin lymphoma</e2> (NHL).","Association"
"The <e1>NBS1</e1> mutation 657del5 on one allele was found in 3 of 270 patients with <e2>ALL</e2> and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).","Association"
"The <e1>NBS1</e1> mutation 657del5 on one allele was found in 3 of 270 patients with <e2>ALL</e2> and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).","Association"
"The <e1>NBS1</e1> mutation 657del5 on one allele was found in 3 of 270 patients with <e2>ALL</e2> and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder <e1>NBS1</e1> mutation, 657del5, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with non-Hodgkin <e2>lymphoma</e2> (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder <e1>NBS1</e1> mutation, 657del5, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with non-Hodgkin <e2>lymphoma</e2> (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder <e1>NBS1</e1> mutation, 657del5, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with non-Hodgkin <e2>lymphoma</e2> (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, <e1>657del5</e1>, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with <e2>non-Hodgkin lymphoma</e2> (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, <e1>657del5</e1>, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with <e2>non-Hodgkin lymphoma</e2> (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, <e1>657del5</e1>, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with <e2>non-Hodgkin lymphoma</e2> (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, <e1>657del5</e1>, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with <e2>non-Hodgkin lymphoma</e2> (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, <e2>657del5</e2>, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with non-Hodgkin <e1>lymphoma</e1> (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, <e2>657del5</e2>, were found in Russian children with <e1>sporadic lymphoid malignancies</e1>, and in Polish adults with non-Hodgkin lymphoma (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, <e2>657del5</e2>, were found in Russian children with <e1>sporadic lymphoid malignancies</e1>, and in Polish adults with non-Hodgkin lymphoma (NHL).","Association"
"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, <e2>657del5</e2>, were found in Russian children with sporadic <e1>lymphoid malignancies</e1>, and in Polish adults with non-Hodgkin lymphoma (NHL).","Association"
"Segregation of a M404V mutation of the <e1>p62</e1>/sequestosome 1 (p62/SQSTM1) gene with polyostotic <e2>Paget's disease of bone</e2> in an Italian family.","Association"
"Segregation of a M404V mutation of the p62/<e1>sequestosome 1</e1> (p62/SQSTM1) gene with polyostotic <e2>Paget's disease of bone</e2> in an Italian family.","Association"
"Segregation of a M404V mutation of the <e1>p62</e1>/sequestosome 1 (p62/SQSTM1) gene with polyostotic <e2>Paget's disease of bone</e2> in an Italian family.","Association"
"Segregation of a M404V mutation of the p62/sequestosome 1 (p62/<e1>SQSTM1</e1>) gene with polyostotic <e2>Paget's disease of bone</e2> in an Italian family.","Association"
"Segregation of a <e2>M404V</e2> mutation of the p62/sequestosome 1 (p62/SQSTM1) gene with polyostotic <e1>Paget's disease of bone</e1> in an Italian family.","Positive_Correlation"
"Mutations of the <e1>p62</e1>/Sequestosome 1 gene (p62/SQSTM1) account for both sporadic and familial forms of <e2>Paget's disease of bone</e2> (PDB).","Association"
"Mutations of the p62/<e1>Sequestosome 1</e1> gene (p62/SQSTM1) account for both sporadic and familial forms of <e2>Paget's disease of bone</e2> (PDB).","Association"
"Mutations of the <e1>p62</e1>/Sequestosome 1 gene (p62/SQSTM1) account for both sporadic and familial forms of <e2>Paget's disease of bone</e2> (PDB).","Association"
"Mutations of the p62/Sequestosome 1 gene (p62/<e1>SQSTM1</e1>) account for both sporadic and familial forms of <e2>Paget's disease of bone</e2> (PDB).","Association"
"Mutations of the <e1>p62</e1>/Sequestosome 1 gene (p62/SQSTM1) account for both sporadic and familial forms of <e2>Paget's disease of bone</e2> (PDB).","Association"
"Mutations of the p62/Sequestosome 1 gene (p62/<e1>SQSTM1</e1>) account for both sporadic and familial forms of <e2>Paget's disease of bone</e2> (PDB).","Association"
"Mutations of the <e1>p62</e1>/Sequestosome 1 gene (p62/SQSTM1) account for both sporadic and familial forms of <e2>Paget's disease of bone</e2> (PDB).","Association"
"Mutations of the p62/Sequestosome 1 gene (p62/<e1>SQSTM1</e1>) account for both sporadic and familial forms of <e2>Paget's disease of bone</e2> (PDB).","Association"
"Mutations of the <e1>p62</e1>/Sequestosome 1 gene (p62/SQSTM1) account for both sporadic and familial forms of <e2>Paget's disease of bone</e2> (PDB).","Association"
"Mutations of the p62/Sequestosome 1 gene (p62/<e1>SQSTM1</e1>) account for both sporadic and familial forms of <e2>Paget's disease of bone</e2> (PDB).","Association"
"Of the five clinically ascertained affected members of the family, four possessed the <e1>M404V</e1> mutation and exhibited the polyostotic form of PDB, except one patient with a single X-ray-assessed skeletal localization and one with a <e2>polyostotic disease</e2> who had died several years before the DNA analysis.","Association"
"Of the five clinically ascertained affected members of the family, four possessed the <e1>M404V</e1> mutation and exhibited the polyostotic form of PDB, except one patient with a single X-ray-assessed skeletal localization and one with a <e2>polyostotic disease</e2> who had died several years before the DNA analysis.","Association"
"Of the five clinically ascertained affected members of the family, four possessed the <e1>M404V</e1> mutation and exhibited the polyostotic form of PDB, except one patient with a single X-ray-assessed skeletal localization and one with a <e2>polyostotic disease</e2> who had died several years before the DNA analysis.","Association"
"Of the five clinically ascertained affected members of the family, four possessed the <e1>M404V</e1> mutation and exhibited the polyostotic form of PDB, except one patient with a single X-ray-assessed skeletal localization and one with a <e2>polyostotic disease</e2> who had died several years before the DNA analysis.","Association"
"Of the five clinically ascertained affected members of the family, four possessed the <e1>M404V</e1> mutation and exhibited the polyostotic form of PDB, except one patient with a single X-ray-assessed skeletal localization and one with a <e2>polyostotic disease</e2> who had died several years before the DNA analysis.","Association"
"We originally described a <e2>methionine-->valine substitution at codon 404</e2> (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian <e1>PDB</e1> patient.","Positive_Correlation"
"We originally described a <e2>methionine-->valine substitution at codon 404</e2> (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian <e1>PDB</e1> patient.","Positive_Correlation"
"We originally described a <e2>methionine-->valine substitution at codon 404</e2> (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian <e1>PDB</e1> patient.","Positive_Correlation"
"We originally described a <e2>methionine-->valine substitution at codon 404</e2> (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian <e1>PDB</e1> patient.","Positive_Correlation"
"We originally described a <e2>methionine-->valine substitution at codon 404</e2> (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian <e1>PDB</e1> patient.","Positive_Correlation"
"We originally described a <e2>methionine-->valine substitution at codon 404</e2> (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian <e1>PDB</e1> patient.","Positive_Correlation"
"We originally described a <e2>methionine-->valine substitution at codon 404</e2> (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian <e1>PDB</e1> patient.","Positive_Correlation"
"We originally described a <e2>methionine-->valine substitution at codon 404</e2> (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian <e1>PDB</e1> patient.","Positive_Correlation"
"We originally described a <e2>methionine-->valine substitution at codon 404</e2> (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian <e1>PDB</e1> patient.","Positive_Correlation"
"<e2>Classical phenylketonuria</e2> is an autosomal recessive disease caused by a deficiency of hepatic phenylalanine hydroxylase (<e1>PAH</e1>).","Association"
"<e2>Classical phenylketonuria</e2> is an autosomal recessive disease caused by a deficiency of hepatic phenylalanine hydroxylase (<e1>PAH</e1>).","Association"
"Classical phenylketonuria is an autosomal recessive disease caused by a <e2>deficiency of hepatic phenylalanine hydroxylase</e2> (<e1>PAH</e1>).","Negative_Correlation"
"Classical phenylketonuria is an autosomal recessive disease caused by a <e2>deficiency of hepatic phenylalanine hydroxylase</e2> (<e1>PAH</e1>).","Negative_Correlation"
"Association of <e1>DRD2</e1> polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese <e2>schizophrenic</e2> patients.","Association"
"Association of DRD2 polymorphisms and <e2>chlorpromazine</e2>-induced extrapyramidal syndrome in Chinese <e1>schizophrenic</e1> patients.","Negative_Correlation"
"Association of <e2>DRD2</e2> polymorphisms and chlorpromazine-induced <e1>extrapyramidal syndrome</e1> in Chinese schizophrenic patients.","Association"
"Association of DRD2 polymorphisms and <e1>chlorpromazine</e1>-induced <e2>extrapyramidal syndrome</e2> in Chinese schizophrenic patients.","Positive_Correlation"
"Recently, many research groups have reported on the positive relationship between the genetic variations in the <e1>DRD2</e1> gene and the therapeutic response in <e2>schizophrenia</e2> patients as a result of the role of variations in the receptor in modulating receptor expression.","Association"
"Recently, many research groups have reported on the positive relationship between the genetic variations in the <e1>DRD2</e1> gene and the therapeutic response in <e2>schizophrenia</e2> patients as a result of the role of variations in the receptor in modulating receptor expression.","Association"
"Recently, many research groups have reported on the positive relationship between the genetic variations in the <e1>DRD2</e1> gene and the therapeutic response in <e2>schizophrenia</e2> patients as a result of the role of variations in the receptor in modulating receptor expression.","Association"
"Recently, many research groups have reported on the positive relationship between the genetic variations in the <e1>DRD2</e1> gene and the therapeutic response in <e2>schizophrenia</e2> patients as a result of the role of variations in the receptor in modulating receptor expression.","Association"
"Recently, many research groups have reported on the positive relationship between the genetic variations in the <e1>DRD2</e1> gene and the therapeutic response in <e2>schizophrenia</e2> patients as a result of the role of variations in the receptor in modulating receptor expression.","Association"
"AIM: Extrapyramidal syndrome (EPS) is most commonly affected by typical <e1>antipsychotic drugs</e1> that have a high affinity with the <e2>D2 receptor</e2>.","Association"
"CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by <e2>chlorpromazine</e2>, at least in Chinese patients with <e1>schizophrenia</e1>.","Negative_Correlation"
"In this study, we evaluate the role DRD2 plays in <e2>chlorpromazine</e2>-induced EPS in <e1>schizophrenic</e1> patients.","Negative_Correlation"
"In this study, we evaluate the role DRD2 plays in <e2>chlorpromazine</e2>-induced EPS in <e1>schizophrenic</e1> patients.","Negative_Correlation"
"CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by <e2>chlorpromazine</e2>, at least in Chinese patients with <e1>schizophrenia</e1>.","Negative_Correlation"
"AIM: <e1>Extrapyramidal syndrome</e1> (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the <e2>D2 receptor</e2>.","Association"
"AIM: Extrapyramidal syndrome (<e1>EPS</e1>) is most commonly affected by typical antipsychotic drugs that have a high affinity with the <e2>D2 receptor</e2>.","Association"
"AIM: Extrapyramidal syndrome (<e1>EPS</e1>) is most commonly affected by typical antipsychotic drugs that have a high affinity with the <e2>D2 receptor</e2>.","Association"
"AIM: Extrapyramidal syndrome (<e1>EPS</e1>) is most commonly affected by typical antipsychotic drugs that have a high affinity with the <e2>D2 receptor</e2>.","Association"
"AIM: Extrapyramidal syndrome (<e1>EPS</e1>) is most commonly affected by typical antipsychotic drugs that have a high affinity with the <e2>D2 receptor</e2>.","Association"
"AIM: Extrapyramidal syndrome (<e1>EPS</e1>) is most commonly affected by typical antipsychotic drugs that have a high affinity with the <e2>D2 receptor</e2>.","Association"
"AIM: <e1>Extrapyramidal syndrome</e1> (EPS) is most commonly affected by typical <e2>antipsychotic drugs</e2> that have a high affinity with the D2 receptor.","Positive_Correlation"
"AIM: Extrapyramidal syndrome (<e1>EPS</e1>) is most commonly affected by typical <e2>antipsychotic drugs</e2> that have a high affinity with the D2 receptor.","Positive_Correlation"
"AIM: Extrapyramidal syndrome (<e1>EPS</e1>) is most commonly affected by typical <e2>antipsychotic drugs</e2> that have a high affinity with the D2 receptor.","Positive_Correlation"
"AIM: Extrapyramidal syndrome (<e1>EPS</e1>) is most commonly affected by typical <e2>antipsychotic drugs</e2> that have a high affinity with the D2 receptor.","Positive_Correlation"
"AIM: Extrapyramidal syndrome (<e1>EPS</e1>) is most commonly affected by typical <e2>antipsychotic drugs</e2> that have a high affinity with the D2 receptor.","Positive_Correlation"
"AIM: Extrapyramidal syndrome (<e1>EPS</e1>) is most commonly affected by typical <e2>antipsychotic drugs</e2> that have a high affinity with the D2 receptor.","Positive_Correlation"
"In this study, we evaluate the role DRD2 plays in <e1>chlorpromazine</e1>-induced <e2>EPS</e2> in schizophrenic patients.","Positive_Correlation"
"In this study, we evaluate the role DRD2 plays in <e1>chlorpromazine</e1>-induced <e2>EPS</e2> in schizophrenic patients.","Positive_Correlation"
"In this study, we evaluate the role DRD2 plays in <e1>chlorpromazine</e1>-induced <e2>EPS</e2> in schizophrenic patients.","Positive_Correlation"
"A novel <e1>IRF6</e1> nonsense mutation (Y67X) in a German family with <e2>Van der Woude syndrome</e2>.","Association"
"A novel IRF6 nonsense mutation (<e1>Y67X</e1>) in a German family with <e2>Van der Woude syndrome</e2>.","Positive_Correlation"
"The premature stop codon was responsible for a truncated protein lacking parts of the DNA- binding domain and the complete <e2>Smad</e2>-<e1>interferon regulatory factor</e1>-binding domain probably essential for interactions with the Smad transcription factors.","Bind"
"<e2>VWS</e2> arises as the result of mutations in the gene encoding <e1>interferon regulatory factor 6</e1> (IRF6).","Association"
"<e2>VWS</e2> arises as the result of mutations in the gene encoding interferon regulatory factor 6 (<e1>IRF6</e1>).","Association"
"<e2>VWS</e2> arises as the result of mutations in the gene encoding interferon regulatory factor 6 (<e1>IRF6</e1>).","Association"
"<e2>VWS</e2> arises as the result of mutations in the gene encoding interferon regulatory factor 6 (<e1>IRF6</e1>).","Association"
"<e2>VWS</e2> arises as the result of mutations in the gene encoding interferon regulatory factor 6 (<e1>IRF6</e1>).","Association"
"<e2>VWS</e2> arises as the result of mutations in the gene encoding <e1>interferon regulatory factor</e1> 6 (IRF6).","Association"
"Skewed X inactivation in an <e1>X linked nystagmus</e1> family resulted from a novel, p.R229G, missense mutation in the <e2>FRMD7</e2> gene.","Association"
"Skewed X inactivation in an <e1>X linked nystagmus</e1> family resulted from a novel, <e2>p.R229G</e2>, missense mutation in the FRMD7 gene.","Positive_Correlation"
"CONCLUSIONS: A novel p.R229G mutation in the <e2>FRMD7</e2> gene causes the <e1>NYS</e1> phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.","Association"
"CONCLUSIONS: A novel p.R229G mutation in the <e2>FRMD7</e2> gene causes the <e1>NYS</e1> phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.","Association"
"CONCLUSIONS: A novel p.R229G mutation in the <e2>FRMD7</e2> gene causes the <e1>NYS</e1> phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.","Association"
"CONCLUSIONS: A novel p.R229G mutation in the <e2>FRMD7</e2> gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in <e1>X linked NYS</e1> females.","Association"
"CONCLUSIONS: A novel <e2>p.R229G</e2> mutation in the FRMD7 gene causes the <e1>NYS</e1> phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.","Positive_Correlation"
"CONCLUSIONS: A novel <e2>p.R229G</e2> mutation in the FRMD7 gene causes the <e1>NYS</e1> phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.","Positive_Correlation"
"CONCLUSIONS: A novel <e2>p.R229G</e2> mutation in the FRMD7 gene causes the <e1>NYS</e1> phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.","Positive_Correlation"
"CONCLUSIONS: A novel <e2>p.R229G</e2> mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in <e1>X linked NYS</e1> females.","Positive_Correlation"
"Identification of <e1>apolipoprotein E</e1> Guangzhou (arginine 150 proline), a new variant associated with <e2>lipoprotein glomerulopathy</e2>.","Association"
"Identification of apolipoprotein E Guangzhou (<e1>arginine 150 proline</e1>), a new variant associated with <e2>lipoprotein glomerulopathy</e2>.","Association"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"This variant (<e1>apoE</e1> Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to <e2>lipids</e2>.","Bind"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of <e1>apolipoprotein E</e1> (apoE).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"BACKGROUND/AIMS: <e2>Lipoprotein glomerulopathy</e2> (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (<e1>apoE</e1>).","Association"
"CONCLUSION: The results of this study suggest that apoE (<e1>arginine 150 proline</e1>) is a novel apoE variant that etiologically related to <e2>LPG</e2>.","Association"
"Mutational analysis of <e1>CYP2C8</e1> in <e2>hypertensive</e2> patients using denaturing high performance liquid chromatography.","Association"
"Genotypes and allelic frequencies of <e1>CYP2C8</e1> between the healthy controls and patients with <e2>hypertension</e2> were compared.","Association"
"Genotypes and allelic frequencies of <e1>CYP2C8</e1> between the healthy controls and patients with <e2>hypertension</e2> were compared.","Association"
"Genotypes and allelic frequencies of <e1>CYP2C8</e1> between the healthy controls and patients with <e2>hypertension</e2> were compared.","Association"
"Genotypes and allelic frequencies of <e1>CYP2C8</e1> between the healthy controls and patients with <e2>hypertension</e2> were compared.","Association"
"<e1>Arachidonic acid</e1> metabolites such as epoxyeicosatrienenoic acids and hydroxyeicosatetrenoic acids, produced may have a role in <e2>hypertension</e2>.","Association"
"A higher frequency of the <e1>C35322T</e1> SNP was observed among <e2>hypertensive</e2> patients than control subjects.","Positive_Correlation"
"Having homozygous <e2>C35322C</e2> could be a protective factor for <e1>hypertension</e1>.","Association"
"Having homozygous <e2>C35322C</e2> could be a protective factor for <e1>hypertension</e1>.","Association"
"Having homozygous <e2>C35322C</e2> could be a protective factor for <e1>hypertension</e1>.","Association"
"<e1>TNFR-associated factor 2</e1> deficiency in B lymphocytes predisposes to <e2>chronic lymphocytic leukemia</e2>/small lymphocytic lymphoma in mice.","Negative_Correlation"
"Altogether, our results suggest that TRAF2 deficiency cooperates with <e1>BCL-2</e1> in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <e2>X-linked inhibitor of apoptosis</e2> expression, and rendering B cells independent of B cell activating factor for survival.","Association"
"Altogether, our results suggest that TRAF2 deficiency cooperates with <e1>BCL-2</e1> in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <e2>X-linked inhibitor of apoptosis</e2> expression, and rendering B cells independent of B cell activating factor for survival.","Association"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <e1>BCL-2</e1> and a TNFR-associated factor 2 (TRAF2) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <e2>small lymphocytic lymphoma</e2> and chronic lymphocytic leukemia with high incidence (Zapata et al.","Association"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <e1>BCL-2</e1> and a TNFR-associated factor 2 (TRAF2) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <e2>small lymphocytic lymphoma</e2> and chronic lymphocytic leukemia with high incidence (Zapata et al.","Association"
"In contrast, TRAF2 deficiency had no effect on CD40-mediated <e2>p38 MAPK</e2> activation but significantly reduced <e1>BCR</e1>-mediated p38 activation.","Association"
"In contrast, TRAF2 deficiency had no effect on CD40-mediated <e2>p38 MAPK</e2> activation but significantly reduced <e1>BCR</e1>-mediated p38 activation.","Association"
"In contrast, TRAF2 deficiency had no effect on <e1>CD40</e1>-mediated <e2>p38 MAPK</e2> activation but significantly reduced BCR-mediated p38 activation.","Association"
"In contrast, TRAF2 deficiency had no effect on <e1>CD40</e1>-mediated <e2>p38 MAPK</e2> activation but significantly reduced BCR-mediated p38 activation.","Association"
"In contrast, TRAF2 deficiency had no effect on <e1>CD40</e1>-mediated <e2>p38 MAPK</e2> activation but significantly reduced BCR-mediated p38 activation.","Association"
"Moreover, consistent with previous results, we also show that TRAF2 was required for efficient JNK and <e1>ERK</e1> activation in response to <e2>CD40</e2> engagement.","Association"
"Moreover, consistent with previous results, we also show that TRAF2 was required for efficient <e1>JNK</e1> and ERK activation in response to <e2>CD40</e2> engagement.","Association"
"Finally, we further confirm that <e1>TRAF2</e1> was required for CD40-mediated proliferation, but its absence relieved B cells of the need for <e2>B cell activating factor</e2> for survival.","Association"
"Finally, we further confirm that <e1>TRAF2</e1> was required for CD40-mediated proliferation, but its absence relieved B cells of the need for <e2>B cell activating factor</e2> for survival.","Association"
"Finally, we further confirm that <e1>TRAF2</e1> was required for CD40-mediated proliferation, but its absence relieved B cells of the need for <e2>B cell activating factor</e2> for survival.","Association"
"Finally, we further confirm that <e1>TRAF2</e1> was required for CD40-mediated proliferation, but its absence relieved B cells of the need for <e2>B cell activating factor</e2> for survival.","Association"
"Finally, we further confirm that <e1>TRAF2</e1> was required for CD40-mediated proliferation, but its absence relieved B cells of the need for <e2>B cell activating factor</e2> for survival.","Association"
"Finally, we further confirm that <e1>TRAF2</e1> was required for CD40-mediated proliferation, but its absence relieved B cells of the need for <e2>B cell activating factor</e2> for survival.","Association"
"Finally, we further confirm that <e1>TRAF2</e1> was required for CD40-mediated proliferation, but its absence relieved B cells of the need for <e2>B cell activating factor</e2> for survival.","Association"
"Finally, we further confirm that <e1>TRAF2</e1> was required for CD40-mediated proliferation, but its absence relieved B cells of the need for <e2>B cell activating factor</e2> for survival.","Association"
"Finally, we further confirm that <e1>TRAF2</e1> was required for CD40-mediated proliferation, but its absence relieved B cells of the need for <e2>B cell activating factor</e2> for survival.","Association"
"Altogether, our results suggest that <e1>TRAF2</e1> deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <e2>X-linked inhibitor of apoptosis</e2> expression, and rendering B cells independent of B cell activating factor for survival.","Negative_Correlation"
"Altogether, our results suggest that <e1>TRAF2</e1> deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <e2>X-linked inhibitor of apoptosis</e2> expression, and rendering B cells independent of B cell activating factor for survival.","Negative_Correlation"
"Altogether, our results suggest that <e1>TRAF2</e1> deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <e2>X-linked inhibitor of apoptosis</e2> expression, and rendering B cells independent of B cell activating factor for survival.","Negative_Correlation"
"Altogether, our results suggest that <e1>TRAF2</e1> deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <e2>X-linked inhibitor of apoptosis</e2> expression, and rendering B cells independent of B cell activating factor for survival.","Negative_Correlation"
"Altogether, our results suggest that <e1>TRAF2</e1> deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <e2>X-linked inhibitor of apoptosis</e2> expression, and rendering B cells independent of B cell activating factor for survival.","Negative_Correlation"
"Altogether, our results suggest that <e1>TRAF2</e1> deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <e2>X-linked inhibitor of apoptosis</e2> expression, and rendering B cells independent of B cell activating factor for survival.","Negative_Correlation"
"Altogether, our results suggest that <e1>TRAF2</e1> deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <e2>X-linked inhibitor of apoptosis</e2> expression, and rendering B cells independent of B cell activating factor for survival.","Negative_Correlation"
"Altogether, our results suggest that <e1>TRAF2</e1> deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <e2>X-linked inhibitor of apoptosis</e2> expression, and rendering B cells independent of B cell activating factor for survival.","Negative_Correlation"
"Altogether, our results suggest that <e1>TRAF2</e1> deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <e2>X-linked inhibitor of apoptosis</e2> expression, and rendering B cells independent of B cell activating factor for survival.","Negative_Correlation"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <e2>BCL-2</e2> and a <e1>TNFR-associated factor 2</e1> (TRAF2) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.","Association"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <e2>BCL-2</e2> and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.","Association"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <e2>BCL-2</e2> and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.","Association"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <e2>BCL-2</e2> and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.","Association"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <e2>BCL-2</e2> and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.","Association"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <e2>BCL-2</e2> and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.","Association"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <e2>BCL-2</e2> and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.","Association"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <e2>BCL-2</e2> and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.","Association"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <e2>BCL-2</e2> and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.","Association"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <e2>BCL-2</e2> and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.","Association"
"In contrast, <e1>TRAF2</e1> deficiency had no effect on CD40-mediated <e2>p38 MAPK</e2> activation but significantly reduced BCR-mediated p38 activation.","Positive_Correlation"
"In contrast, <e1>TRAF2</e1> deficiency had no effect on CD40-mediated <e2>p38 MAPK</e2> activation but significantly reduced BCR-mediated p38 activation.","Positive_Correlation"
"In contrast, <e1>TRAF2</e1> deficiency had no effect on CD40-mediated <e2>p38 MAPK</e2> activation but significantly reduced BCR-mediated p38 activation.","Positive_Correlation"
"In contrast, <e1>TRAF2</e1> deficiency had no effect on CD40-mediated <e2>p38 MAPK</e2> activation but significantly reduced BCR-mediated p38 activation.","Positive_Correlation"
"In contrast, <e1>TRAF2</e1> deficiency had no effect on CD40-mediated <e2>p38 MAPK</e2> activation but significantly reduced BCR-mediated p38 activation.","Positive_Correlation"
"In contrast, <e1>TRAF2</e1> deficiency had no effect on CD40-mediated <e2>p38 MAPK</e2> activation but significantly reduced BCR-mediated p38 activation.","Positive_Correlation"
"In contrast, <e1>TRAF2</e1> deficiency had no effect on CD40-mediated <e2>p38 MAPK</e2> activation but significantly reduced BCR-mediated p38 activation.","Positive_Correlation"
"In contrast, <e1>TRAF2</e1> deficiency had no effect on CD40-mediated <e2>p38 MAPK</e2> activation but significantly reduced BCR-mediated p38 activation.","Positive_Correlation"
"In contrast, <e1>TRAF2</e1> deficiency had no effect on CD40-mediated <e2>p38 MAPK</e2> activation but significantly reduced BCR-mediated p38 activation.","Positive_Correlation"
"However, <e1>TRAF2</e1> was deleterious for <e2>BCR</e2>-mediated activation of these kinases.","Association"
"However, <e1>TRAF2</e1> was deleterious for <e2>BCR</e2>-mediated activation of these kinases.","Association"
"However, <e1>TRAF2</e1> was deleterious for <e2>BCR</e2>-mediated activation of these kinases.","Association"
"However, <e1>TRAF2</e1> was deleterious for <e2>BCR</e2>-mediated activation of these kinases.","Association"
"However, <e1>TRAF2</e1> was deleterious for <e2>BCR</e2>-mediated activation of these kinases.","Association"
"However, <e1>TRAF2</e1> was deleterious for <e2>BCR</e2>-mediated activation of these kinases.","Association"
"However, <e1>TRAF2</e1> was deleterious for <e2>BCR</e2>-mediated activation of these kinases.","Association"
"However, <e1>TRAF2</e1> was deleterious for <e2>BCR</e2>-mediated activation of these kinases.","Association"
"However, <e1>TRAF2</e1> was deleterious for <e2>BCR</e2>-mediated activation of these kinases.","Association"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and ERK activation in response to <e2>CD40</e2> engagement.","Association"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and ERK activation in response to <e2>CD40</e2> engagement.","Association"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and ERK activation in response to <e2>CD40</e2> engagement.","Association"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and ERK activation in response to <e2>CD40</e2> engagement.","Association"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and ERK activation in response to <e2>CD40</e2> engagement.","Association"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and ERK activation in response to <e2>CD40</e2> engagement.","Association"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and ERK activation in response to <e2>CD40</e2> engagement.","Association"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and ERK activation in response to <e2>CD40</e2> engagement.","Association"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and ERK activation in response to <e2>CD40</e2> engagement.","Association"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and <e2>ERK</e2> activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and <e2>ERK</e2> activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and <e2>ERK</e2> activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and <e2>ERK</e2> activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and <e2>ERK</e2> activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and <e2>ERK</e2> activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and <e2>ERK</e2> activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and <e2>ERK</e2> activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient JNK and <e2>ERK</e2> activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient <e2>JNK</e2> and ERK activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient <e2>JNK</e2> and ERK activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient <e2>JNK</e2> and ERK activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient <e2>JNK</e2> and ERK activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient <e2>JNK</e2> and ERK activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient <e2>JNK</e2> and ERK activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient <e2>JNK</e2> and ERK activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient <e2>JNK</e2> and ERK activation in response to CD40 engagement.","Positive_Correlation"
"Moreover, consistent with previous results, we also show that <e1>TRAF2</e1> was required for efficient <e2>JNK</e2> and ERK activation in response to CD40 engagement.","Positive_Correlation"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a <e1>TNFR-associated factor 2</e1> (TRAF2) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <e2>small lymphocytic lymphoma</e2> and chronic lymphocytic leukemia with high incidence (Zapata et al.","Negative_Correlation"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <e2>small lymphocytic lymphoma</e2> and chronic lymphocytic leukemia with high incidence (Zapata et al.","Negative_Correlation"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <e2>small lymphocytic lymphoma</e2> and chronic lymphocytic leukemia with high incidence (Zapata et al.","Negative_Correlation"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <e2>small lymphocytic lymphoma</e2> and chronic lymphocytic leukemia with high incidence (Zapata et al.","Negative_Correlation"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <e2>small lymphocytic lymphoma</e2> and chronic lymphocytic leukemia with high incidence (Zapata et al.","Negative_Correlation"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <e2>small lymphocytic lymphoma</e2> and chronic lymphocytic leukemia with high incidence (Zapata et al.","Negative_Correlation"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <e2>small lymphocytic lymphoma</e2> and chronic lymphocytic leukemia with high incidence (Zapata et al.","Negative_Correlation"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <e2>small lymphocytic lymphoma</e2> and chronic lymphocytic leukemia with high incidence (Zapata et al.","Negative_Correlation"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <e2>small lymphocytic lymphoma</e2> and chronic lymphocytic leukemia with high incidence (Zapata et al.","Negative_Correlation"
"We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (<e1>TRAF2</e1>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <e2>small lymphocytic lymphoma</e2> and chronic lymphocytic leukemia with high incidence (Zapata et al.","Negative_Correlation"
"<e1>CTR9</e1>/PAF1c regulates molecular lineage identity, <e2>histone H3</e2>K36 trimethylation and genomic imprinting during preimplantation development.","Association"
"CTR9/PAF1c regulates molecular lineage identity, histone H3K36 trimethylation and genomic imprinting during preimplantation development.","Bind"
"We document a loss of <e2>histone H3</e2> lysine 36 trimethylation (H3K36me3) in Ctr9-deficient embryos and confirm that knockdown of either <e1>Setd2</e1> or Rtf1 results in similar phenotypes.","Association"
"We document a loss of <e2>histone H3</e2> lysine 36 trimethylation (H3K36me3) in Ctr9-deficient embryos and confirm that knockdown of either Setd2 or <e1>Rtf1</e1> results in similar phenotypes.","Association"
"We document a loss of <e2>histone H3</e2> lysine 36 trimethylation (H3K36me3) in Ctr9-deficient embryos and confirm that knockdown of either Setd2 or <e1>Rtf1</e1> results in similar phenotypes.","Association"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and <e2>Sox17</e2>).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and <e2>Sox17</e2>).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and <e2>Sox17</e2>).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and <e2>Sox17</e2>).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, <e2>Fgf4</e2> and Sox17).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, <e2>Fgf4</e2> and Sox17).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, <e2>Fgf4</e2> and Sox17).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, <e2>Fgf4</e2> and Sox17).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, <e2>Gata6</e2>, Fgf4 and Sox17).","Association"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, <e2>Gata6</e2>, Fgf4 and Sox17).","Association"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, <e2>Gata6</e2>, Fgf4 and Sox17).","Association"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, <e2>Gata6</e2>, Fgf4 and Sox17).","Association"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, <e2>Nanog</e2>, Gata6, Fgf4 and Sox17).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, <e2>Nanog</e2>, Gata6, Fgf4 and Sox17).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, <e2>Nanog</e2>, Gata6, Fgf4 and Sox17).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, <e2>Nanog</e2>, Gata6, Fgf4 and Sox17).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (<e2>Oct4</e2>, Nanog, Gata6, Fgf4 and Sox17).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (<e2>Oct4</e2>, Nanog, Gata6, Fgf4 and Sox17).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (<e2>Oct4</e2>, Nanog, Gata6, Fgf4 and Sox17).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (<e2>Oct4</e2>, Nanog, Gata6, Fgf4 and Sox17).","Negative_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and <e2>Sox2</e2>, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).","Positive_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and <e2>Sox2</e2>, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).","Positive_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and <e2>Sox2</e2>, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).","Positive_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, Elf5 and <e2>Sox2</e2>, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).","Positive_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, <e2>Elf5</e2> and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).","Positive_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, <e2>Elf5</e2> and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).","Positive_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, <e2>Elf5</e2> and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).","Positive_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including Eomes, <e2>Elf5</e2> and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).","Positive_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including <e2>Eomes</e2>, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).","Positive_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including <e2>Eomes</e2>, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).","Positive_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including <e2>Eomes</e2>, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).","Positive_Correlation"
"Expression of some lineage specific factors is markedly reduced in <e1>Ctr9</e1> knockdown embryos, including <e2>Eomes</e2>, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).","Positive_Correlation"
"We document a loss of <e2>histone H3</e2> lysine 36 trimethylation (H3K36me3) in <e1>Ctr9</e1>-deficient embryos and confirm that knockdown of either Setd2 or Rtf1 results in similar phenotypes.","Association"
"We document a loss of <e2>histone H3</e2> lysine 36 trimethylation (H3K36me3) in <e1>Ctr9</e1>-deficient embryos and confirm that knockdown of either Setd2 or Rtf1 results in similar phenotypes.","Association"
"We document a loss of <e2>histone H3</e2> lysine 36 trimethylation (H3K36me3) in <e1>Ctr9</e1>-deficient embryos and confirm that knockdown of either Setd2 or Rtf1 results in similar phenotypes.","Association"
"We document a loss of <e2>histone H3</e2> lysine 36 trimethylation (H3K36me3) in <e1>Ctr9</e1>-deficient embryos and confirm that knockdown of either Setd2 or Rtf1 results in similar phenotypes.","Association"
"Here we report that two members of the RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex (PAF1 complex) components, <e1>Ctr9</e1> and <e2>Rtf1</e2>, are required during mammalian preimplantation development.","Bind"
"Here we report that two members of the RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex (PAF1 complex) components, <e1>Ctr9</e1> and <e2>Rtf1</e2>, are required during mammalian preimplantation development.","Bind"
"Here we report that two members of the RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex (PAF1 complex) components, <e1>Ctr9</e1> and <e2>Rtf1</e2>, are required during mammalian preimplantation development.","Bind"
"Here we report that two members of the RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex (PAF1 complex) components, <e1>Ctr9</e1> and <e2>Rtf1</e2>, are required during mammalian preimplantation development.","Bind"
"Here we report that two members of the RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex (PAF1 complex) components, Ctr9 and Rtf1, are required during mammalian preimplantation development.","Bind"
"Here we report that two members of the RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex (PAF1 complex) components, Ctr9 and Rtf1, are required during mammalian preimplantation development.","Bind"
"Here we report that two members of the RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex (PAF1 complex) components, Ctr9 and Rtf1, are required during mammalian preimplantation development.","Bind"
"Here we report that two members of the RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex (PAF1 complex) components, Ctr9 and Rtf1, are required during mammalian preimplantation development.","Bind"
"Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates <e1>isoproterenol</e1>-induced acute <e2>myocardial injury</e2> in rats.","Positive_Correlation"
"Regulation of <e2>signal transducer and activator of transcription 3</e2> and apoptotic pathways by betaine attenuates <e1>isoproterenol</e1>-induced acute myocardial injury in rats.","Association"
"Regulation of <e2>signal transducer and activator of transcription 3</e2> and apoptotic pathways by betaine attenuates isoproterenol-induced acute <e1>myocardial injury</e1> in rats.","Association"
"Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by <e1>betaine</e1> attenuates <e2>isoproterenol</e2>-induced acute myocardial injury in rats.","Negative_Correlation"
"Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by <e1>betaine</e1> attenuates isoproterenol-induced acute <e2>myocardial injury</e2> in rats.","Negative_Correlation"
"Regulation of <e2>signal transducer and activator of transcription 3</e2> and apoptotic pathways by <e1>betaine</e1> attenuates isoproterenol-induced acute myocardial injury in rats.","Association"
"In summary, our results showed that betaine pretreatment attenuated <e2>isoproterenol</e2>-induced acute <e1>myocardial ischemia</e1> via the regulation of STAT3 and apoptotic pathways.","Positive_Correlation"
"Acute <e1>myocardial ischemic injury</e1> was induced in rats by subcutaneous injection of <e2>isoproterenol</e2> (85 mg/kg), for two consecutive days.","Positive_Correlation"
"In summary, our results showed that betaine pretreatment attenuated <e2>isoproterenol</e2>-induced acute <e1>myocardial ischemia</e1> via the regulation of STAT3 and apoptotic pathways.","Positive_Correlation"
"The present study was designed to investigate the cardioprotective effects of betaine on acute <e1>myocardial ischemia</e1> induced experimentally in rats focusing on regulation of <e2>signal transducer and activator of transcription 3</e2> (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Association"
"The present study was designed to investigate the cardioprotective effects of betaine on acute <e1>myocardial ischemia</e1> induced experimentally in rats focusing on regulation of <e2>signal transducer and activator of transcription 3</e2> (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Association"
"Western blot analysis showed that <e1>isoproterenol</e1>-induced phosphorylation of <e2>STAT3</e2> was maintained or further enhanced by betaine treatment in myocardium.","Association"
"Western blot analysis showed that <e1>isoproterenol</e1>-induced phosphorylation of <e2>STAT3</e2> was maintained or further enhanced by betaine treatment in myocardium.","Association"
"Western blot analysis showed that <e1>isoproterenol</e1>-induced phosphorylation of <e2>STAT3</e2> was maintained or further enhanced by betaine treatment in myocardium.","Association"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of <e2>Bax</e2>, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Negative_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of <e2>Bax</e2>, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Negative_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of <e2>Bax</e2>, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Negative_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of <e2>Bax</e2>, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Negative_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of <e2>Bax</e2>, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Negative_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of <e2>Bax</e2>, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Negative_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of <e2>Bax</e2>, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Negative_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of <e2>Bcl-2</e2> and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Positive_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of <e2>Bcl-2</e2> and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Positive_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of <e2>Bcl-2</e2> and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Positive_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of <e2>Bcl-2</e2> and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Positive_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of <e2>Bcl-2</e2> and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Positive_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of <e2>Bcl-2</e2> and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Positive_Correlation"
"Furthermore, <e1>betaine</e1> (200 and 400 mg/kg) treatment increased the ventricular expression of <e2>Bcl-2</e2> and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax.","Positive_Correlation"
"Oral administration of <e1>betaine</e1> (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left <e2>ventricular remodeling</e2>.","Negative_Correlation"
"Oral administration of <e1>betaine</e1> (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left <e2>ventricular remodeling</e2>.","Negative_Correlation"
"Oral administration of <e1>betaine</e1> (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left <e2>ventricular remodeling</e2>.","Negative_Correlation"
"Oral administration of <e1>betaine</e1> (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left <e2>ventricular remodeling</e2>.","Negative_Correlation"
"Oral administration of <e1>betaine</e1> (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left <e2>ventricular remodeling</e2>.","Negative_Correlation"
"Oral administration of <e1>betaine</e1> (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left <e2>ventricular remodeling</e2>.","Negative_Correlation"
"Oral administration of <e1>betaine</e1> (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left <e2>ventricular remodeling</e2>.","Negative_Correlation"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute <e2>myocardial ischemia</e2> induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Negative_Correlation"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute <e2>myocardial ischemia</e2> induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Negative_Correlation"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute <e2>myocardial ischemia</e2> induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Negative_Correlation"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute <e2>myocardial ischemia</e2> induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Negative_Correlation"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute <e2>myocardial ischemia</e2> induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Negative_Correlation"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute <e2>myocardial ischemia</e2> induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Negative_Correlation"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute <e2>myocardial ischemia</e2> induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Negative_Correlation"
"Western blot analysis showed that <e2>isoproterenol</e2>-induced phosphorylation of STAT3 was maintained or further enhanced by <e1>betaine</e1> treatment in myocardium.","Negative_Correlation"
"Western blot analysis showed that <e2>isoproterenol</e2>-induced phosphorylation of STAT3 was maintained or further enhanced by <e1>betaine</e1> treatment in myocardium.","Negative_Correlation"
"Western blot analysis showed that <e2>isoproterenol</e2>-induced phosphorylation of STAT3 was maintained or further enhanced by <e1>betaine</e1> treatment in myocardium.","Negative_Correlation"
"Western blot analysis showed that <e2>isoproterenol</e2>-induced phosphorylation of STAT3 was maintained or further enhanced by <e1>betaine</e1> treatment in myocardium.","Negative_Correlation"
"Western blot analysis showed that <e2>isoproterenol</e2>-induced phosphorylation of STAT3 was maintained or further enhanced by <e1>betaine</e1> treatment in myocardium.","Negative_Correlation"
"Western blot analysis showed that <e2>isoproterenol</e2>-induced phosphorylation of STAT3 was maintained or further enhanced by <e1>betaine</e1> treatment in myocardium.","Negative_Correlation"
"Western blot analysis showed that <e2>isoproterenol</e2>-induced phosphorylation of STAT3 was maintained or further enhanced by <e1>betaine</e1> treatment in myocardium.","Negative_Correlation"
"The protective role of <e1>betaine</e1> on <e2>myocardial damage</e2> was further confirmed by histopathological examination.","Negative_Correlation"
"The protective role of <e1>betaine</e1> on <e2>myocardial damage</e2> was further confirmed by histopathological examination.","Negative_Correlation"
"The protective role of <e1>betaine</e1> on <e2>myocardial damage</e2> was further confirmed by histopathological examination.","Negative_Correlation"
"The protective role of <e1>betaine</e1> on <e2>myocardial damage</e2> was further confirmed by histopathological examination.","Negative_Correlation"
"The protective role of <e1>betaine</e1> on <e2>myocardial damage</e2> was further confirmed by histopathological examination.","Negative_Correlation"
"The protective role of <e1>betaine</e1> on <e2>myocardial damage</e2> was further confirmed by histopathological examination.","Negative_Correlation"
"The protective role of <e1>betaine</e1> on <e2>myocardial damage</e2> was further confirmed by histopathological examination.","Negative_Correlation"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute myocardial ischemia induced experimentally in rats focusing on regulation of <e2>signal transducer and activator of transcription 3</e2> (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Association"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute myocardial ischemia induced experimentally in rats focusing on regulation of <e2>signal transducer and activator of transcription 3</e2> (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Association"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute myocardial ischemia induced experimentally in rats focusing on regulation of <e2>signal transducer and activator of transcription 3</e2> (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Association"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute myocardial ischemia induced experimentally in rats focusing on regulation of <e2>signal transducer and activator of transcription 3</e2> (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Association"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute myocardial ischemia induced experimentally in rats focusing on regulation of <e2>signal transducer and activator of transcription 3</e2> (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Association"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute myocardial ischemia induced experimentally in rats focusing on regulation of <e2>signal transducer and activator of transcription 3</e2> (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Association"
"The present study was designed to investigate the cardioprotective effects of <e1>betaine</e1> on acute myocardial ischemia induced experimentally in rats focusing on regulation of <e2>signal transducer and activator of transcription 3</e2> (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.","Association"
"Combination of the <e1>histone deacetylase</e1> inhibitor <e2>depsipeptide</e2> and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.","Negative_Correlation"
"Combination of the histone deacetylase inhibitor depsipeptide and <e1>5-fluorouracil</e1> upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human <e2>colon cancer</e2> HCT-116 cells.","Negative_Correlation"
"Combination of the histone deacetylase inhibitor depsipeptide and <e1>5-fluorouracil</e1> upregulates major histocompatibility complex class II and <e2>p21</e2> genes and activates caspase-3/7 in human colon cancer HCT-116 cells.","Positive_Correlation"
"Combination of the histone deacetylase inhibitor <e1>depsipeptide</e1> and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human <e2>colon cancer</e2> HCT-116 cells.","Negative_Correlation"
"Combination of the histone deacetylase inhibitor <e1>depsipeptide</e1> and <e2>5-fluorouracil</e2> upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.","Cotreatment"
"Combination of the histone deacetylase inhibitor <e1>depsipeptide</e1> and 5-fluorouracil upregulates major histocompatibility complex class II and <e2>p21</e2> genes and activates caspase-3/7 in human colon cancer HCT-116 cells.","Positive_Correlation"
"Combination of the histone deacetylase inhibitor depsipeptide and <e2>5-fluorouracil</e2> upregulates <e1>major histocompatibility complex class II</e1> and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.","Positive_Correlation"
"Combination of the histone deacetylase inhibitor <e2>depsipeptide</e2> and 5-fluorouracil upregulates <e1>major histocompatibility complex class II</e1> and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.","Positive_Correlation"
"These analyses indicated marked upregulation of antigen processing and presentation of peptide or <e1>polysaccharide</e1> antigen via <e2>major histocompatibility complex (MHC) class</e2> (GO:0002504) and MHC protein complex (GO:0042611).","Association"
"In the present study, we found that a very low concentration of <e2>depsipeptide</e2>, an <e1>HDAC</e1> inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of <e2>depsipeptide</e2>, an <e1>HDAC</e1> inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of <e1>5-fluorouracil</e1> (5-FU) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (<e1>5-FU</e1>) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (<e1>5-FU</e1>) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (<e1>5-FU</e1>) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (<e1>5-FU</e1>) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (<e1>5-FU</e1>) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (<e1>5-FU</e1>) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (<e1>5-FU</e1>) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (<e1>5-FU</e1>) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (<e1>5-FU</e1>) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of <e1>5-FU</e1> and depsipeptide.","Association"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human <e2>colon cancer</e2> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Negative_Correlation"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <e2>CIITA</e2> after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <e2>PCAF</e2> and CIITA after the combination of 5-FU and <e1>depsipeptide</e1>.","Association"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of <e2>5-fluorouracil</e2> (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Cotreatment"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of <e2>5-fluorouracil</e2> (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Cotreatment"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of <e2>5-fluorouracil</e2> (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Cotreatment"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of <e2>5-fluorouracil</e2> (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Cotreatment"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of <e2>5-fluorouracil</e2> (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Cotreatment"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of <e2>5-fluorouracil</e2> (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Cotreatment"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of <e2>5-fluorouracil</e2> (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Cotreatment"
"In the present study, we found that a very low concentration of <e1>depsipeptide</e1>, an HDAC inhibitor, potentiated the antitumor activity of <e2>5-fluorouracil</e2> (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.","Cotreatment"
"Compared with vehicle controls, the cells treated with the combination of <e2>5-FU</e2> and depsipeptide showed marked induction (3- to 8.5-fold) of expression of <e1>MHC class II genes</e1>, but not of MHC class I genes.","Positive_Correlation"
"Compared with vehicle controls, the cells treated with the combination of <e2>5-FU</e2> and depsipeptide showed marked induction (3- to 8.5-fold) of expression of <e1>MHC class II genes</e1>, but not of MHC class I genes.","Positive_Correlation"
"Compared with vehicle controls, the cells treated with the combination of <e2>5-FU</e2> and depsipeptide showed marked induction (3- to 8.5-fold) of expression of <e1>MHC class II</e1> genes, but not of MHC class I genes.","Positive_Correlation"
"Compared with vehicle controls, the cells treated with the combination of <e2>5-FU</e2> and depsipeptide showed marked induction (3- to 8.5-fold) of expression of <e1>MHC class II</e1> genes, but not of MHC class I genes.","Positive_Correlation"
"Compared with vehicle controls, the cells treated with the combination of 5-FU and <e2>depsipeptide</e2> showed marked induction (3- to 8.5-fold) of expression of <e1>MHC class II genes</e1>, but not of MHC class I genes.","Positive_Correlation"
"Compared with vehicle controls, the cells treated with the combination of 5-FU and <e2>depsipeptide</e2> showed marked induction (3- to 8.5-fold) of expression of <e1>MHC class II genes</e1>, but not of MHC class I genes.","Positive_Correlation"
"Compared with vehicle controls, the cells treated with the combination of 5-FU and <e2>depsipeptide</e2> showed marked induction (3- to 8.5-fold) of expression of <e1>MHC class II</e1> genes, but not of MHC class I genes.","Positive_Correlation"
"Compared with vehicle controls, the cells treated with the combination of 5-FU and <e2>depsipeptide</e2> showed marked induction (3- to 8.5-fold) of expression of <e1>MHC class II</e1> genes, but not of MHC class I genes.","Positive_Correlation"
"Seven novel and six de novo <e1>PHEX</e1> gene mutations in patients with <e2>hypophosphatemic rickets</e2>.","Association"
"Inactivating mutations in <e1>phosphate-regulating gene with homologies to endopeptidase on the X chromosome</e1> (PHEX) have been identified as a cause of <e2>X-linked hypophosphatemic rickets</e2> (XLH; OMIM 307800).","Negative_Correlation"
"Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (<e1>PHEX</e1>) have been identified as a cause of <e2>X-linked hypophosphatemic rickets</e2> (XLH; OMIM 307800).","Negative_Correlation"
"Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (<e1>PHEX</e1>) have been identified as a cause of <e2>X-linked hypophosphatemic rickets</e2> (XLH; OMIM 307800).","Negative_Correlation"
"Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (<e1>PHEX</e1>) have been identified as a cause of <e2>X-linked hypophosphatemic rickets</e2> (XLH; OMIM 307800).","Negative_Correlation"
"Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (<e1>PHEX</e1>) have been identified as a cause of <e2>X-linked hypophosphatemic rickets</e2> (XLH; OMIM 307800).","Negative_Correlation"
"Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (<e1>PHEX</e1>) have been identified as a cause of <e2>X-linked hypophosphatemic rickets</e2> (XLH; OMIM 307800).","Negative_Correlation"
"Inactivating mutations in <e1>phosphate-regulating gene with homologies to endopeptidase on the X chromosome</e1> (PHEX) have been identified as a cause of X-linked <e2>hypophosphatemic rickets</e2> (XLH; OMIM 307800).","Association"
"Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (<e1>PHEX</e1>) have been identified as a cause of X-linked <e2>hypophosphatemic rickets</e2> (XLH; OMIM 307800).","Association"
"Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (<e1>PHEX</e1>) have been identified as a cause of X-linked <e2>hypophosphatemic rickets</e2> (XLH; OMIM 307800).","Association"
"Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (<e1>PHEX</e1>) have been identified as a cause of X-linked <e2>hypophosphatemic rickets</e2> (XLH; OMIM 307800).","Association"
"Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (<e1>PHEX</e1>) have been identified as a cause of X-linked <e2>hypophosphatemic rickets</e2> (XLH; OMIM 307800).","Association"
"Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (<e1>PHEX</e1>) have been identified as a cause of X-linked <e2>hypophosphatemic rickets</e2> (XLH; OMIM 307800).","Association"
"A linkage study in 30 <e2>Becker muscular dystrophy</e2> (<e1>BMD</e1>) kindreds using three cloned DNA sequences from the X chromosome which demonstrate restriction fragment length polymorphisms (RFLPs), suggests that the BMD gene is located on the short arm of the X chromosome, in the p21 region.","Association"
"<e1>X-linked adrenoleukodystrophy</e1> (<e2>ALD</e2>): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes.","Association"
"X-linked adrenoleukodystrophy (<e1>ALD</e1>): a novel mutation of the <e2>ALD</e2> gene in 6 members of a family presenting with 5 different phenotypes.","Association"
"Five of nine siblings of the patient, comprising two cerebral <e1>ALD</e1>, one adrenomyeloneuropathy, one <e2>Addison</e2> only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls.","Association"
"Fragments of the <e1>adrenoleukodystrophy</e1> (<e2>ALD</e2>) cDNA from a patient with adolescent ALD were amplified by polymerase chain reaction and subcloned.","Association"
"Fragments of the adrenoleukodystrophy (<e1>ALD</e1>) cDNA from a patient with adolescent <e2>ALD</e2> were amplified by polymerase chain reaction and subcloned.","Association"
"Fragments of the adrenoleukodystrophy (<e1>ALD</e1>) cDNA from a patient with adolescent <e2>ALD</e2> were amplified by polymerase chain reaction and subcloned.","Association"
"Fragments of the adrenoleukodystrophy (<e1>ALD</e1>) cDNA from a patient with adolescent <e2>ALD</e2> were amplified by polymerase chain reaction and subcloned.","Association"
"Five of nine siblings of the patient, comprising two cerebral <e2>ALD</e2>, one <e1>adrenomyeloneuropathy</e1>, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls.","Association"
"Fragments of the adrenoleukodystrophy (<e1>ALD</e1>) cDNA from a patient with adolescent <e2>ALD</e2> were amplified by polymerase chain reaction and subcloned.","Association"
"Bidirectional sequencing of the entire coding <e2>ALD</e2> gene disclosed a <e1>cytosine to guanine transversion at nucleotide 1451</e1> in exon five, resulting in substitution of proline 484 by arginine.","Positive_Correlation"
"Bidirectional sequencing of the entire coding <e2>ALD</e2> gene disclosed a cytosine to guanine transversion at nucleotide 1451 in exon five, resulting in substitution of <e1>proline 484 by arginine</e1>.","Positive_Correlation"
"Single nucleotide polymorphisms of the <e1>HNF4alpha</e1> gene are associated with the conversion to <e2>type 2 diabetes mellitus</e2>: the STOP-NIDDM trial.","Association"
"Haplotype analysis based on three SNPs (rs4810424, <e1>rs2071197</e1>, and <e2>rs3818247</e2>) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.","Association"
"Haplotype analysis based on three SNPs (<e1>rs4810424</e1>, rs2071197, and <e2>rs3818247</e2>) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.","Association"
"Haplotype analysis based on three SNPs (<e1>rs4810424</e1>, rs2071197, and <e2>rs3818247</e2>) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.","Association"
"Haplotype analysis based on three SNPs (<e1>rs4810424</e1>, rs2071197, and <e2>rs3818247</e2>) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.","Association"
"Haplotype analysis based on three SNPs (<e1>rs4810424</e1>, rs2071197, and <e2>rs3818247</e2>) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.","Association"
"Haplotype analysis based on three SNPs (<e1>rs4810424</e1>, <e2>rs2071197</e2>, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.","Association"
"Haplotype analysis based on three SNPs (<e1>rs4810424</e1>, <e2>rs2071197</e2>, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.","Association"
"Haplotype analysis based on three SNPs (<e1>rs4810424</e1>, <e2>rs2071197</e2>, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.","Association"
"Haplotype analysis based on three SNPs (<e1>rs4810424</e1>, <e2>rs2071197</e2>, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.","Association"
"Female carriers of the less frequent C allele of <e1>rs4810424</e1> had a 1.7-fold elevated risk [95% confidence interval (CI) 1.09-2.66; P=0.020] for the conversion to <e2>diabetes</e2> compared to women with the common genotype after the adjustment for age, treatment group (placebo or acarbose), smoking, weight at baseline, and weight change.","Positive_Correlation"
"Female carriers of the less frequent C allele of <e1>rs4810424</e1> had a 1.7-fold elevated risk [95% confidence interval (CI) 1.09-2.66; P=0.020] for the conversion to <e2>diabetes</e2> compared to women with the common genotype after the adjustment for age, treatment group (placebo or acarbose), smoking, weight at baseline, and weight change.","Positive_Correlation"
"Female carriers of the less frequent C allele of <e1>rs4810424</e1> had a 1.7-fold elevated risk [95% confidence interval (CI) 1.09-2.66; P=0.020] for the conversion to <e2>diabetes</e2> compared to women with the common genotype after the adjustment for age, treatment group (placebo or acarbose), smoking, weight at baseline, and weight change.","Positive_Correlation"
"Female carriers of the less frequent C allele of <e1>rs4810424</e1> had a 1.7-fold elevated risk [95% confidence interval (CI) 1.09-2.66; P=0.020] for the conversion to <e2>diabetes</e2> compared to women with the common genotype after the adjustment for age, treatment group (placebo or acarbose), smoking, weight at baseline, and weight change.","Positive_Correlation"
"This trial aimed at evaluating the effect of <e1>acarbose</e1> compared to placebo in the prevention of <e2>type 2 diabetes mellitus</e2>.","Negative_Correlation"
"This trial aimed at evaluating the effect of <e1>acarbose</e1> compared to placebo in the prevention of <e2>type 2 diabetes mellitus</e2>.","Negative_Correlation"
"Haplotype analysis based on three SNPs (rs4810424, rs2071197, and <e2>rs3818247</e2>) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <e1>type 2 diabetes mellitus</e1> was dependent on the number of risk alleles in different haplotypes in women.","Positive_Correlation"
"Haplotype analysis based on three SNPs (rs4810424, rs2071197, and <e2>rs3818247</e2>) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <e1>type 2 diabetes mellitus</e1> was dependent on the number of risk alleles in different haplotypes in women.","Positive_Correlation"
"Haplotype analysis based on three SNPs (rs4810424, rs2071197, and <e2>rs3818247</e2>) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <e1>type 2 diabetes mellitus</e1> was dependent on the number of risk alleles in different haplotypes in women.","Positive_Correlation"
"Haplotype analysis based on three SNPs (rs4810424, rs2071197, and <e2>rs3818247</e2>) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <e1>type 2 diabetes mellitus</e1> was dependent on the number of risk alleles in different haplotypes in women.","Positive_Correlation"
"Haplotype analysis based on three SNPs (rs4810424, <e2>rs2071197</e2>, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <e1>type 2 diabetes mellitus</e1> was dependent on the number of risk alleles in different haplotypes in women.","Positive_Correlation"
"Haplotype analysis based on three SNPs (rs4810424, <e2>rs2071197</e2>, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <e1>type 2 diabetes mellitus</e1> was dependent on the number of risk alleles in different haplotypes in women.","Positive_Correlation"
"Haplotype analysis based on three SNPs (rs4810424, <e2>rs2071197</e2>, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <e1>type 2 diabetes mellitus</e1> was dependent on the number of risk alleles in different haplotypes in women.","Positive_Correlation"
"Haplotype analysis based on three SNPs (rs4810424, <e2>rs2071197</e2>, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <e1>type 2 diabetes mellitus</e1> was dependent on the number of risk alleles in different haplotypes in women.","Positive_Correlation"
"Haplotype analysis based on three SNPs (<e2>rs4810424</e2>, rs2071197, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <e1>type 2 diabetes mellitus</e1> was dependent on the number of risk alleles in different haplotypes in women.","Positive_Correlation"
"Haplotype analysis based on three SNPs (<e2>rs4810424</e2>, rs2071197, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <e1>type 2 diabetes mellitus</e1> was dependent on the number of risk alleles in different haplotypes in women.","Positive_Correlation"
"Haplotype analysis based on three SNPs (<e2>rs4810424</e2>, rs2071197, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <e1>type 2 diabetes mellitus</e1> was dependent on the number of risk alleles in different haplotypes in women.","Positive_Correlation"
"Haplotype analysis based on three SNPs (<e2>rs4810424</e2>, rs2071197, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <e1>type 2 diabetes mellitus</e1> was dependent on the number of risk alleles in different haplotypes in women.","Positive_Correlation"
"We investigated whether single nucleotide polymorphisms (SNPs) of HNF4A, encoding <e1>HNF4alpha</e1>, influenced the conversion from impaired glucose tolerance (IGT) to <e2>type 2 diabetes mellitus</e2> in subjects of the STOP-NIDDM trial.","Association"
"We investigated whether single nucleotide polymorphisms (SNPs) of <e1>HNF4A</e1>, encoding HNF4alpha, influenced the conversion from impaired glucose tolerance (IGT) to <e2>type 2 diabetes mellitus</e2> in subjects of the STOP-NIDDM trial.","Association"
"We investigated whether single nucleotide polymorphisms (SNPs) of HNF4A, encoding <e1>HNF4alpha</e1>, influenced the conversion from impaired glucose tolerance (IGT) to <e2>type 2 diabetes mellitus</e2> in subjects of the STOP-NIDDM trial.","Association"
"We investigated whether single nucleotide polymorphisms (SNPs) of <e1>HNF4A</e1>, encoding HNF4alpha, influenced the conversion from impaired glucose tolerance (IGT) to <e2>type 2 diabetes mellitus</e2> in subjects of the STOP-NIDDM trial.","Association"
"We investigated whether single nucleotide polymorphisms (SNPs) of <e1>HNF4A</e1>, encoding HNF4alpha, influenced the conversion from impaired glucose tolerance (IGT) to <e2>type 2 diabetes mellitus</e2> in subjects of the STOP-NIDDM trial.","Association"
"Hepatic but not brain <e2>iron</e2> is rapidly chelated by deferasirox in <e1>aceruloplasminemia</e1> due to a novel gene mutation.","Positive_Correlation"
"Hepatic but not brain iron is rapidly chelated by <e1>deferasirox</e1> in <e2>aceruloplasminemia</e2> due to a novel gene mutation.","Negative_Correlation"
"Hepatic but not brain <e1>iron</e1> is rapidly chelated by <e2>deferasirox</e2> in aceruloplasminemia due to a novel gene mutation.","Bind"
"Aceruloplasminemia was associated with severe brain and liver <e2>iron overload</e2>, where hepatic mRNA expression of the iron hormone <e1>hepcidin</e1> was increased, corresponding to the degree of iron overload.","Negative_Correlation"
"Aceruloplasminemia was associated with severe brain and liver <e2>iron overload</e2>, where hepatic mRNA expression of the iron hormone <e1>hepcidin</e1> was increased, corresponding to the degree of iron overload.","Negative_Correlation"
"Aceruloplasminemia was associated with severe brain and liver <e1><e2>iron</e2> overload</e1>, where hepatic mRNA expression of the iron hormone hepcidin was increased, corresponding to the degree of iron overload.","Positive_Correlation"
"Aceruloplasminemia was associated with severe brain and liver <e1><e2>iron</e2> overload</e1>, where hepatic mRNA expression of the iron hormone hepcidin was increased, corresponding to the degree of iron overload.","Positive_Correlation"
"Aceruloplasminemia was associated with severe brain and liver <e1><e2>iron</e2> overload</e1>, where hepatic mRNA expression of the iron hormone hepcidin was increased, corresponding to the degree of iron overload.","Positive_Correlation"
"Aceruloplasminemia was associated with severe brain and liver <e1><e2>iron</e2> overload</e1>, where hepatic mRNA expression of the iron hormone hepcidin was increased, corresponding to the degree of iron overload.","Positive_Correlation"
"RESULTS: A novel homozygous ceruloplasmin gene mutation, <e1>c.2554+1G>T</e1>, was identified as the cause of <e2>aceruloplasminemia</e2> in three affected siblings.","Positive_Correlation"
"BACKGROUND _#38; AIMS: A<e1>ceruloplasmin</e1>emia is a rare autosomal recessive neurodegenerative disease associated with brain and liver iron accumulation which typically presents with movement disorders, retinal degeneration, and <e2>diabetes mellitus</e2>.","Association"
"BACKGROUND _#38; AIMS: A<e1>ceruloplasmin</e1>emia is a rare autosomal recessive neurodegenerative disease associated with brain and liver iron accumulation which typically presents with <e2>movement disorders</e2>, retinal degeneration, and diabetes mellitus.","Association"
"BACKGROUND _#38; AIMS: A<e1>ceruloplasmin</e1>emia is a rare autosomal recessive neurodegenerative disease associated with brain and liver iron accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus.","Association"
"<e1>Ceruloplasmin</e1> is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <e2>iron</e2> export and iron binding to transferrin.","Association"
"BACKGROUND _#38; AIMS: A<e1>ceruloplasmin</e1>emia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e2>iron</e2> accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus.","Association"
"<e1>Aceruloplasminemia</e1> was associated with severe brain and liver iron overload, where hepatic mRNA expression of the iron hormone <e2>hepcidin</e2> was increased, corresponding to the degree of iron overload.","Association"
"Iron accumulation in <e1>aceruloplasminemia</e1> is a result of defective cellular iron export, where <e2>hepcidin</e2> regulation is appropriate for the degree of iron overload.","Association"
"<e1>Aceruloplasminemia</e1> was associated with severe brain and liver iron overload, where hepatic mRNA expression of the iron hormone <e2>hepcidin</e2> was increased, corresponding to the degree of iron overload.","Association"
"<e1>Aceruloplasminemia</e1> was associated with severe brain and liver iron overload, where hepatic mRNA expression of the iron hormone <e2>hepcidin</e2> was increased, corresponding to the degree of iron overload.","Association"
"Iron accumulation in <e1>aceruloplasminemia</e1> is a result of defective cellular iron export, where <e2>hepcidin</e2> regulation is appropriate for the degree of iron overload.","Association"
"BACKGROUND _#38; AIMS: <e1>Aceruloplasminemia</e1> is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e2>iron</e2> accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"Iron accumulation in <e1>aceruloplasminemia</e1> is a result of defective cellular <e2>iron</e2> export, where hepcidin regulation is appropriate for the degree of iron overload.","Positive_Correlation"
"BACKGROUND _#38; AIMS: <e1>Aceruloplasminemia</e1> is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e2>iron</e2> accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: <e1>Aceruloplasminemia</e1> is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e2>iron</e2> accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"Iron accumulation in <e1>aceruloplasminemia</e1> is a result of defective cellular <e2>iron</e2> export, where hepcidin regulation is appropriate for the degree of iron overload.","Positive_Correlation"
"Hepatic iron concentration normalized after 3 and 5months of iron chelation therapy with <e1>deferasirox</e1>, which was also associated with reduced <e2>insulin</e2> demands.","Negative_Correlation"
"Hepatic iron concentration normalized after 3 and 5months of iron chelation therapy with <e1>deferasirox</e1>, which was also associated with reduced <e2>insulin</e2> demands.","Negative_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, <e2>retinal degeneration</e2>, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, <e2>retinal degeneration</e2>, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, <e2>retinal degeneration</e2>, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, <e2>retinal degeneration</e2>, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, <e2>retinal degeneration</e2>, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, <e2>retinal degeneration</e2>, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, <e2>retinal degeneration</e2>, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, <e2>retinal degeneration</e2>, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, <e2>retinal degeneration</e2>, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, <e2>retinal degeneration</e2>, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, retinal degeneration, and <e2>diabetes mellitus</e2>.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, retinal degeneration, and <e2>diabetes mellitus</e2>.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, retinal degeneration, and <e2>diabetes mellitus</e2>.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, retinal degeneration, and <e2>diabetes mellitus</e2>.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, retinal degeneration, and <e2>diabetes mellitus</e2>.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, retinal degeneration, and <e2>diabetes mellitus</e2>.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, retinal degeneration, and <e2>diabetes mellitus</e2>.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, retinal degeneration, and <e2>diabetes mellitus</e2>.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, retinal degeneration, and <e2>diabetes mellitus</e2>.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with movement disorders, retinal degeneration, and <e2>diabetes mellitus</e2>.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with <e2>movement disorders</e2>, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with <e2>movement disorders</e2>, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with <e2>movement disorders</e2>, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with <e2>movement disorders</e2>, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with <e2>movement disorders</e2>, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with <e2>movement disorders</e2>, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with <e2>movement disorders</e2>, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with <e2>movement disorders</e2>, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with <e2>movement disorders</e2>, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <e1>iron</e1> accumulation which typically presents with <e2>movement disorders</e2>, retinal degeneration, and diabetes mellitus.","Positive_Correlation"
"Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <e1>iron</e1> export and iron binding to <e2>transferrin</e2>.","Bind"
"Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <e1>iron</e1> export and iron binding to <e2>transferrin</e2>.","Bind"
"Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <e1>iron</e1> export and iron binding to <e2>transferrin</e2>.","Bind"
"Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <e1>iron</e1> export and iron binding to <e2>transferrin</e2>.","Bind"
"Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <e1>iron</e1> export and iron binding to <e2>transferrin</e2>.","Bind"
"Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <e1>iron</e1> export and iron binding to <e2>transferrin</e2>.","Bind"
"Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <e1>iron</e1> export and iron binding to <e2>transferrin</e2>.","Bind"
"Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <e1>iron</e1> export and iron binding to <e2>transferrin</e2>.","Bind"
"Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <e1>iron</e1> export and iron binding to <e2>transferrin</e2>.","Bind"
"Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <e1>iron</e1> export and iron binding to <e2>transferrin</e2>.","Bind"
"Hepatic <e1>iron</e1> concentration normalized after 3 and 5months of iron chelation therapy with <e2>deferasirox</e2>, which was also associated with reduced insulin demands.","Bind"
"Hepatic <e1>iron</e1> concentration normalized after 3 and 5months of iron chelation therapy with <e2>deferasirox</e2>, which was also associated with reduced insulin demands.","Bind"
"Hepatic <e1>iron</e1> concentration normalized after 3 and 5months of iron chelation therapy with <e2>deferasirox</e2>, which was also associated with reduced insulin demands.","Bind"
"Hepatic <e1>iron</e1> concentration normalized after 3 and 5months of iron chelation therapy with <e2>deferasirox</e2>, which was also associated with reduced insulin demands.","Bind"
"Hepatic <e1>iron</e1> concentration normalized after 3 and 5months of iron chelation therapy with <e2>deferasirox</e2>, which was also associated with reduced insulin demands.","Bind"
"Hepatic <e1>iron</e1> concentration normalized after 3 and 5months of iron chelation therapy with <e2>deferasirox</e2>, which was also associated with reduced insulin demands.","Bind"
"Hepatic <e1>iron</e1> concentration normalized after 3 and 5months of iron chelation therapy with <e2>deferasirox</e2>, which was also associated with reduced insulin demands.","Bind"
"<e1>Iron</e1> chelation with <e2>deferasirox</e2> was effective in mobilizing hepatic iron but has no effect on brain iron.","Bind"
"Hepatic <e1>iron</e1> concentration normalized after 3 and 5months of iron chelation therapy with <e2>deferasirox</e2>, which was also associated with reduced insulin demands.","Bind"
"<e1>Iron</e1> chelation with <e2>deferasirox</e2> was effective in mobilizing hepatic iron but has no effect on brain iron.","Bind"
"Hepatic <e1>iron</e1> concentration normalized after 3 and 5months of iron chelation therapy with <e2>deferasirox</e2>, which was also associated with reduced insulin demands.","Bind"
"Hepatic <e1>iron</e1> concentration normalized after 3 and 5months of iron chelation therapy with <e2>deferasirox</e2>, which was also associated with reduced insulin demands.","Bind"
"The <e2>androgen receptor</e2> confers protection against diet-induced atherosclerosis, obesity, and <e1>dyslipidemia</e1> in female mice.","Negative_Correlation"
"The <e1>androgen receptor</e1> confers protection against diet-induced <e2>atherosclerosis</e2>, obesity, and dyslipidemia in female mice.","Negative_Correlation"
"The <e1>androgen receptor</e1> confers protection against diet-induced atherosclerosis, <e2>obesity</e2>, and dyslipidemia in female mice.","Negative_Correlation"
"Furthermore, the AR agonist <e1>dihydrotestosterone</e1> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte <e2>lipid</e2> accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Negative_Correlation"
"Furthermore, the AR agonist <e1>dihydrotestosterone</e1> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and <e2>cholesterol</e2> levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Negative_Correlation"
"Furthermore, the AR agonist <e1>dihydrotestosterone</e1> reduced <e2>atherosclerosis</e2> (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Negative_Correlation"
"Differences in <e1>atherosclerosis</e1>, body weight, and <e2>lipid</e2> levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.","Association"
"Differences in <e1>atherosclerosis</e1>, body weight, and <e2>lipid</e2> levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.","Association"
"They also displayed increased body weight (+18%), body fat percentage (+62%), and hepatic triglyceride levels, reduced insulin sensitivity, and a marked <e1>atherogenic</e1> dys<e2>lipid</e2>emia (serum cholesterol, +52%).","Association"
"Differences in <e1>atherosclerosis</e1>, body weight, and <e2>lipid</e2> levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.","Association"
"Differences in <e1>atherosclerosis</e1>, body weight, and <e2>lipid</e2> levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.","Association"
"Differences in <e1>atherosclerosis</e1>, body weight, and <e2>lipid</e2> levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.","Association"
"Furthermore, the AR agonist dihydrotestosterone reduced <e1>atherosclerosis</e1> (-41%; thoracic aorta), subcutaneous fat mass (-44%), and <e2>cholesterol</e2> levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"Furthermore, the AR agonist dihydrotestosterone reduced <e1>atherosclerosis</e1> (-41%; thoracic aorta), subcutaneous fat mass (-44%), and <e2>cholesterol</e2> levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"They also displayed increased body weight (+18%), body fat percentage (+62%), and hepatic triglyceride levels, reduced insulin sensitivity, and a marked <e1>atherogenic</e1> dyslipidemia (serum <e2>cholesterol</e2>, +52%).","Positive_Correlation"
"Furthermore, the AR agonist dihydrotestosterone reduced <e1>atherosclerosis</e1> (-41%; thoracic aorta), subcutaneous fat mass (-44%), and <e2>cholesterol</e2> levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"Furthermore, the AR agonist dihydrotestosterone reduced <e1>atherosclerosis</e1> (-41%; thoracic aorta), subcutaneous fat mass (-44%), and <e2>cholesterol</e2> levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"Furthermore, the AR agonist dihydrotestosterone reduced <e1>atherosclerosis</e1> (-41%; thoracic aorta), subcutaneous fat mass (-44%), and <e2>cholesterol</e2> levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"They also displayed increased body weight (+18%), body fat percentage (+62%), and hepatic triglyceride levels, reduced insulin sensitivity, and a marked atherogenic <e1>dyslipidemia</e1> (serum <e2>cholesterol</e2>, +52%).","Positive_Correlation"
"Furthermore, the <e1>AR</e1> agonist <e2>dihydrotestosterone</e2> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"Furthermore, the <e1>AR</e1> agonist <e2>dihydrotestosterone</e2> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"Furthermore, the <e1>AR</e1> agonist <e2>dihydrotestosterone</e2> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"Furthermore, the <e1>AR</e1> agonist <e2>dihydrotestosterone</e2> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"Furthermore, the <e1>AR</e1> agonist <e2>dihydrotestosterone</e2> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"Furthermore, the <e1>AR</e1> agonist <e2>dihydrotestosterone</e2> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"Furthermore, the <e1>AR</e1> agonist <e2>dihydrotestosterone</e2> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"Furthermore, the <e1>AR</e1> agonist <e2>dihydrotestosterone</e2> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"Furthermore, the <e1>AR</e1> agonist <e2>dihydrotestosterone</e2> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.","Positive_Correlation"
"To determine the physiologic <e1>androgen receptor</e1> (AR)-dependent actions of <e2>androgens</e2> on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Bind"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of <e2>androgens</e2> on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Bind"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of <e2>androgens</e2> on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Bind"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of <e2>androgens</e2> on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Bind"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of <e2>androgens</e2> on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Bind"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of <e2>androgens</e2> on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Bind"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of <e2>androgens</e2> on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Bind"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of <e2>androgens</e2> on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Bind"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of <e2>androgens</e2> on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Bind"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of <e2>androgens</e2> on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Bind"
"To determine the physiologic <e1>androgen receptor</e1> (AR)-dependent actions of androgens on <e2>atherogenesis</e2> in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Negative_Correlation"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of androgens on <e2>atherogenesis</e2> in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Negative_Correlation"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of androgens on <e2>atherogenesis</e2> in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Negative_Correlation"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of androgens on <e2>atherogenesis</e2> in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Negative_Correlation"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of androgens on <e2>atherogenesis</e2> in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Negative_Correlation"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of androgens on <e2>atherogenesis</e2> in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Negative_Correlation"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of androgens on <e2>atherogenesis</e2> in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Negative_Correlation"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of androgens on <e2>atherogenesis</e2> in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Negative_Correlation"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of androgens on <e2>atherogenesis</e2> in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Negative_Correlation"
"To determine the physiologic androgen receptor (<e1>AR</e1>)-dependent actions of androgens on <e2>atherogenesis</e2> in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.","Negative_Correlation"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with hypertension and <e2>metabolic dysfunction</e2>.","Association"
"The enzyme FASN (<e1>fatty acid synthase</e1>) is potentially related with hypertension and <e2>metabolic dysfunction</e2>.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with hypertension and <e2>metabolic dysfunction</e2>.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with hypertension and <e2>metabolic dysfunction</e2>.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with hypertension and <e2>metabolic dysfunction</e2>.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with hypertension and <e2>metabolic dysfunction</e2>.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with hypertension and <e2>metabolic dysfunction</e2>.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with hypertension and <e2>metabolic dysfunction</e2>.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with hypertension and <e2>metabolic dysfunction</e2>.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with hypertension and <e2>metabolic dysfunction</e2>.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with hypertension and <e2>metabolic dysfunction</e2>.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with <e2>hypertension</e2> and metabolic dysfunction.","Association"
"The enzyme FASN (<e1>fatty acid synthase</e1>) is potentially related with <e2>hypertension</e2> and metabolic dysfunction.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with <e2>hypertension</e2> and metabolic dysfunction.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with <e2>hypertension</e2> and metabolic dysfunction.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with <e2>hypertension</e2> and metabolic dysfunction.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with <e2>hypertension</e2> and metabolic dysfunction.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with <e2>hypertension</e2> and metabolic dysfunction.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with <e2>hypertension</e2> and metabolic dysfunction.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with <e2>hypertension</e2> and metabolic dysfunction.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with <e2>hypertension</e2> and metabolic dysfunction.","Association"
"The enzyme <e1>FASN</e1> (fatty acid synthase) is potentially related with <e2>hypertension</e2> and metabolic dysfunction.","Association"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with <e2>C-peptide</e2>, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with <e2>C-peptide</e2>, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with <e2>C-peptide</e2>, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with <e2>C-peptide</e2>, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with <e2>C-peptide</e2>, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with <e2>C-peptide</e2>, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with <e2>C-peptide</e2>, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with <e2>C-peptide</e2>, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with <e2>C-peptide</e2>, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with <e2>C-peptide</e2>, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Higher circulating <e1>FASN</e1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, <e2>HbAc1</e2>, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).","Negative_Correlation"
"Higher circulating <e1>FASN</e1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, <e2>HbAc1</e2>, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).","Negative_Correlation"
"Higher circulating <e1>FASN</e1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, <e2>HbAc1</e2>, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).","Negative_Correlation"
"Higher circulating <e1>FASN</e1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, <e2>HbAc1</e2>, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).","Negative_Correlation"
"Higher circulating <e1>FASN</e1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, <e2>HbAc1</e2>, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).","Negative_Correlation"
"Higher circulating <e1>FASN</e1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, <e2>HbAc1</e2>, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).","Negative_Correlation"
"Higher circulating <e1>FASN</e1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, <e2>HbAc1</e2>, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).","Negative_Correlation"
"Higher circulating <e1>FASN</e1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, <e2>HbAc1</e2>, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).","Negative_Correlation"
"Higher circulating <e1>FASN</e1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, <e2>HbAc1</e2>, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).","Negative_Correlation"
"Higher circulating <e1>FASN</e1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, <e2>HbAc1</e2>, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and <e2>insulin</e2>, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and <e2>insulin</e2>, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and <e2>insulin</e2>, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and <e2>insulin</e2>, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and <e2>insulin</e2>, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and <e2>insulin</e2>, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and <e2>insulin</e2>, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and <e2>insulin</e2>, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and <e2>insulin</e2>, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and <e2>insulin</e2>, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting <e2>glucose</e2> and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting <e2>glucose</e2> and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting <e2>glucose</e2> and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting <e2>glucose</e2> and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting <e2>glucose</e2> and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting <e2>glucose</e2> and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting <e2>glucose</e2> and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting <e2>glucose</e2> and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting <e2>glucose</e2> and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating <e1>FASN</e1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting <e2>glucose</e2> and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).","Negative_Correlation"
"Circulating FASN was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and insulin, post-load glucose lipids, <e1>HMW</e1>-<e2>adiponectin</e2> and blood pressure (the latter was assessed in each trimester of gestation).","Association"
"<e1>Sildenafil</e1> attenuates <e2>hypoxic pulmonary remodelling</e2> by inhibiting bone marrow progenitor cells.","Negative_Correlation"
"Although <e1>sildenafil</e1> is a known target in <e2>PH</e2> treatment, the underlying molecular mechanism is still elusive.","Negative_Correlation"
"Although <e1>sildenafil</e1> is a known target in <e2>PH</e2> treatment, the underlying molecular mechanism is still elusive.","Negative_Correlation"
"Although <e1>sildenafil</e1> is a known target in <e2>PH</e2> treatment, the underlying molecular mechanism is still elusive.","Negative_Correlation"
"Although <e1>sildenafil</e1> is a known target in <e2>PH</e2> treatment, the underlying molecular mechanism is still elusive.","Negative_Correlation"
"Although <e1>sildenafil</e1> is a known target in <e2>PH</e2> treatment, the underlying molecular mechanism is still elusive.","Negative_Correlation"
"Although <e1>sildenafil</e1> is a known target in <e2>PH</e2> treatment, the underlying molecular mechanism is still elusive.","Negative_Correlation"
"Although <e1>sildenafil</e1> is a known target in <e2>PH</e2> treatment, the underlying molecular mechanism is still elusive.","Negative_Correlation"
"Although <e1>sildenafil</e1> is a known target in <e2>PH</e2> treatment, the underlying molecular mechanism is still elusive.","Negative_Correlation"
"Although <e1>sildenafil</e1> is a known target in <e2>PH</e2> treatment, the underlying molecular mechanism is still elusive.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced <e2>pulmonary remodelling</e2> in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced <e2>pulmonary remodelling</e2> in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced <e2>pulmonary remodelling</e2> in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced <e2>pulmonary remodelling</e2> in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced <e2>pulmonary remodelling</e2> in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced <e2>pulmonary remodelling</e2> in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced <e2>pulmonary remodelling</e2> in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced <e2>pulmonary remodelling</e2> in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced <e2>pulmonary remodelling</e2> in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"Furthermore, <e1>sildenafil</e1> depressed the number of <e2>CXCR4</e2>(+) cells.","Negative_Correlation"
"Furthermore, <e1>sildenafil</e1> depressed the number of <e2>CXCR4</e2>(+) cells.","Negative_Correlation"
"Furthermore, <e1>sildenafil</e1> depressed the number of <e2>CXCR4</e2>(+) cells.","Negative_Correlation"
"Furthermore, <e1>sildenafil</e1> depressed the number of <e2>CXCR4</e2>(+) cells.","Negative_Correlation"
"Furthermore, <e1>sildenafil</e1> depressed the number of <e2>CXCR4</e2>(+) cells.","Negative_Correlation"
"Furthermore, <e1>sildenafil</e1> depressed the number of <e2>CXCR4</e2>(+) cells.","Negative_Correlation"
"Furthermore, <e1>sildenafil</e1> depressed the number of <e2>CXCR4</e2>(+) cells.","Negative_Correlation"
"Furthermore, <e1>sildenafil</e1> depressed the number of <e2>CXCR4</e2>(+) cells.","Negative_Correlation"
"Furthermore, <e1>sildenafil</e1> depressed the number of <e2>CXCR4</e2>(+) cells.","Negative_Correlation"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and <e2>inflammation</e2> without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Negative_Correlation"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and <e2>inflammation</e2> without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Negative_Correlation"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and <e2>inflammation</e2> without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Negative_Correlation"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and <e2>inflammation</e2> without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Negative_Correlation"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and <e2>inflammation</e2> without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Negative_Correlation"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and <e2>inflammation</e2> without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Negative_Correlation"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and <e2>inflammation</e2> without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Negative_Correlation"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and <e2>inflammation</e2> without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Negative_Correlation"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and <e2>inflammation</e2> without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Negative_Correlation"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and <e2>CD68</e2> (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and <e2>CD68</e2> (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and <e2>CD68</e2> (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and <e2>CD68</e2> (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and <e2>CD68</e2> (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and <e2>CD68</e2> (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and <e2>CD68</e2> (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and <e2>CD68</e2> (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and <e2>CD68</e2> (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with <e2>tyrosine kinase receptor 2</e2> (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with <e2>tyrosine kinase receptor 2</e2> (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with <e2>tyrosine kinase receptor 2</e2> (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with <e2>tyrosine kinase receptor 2</e2> (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with <e2>tyrosine kinase receptor 2</e2> (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with <e2>tyrosine kinase receptor 2</e2> (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with <e2>tyrosine kinase receptor 2</e2> (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with <e2>tyrosine kinase receptor 2</e2> (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"Moreover, <e1>sildenafil</e1> reduced the number of c-kit(+) cells that colocalize with <e2>tyrosine kinase receptor 2</e2> (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.","Association"
"As expected, <e1>sildenafil</e1> attenuated the CH-induced increase in right ventricular systolic pressure and <e2>right ventricular hypertrophy</e2>.","Negative_Correlation"
"As expected, <e1>sildenafil</e1> attenuated the CH-induced increase in right ventricular systolic pressure and <e2>right ventricular hypertrophy</e2>.","Negative_Correlation"
"As expected, <e1>sildenafil</e1> attenuated the CH-induced increase in right ventricular systolic pressure and <e2>right ventricular hypertrophy</e2>.","Negative_Correlation"
"As expected, <e1>sildenafil</e1> attenuated the CH-induced increase in right ventricular systolic pressure and <e2>right ventricular hypertrophy</e2>.","Negative_Correlation"
"As expected, <e1>sildenafil</e1> attenuated the CH-induced increase in right ventricular systolic pressure and <e2>right ventricular hypertrophy</e2>.","Negative_Correlation"
"As expected, <e1>sildenafil</e1> attenuated the CH-induced increase in right ventricular systolic pressure and <e2>right ventricular hypertrophy</e2>.","Negative_Correlation"
"As expected, <e1>sildenafil</e1> attenuated the CH-induced increase in right ventricular systolic pressure and <e2>right ventricular hypertrophy</e2>.","Negative_Correlation"
"As expected, <e1>sildenafil</e1> attenuated the CH-induced increase in right ventricular systolic pressure and <e2>right ventricular hypertrophy</e2>.","Negative_Correlation"
"As expected, <e1>sildenafil</e1> attenuated the CH-induced increase in right ventricular systolic pressure and <e2>right ventricular hypertrophy</e2>.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic <e2>hypoxia</e2> (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic <e2>hypoxia</e2> (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic <e2>hypoxia</e2> (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic <e2>hypoxia</e2> (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic <e2>hypoxia</e2> (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic <e2>hypoxia</e2> (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic <e2>hypoxia</e2> (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic <e2>hypoxia</e2> (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"To test the hypothesis that the therapeutic effect of <e1>sildenafil</e1> is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic <e2>hypoxia</e2> (CH, 10% oxygen), a trigger of BM-derived progenitor cells.","Negative_Correlation"
"Genetic variants of the <e1>T-cell immunoglobulin mucin 1</e1> but not the T-cell immunoglobulin mucin 3 gene are associated with <e2>asthma</e2> in an African American population.","Association"
"RESULTS: In the case-control design, the frequencies of the TT genotype for SNP rs2277025 and the homozygous deletion variant (<e1>157delMTTTVP</e1>) in the fourth exon of the TIM-1 gene were higher among patients with patients with <e2>asthma</e2> compared with the controls (odds ratio [OR], 2.779, P = .016; and OR, 3.09, P = .022, respectively).","Positive_Correlation"
"RESULTS: In the case-control design, the frequencies of the TT genotype for SNP rs2277025 and the homozygous deletion variant (<e1>157delMTTTVP</e1>) in the fourth exon of the TIM-1 gene were higher among patients with patients with <e2>asthma</e2> compared with the controls (odds ratio [OR], 2.779, P = .016; and OR, 3.09, P = .022, respectively).","Positive_Correlation"
"RESULTS: In the case-control design, the frequencies of the TT genotype for SNP <e1>rs2277025</e1> and the homozygous deletion variant (157delMTTTVP) in the fourth exon of the TIM-1 gene were higher among patients with patients with <e2>asthma</e2> compared with the controls (odds ratio [OR], 2.779, P = .016; and OR, 3.09, P = .022, respectively).","Positive_Correlation"
"OBJECTIVE: Genetic association of the sequence variants for <e1>TIM-1</e1> and TIM-3 genes with <e2>asthma</e2> in an African American population was investigated.","Association"
"OBJECTIVE: Genetic association of the sequence variants for <e1>TIM-1</e1> and TIM-3 genes with <e2>asthma</e2> in an African American population was investigated.","Association"
"OBJECTIVE: Genetic association of the sequence variants for <e1>TIM-1</e1> and TIM-3 genes with <e2>asthma</e2> in an African American population was investigated.","Association"
"Identification of the BRAF <e1>V600E</e1> mutation in <e2>gastroenteropancreatic neuroendocrine tumors</e2>.","Association"
"Identification of the <e1>BRAF</e1> V600E mutation in <e2>gastroenteropancreatic neuroendocrine tumors</e2>.","Association"
"We found BRAF V600E (G1 <e2>NET</e2> from rectum and two G3 NETs from colon) and BRAF <e1>G593S</e1> (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.","Association"
"Here, we performed whole exome sequencing of 12 GEP-NETs from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for <e2>pazopanib</e2>, and integrated our results with previously published results on pancreas (n = 12) and small <e1>intestine NETs</e1> (n = 50).","Negative_Correlation"
"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small <e1>intestinal grade (G) 1 NET</e1> patient with BRAF V600E mutation showed progression after <e2>pazopanib</e2> treatment.","Negative_Correlation"
"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small <e1>intestinal grade (G) 1 NET</e1> patient with BRAF <e2>V600E</e2> mutation showed progression after pazopanib treatment.","Association"
"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small <e1>intestinal grade (G) 1 NET</e1> patient with <e2>BRAF</e2> V600E mutation showed progression after pazopanib treatment.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and <e1>VHL</e1>.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, <e1>TBC1D12</e1>, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, <e1>SPEN</e1>, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, <e1>SMARCB1</e1>, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, <e1>RASA1</e1>, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, <e1>PTEN</e1>, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, <e1>MLL3</e1>, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, <e1>MGA</e1>, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, <e1>KRAS</e1>, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, <e1>KDM6A</e1>, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, <e1>EP300</e1>, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, <e1>EGFR</e1>, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, <e1>CTNNB1</e1>, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, <e1>BCOR</e1>, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, <e1>APC</e1>, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, <e1>RB1</e1>, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, <e1>RB1</e1>, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, <e1>CNBD1</e1>, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, <e1>CNBD1</e1>, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e1>cancer</e1>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, <e2>ERBB3</e2>, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including <e1>TP53</e1>, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including <e1>TP53</e1>, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including <e1>TP53</e1>, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Three GEP-<e2>NET</e2> patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF <e1>V600E</e1> mutation showed progression after pazopanib treatment.","Association"
"Three GEP-<e2>NET</e2> patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF <e1>V600E</e1> mutation showed progression after pazopanib treatment.","Association"
"Three GEP-<e2>NET</e2> patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF <e1>V600E</e1> mutation showed progression after pazopanib treatment.","Association"
"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF <e1>V600E</e1> mutation showed progression after <e2>pazopanib</e2> treatment.","Negative_Correlation"
"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF <e1>V600E</e1> mutation showed progression after <e2>pazopanib</e2> treatment.","Negative_Correlation"
"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF <e1>V600E</e1> mutation showed progression after <e2>pazopanib</e2> treatment.","Negative_Correlation"
"We found BRAF <e1>V600E</e1> (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 <e2>GEP-NETs</e2> from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.","Association"
"We found BRAF <e1>V600E</e1> (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 <e2>GEP-NETs</e2> from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.","Association"
"We found BRAF <e1>V600E</e1> (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 <e2>GEP-NETs</e2> from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.","Association"
"We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF <e2>G593S</e2> (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 <e1>GEP-NETs</e1> from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.","Association"
"We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF <e2>G593S</e2> (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 <e1>GEP-NETs</e1> from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.","Association"
"We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF <e2>G593S</e2> (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 <e1>GEP-NETs</e1> from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.","Association"
"We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF <e2>G593S</e2> (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 <e1>GEP-NET</e1>s from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.","Association"
"We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF <e2>G593S</e2> (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 <e1>GEP-NETs</e1> from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.","Association"
"We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF <e2>G593S</e2> (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 <e1>GEP-NETs</e1> from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.","Association"
"Here, we performed whole exome sequencing of 12 <e1>GEP-NETs</e1> from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for <e2>pazopanib</e2>, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50).","Negative_Correlation"
"Here, we performed whole exome sequencing of 12 <e1>GEP-NETs</e1> from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for <e2>pazopanib</e2>, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50).","Negative_Correlation"
"Here, we performed whole exome sequencing of 12 <e1>GEP-NETs</e1> from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for <e2>pazopanib</e2>, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50).","Negative_Correlation"
"Here, we performed whole exome sequencing of 12 <e1>GEP-NET</e1>s from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for <e2>pazopanib</e2>, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50).","Negative_Correlation"
"Here, we performed whole exome sequencing of 12 <e1>GEP-NETs</e1> from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for <e2>pazopanib</e2>, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50).","Negative_Correlation"
"Here, we performed whole exome sequencing of 12 <e1>GEP-NETs</e1> from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for <e2>pazopanib</e2>, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50).","Negative_Correlation"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and <e2>VHL</e2>.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and <e2>VHL</e2>.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and <e2>VHL</e2>.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and <e2>VHL</e2>.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and <e2>VHL</e2>.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and <e2>VHL</e2>.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, <e2>TBC1D12</e2>, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, <e2>TBC1D12</e2>, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, <e2>TBC1D12</e2>, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, <e2>TBC1D12</e2>, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, <e2>TBC1D12</e2>, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, <e2>TBC1D12</e2>, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, <e2>SPEN</e2>, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, <e2>SPEN</e2>, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, <e2>SPEN</e2>, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, <e2>SPEN</e2>, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, <e2>SPEN</e2>, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, <e2>SPEN</e2>, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, <e2>SMARCB1</e2>, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, <e2>SMARCB1</e2>, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, <e2>SMARCB1</e2>, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, <e2>SMARCB1</e2>, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, <e2>SMARCB1</e2>, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, <e2>SMARCB1</e2>, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, <e2>RASA1</e2>, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, <e2>RASA1</e2>, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, <e2>RASA1</e2>, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, <e2>RASA1</e2>, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, <e2>RASA1</e2>, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, <e2>RASA1</e2>, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, <e2>PTEN</e2>, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, <e2>PTEN</e2>, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, <e2>PTEN</e2>, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, <e2>PTEN</e2>, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, <e2>PTEN</e2>, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, <e2>PTEN</e2>, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, <e2>MLL3</e2>, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, <e2>MLL3</e2>, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, <e2>MLL3</e2>, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, <e2>MLL3</e2>, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, <e2>MLL3</e2>, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, <e2>MLL3</e2>, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, <e2>MGA</e2>, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, <e2>MGA</e2>, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, <e2>MGA</e2>, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, <e2>MGA</e2>, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, <e2>MGA</e2>, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, <e2>MGA</e2>, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, <e2>KRAS</e2>, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, <e2>KRAS</e2>, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, <e2>KRAS</e2>, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, <e2>KRAS</e2>, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, <e2>KRAS</e2>, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, <e2>KRAS</e2>, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, <e2>KDM6A</e2>, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, <e2>KDM6A</e2>, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, <e2>KDM6A</e2>, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, <e2>KDM6A</e2>, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, <e2>KDM6A</e2>, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, <e2>KDM6A</e2>, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, <e2>ERBB3</e2>, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, <e2>ERBB3</e2>, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, <e2>ERBB3</e2>, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, <e2>ERBB3</e2>, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, <e2>ERBB3</e2>, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, <e2>ERBB3</e2>, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, <e2>EP300</e2>, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, <e2>EP300</e2>, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, <e2>EP300</e2>, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, <e2>EP300</e2>, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, <e2>EP300</e2>, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, <e2>EP300</e2>, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, <e2>EGFR</e2>, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, <e2>EGFR</e2>, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, <e2>EGFR</e2>, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, <e2>EGFR</e2>, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, <e2>EGFR</e2>, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, <e2>EGFR</e2>, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, <e2>CTNNB1</e2>, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, <e2>CTNNB1</e2>, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, <e2>CTNNB1</e2>, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, <e2>CTNNB1</e2>, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, <e2>CTNNB1</e2>, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, <e2>CTNNB1</e2>, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, <e2>BCOR</e2>, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, <e2>BCOR</e2>, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, <e2>BCOR</e2>, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, <e2>BCOR</e2>, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, <e2>BCOR</e2>, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, <e2>BCOR</e2>, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, <e2>APC</e2>, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, <e2>APC</e2>, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, <e2>APC</e2>, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, <e2>APC</e2>, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, <e2>APC</e2>, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, <e2>APC</e2>, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, <e2>RB1</e2>, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, <e2>RB1</e2>, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, <e2>RB1</e2>, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, <e2>RB1</e2>, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, <e2>RB1</e2>, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, <e2>RB1</e2>, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, <e2>CNBD1</e2>, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, <e2>CNBD1</e2>, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, <e2>CNBD1</e2>, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including TP53, <e2>CNBD1</e2>, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, <e2>CNBD1</e2>, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including TP53, <e2>CNBD1</e2>, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including <e2>TP53</e2>, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including <e2>TP53</e2>, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including <e2>TP53</e2>, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NET</e1>s, eight showed mutations of more than one cancer-related gene, including <e2>TP53</e2>, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including <e2>TP53</e2>, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e1>GEP-NETs</e1>, eight showed mutations of more than one cancer-related gene, including <e2>TP53</e2>, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-<e2>NET</e2>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-<e2>NET</e2>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-<e2>NET</e2>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-<e2>NET</e2>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-<e2>NET</e2>s, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with <e1>BRAF</e1> V600E mutation showed progression after <e2>pazopanib</e2> treatment.","Negative_Correlation"
"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with <e1>BRAF</e1> V600E mutation showed progression after <e2>pazopanib</e2> treatment.","Negative_Correlation"
"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with <e1>BRAF</e1> V600E mutation showed progression after <e2>pazopanib</e2> treatment.","Negative_Correlation"
"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with <e1>BRAF</e1> V600E mutation showed progression after <e2>pazopanib</e2> treatment.","Negative_Correlation"
"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with <e1>BRAF</e1> V600E mutation showed progression after <e2>pazopanib</e2> treatment.","Negative_Correlation"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 GEP-NETs, eight showed mutations of more than one <e2>cancer</e2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e2>GEP-NETs</e2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e2>GEP-NETs</e2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e2>GEP-NETs</e2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e2>GEP-NETs</e2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"Among 12 <e2>GEP-NETs</e2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, <e1>BRAF</e1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.","Association"
"MicroRNA deep sequencing in two adult stem cell populations identifies <e1>miR-501</e1> as a novel regulator of <e2>myosin heavy chain</e2> during muscle regeneration.","Negative_Correlation"
"Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during <e1>cardiotoxin</e1> (CTX)-induced <e2>muscle injury</e2> uncovered miR-501 as a novel muscle-specific miRNA.","Positive_Correlation"
"Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during cardiotoxin (<e1>CTX</e1>)-induced <e2>muscle injury</e2> uncovered miR-501 as a novel muscle-specific miRNA.","Positive_Correlation"
"<e1>miR-501</e1> is an intronic miRNA and its expression levels in MPs correlated with its host gene, <e2>chloride channel, voltage-sensitive 5</e2> (Clcn5).","Association"
"<e1>miR-501</e1> is an intronic miRNA and its expression levels in MPs correlated with its host gene, <e2>chloride channel, voltage-sensitive 5</e2> (Clcn5).","Association"
"<e1>miR-501</e1> is an intronic miRNA and its expression levels in MPs correlated with its host gene, <e2>chloride channel, voltage-sensitive 5</e2> (Clcn5).","Association"
"<e1>miR-501</e1> is an intronic miRNA and its expression levels in MPs correlated with its host gene, <e2>chloride channel, voltage-sensitive 5</e2> (Clcn5).","Association"
"<e1>miR-501</e1> is an intronic miRNA and its expression levels in MPs correlated with its host gene, <e2>chloride channel, voltage-sensitive 5</e2> (Clcn5).","Association"
"<e1>miR-501</e1> is an intronic miRNA and its expression levels in MPs correlated with its host gene, <e2>chloride channel, voltage-sensitive 5</e2> (Clcn5).","Association"
"<e1>miR-501</e1> is an intronic miRNA and its expression levels in MPs correlated with its host gene, <e2>chloride channel, voltage-sensitive 5</e2> (Clcn5).","Association"
"Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during cardiotoxin (CTX)-induced <e2>muscle injury</e2> uncovered <e1>miR-501</e1> as a novel muscle-specific miRNA.","Association"
"Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during cardiotoxin (CTX)-induced <e2>muscle injury</e2> uncovered <e1>miR-501</e1> as a novel muscle-specific miRNA.","Association"
"Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during cardiotoxin (CTX)-induced <e2>muscle injury</e2> uncovered <e1>miR-501</e1> as a novel muscle-specific miRNA.","Association"
"Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during cardiotoxin (CTX)-induced <e2>muscle injury</e2> uncovered <e1>miR-501</e1> as a novel muscle-specific miRNA.","Association"
"Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during cardiotoxin (CTX)-induced <e2>muscle injury</e2> uncovered <e1>miR-501</e1> as a novel muscle-specific miRNA.","Association"
"Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during cardiotoxin (CTX)-induced <e2>muscle injury</e2> uncovered <e1>miR-501</e1> as a novel muscle-specific miRNA.","Association"
"Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during cardiotoxin (CTX)-induced <e2>muscle injury</e2> uncovered <e1>miR-501</e1> as a novel muscle-specific miRNA.","Association"
"Pharmacological inhibition of <e1>miR-501</e1> dramatically blunted the induction of embryonic <e2>myosin heavy chain</e2> (MYH3) and, to a lesser extent, adult myosin isoforms during muscle regeneration, and promoted small-diameter neofibers.","Negative_Correlation"
"Pharmacological inhibition of <e1>miR-501</e1> dramatically blunted the induction of embryonic <e2>myosin heavy chain</e2> (MYH3) and, to a lesser extent, adult myosin isoforms during muscle regeneration, and promoted small-diameter neofibers.","Negative_Correlation"
"Pharmacological inhibition of <e1>miR-501</e1> dramatically blunted the induction of embryonic <e2>myosin heavy chain</e2> (MYH3) and, to a lesser extent, adult myosin isoforms during muscle regeneration, and promoted small-diameter neofibers.","Negative_Correlation"
"Pharmacological inhibition of <e1>miR-501</e1> dramatically blunted the induction of embryonic <e2>myosin heavy chain</e2> (MYH3) and, to a lesser extent, adult myosin isoforms during muscle regeneration, and promoted small-diameter neofibers.","Negative_Correlation"
"Pharmacological inhibition of <e1>miR-501</e1> dramatically blunted the induction of embryonic <e2>myosin heavy chain</e2> (MYH3) and, to a lesser extent, adult myosin isoforms during muscle regeneration, and promoted small-diameter neofibers.","Negative_Correlation"
"Pharmacological inhibition of <e1>miR-501</e1> dramatically blunted the induction of embryonic <e2>myosin heavy chain</e2> (MYH3) and, to a lesser extent, adult myosin isoforms during muscle regeneration, and promoted small-diameter neofibers.","Negative_Correlation"
"Pharmacological inhibition of <e1>miR-501</e1> dramatically blunted the induction of embryonic <e2>myosin heavy chain</e2> (MYH3) and, to a lesser extent, adult myosin isoforms during muscle regeneration, and promoted small-diameter neofibers.","Negative_Correlation"
"An unbiased target identification approach in primary myoblasts validated <e1>gigaxonin</e1> as a target of <e2>miR-501</e2> that mimicked the effect of miR-501 inhibition on MYH3 expression.","Negative_Correlation"
"Strong association of <e1>677 C>T</e1> substitution in the MTHFR gene with <e2>male infertility</e2>--a study on an indian population and a meta-analysis.","Positive_Correlation"
"Strong association of 677 C>T substitution in the <e1>MTHFR</e1> gene with <e2>male infertility</e2>--a study on an indian population and a meta-analysis.","Association"
"Those studies analyzing <e1>677C>T</e1> polymorphism in <e2>male infertility</e2> and presenting all relevant data were included in meta-analysis.","Positive_Correlation"
"Those studies analyzing <e1>677C>T</e1> polymorphism in <e2>male infertility</e2> and presenting all relevant data were included in meta-analysis.","Positive_Correlation"
"Those studies analyzing <e1>677C>T</e1> polymorphism in <e2>male infertility</e2> and presenting all relevant data were included in meta-analysis.","Positive_Correlation"
"Those studies analyzing <e1>677C>T</e1> polymorphism in <e2>male infertility</e2> and presenting all relevant data were included in meta-analysis.","Positive_Correlation"
"BACKGROUND: <e1>Methylenetetrahydrofolate reductase</e1> (MTHFR) is an important enzyme of folate and <e2>methionine</e2> metabolism, making it crucial for DNA synthesis and methylation.","Association"
"BACKGROUND: Methylenetetrahydrofolate reductase (<e1>MTHFR</e1>) is an important enzyme of folate and <e2>methionine</e2> metabolism, making it crucial for DNA synthesis and methylation.","Association"
"BACKGROUND: Methylenetetrahydrofolate reductase (<e1>MTHFR</e1>) is an important enzyme of folate and <e2>methionine</e2> metabolism, making it crucial for DNA synthesis and methylation.","Association"
"BACKGROUND: <e1>Methylenetetrahydro<e2>folate</e2> reductase</e1> (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation.","Association"
"BACKGROUND: Methylenetetrahydro<e2>folate</e2> reductase (<e1>MTHFR</e1>) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation.","Association"
"BACKGROUND: Methylenetetrahydro<e2>folate</e2> reductase (<e1>MTHFR</e1>) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation.","Association"
"BACKGROUND: Exonic deletions in MSH2 and <e1>MLH1</e1> are significant contributors to the mutation spectrum in <e2>HNPCC</e2>, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.","Association"
"BACKGROUND: Exonic deletions in MSH2 and <e1>MLH1</e1> are significant contributors to the mutation spectrum in <e2>HNPCC</e2>, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.","Association"
"BACKGROUND: Exonic deletions in MSH2 and <e1>MLH1</e1> are significant contributors to the mutation spectrum in <e2>HNPCC</e2>, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.","Association"
"BACKGROUND: Exonic deletions in MSH2 and <e1>MLH1</e1> are significant contributors to the mutation spectrum in <e2>HNPCC</e2>, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.","Association"
"BACKGROUND: Exonic deletions in <e1>MSH2</e1> and MLH1 are significant contributors to the mutation spectrum in <e2>HNPCC</e2>, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.","Association"
"BACKGROUND: Exonic deletions in <e1>MSH2</e1> and MLH1 are significant contributors to the mutation spectrum in <e2>HNPCC</e2>, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.","Association"
"BACKGROUND: Exonic deletions in <e1>MSH2</e1> and MLH1 are significant contributors to the mutation spectrum in <e2>HNPCC</e2>, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.","Association"
"BACKGROUND: Exonic deletions in <e1>MSH2</e1> and MLH1 are significant contributors to the mutation spectrum in <e2>HNPCC</e2>, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.","Association"
"BACKGROUND: Exonic deletions in <e1>MSH2</e1> and MLH1 are significant contributors to the mutation spectrum in <e2>HNPCC</e2>, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.","Association"
"<e1>IL-10</e1> is a multi-functional cytokine thought to play a role in the pathogenesis of <e2>periodontitis</e2>.","Association"
"<e1>IL-10</e1> is a multi-functional cytokine thought to play a role in the pathogenesis of <e2>periodontitis</e2>.","Association"
"<e1>IL-10</e1> is a multi-functional cytokine thought to play a role in the pathogenesis of <e2>periodontitis</e2>.","Association"
"<e1>IL-10</e1> is a multi-functional cytokine thought to play a role in the pathogenesis of <e2>periodontitis</e2>.","Association"
"<e1>IL-10</e1> is a multi-functional cytokine thought to play a role in the pathogenesis of <e2>periodontitis</e2>.","Association"
"Repeated <e1>otilonium bromide</e1> administration prevents <e2>neurotransmitter</e2> changes in colon of rats underwent to wrap restraint stress.","Association"
"The ability of <e2>OB</e2> to block <e1>L-type Ca(2+) channels</e1>, also expressed by enteric neurons, might represent a possible mechanism through which OB exerts its actions.","Negative_Correlation"
"Furthermore, in healthy rats, repeated <e1>OB</e1> administration modified <e2>neurotransmitter</e2> expression and function suggesting other mechanisms of action.","Association"
"Furthermore, in healthy rats, repeated <e1>OB</e1> administration modified <e2>neurotransmitter</e2> expression and function suggesting other mechanisms of action.","Association"
"Furthermore, in healthy rats, repeated <e1>OB</e1> administration modified <e2>neurotransmitter</e2> expression and function suggesting other mechanisms of action.","Association"
"Furthermore, in healthy rats, repeated <e1>OB</e1> administration modified <e2>neurotransmitter</e2> expression and function suggesting other mechanisms of action.","Association"
"Furthermore, in healthy rats, repeated <e1>OB</e1> administration modified <e2>neurotransmitter</e2> expression and function suggesting other mechanisms of action.","Association"
"Furthermore, in healthy rats, repeated <e1>OB</e1> administration modified <e2>neurotransmitter</e2> expression and function suggesting other mechanisms of action.","Association"
"Furthermore, in healthy rats, repeated <e1>OB</e1> administration modified <e2>neurotransmitter</e2> expression and function suggesting other mechanisms of action.","Association"
"Furthermore, in healthy rats, repeated <e1>OB</e1> administration modified <e2>neurotransmitter</e2> expression and function suggesting other mechanisms of action.","Association"
"Furthermore, in healthy rats, repeated <e1>OB</e1> administration modified <e2>neurotransmitter</e2> expression and function suggesting other mechanisms of action.","Association"
"Furthermore, in healthy rats, repeated <e1>OB</e1> administration modified <e2>neurotransmitter</e2> expression and function suggesting other mechanisms of action.","Association"
"<e1>Otilonium bromide</e1> (OB) is a spasmolytic drug successfully used for the treatment of <e2>irritable bowel syndrome</e2> (IBS).","Negative_Correlation"
"Otilonium bromide (<e1>OB</e1>) is a spasmolytic drug successfully used for the treatment of <e2>irritable bowel syndrome</e2> (IBS).","Negative_Correlation"
"Otilonium bromide (<e1>OB</e1>) is a spasmolytic drug successfully used for the treatment of <e2>irritable bowel syndrome</e2> (IBS).","Negative_Correlation"
"Otilonium bromide (<e1>OB</e1>) is a spasmolytic drug successfully used for the treatment of <e2>irritable bowel syndrome</e2> (IBS).","Negative_Correlation"
"Otilonium bromide (<e1>OB</e1>) is a spasmolytic drug successfully used for the treatment of <e2>irritable bowel syndrome</e2> (IBS).","Negative_Correlation"
"Otilonium bromide (<e1>OB</e1>) is a spasmolytic drug successfully used for the treatment of <e2>irritable bowel syndrome</e2> (IBS).","Negative_Correlation"
"Otilonium bromide (<e1>OB</e1>) is a spasmolytic drug successfully used for the treatment of <e2>irritable bowel syndrome</e2> (IBS).","Negative_Correlation"
"Otilonium bromide (<e1>OB</e1>) is a spasmolytic drug successfully used for the treatment of <e2>irritable bowel syndrome</e2> (IBS).","Negative_Correlation"
"Otilonium bromide (<e1>OB</e1>) is a spasmolytic drug successfully used for the treatment of <e2>irritable bowel syndrome</e2> (IBS).","Negative_Correlation"
"Otilonium bromide (<e1>OB</e1>) is a spasmolytic drug successfully used for the treatment of <e2>irritable bowel syndrome</e2> (IBS).","Negative_Correlation"
"Otilonium bromide (<e1>OB</e1>) is a spasmolytic drug successfully used for the treatment of <e2>irritable bowel syndrome</e2> (IBS).","Negative_Correlation"
"Finally, <e1>OB</e1> per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric <e2>ChAT</e2>-IR neurons.","Negative_Correlation"
"Finally, <e1>OB</e1> per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric <e2>ChAT</e2>-IR neurons.","Negative_Correlation"
"Finally, <e1>OB</e1> per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric <e2>ChAT</e2>-IR neurons.","Negative_Correlation"
"Finally, <e1>OB</e1> per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric <e2>ChAT</e2>-IR neurons.","Negative_Correlation"
"Finally, <e1>OB</e1> per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric <e2>ChAT</e2>-IR neurons.","Negative_Correlation"
"Finally, <e1>OB</e1> per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric <e2>ChAT</e2>-IR neurons.","Negative_Correlation"
"Finally, <e1>OB</e1> per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric <e2>ChAT</e2>-IR neurons.","Negative_Correlation"
"Finally, <e1>OB</e1> per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric <e2>ChAT</e2>-IR neurons.","Negative_Correlation"
"Finally, <e1>OB</e1> per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric <e2>ChAT</e2>-IR neurons.","Negative_Correlation"
"Finally, <e1>OB</e1> per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric <e2>ChAT</e2>-IR neurons.","Negative_Correlation"
"Finally, <e1>OB</e1> per se increases the <e2>Mr2</e2> expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.","Positive_Correlation"
"Finally, <e1>OB</e1> per se increases the <e2>Mr2</e2> expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.","Positive_Correlation"
"Finally, <e1>OB</e1> per se increases the <e2>Mr2</e2> expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.","Positive_Correlation"
"Finally, <e1>OB</e1> per se increases the <e2>Mr2</e2> expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.","Positive_Correlation"
"Finally, <e1>OB</e1> per se increases the <e2>Mr2</e2> expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.","Positive_Correlation"
"Finally, <e1>OB</e1> per se increases the <e2>Mr2</e2> expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.","Positive_Correlation"
"Finally, <e1>OB</e1> per se increases the <e2>Mr2</e2> expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.","Positive_Correlation"
"Finally, <e1>OB</e1> per se increases the <e2>Mr2</e2> expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.","Positive_Correlation"
"Finally, <e1>OB</e1> per se increases the <e2>Mr2</e2> expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.","Positive_Correlation"
"Finally, <e1>OB</e1> per se increases the <e2>Mr2</e2> expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.","Positive_Correlation"
"An inducible mouse model of <e1>podocin</e1>-mutation-related <e2>nephrotic syndrome</e2>.","Association"
"The most common <e1>podocin</e1> mutation, R138Q, is associated with early disease onset and rapid progression to end-stage <e2>renal disease</e2>.","Association"
"The most common <e1>podocin</e1> mutation, R138Q, is associated with early disease onset and rapid progression to end-stage <e2>renal disease</e2>.","Association"
"Mutations in the <e1>NPHS2</e1> gene, encoding podocin, cause hereditary <e2>nephrotic syndrome</e2>.","Association"
"Mutations in the NPHS2 gene, encoding <e1>podocin</e1>, cause hereditary <e2>nephrotic syndrome</e2>.","Association"
"Mutations in the NPHS2 gene, encoding <e1>podocin</e1>, cause hereditary <e2>nephrotic syndrome</e2>.","Association"
"Mutations in the NPHS2 gene, encoding <e1>podocin</e1>, cause hereditary <e2>nephrotic syndrome</e2>.","Association"
"Mutations in the <e1>NPHS2</e1> gene, encoding podocin, cause hereditary <e2>nephrotic syndrome</e2>.","Association"
"Mutations in the NPHS2 gene, encoding <e1>podocin</e1>, cause hereditary <e2>nephrotic syndrome</e2>.","Association"
"Mutations in the NPHS2 gene, encoding <e1>podocin</e1>, cause hereditary <e2>nephrotic syndrome</e2>.","Association"
"The most common podocin mutation, <e1>R138Q</e1>, is associated with early disease onset and rapid progression to end-stage <e2>renal disease</e2>.","Positive_Correlation"
"The most common podocin mutation, <e1>R138Q</e1>, is associated with early disease onset and rapid progression to end-stage <e2>renal disease</e2>.","Positive_Correlation"
"Knock-in mice carrying a R140Q mutation, the mouse analogue of human <e1>R138Q</e1>, show developmental arrest of podocytes and lethal <e2>renal failure</e2> at neonatal age.","Positive_Correlation"
"Knock-in mice carrying a R140Q mutation, the mouse analogue of human <e1>R138Q</e1>, show developmental arrest of podocytes and lethal <e2>renal failure</e2> at neonatal age.","Positive_Correlation"
"In conclusion, the inducible <e1>R140Q</e1>-podocin mouse model is an auspicious model of the most common genetic cause of human <e2>nephrotic syndrome</e2>, with a spontaneous disease course strongly reminiscent of the human disorder.","Positive_Correlation"
"In conclusion, the inducible <e1>R140Q</e1>-podocin mouse model is an auspicious model of the most common genetic cause of human <e2>nephrotic syndrome</e2>, with a spontaneous disease course strongly reminiscent of the human disorder.","Positive_Correlation"
"In conclusion, the inducible <e1>R140Q</e1>-podocin mouse model is an auspicious model of the most common genetic cause of human <e2>nephrotic syndrome</e2>, with a spontaneous disease course strongly reminiscent of the human disorder.","Positive_Correlation"
"In conclusion, the inducible <e1>R140Q</e1>-podocin mouse model is an auspicious model of the most common genetic cause of human <e2>nephrotic syndrome</e2>, with a spontaneous disease course strongly reminiscent of the human disorder.","Positive_Correlation"
"In conclusion, the inducible <e1>R140Q</e1>-podocin mouse model is an auspicious model of the most common genetic cause of human <e2>nephrotic syndrome</e2>, with a spontaneous disease course strongly reminiscent of the human disorder.","Positive_Correlation"
"Within the first week of <e1>R140Q</e1> hemizygosity induction the animals developed <e2>proteinuria</e2>, which peaked after 4-5 weeks.","Positive_Correlation"
"Within the first week of <e1>R140Q</e1> hemizygosity induction the animals developed <e2>proteinuria</e2>, which peaked after 4-5 weeks.","Positive_Correlation"
"Within the first week of <e1>R140Q</e1> hemizygosity induction the animals developed <e2>proteinuria</e2>, which peaked after 4-5 weeks.","Positive_Correlation"
"Within the first week of <e1>R140Q</e1> hemizygosity induction the animals developed <e2>proteinuria</e2>, which peaked after 4-5 weeks.","Positive_Correlation"
"Within the first week of <e1>R140Q</e1> hemizygosity induction the animals developed <e2>proteinuria</e2>, which peaked after 4-5 weeks.","Positive_Correlation"
"Knock-in mice carrying a <e1>R140Q</e1> mutation, the mouse analogue of human R138Q, show developmental arrest of podocytes and lethal <e2>renal failure</e2> at neonatal age.","Positive_Correlation"
"Knock-in mice carrying a <e1>R140Q</e1> mutation, the mouse analogue of human R138Q, show developmental arrest of podocytes and lethal <e2>renal failure</e2> at neonatal age.","Positive_Correlation"
"Knock-in mice carrying a <e1>R140Q</e1> mutation, the mouse analogue of human R138Q, show developmental arrest of podocytes and lethal <e2>renal failure</e2> at neonatal age.","Positive_Correlation"
"Knock-in mice carrying a <e1>R140Q</e1> mutation, the mouse analogue of human R138Q, show developmental arrest of podocytes and lethal <e2>renal failure</e2> at neonatal age.","Positive_Correlation"
"Knock-in mice carrying a <e1>R140Q</e1> mutation, the mouse analogue of human R138Q, show developmental arrest of podocytes and lethal <e2>renal failure</e2> at neonatal age.","Positive_Correlation"
"Over-expression of BMP4 and <e2>BMP5</e2> in a child with axial skeletal malformations and <e1>heterotopic ossification</e1>: a new syndrome.","Association"
"Over-expression of <e2>BMP4</e2> and BMP5 in a child with axial skeletal malformations and <e1>heterotopic ossification</e1>: a new syndrome.","Association"
"Over-expression of BMP4 and <e2>BMP5</e2> in a child with <e1>axial skeletal malformations</e1> and heterotopic ossification: a new syndrome.","Association"
"Over-expression of <e2>BMP4</e2> and BMP5 in a child with <e1>axial skeletal malformations</e1> and heterotopic ossification: a new syndrome.","Association"
"Our data suggest that dysregulated expression of BMP4 and <e1>BMP5</e1> genes is associated with an array of human axial skeletal abnormalities similar to the short ear mouse and <e2>FOP</e2>.","Association"
"Our data suggest that dysregulated expression of BMP4 and <e1>BMP5</e1> genes is associated with an array of human axial skeletal abnormalities similar to the short ear mouse and <e2>FOP</e2>.","Association"
"Our data suggest that dysregulated expression of BMP4 and <e1>BMP5</e1> genes is associated with an array of human axial skeletal abnormalities similar to the short ear mouse and <e2>FOP</e2>.","Association"
"Loss of function mutations in the <e1>bone morphogenetic protein 5</e1> (bmp5) gene leading to under-expression of BMP5 cause the murine <e2>short ear syndrome</e2>, characterized by small malformed ears and a broad range of axial skeletal malformations.","Association"
"Loss of function mutations in the bone morphogenetic protein 5 (<e1>bmp5</e1>) gene leading to under-expression of BMP5 cause the murine <e2>short ear syndrome</e2>, characterized by small malformed ears and a broad range of axial skeletal malformations.","Association"
"Loss of function mutations in the bone morphogenetic protein 5 (bmp5) gene leading to under-expression of <e1>BMP5</e1> cause the murine <e2>short ear syndrome</e2>, characterized by small malformed ears and a broad range of axial skeletal malformations.","Association"
"Loss of function mutations in the bone morphogenetic protein 5 (bmp5) gene leading to under-expression of <e1>BMP5</e1> cause the murine <e2>short ear syndrome</e2>, characterized by small malformed ears and a broad range of axial skeletal malformations.","Association"
"Loss of function mutations in the bone morphogenetic protein 5 (bmp5) gene leading to under-expression of <e1>BMP5</e1> cause the murine <e2>short ear syndrome</e2>, characterized by small malformed ears and a broad range of axial skeletal malformations.","Association"
"Dysregulated expression of <e2>bone morphogenetic protein 4</e2> (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive <e1>heterotopic ossification</e1>.","Association"
"Dysregulated expression of <e2>bone morphogenetic protein 4</e2> (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive <e1>heterotopic ossification</e1>.","Association"
"Dysregulated expression of <e1>bone morphogenetic protein 4</e1> (BMP4) is found in the cells of patients who have <e2>fibrodysplasia ossificans progressiva</e2> (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.","Association"
"Dysregulated expression of bone morphogenetic protein 4 (<e1>BMP4</e1>) is found in the cells of patients who have <e2>fibrodysplasia ossificans progressiva</e2> (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.","Association"
"Dysregulated expression of bone morphogenetic protein 4 (<e1>BMP4</e1>) is found in the cells of patients who have <e2>fibrodysplasia ossificans progressiva</e2> (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.","Association"
"Dysregulated expression of bone morphogenetic protein 4 (<e1>BMP4</e1>) is found in the cells of patients who have <e2>fibrodysplasia ossificans progressiva</e2> (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.","Association"
"Loss of function mutations in the <e2>bone morphogenetic protein 5</e2> (bmp5) gene leading to under-expression of BMP5 cause the murine short ear syndrome, characterized by small malformed ears and a broad range of <e1>axial skeletal malformations</e1>.","Association"
"Our data suggest that dysregulated expression of BMP4 and <e2>BMP5</e2> genes is associated with an array of human <e1>axial skeletal abnormalities</e1> similar to the short ear mouse and FOP.","Association"
"Dysregulated expression of <e2>bone morphogenetic protein 4</e2> (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of <e1>axial and appendicular skeletal malformation</e1> and progressive heterotopic ossification.","Association"
"Our data suggest that dysregulated expression of <e2>BMP4</e2> and BMP5 genes is associated with an array of human <e1>axial skeletal abnormalities</e1> similar to the short ear mouse and FOP.","Association"
"Sex-differential genetic effect of <e1>phosphodiesterase 4D</e1> (PDE4D) on <e2>carotid atherosclerosis</e2>.","Association"
"Sex-differential genetic effect of phosphodiesterase 4D (<e1>PDE4D</e1>) on <e2>carotid atherosclerosis</e2>.","Association"
"<e1>Rs702553</e1> at the PDE4D gene was selected because it conferred a risk for young <e2>stroke</e2> in our previous report.","Positive_Correlation"
"Similarly, SNP <e1>rs702553</e1> was only significant in young <e2>stroke</e2> men (OR = 1.8, p = 0.025) but not in women (p = 0.27).","Positive_Correlation"
"Similarly, SNP <e1>rs702553</e1> was only significant in young <e2>stroke</e2> men (OR = 1.8, p = 0.025) but not in women (p = 0.27).","Positive_Correlation"
"Similarly, SNP <e1>rs702553</e1> was only significant in young <e2>stroke</e2> men (OR = 1.8, p = 0.025) but not in women (p = 0.27).","Positive_Correlation"
"CONCLUSIONS: The present study demonstrates a sex-differential effect of <e1>PDE4D</e1> on IMT, plaque index and stroke, which highlights its influence on various aspects of <e2>atherogenesis</e2>.","Association"
"CONCLUSIONS: The present study demonstrates a sex-differential effect of <e1>PDE4D</e1> on IMT, plaque index and stroke, which highlights its influence on various aspects of <e2>atherogenesis</e2>.","Association"
"CONCLUSIONS: The present study demonstrates a sex-differential effect of <e1>PDE4D</e1> on IMT, plaque index and stroke, which highlights its influence on various aspects of <e2>atherogenesis</e2>.","Association"
"BACKGROUND: The <e1>phosphodiesterase 4D</e1> (PDE4D) gene was reported as a susceptibility gene to <e2>stroke</e2>.","Association"
"BACKGROUND: The phosphodiesterase 4D (<e1>PDE4D</e1>) gene was reported as a susceptibility gene to <e2>stroke</e2>.","Association"
"BACKGROUND: The phosphodiesterase 4D (<e1>PDE4D</e1>) gene was reported as a susceptibility gene to <e2>stroke</e2>.","Association"
"BACKGROUND: The phosphodiesterase 4D (<e1>PDE4D</e1>) gene was reported as a susceptibility gene to <e2>stroke</e2>.","Association"
"Detection of <e1>EGFR</e1> mutations in plasma DNA from <e2>lung cancer</e2> patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.","Association"
"Detection of <e1>EGFR</e1> mutations in plasma DNA from <e2>lung cancer</e2> patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.","Association"
"Detection of <e1>EGFR</e1> mutations in plasma DNA from <e2>lung cancer</e2> patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.","Association"
"Detection of <e1>EGFR</e1> mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of <e2>tumor</e2> EGFR status and response to EGFR inhibitors.","Association"
"Detection of <e1>EGFR</e1> mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of <e2>tumor</e2> EGFR status and response to EGFR inhibitors.","Association"
"Detection of <e1>EGFR</e1> mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of <e2>tumor</e2> EGFR status and response to EGFR inhibitors.","Association"
"By mass spectrometry genotyping, the plasma samples contained mutant DNA corresponding to 5/14 EGFR Exon 19 deletions and 3/4 EGFR <e1>L858R</e1> mutations previously diagnosed in the matched <e2>tumor</e2>s.","Association"
"By mass spectrometry genotyping, the plasma samples contained mutant DNA corresponding to 5/14 EGFR Exon 19 deletions and 3/4 EGFR <e1>L858R</e1> mutations previously diagnosed in the matched <e2>tumor</e2>s.","Association"
"For patients treated with <e1>erlotinib</e1>, overall survival was correlated with the presence of EGFR mutation in plasma and/or <e2>tumor</e2> tissue (p=0.002), with the two patients positive only in plasma DNA showing responses and favorable outcomes.","Negative_Correlation"
"For patients treated with <e1>erlotinib</e1>, overall survival was correlated with the presence of <e2>EGFR</e2> mutation in plasma and/or tumor tissue (p=0.002), with the two patients positive only in plasma DNA showing responses and favorable outcomes.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"AIMS: <e1>EGFR</e1> mutations now guide the clinical use of EGFR-targeted therapy in <e2>lung cancer</e2>.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"However, standard <e1>EGFR</e1> mutation analysis requires a minimum amount of <e2>tumor</e2> tissue, which may not be available in certain situations.","Association"
"<e1>Psoriasin</e1> promotes invasion, aggregation and survival of <e2>pancreatic cancer</e2> cells; association with disease progression.","Positive_Correlation"
"In addition, Psoriasin overexpression resulted in increased <e1>pancreatic cancer</e1> cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, Psoriasin overexpression resulted in increased <e1>pancreatic cancer</e1> cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, Psoriasin overexpression resulted in increased <e1>pancreatic cancer</e1> cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, Psoriasin overexpression resulted in increased <e1>pancreatic cancer</e1> cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, Psoriasin overexpression resulted in increased <e1>pancreatic cancer</e1> cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, Psoriasin overexpression resulted in increased <e1>pancreatic cancer</e1> cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, Psoriasin overexpression resulted in increased <e1>pancreatic cancer</e1> cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, Psoriasin overexpression resulted in increased <e1>pancreatic cancer</e1> cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, Psoriasin overexpression resulted in increased <e1>pancreatic cancer</e1> cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, Psoriasin overexpression resulted in increased <e1>pancreatic cancer</e1> cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, Psoriasin overexpression resulted in increased <e1>pancreatic cancer</e1> cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, Psoriasin overexpression resulted in increased <e1>pancreatic cancer</e1> cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"Aberrant <e1>Psoriasin</e1> expression has been implicated in a range of <e2>cancers</e2> and is often associated with poor prognosis.","Association"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <e2>MMP-9</e2>.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"In addition, <e1>Psoriasin</e1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <e2>matrix metalloproteinase-2</e2> (MMP-2) and MMP-9.","Positive_Correlation"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"Psoriasin (<e1>S100A7</e1>) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"Psoriasin (S100A7) is an 11-kDa small <e1>calcium binding protein</e1> initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"Psoriasin (<e1>S100</e1>A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"<e1>Psoriasin</e1> (S100A7) is an 11-kDa small calcium binding protein initially isolated from <e2>psoriatic skin lesions</e2>.","Association"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"This study examined the role of <e1>Psoriasin</e1> on <e2>pancreatic cancer</e2> cell functions and the implication in progression of the disease.","Positive_Correlation"
"Two novel mutations in <e2>SRY</e2> gene form Chinese <e1>sex reversal XY</e1> females.","Association"
"Deletion and inactivating mutations of <e2>SRY</e2> are among the known causes of <e1>XY sex reversal</e1>.","Association"
"Here, we described the screening of 10 patients who presented with <e1>46,XY sex reversal</e1> for mutations in open reading frame (ORF) of <e2>SRY</e2> gene.","Association"
"Deletion and inactivating mutations of <e2>SRY</e2> are among the known causes of XY <e1>sex reversal</e1>.","Association"
"The two novel mutations in <e2>SRY</e2> gene provided valuable information for understanding the molecular mechanism of the patient with <e1>46,XY female sex reversal</e1>.","Association"
"A novel missense mutation, F826Y, in the <e1>mineralocorticoid receptor</e1> gene in Japanese <e2>hypertensives</e2>: its implications for clinical phenotypes.","Association"
"A novel missense mutation, <e1>F826Y</e1>, in the mineralocorticoid receptor gene in Japanese <e2>hypertensives</e2>: its implications for clinical phenotypes.","Association"
"A gain-of-function mutation resulting in the <e1>S810L</e1> amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset <e2>hypertension</e2> that is exacerbated in pregnancy.","Positive_Correlation"
"A gain-of-function mutation resulting in the <e1>S810L</e1> amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset <e2>hypertension</e2> that is exacerbated in pregnancy.","Positive_Correlation"
"A gain-of-function mutation resulting in the <e1>S810L</e1> amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset <e2>hypertension</e2> that is exacerbated in pregnancy.","Positive_Correlation"
"A gain-of-function mutation resulting in the <e1>S810L</e1> amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset <e2>hypertension</e2> that is exacerbated in pregnancy.","Positive_Correlation"
"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the <e1>mineralocorticoid receptor</e1> (MR, locus symbol NR3C2) is responsible for early-onset <e2>hypertension</e2> that is exacerbated in pregnancy.","Association"
"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (<e1>MR</e1>, locus symbol NR3C2) is responsible for early-onset <e2>hypertension</e2> that is exacerbated in pregnancy.","Association"
"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol <e1>NR3C2</e1>) is responsible for early-onset <e2>hypertension</e2> that is exacerbated in pregnancy.","Association"
"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (<e1>MR</e1>, locus symbol NR3C2) is responsible for early-onset <e2>hypertension</e2> that is exacerbated in pregnancy.","Association"
"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (<e1>MR</e1>, locus symbol NR3C2) is responsible for early-onset <e2>hypertension</e2> that is exacerbated in pregnancy.","Association"
"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the <e1>mineralocorticoid receptor</e1> (MR, locus symbol NR3C2) is responsible for early-onset <e2>hypertension</e2> that is exacerbated in pregnancy.","Association"
"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (<e1>MR</e1>, locus symbol NR3C2) is responsible for early-onset <e2>hypertension</e2> that is exacerbated in pregnancy.","Association"
"The frequencies of the <e1>F826Y</e1> mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect <e2>hypertension</e2>.","Association"
"The frequencies of the <e1>F826Y</e1> mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect <e2>hypertension</e2>.","Association"
"The frequencies of the <e1>F826Y</e1> mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect <e2>hypertension</e2>.","Association"
"The frequencies of the <e1>F826Y</e1> mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect <e2>hypertension</e2>.","Association"
"The frequencies of the <e1>F826Y</e1> mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect <e2>hypertension</e2>.","Association"
"Myocardial Fas ligand expression increases susceptibility to <e1>AZT</e1>-induced <e2>cardiomyopathy</e2>.","Positive_Correlation"
"Myocardial <e1>Fas ligand</e1> expression increases susceptibility to AZT-induced <e2>cardiomyopathy</e2>.","Association"
"Myocardial <e1>Fas ligand</e1> expression increases susceptibility to <e2>AZT</e2>-induced cardiomyopathy.","Positive_Correlation"
"In contrast, AZT-treated <e1>FasL</e1> Tg mice developed cardiac dilation and <e2>depressed cardiac function</e2> in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.","Association"
"In contrast, AZT-treated <e1>FasL</e1> Tg mice developed cardiac dilation and <e2>depressed cardiac function</e2> in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.","Association"
"In contrast, AZT-treated <e1>FasL</e1> Tg mice developed cardiac dilation and <e2>depressed cardiac function</e2> in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.","Association"
"In contrast, AZT-treated <e1>FasL</e1> Tg mice developed cardiac dilation and <e2>depressed cardiac function</e2> in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2>DCM</e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: <e1>FasL</e1> Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2>DCM</e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: <e1>FasL</e1> Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2>DCM</e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: <e1>FasL</e1> Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2>DCM</e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: <e1>FasL</e1> Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"In contrast, AZT-treated <e2>Fas</e2>L Tg mice developed cardiac dilation and <e1>depressed cardiac function</e1> in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the <e2>Fas</e2>-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e1>DCM</e1>, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the <e2>Fas</e2>-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e1>DCM</e1>, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"In contrast, AZT-treated <e2>Fas</e2>L Tg mice developed <e1>cardiac dilation</e1> and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component <e1>zidovudine</e1> (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: <e2>FasL</e2> Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (<e1>3'-azido-2',3'-deoxythymidine</e1>; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: <e2>FasL</e2> Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; <e1>AZT</e1>) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: <e2>FasL</e2> Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; <e1>AZT</e1>) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: <e2>FasL</e2> Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; <e1>AZT</e1>) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: <e2>FasL</e2> Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"In contrast, <e1>AZT</e1>-treated FasL Tg mice developed cardiac dilation and <e2>depressed cardiac function</e2> in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.","Positive_Correlation"
"In contrast, <e1>AZT</e1>-treated FasL Tg mice developed cardiac dilation and <e2>depressed cardiac function</e2> in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.","Positive_Correlation"
"In contrast, <e1>AZT</e1>-treated FasL Tg mice developed cardiac dilation and <e2>depressed cardiac function</e2> in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.","Positive_Correlation"
"METHODS AND RESULTS: In order to investigate whether the HAART component <e1>zidovudine</e1> (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2>DCM</e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Positive_Correlation"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (<e1>3'-azido-2',3'-deoxythymidine</e1>; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2>DCM</e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Positive_Correlation"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; <e1>AZT</e1>) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2>DCM</e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Positive_Correlation"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; <e1>AZT</e1>) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2>DCM</e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Positive_Correlation"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; <e1>AZT</e1>) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2>DCM</e2>, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Positive_Correlation"
"METHODS AND RESULTS: In order to investigate whether the HAART component <e1>zidovudine</e1> (3'-azido-2',3'-deoxythymidine; AZT) triggers the <e2>Fas</e2>-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Positive_Correlation"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (<e1>3'-azido-2',3'-deoxythymidine</e1>; AZT) triggers the <e2>Fas</e2>-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Positive_Correlation"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; <e1>AZT</e1>) triggers the <e2>Fas</e2>-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Positive_Correlation"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; <e1>AZT</e1>) triggers the <e2>Fas</e2>-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Positive_Correlation"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; <e1>AZT</e1>) triggers the <e2>Fas</e2>-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Positive_Correlation"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2>DCM</e2>, 8-week-old transgenic (expressing <e1>Fas ligand</e1> in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <e2>DCM</e2>, 8-week-old transgenic (expressing <e1>Fas ligand</e1> in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Association"
"CONCLUSIONS: The expression of <e1>Fas ligand</e1> in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced <e2>cardiomyopathy</e2> due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.","Association"
"CONCLUSIONS: The expression of <e1>Fas ligand</e1> in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced <e2>cardiomyopathy</e2> due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.","Association"
"METHODS AND RESULTS: In order to investigate whether the HAART component <e2>zidovudine</e2> (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing <e1>Fas ligand</e1> in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Positive_Correlation"
"METHODS AND RESULTS: In order to investigate whether the HAART component <e2>zidovudine</e2> (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing <e1>Fas ligand</e1> in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).","Positive_Correlation"
"Familial <e1>glucocorticoid receptor</e1> haploinsufficiency by non-sense mediated mRNA decay, <e2>adrenal hyperplasia</e2> and apparent mineralocorticoid excess.","Association"
"Familial <e1>glucocorticoid receptor</e1> haploinsufficiency by non-sense mediated mRNA decay, adrenal hyperplasia and <e2>apparent mineralocorticoid excess</e2>.","Association"
"Primary <e1><e2>glucocorticoid</e2> resistance</e1> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (GR).","Association"
"Primary <e1><e2>glucocorticoid</e2> resistance</e1> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (GR).","Association"
"Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the <e1>11b-hydroxysteroid dehydrogenase type 2</e1>, a <e2>GR</e2> regulated gene.","Association"
"GR haploinsufficiency leads to hypertension due to illicit occupation of renal <e1>mineralocorticoid receptor</e1> by elevated <e2>cortisol</e2> rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"We propose thus that GR haploinsufficiency compromises <e1>glucocorticoid</e1> sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that GR haploinsufficiency compromises <e1>glucocorticoid</e1> sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that GR haploinsufficiency compromises <e1>glucocorticoid</e1> sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that GR haploinsufficiency compromises <e1>glucocorticoid</e1> sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that GR haploinsufficiency compromises <e1>glucocorticoid</e1> sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced <e1>glucocorticoid</e1> degradation by renal activity of the <e2>11b-hydroxysteroid dehydrogenase type 2</e2>, a GR regulated gene.","Positive_Correlation"
"Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced <e1>glucocorticoid</e1> degradation by renal activity of the <e2>11b-hydroxysteroid dehydrogenase type 2</e2>, a GR regulated gene.","Positive_Correlation"
"Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced <e1>glucocorticoid</e1> degradation by renal activity of the <e2>11b-hydroxysteroid dehydrogenase type 2</e2>, a GR regulated gene.","Positive_Correlation"
"Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced <e1>glucocorticoid</e1> degradation by renal activity of the <e2>11b-hydroxysteroid dehydrogenase type 2</e2>, a GR regulated gene.","Positive_Correlation"
"Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced <e1>glucocorticoid</e1> degradation by renal activity of the <e2>11b-hydroxysteroid dehydrogenase type 2</e2>, a GR regulated gene.","Positive_Correlation"
"This reduced GR expression leads to a significantly below-normal induction of <e1>glucocorticoid</e1>-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced GR expression leads to a significantly below-normal induction of <e1>glucocorticoid</e1>-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced GR expression leads to a significantly below-normal induction of <e1>glucocorticoid</e1>-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced GR expression leads to a significantly below-normal induction of <e1>glucocorticoid</e1>-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced GR expression leads to a significantly below-normal induction of <e1>glucocorticoid</e1>-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"We propose thus that GR haploinsufficiency compromises <e2>glucocorticoid</e2> sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e1>bilateral adrenal hyperplasia</e1> and mineralocorticoid-independent hypertension.","Association"
"We propose thus that GR haploinsufficiency compromises <e2>glucocorticoid</e2> sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e1>bilateral adrenal hyperplasia</e1> and mineralocorticoid-independent hypertension.","Association"
"Investigation of adrenal incidentalomas led to the discovery of a family (eight affected individuals spanning three generations), prone to <e2>cortisol</e2> resistance, bilateral adrenal hyperplasia, arterial <e1>hypertension</e1> and hypokalemia.","Association"
"Investigation of adrenal incidentalomas led to the discovery of a family (eight affected individuals spanning three generations), prone to <e2>cortisol</e2> resistance, bilateral adrenal hyperplasia, arterial <e1>hypertension</e1> and hypokalemia.","Association"
"Investigation of adrenal incidentalomas led to the discovery of a family (eight affected individuals spanning three generations), prone to <e2>cortisol</e2> resistance, bilateral adrenal hyperplasia, arterial <e1>hypertension</e1> and hypokalemia.","Association"
"GR haploinsufficiency leads to <e1>hypertension</e1> due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"GR haploinsufficiency leads to <e1>hypertension</e1> due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"GR haploinsufficiency leads to <e1>hypertension</e1> due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"Indeed, <e1>apparent mineralocorticoid excess</e1> was demonstrated by a decrease in urinary tetrahydrocortisone-<e2>tetrahydrocortisol</e2> ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a GR regulated gene.","Association"
"Indeed, <e1>apparent mineralocorticoid excess</e1> was demonstrated by a decrease in urinary <e2>tetrahydrocortisone</e2>-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a GR regulated gene.","Association"
"Primary <e2>glucocorticoid resistance</e2> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the <e1>glucocorticoid receptor</e1> (GR).","Association"
"Primary <e2>glucocorticoid resistance</e2> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Association"
"Primary <e2>glucocorticoid resistance</e2> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Association"
"Primary <e2>glucocorticoid resistance</e2> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Association"
"Primary <e2>glucocorticoid resistance</e2> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Association"
"Primary <e2>glucocorticoid resistance</e2> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Association"
"Primary <e2>glucocorticoid resistance</e2> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Association"
"Primary <e2>glucocorticoid resistance</e2> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Association"
"Primary <e2>glucocorticoid resistance</e2> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Association"
"Primary <e2>glucocorticoid resistance</e2> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Association"
"Primary <e2>glucocorticoid resistance</e2> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Association"
"Primary <e2>glucocorticoid resistance</e2> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical <e2>hypercortisolism</e2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.","Association"
"<e1>GR</e1> haploinsufficiency leads to hypertension due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to hypertension due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to hypertension due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to hypertension due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to hypertension due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to hypertension due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to hypertension due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to hypertension due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to hypertension due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to hypertension due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to hypertension due to illicit occupation of renal <e2>mineralocorticoid receptor</e2> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"Primary <e2>glucocorticoid</e2> resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the <e1>glucocorticoid receptor</e1> (GR).","Bind"
"Primary <e2>glucocorticoid</e2> resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Bind"
"Primary <e2>glucocorticoid</e2> resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Bind"
"Primary <e2>glucocorticoid</e2> resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Bind"
"Primary <e2>glucocorticoid</e2> resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Bind"
"Primary <e2>glucocorticoid</e2> resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Bind"
"Primary <e2>glucocorticoid</e2> resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Bind"
"Primary <e2>glucocorticoid</e2> resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Bind"
"Primary <e2>glucocorticoid</e2> resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Bind"
"Primary <e2>glucocorticoid</e2> resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Bind"
"Primary <e2>glucocorticoid</e2> resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Bind"
"Primary <e2>glucocorticoid</e2> resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (<e1>GR</e1>).","Bind"
"This reduced <e1>GR</e1> expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced <e1>GR</e1> expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced <e1>GR</e1> expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced <e1>GR</e1> expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced <e1>GR</e1> expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced <e1>GR</e1> expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced <e1>GR</e1> expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced <e1>GR</e1> expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced <e1>GR</e1> expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced <e1>GR</e1> expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"This reduced <e1>GR</e1> expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, <e2>FKBP5</e2> in fibroblasts.","Positive_Correlation"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e2>bilateral adrenal hyperplasia</e2> and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e2>bilateral adrenal hyperplasia</e2> and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e2>bilateral adrenal hyperplasia</e2> and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e2>bilateral adrenal hyperplasia</e2> and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e2>bilateral adrenal hyperplasia</e2> and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e2>bilateral adrenal hyperplasia</e2> and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e2>bilateral adrenal hyperplasia</e2> and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e2>bilateral adrenal hyperplasia</e2> and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e2>bilateral adrenal hyperplasia</e2> and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e2>bilateral adrenal hyperplasia</e2> and mineralocorticoid-independent hypertension.","Association"
"We propose thus that <e1>GR</e1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <e2>bilateral adrenal hyperplasia</e2> and mineralocorticoid-independent hypertension.","Association"
"<e1>GR</e1> haploinsufficiency leads to <e2>hypertension</e2> due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to <e2>hypertension</e2> due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to <e2>hypertension</e2> due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to <e2>hypertension</e2> due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to <e2>hypertension</e2> due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to <e2>hypertension</e2> due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to <e2>hypertension</e2> due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to <e2>hypertension</e2> due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to <e2>hypertension</e2> due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to <e2>hypertension</e2> due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"<e1>GR</e1> haploinsufficiency leads to <e2>hypertension</e2> due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.","Association"
"Indeed, <e2>apparent mineralocorticoid excess</e2> was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <e1>GR</e1> regulated gene.","Association"
"Indeed, <e2>apparent mineralocorticoid excess</e2> was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <e1>GR</e1> regulated gene.","Association"
"Indeed, <e2>apparent mineralocorticoid excess</e2> was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <e1>GR</e1> regulated gene.","Association"
"Indeed, <e2>apparent mineralocorticoid excess</e2> was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <e1>GR</e1> regulated gene.","Association"
"Indeed, <e2>apparent mineralocorticoid excess</e2> was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <e1>GR</e1> regulated gene.","Association"
"Indeed, <e2>apparent mineralocorticoid excess</e2> was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <e1>GR</e1> regulated gene.","Association"
"Indeed, <e2>apparent mineralocorticoid excess</e2> was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <e1>GR</e1> regulated gene.","Association"
"Indeed, <e2>apparent mineralocorticoid excess</e2> was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <e1>GR</e1> regulated gene.","Association"
"Indeed, <e2>apparent mineralocorticoid excess</e2> was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <e1>GR</e1> regulated gene.","Association"
"Indeed, <e2>apparent mineralocorticoid excess</e2> was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <e1>GR</e1> regulated gene.","Association"
"Indeed, <e2>apparent mineralocorticoid excess</e2> was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <e1>GR</e1> regulated gene.","Association"
"Polymorphism of the <e1>PEMT</e1> gene and susceptibility to <e2>nonalcoholic fatty liver disease</e2> (NAFLD).","Association"
"<e1>PEMT</e1> knockout mice have <e2>fatty livers</e2>, and it is possible that, in humans, nonalcoholic fatty liver disease (NAFLD) might be associated with PEMT gene polymorphisms.","Negative_Correlation"
"<e1>PEMT</e1> knockout mice have fatty livers, and it is possible that, in humans, <e2>nonalcoholic fatty liver disease</e2> (NAFLD) might be associated with PEMT gene polymorphisms.","Association"
"DNA samples from 59 humans without fatty liver and from 28 humans with <e1>NAFLD</e1> were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a <e2>V175M</e2> substitution.","Positive_Correlation"
"DNA samples from 59 humans without fatty liver and from 28 humans with <e1>NAFLD</e1> were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a <e2>V175M</e2> substitution.","Positive_Correlation"
"DNA samples from 59 humans without fatty liver and from 28 humans with <e1>NAFLD</e1> were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a <e2>V175M</e2> substitution.","Positive_Correlation"
"DNA samples from 59 humans without fatty liver and from 28 humans with <e1>NAFLD</e1> were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a <e2>V175M</e2> substitution.","Positive_Correlation"
"<e1>Phosphatidylethanolamine N-methyltransferase</e1> (PEMT) catalyzes <e2>phosphatidylcholine</e2> synthesis.","Positive_Correlation"
"Phosphatidylethanolamine N-methyltransferase (<e1>PEMT</e1>) catalyzes <e2>phosphatidylcholine</e2> synthesis.","Positive_Correlation"
"Phosphatidylethanolamine N-methyltransferase (<e1>PEMT</e1>) catalyzes <e2>phosphatidylcholine</e2> synthesis.","Positive_Correlation"
"Phosphatidylethanolamine N-methyltransferase (<e1>PEMT</e1>) catalyzes <e2>phosphatidylcholine</e2> synthesis.","Positive_Correlation"
"Phosphatidylethanolamine N-methyltransferase (<e1>PEMT</e1>) catalyzes <e2>phosphatidylcholine</e2> synthesis.","Positive_Correlation"
"<e1>PEMT</e1> knockout mice have fatty livers, and it is possible that, in humans, <e2>nonalcoholic fatty liver disease</e2> (NAFLD) might be associated with PEMT gene polymorphisms.","Association"
"<e1>PEMT</e1> knockout mice have fatty livers, and it is possible that, in humans, <e2>nonalcoholic fatty liver disease</e2> (NAFLD) might be associated with PEMT gene polymorphisms.","Association"
"<e1>PEMT</e1> knockout mice have fatty livers, and it is possible that, in humans, <e2>nonalcoholic fatty liver disease</e2> (NAFLD) might be associated with PEMT gene polymorphisms.","Association"
"<e1>PEMT</e1> knockout mice have fatty livers, and it is possible that, in humans, <e2>nonalcoholic fatty liver disease</e2> (NAFLD) might be associated with PEMT gene polymorphisms.","Association"
"Polymorphisms in the <e1>FOXP3</e1> gene in Han Chinese <e2>psoriasis</e2> patients.","Association"
"Meanwhile, the FOXP3 <e1>IVS9+459 GA+GG</e1> genotype was also associated with severe <e2>psoriasis</e2> patients (adjusted OR=1.69, 95% CI=1.21-2.36).","Positive_Correlation"
"In combined genotype analyses, the FOXP3<e1>-3279 AC+AA</e1> genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe <e2>psoriasis</e2> patients (PASI score >20; adjusted OR=1.97, 95% CI=1.41-2.75).","Association"
"We also found that an increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>IVS9+459 GG</e2> genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).","Positive_Correlation"
"We also found that an increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>IVS9+459 GG</e2> genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).","Positive_Correlation"
"We also found that an increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>IVS9+459 GG</e2> genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).","Positive_Correlation"
"We also found that an increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>IVS9+459 GG</e2> genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).","Positive_Correlation"
"We also found that an increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>IVS9+459 GG</e2> genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).","Positive_Correlation"
"We also found that an increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>IVS9+459 GG</e2> genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).","Positive_Correlation"
"We also found that an increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>IVS9+459 GG</e2> genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).","Positive_Correlation"
"We also found that an increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>IVS9+459 GG</e2> genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).","Positive_Correlation"
"We also found that an increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>IVS9+459 GG</e2> genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).","Positive_Correlation"
"RESULTS: We found that increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>-3279 AC</e2> genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.","Positive_Correlation"
"RESULTS: We found that increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>-3279 AC</e2> genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.","Positive_Correlation"
"RESULTS: We found that increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>-3279 AC</e2> genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.","Positive_Correlation"
"RESULTS: We found that increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>-3279 AC</e2> genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.","Positive_Correlation"
"RESULTS: We found that increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>-3279 AC</e2> genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.","Positive_Correlation"
"RESULTS: We found that increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>-3279 AC</e2> genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.","Positive_Correlation"
"RESULTS: We found that increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>-3279 AC</e2> genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.","Positive_Correlation"
"RESULTS: We found that increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>-3279 AC</e2> genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.","Positive_Correlation"
"RESULTS: We found that increased risk of <e1>psoriasis</e1> was associated with the FOXP3 <e2>-3279 AC</e2> genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.","Positive_Correlation"
"However, information about <e1>FOXP3</e1> gene in <e2>psoriasis</e2> is limited.","Association"
"However, information about <e1>FOXP3</e1> gene in <e2>psoriasis</e2> is limited.","Association"
"However, information about <e1>FOXP3</e1> gene in <e2>psoriasis</e2> is limited.","Association"
"However, information about <e1>FOXP3</e1> gene in <e2>psoriasis</e2> is limited.","Association"
"However, information about <e1>FOXP3</e1> gene in <e2>psoriasis</e2> is limited.","Association"
"However, information about <e1>FOXP3</e1> gene in <e2>psoriasis</e2> is limited.","Association"
"However, information about <e1>FOXP3</e1> gene in <e2>psoriasis</e2> is limited.","Association"
"However, information about <e1>FOXP3</e1> gene in <e2>psoriasis</e2> is limited.","Association"
"However, information about <e1>FOXP3</e1> gene in <e2>psoriasis</e2> is limited.","Association"
"However, information about <e1>FOXP3</e1> gene in <e2>psoriasis</e2> is limited.","Association"
"However, information about <e1>FOXP3</e1> gene in <e2>psoriasis</e2> is limited.","Association"
"However, information about <e1>FOXP3</e1> gene in <e2>psoriasis</e2> is limited.","Association"
"Studies have found that single-nucleotide polymorphisms (SNPs) in the <e1>FOXP3</e1> gene contribute to susceptibility to some <e2>autoimmune disorders</e2>.","Association"
"Studies have found that single-nucleotide polymorphisms (SNPs) in the <e1>FOXP3</e1> gene contribute to susceptibility to some <e2>autoimmune disorders</e2>.","Association"
"Studies have found that single-nucleotide polymorphisms (SNPs) in the <e1>FOXP3</e1> gene contribute to susceptibility to some <e2>autoimmune disorders</e2>.","Association"
"Studies have found that single-nucleotide polymorphisms (SNPs) in the <e1>FOXP3</e1> gene contribute to susceptibility to some <e2>autoimmune disorders</e2>.","Association"
"Studies have found that single-nucleotide polymorphisms (SNPs) in the <e1>FOXP3</e1> gene contribute to susceptibility to some <e2>autoimmune disorders</e2>.","Association"
"Studies have found that single-nucleotide polymorphisms (SNPs) in the <e1>FOXP3</e1> gene contribute to susceptibility to some <e2>autoimmune disorders</e2>.","Association"
"Studies have found that single-nucleotide polymorphisms (SNPs) in the <e1>FOXP3</e1> gene contribute to susceptibility to some <e2>autoimmune disorders</e2>.","Association"
"Studies have found that single-nucleotide polymorphisms (SNPs) in the <e1>FOXP3</e1> gene contribute to susceptibility to some <e2>autoimmune disorders</e2>.","Association"
"Studies have found that single-nucleotide polymorphisms (SNPs) in the <e1>FOXP3</e1> gene contribute to susceptibility to some <e2>autoimmune disorders</e2>.","Association"
"Studies have found that single-nucleotide polymorphisms (SNPs) in the <e1>FOXP3</e1> gene contribute to susceptibility to some <e2>autoimmune disorders</e2>.","Association"
"Studies have found that single-nucleotide polymorphisms (SNPs) in the <e1>FOXP3</e1> gene contribute to susceptibility to some <e2>autoimmune disorders</e2>.","Association"
"Studies have found that single-nucleotide polymorphisms (SNPs) in the <e1>FOXP3</e1> gene contribute to susceptibility to some <e2>autoimmune disorders</e2>.","Association"
"Autosomal dominant mutation in the signal peptide of <e1>renin</e1> in a kindred with anemia, hyperuricemia, and <e2>CKD</e2>.","Association"
"Autosomal dominant mutation in the signal peptide of <e1>renin</e1> in a kindred with <e2>anemia</e2>, hyperuricemia, and CKD.","Association"
"Autosomal dominant mutation in the signal peptide of <e1>renin</e1> in a kindred with anemia, <e2>hyperuricemia</e2>, and CKD.","Association"
"Homozygous or compound heterozygous mutations in <e1>renin</e1> (REN) cause <e2>renal tubular dysgenesis</e2>, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.","Association"
"Homozygous or compound heterozygous mutations in renin (<e1>REN</e1>) cause <e2>renal tubular dysgenesis</e2>, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.","Association"
"Homozygous or compound heterozygous mutations in renin (<e1>REN</e1>) cause <e2>renal tubular dysgenesis</e2>, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.","Association"
"Homozygous or compound heterozygous mutations in renin (<e1>REN</e1>) cause <e2>renal tubular dysgenesis</e2>, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.","Association"
"Homozygous or compound heterozygous mutations in renin (<e1>REN</e1>) cause <e2>renal tubular dysgenesis</e2>, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.","Association"
"Homozygous or compound heterozygous mutations in renin (<e1>REN</e1>) cause <e2>renal tubular dysgenesis</e2>, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.","Association"
"Homozygous or compound heterozygous mutations in renin (<e1>REN</e1>) cause <e2>renal tubular dysgenesis</e2>, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.","Association"
"Homozygous or compound heterozygous mutations in renin (<e1>REN</e1>) cause <e2>renal tubular dysgenesis</e2>, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.","Association"
"Homozygous or compound heterozygous mutations in renin (<e1>REN</e1>) cause <e2>renal tubular dysgenesis</e2>, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.","Association"
"Homozygous or compound heterozygous mutations in renin (<e1>REN</e1>) cause <e2>renal tubular dysgenesis</e2>, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, anemia, and <e2>chronic kidney disease</e2> (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, anemia, and <e2>chronic kidney disease</e2> (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, anemia, and <e2>chronic kidney disease</e2> (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, anemia, and <e2>chronic kidney disease</e2> (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, anemia, and <e2>chronic kidney disease</e2> (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, anemia, and <e2>chronic kidney disease</e2> (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, anemia, and <e2>chronic kidney disease</e2> (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, anemia, and <e2>chronic kidney disease</e2> (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, anemia, and <e2>chronic kidney disease</e2> (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, <e2>anemia</e2>, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, <e2>anemia</e2>, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, <e2>anemia</e2>, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, <e2>anemia</e2>, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, <e2>anemia</e2>, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, <e2>anemia</e2>, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, <e2>anemia</e2>, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, <e2>anemia</e2>, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset hyperuricemia, <e2>anemia</e2>, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset <e2>hyperuricemia</e2>, anemia, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset <e2>hyperuricemia</e2>, anemia, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset <e2>hyperuricemia</e2>, anemia, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset <e2>hyperuricemia</e2>, anemia, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset <e2>hyperuricemia</e2>, anemia, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset <e2>hyperuricemia</e2>, anemia, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset <e2>hyperuricemia</e2>, anemia, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset <e2>hyperuricemia</e2>, anemia, and chronic kidney disease (CKD).","Association"
"Recently, heterozygous <e1>REN</e1> mutations were shown to result in early-onset <e2>hyperuricemia</e2>, anemia, and chronic kidney disease (CKD).","Association"
"The phenotype resembles the <e1>fetopathy</e1> caused by angiotensin-converting enzyme inhibitor or <e2>angiotensin receptor blocker</e2> intake during pregnancy.","Positive_Correlation"
"The phenotype resembles the <e1>fetopathy</e1> caused by <e2>angiotensin-converting enzyme inhibitor</e2> or angiotensin receptor blocker intake during pregnancy.","Positive_Correlation"
"On the pivotal role of <e2>PPARa</e2> in adaptation of the heart to <e1>hypoxia</e1> and why fat in the diet increases hypoxic injury.","Negative_Correlation"
"On the pivotal role of <e2>PPARa</e2> in adaptation of the heart to hypoxia and why fat in the diet increases <e1>hypoxic</e1> injury.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and <e1>mitochondrial uncoupling protein 3</e1> (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (<e1>UCP3</e1>) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (<e1>UCP3</e1>) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, <e1>fatty acid</e1> oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, <e1>fatty acid</e1> oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, <e1>fatty acid</e1> oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased <e1>PPARa</e1> expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased <e1>PPARa</e1> expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased <e1>PPARa</e1> expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased <e1>PPARa</e1> expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased <e1>PPARa</e1> expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased <e1>PPARa</e1> expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased <e1>PPARa</e1> expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased <e1>PPARa</e1> expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Association"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"<e1>Hypoxia</e1> was unable to alter the high PPARa expression or reverse the metabolic changes caused by the high-fat diet, with the result that [<e2>ATP</e2>] and contractile function decreased significantly.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <e2>ATP</e2> concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and <e2>mitochondrial uncoupling protein 3</e2> (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and <e2>mitochondrial uncoupling protein 3</e2> (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and <e2>mitochondrial uncoupling protein 3</e2> (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and <e2>mitochondrial uncoupling protein 3</e2> (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and <e2>mitochondrial uncoupling protein 3</e2> (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and <e2>mitochondrial uncoupling protein 3</e2> (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, fatty acid oxidation, and <e2>mitochondrial uncoupling protein 3</e2> (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, <e2>fatty acid</e2> oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, <e2>fatty acid</e2> oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, <e2>fatty acid</e2> oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, <e2>fatty acid</e2> oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, <e2>fatty acid</e2> oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, <e2>fatty acid</e2> oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"Compared with a normoxic, chow-fed control mouse heart, <e1>hypoxia</e1> decreased PPARa expression, <e2>fatty acid</e2> oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.","Negative_Correlation"
"The role of <e2>peroxisome proliferator-activated receptor a</e2> (PPARa)-mediated metabolic remodeling in cardiac adaptation to <e1>hypoxia</e1> has yet to be defined.","Negative_Correlation"
"The role of <e2>peroxisome proliferator-activated receptor a</e2> (PPARa)-mediated metabolic remodeling in cardiac adaptation to <e1>hypoxia</e1> has yet to be defined.","Negative_Correlation"
"The role of <e2>peroxisome proliferator-activated receptor a</e2> (PPARa)-mediated metabolic remodeling in cardiac adaptation to <e1>hypoxia</e1> has yet to be defined.","Negative_Correlation"
"<e1>Hypoxia</e1> was unable to alter the high <e2>PPARa</e2> expression or reverse the metabolic changes caused by the high-fat diet, with the result that [ATP] and contractile function decreased significantly.","Negative_Correlation"
"The role of <e2>peroxisome proliferator-activated receptor a</e2> (PPARa)-mediated metabolic remodeling in cardiac adaptation to <e1>hypoxia</e1> has yet to be defined.","Negative_Correlation"
"The role of <e2>peroxisome proliferator-activated receptor a</e2> (PPARa)-mediated metabolic remodeling in cardiac adaptation to <e1>hypoxia</e1> has yet to be defined.","Negative_Correlation"
"The role of <e2>peroxisome proliferator-activated receptor a</e2> (PPARa)-mediated metabolic remodeling in cardiac adaptation to <e1>hypoxia</e1> has yet to be defined.","Negative_Correlation"
"The role of <e2>peroxisome proliferator-activated receptor a</e2> (PPARa)-mediated metabolic remodeling in cardiac adaptation to <e1>hypoxia</e1> has yet to be defined.","Negative_Correlation"
"We conclude that decreased cardiac <e2>PPARa</e2> expression is essential for adaptive metabolic remodeling in hypoxia, but is prevented by dietary fat.-Cole, M. A., Abd Jamil, A. H., Heather, L. C., Murray, A. J., Sutton, E. R., Slingo, M., Sebag-Montefiore, L., Tan, S. C., Aksentijevic, D., Gildea, O. S., Stuckey, D. J., Yeoh, K. K., Carr, C. A., Evans, R. D., Aasum, E., Schofield, C. J., Ratcliffe, P. J., Neubauer, S., Robbins, P. A., Clarke, K. On the pivotal role of PPARa in adaptation of the heart to hypoxia and why fat in the diet increases <e1>hypoxic</e1> injury.","Negative_Correlation"
"<e1>Gartanin</e1> induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human <e2>glioma</e2> cells.","Negative_Correlation"
"Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/<e1>Akt</e1>/<e2>mTOR</e2> and MAPK signalling pathway in human glioma cells.","Association"
"Gartanin induces cell cycle arrest and autophagy and suppresses migration involving <e1>PI3K</e1>/Akt/<e2>mTOR</e2> and MAPK signalling pathway in human glioma cells.","Association"
"Gartanin induces cell cycle arrest and autophagy and suppresses migration involving <e1>PI3K</e1>/<e2>Akt</e2>/mTOR and MAPK signalling pathway in human glioma cells.","Association"
"Gartanin, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins cyclin D1, while increased expression level of <e1>cyclin-dependent kinase</e1> inhibitor <e2>p27Kip1</e2>.","Negative_Correlation"
"Gartanin, a natural <e1>xanthone</e1> of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G <e2>glioma</e2> cells but not in mouse normal neuronal HT22 cells.","Association"
"Notably, <e1>gartanin</e1>-mediated anti-viability was significantly abrogated by autophagy inhibitors including 3-methyladenine (3-MA) and <e2>chloroquine</e2> (CQ).","Negative_Correlation"
"Notably, <e1>gartanin</e1>-mediated anti-viability was significantly abrogated by autophagy inhibitors including 3-methyladenine (3-MA) and <e2>chloroquine</e2> (CQ).","Negative_Correlation"
"Notably, <e1>gartanin</e1>-mediated anti-viability was significantly abrogated by autophagy inhibitors including 3-methyladenine (3-MA) and <e2>chloroquine</e2> (CQ).","Negative_Correlation"
"Notably, <e1>gartanin</e1>-mediated anti-viability was significantly abrogated by autophagy inhibitors including 3-methyladenine (3-MA) and <e2>chloroquine</e2> (CQ).","Negative_Correlation"
"Notably, <e1>gartanin</e1>-mediated anti-viability was significantly abrogated by autophagy inhibitors including <e2>3-methyladenine</e2> (3-MA) and chloroquine (CQ).","Negative_Correlation"
"Notably, <e1>gartanin</e1>-mediated anti-viability was significantly abrogated by autophagy inhibitors including <e2>3-methyladenine</e2> (3-MA) and chloroquine (CQ).","Negative_Correlation"
"Notably, <e1>gartanin</e1>-mediated anti-viability was significantly abrogated by autophagy inhibitors including <e2>3-methyladenine</e2> (3-MA) and chloroquine (CQ).","Negative_Correlation"
"Notably, <e1>gartanin</e1>-mediated anti-viability was significantly abrogated by autophagy inhibitors including <e2>3-methyladenine</e2> (3-MA) and chloroquine (CQ).","Negative_Correlation"
"Moreover, <e1>gartanin</e1> significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of <e2>p62</e2>.","Negative_Correlation"
"Moreover, <e1>gartanin</e1> significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of <e2>p62</e2>.","Negative_Correlation"
"Moreover, <e1>gartanin</e1> significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of <e2>p62</e2>.","Negative_Correlation"
"Moreover, <e1>gartanin</e1> significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of <e2>p62</e2>.","Negative_Correlation"
"Moreover, <e1>gartanin</e1> significantly induced autophagy in T98G cells and increased GFP-<e2>LC3</e2> punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of p62.","Positive_Correlation"
"Moreover, <e1>gartanin</e1> significantly induced autophagy in T98G cells and increased GFP-<e2>LC3</e2> punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of p62.","Positive_Correlation"
"Moreover, <e1>gartanin</e1> significantly induced autophagy in T98G cells and increased GFP-<e2>LC3</e2> punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of p62.","Positive_Correlation"
"Moreover, <e1>gartanin</e1> significantly induced autophagy in T98G cells and increased GFP-<e2>LC3</e2> punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of p62.","Positive_Correlation"
"Moreover, <e1>gartanin</e1> significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of <e2>Beclin 1</e2> and LC3-II, while suppressed expression level of p62.","Positive_Correlation"
"Moreover, <e1>gartanin</e1> significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of <e2>Beclin 1</e2> and LC3-II, while suppressed expression level of p62.","Positive_Correlation"
"Moreover, <e1>gartanin</e1> significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of <e2>Beclin 1</e2> and LC3-II, while suppressed expression level of p62.","Positive_Correlation"
"Moreover, <e1>gartanin</e1> significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of <e2>Beclin 1</e2> and LC3-II, while suppressed expression level of p62.","Positive_Correlation"
"<e1>Gartanin</e1>, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins cyclin D1, while increased expression level of cyclin-dependent kinase inhibitor <e2>p27Kip1</e2>.","Positive_Correlation"
"<e1>Gartanin</e1>, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins cyclin D1, while increased expression level of cyclin-dependent kinase inhibitor <e2>p27Kip1</e2>.","Positive_Correlation"
"<e1>Gartanin</e1>, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins cyclin D1, while increased expression level of cyclin-dependent kinase inhibitor <e2>p27Kip1</e2>.","Positive_Correlation"
"<e1>Gartanin</e1>, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins <e2>cyclin D1</e2>, while increased expression level of cyclin-dependent kinase inhibitor p27Kip1.","Negative_Correlation"
"<e1>Gartanin</e1>, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins <e2>cyclin D1</e2>, while increased expression level of cyclin-dependent kinase inhibitor p27Kip1.","Negative_Correlation"
"<e1>Gartanin</e1>, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins <e2>cyclin D1</e2>, while increased expression level of cyclin-dependent kinase inhibitor p27Kip1.","Negative_Correlation"
"<e1>Gartanin</e1>, a natural xanthone of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G <e2>glioma</e2> cells but not in mouse normal neuronal HT22 cells.","Negative_Correlation"
"<e1>Gartanin</e1>, a natural xanthone of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G <e2>glioma</e2> cells but not in mouse normal neuronal HT22 cells.","Negative_Correlation"
"In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with <e1>gartanin</e1>, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G <e2>glioma</e2> cells.","Negative_Correlation"
"In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with <e1>gartanin</e1>, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G <e2>glioma</e2> cells.","Negative_Correlation"
"<e1>Gartanin</e1>, a natural xanthone of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G <e2>glioma</e2> cells but not in mouse normal neuronal HT22 cells.","Negative_Correlation"
"In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with <e1>gartanin</e1>, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G <e2>glioma</e2> cells.","Negative_Correlation"
"In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with <e1>gartanin</e1>, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G <e2>glioma</e2> cells.","Negative_Correlation"
"Gartanin treatment resulted in obvious inhibition of PI3K/<e1>Akt</e1>/<e2>mTOR</e2> signalling pathway, which is important in modulating autophagy.","Association"
"Gartanin treatment resulted in obvious inhibition of PI3K/<e1>Akt</e1>/<e2>mTOR</e2> signalling pathway, which is important in modulating autophagy.","Association"
"Gartanin treatment resulted in obvious inhibition of <e1>PI3K</e1>/Akt/<e2>mTOR</e2> signalling pathway, which is important in modulating autophagy.","Association"
"Gartanin treatment resulted in obvious inhibition of <e1>PI3K</e1>/Akt/<e2>mTOR</e2> signalling pathway, which is important in modulating autophagy.","Association"
"Gartanin treatment resulted in obvious inhibition of <e1>PI3K</e1>/<e2>Akt</e2>/mTOR signalling pathway, which is important in modulating autophagy.","Association"
"Gartanin treatment resulted in obvious inhibition of <e1>PI3K</e1>/<e2>Akt</e2>/mTOR signalling pathway, which is important in modulating autophagy.","Association"
"However, despite the cloning of the <e1>cystic fibrosis transmembrane conductance regulator</e1> gene in 1989, over 15 years later a practical gene therapy for <e2>CF</e2> has not eventuated.","Association"
"Mutation in the auxiliary calcium-channel subunit <e1>CACNA2D4</e1> causes autosomal recessive <e2>cone dystrophy</e2>.","Association"
"Mutation in the auxiliary <e1>calcium</e1>-channel subunit <e2>CACNA2D4</e2> causes autosomal recessive cone dystrophy.","Association"
"The <e1>Cacna2d4</e1> gene encodes an <e2>l-type calcium-channel auxiliary subunit of the alpha (2) delta type</e2>.","Association"
"The <e1>Cacna2d4</e1> gene encodes an <e2>l-type calcium-channel auxiliary subunit of the alpha (2) delta type</e2>.","Association"
"We performed mutation analyses of 34 patients who received an initial diagnosis of <e2>night blindness</e2>, and, in two affected siblings, we detected a homozygous nucleotide substitution (<e1>c.2406C-->A</e1>) in CACNA2D4.","Association"
"We performed mutation analyses of 34 patients who received an initial diagnosis of <e2>night blindness</e2>, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in <e1>CACNA2D4</e1>.","Association"
"We performed mutation analyses of 34 patients who received an initial diagnosis of <e2>night blindness</e2>, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in <e1>CACNA2D4</e1>.","Association"
"We performed mutation analyses of 34 patients who received an initial diagnosis of <e2>night blindness</e2>, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in <e1>CACNA2D4</e1>.","Association"
"These findings represent the first report of a mutation in the human <e1>CACNA2D4</e1> gene and define a novel gene defect that causes autosomal recessive <e2>cone dystrophy</e2>.","Association"
"These findings represent the first report of a mutation in the human <e1>CACNA2D4</e1> gene and define a novel gene defect that causes autosomal recessive <e2>cone dystrophy</e2>.","Association"
"These findings represent the first report of a mutation in the human <e1>CACNA2D4</e1> gene and define a novel gene defect that causes autosomal recessive <e2>cone dystrophy</e2>.","Association"
"A homozygous mutation in <e1>LYRM7</e1>/MZM1L associated with early onset encephalopathy, <e2>lactic acidosis</e2>, and severe reduction of mitochondrial complex III activity.","Association"
"A homozygous mutation in LYRM7/<e1>MZM1L</e1> associated with early onset encephalopathy, <e2>lactic acidosis</e2>, and severe reduction of mitochondrial complex III activity.","Association"
"A homozygous mutation in <e1>LYRM7</e1>/MZM1L associated with early onset encephalopathy, lactic acidosis, and severe <e2>reduction of mitochondrial complex III</e2> activity.","Association"
"A homozygous mutation in LYRM7/<e1>MZM1L</e1> associated with early onset encephalopathy, lactic acidosis, and severe <e2>reduction of mitochondrial complex III</e2> activity.","Association"
"A homozygous mutation in <e1>LYRM7</e1>/MZM1L associated with early onset <e2>encephalopathy</e2>, lactic acidosis, and severe reduction of mitochondrial complex III activity.","Association"
"A homozygous mutation in LYRM7/<e1>MZM1L</e1> associated with early onset <e2>encephalopathy</e2>, lactic acidosis, and severe reduction of mitochondrial complex III activity.","Association"
"In a mzm1D yeast strain, the expression of a mzm1(<e1>D25N</e1>) mutant allele caused temperature-sensitive respiratory growth defect, decreased <e2>oxygen</e2> consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.","Association"
"In a mzm1D yeast strain, the expression of a mzm1(<e1>D25N</e1>) mutant allele caused temperature-sensitive <e2>respiratory growth defect</e2>, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.","Positive_Correlation"
"In a baby patient with early onset, severe <e2>encephalopathy</e2>, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (<e1>c.73G>A</e1>) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Positive_Correlation"
"In a baby patient with early onset, severe <e2>encephalopathy</e2>, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (<e1>p.Asp25Asn</e1>).","Positive_Correlation"
"Recently, human LYRM7/<e1>MZM1</e1>L, the ortholog of yeast MZM1, has been identified as a new assembly factor for <e2>cIII</e2>.","Negative_Correlation"
"In a <e1>mzm1D</e1> yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced <e2>complex III</e2> activity and amount.","Negative_Correlation"
"In a <e1>mzm1</e1>D yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced <e2>complex III</e2> activity and amount.","Negative_Correlation"
"In a <e1>mzm1D</e1> yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased <e2>oxygen</e2> consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.","Association"
"In a <e1>mzm1</e1>D yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased <e2>oxygen</e2> consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.","Association"
"In a <e1>mzm1D</e1> yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the <e2>Rieske Fe-S protein</e2>, and reduced complex III activity and amount.","Association"
"In a <e1>mzm1</e1>D yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the <e2>Rieske Fe-S protein</e2>, and reduced complex III activity and amount.","Association"
"In a <e1>mzm1D</e1> yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive <e2>respiratory growth defect</e2>, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.","Association"
"In a <e1>mzm1</e1>D yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive <e2>respiratory growth defect</e2>, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.","Association"
"In a baby patient with early onset, severe encephalopathy, <e1>lactic acidosis</e1> and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (<e2>c.73G>A</e2>) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Positive_Correlation"
"In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated <e1>cIII deficiency</e1> in skeletal muscle, we identified a disease-segregating homozygous mutation (<e2>c.73G>A</e2>) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Positive_Correlation"
"Mutations in nuclear genes associated with <e1>defective complex III (<e2>cIII</e2>) of the mitochondrial</e1> respiratory chain are rare, having been found in only two cIII assembly factors and, as private changes in single families, three cIII structural subunits.","Negative_Correlation"
"In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated <e1><e2>cIII</e2> deficiency</e1> in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Negative_Correlation"
"LYRM7/MZM1L is a novel disease gene, causing <e1><e2>cIII</e2>-defective</e1>, early onset, severe mitochondrial encephalopathy.","Negative_Correlation"
"<e1>LYRM7</e1>/MZM1L is a novel disease gene, causing cIII-defective, early onset, severe <e2>mitochondrial encephalopathy</e2>.","Association"
"LYRM7/<e1>MZM1L</e1> is a novel disease gene, causing cIII-defective, early onset, severe <e2>mitochondrial encephalopathy</e2>.","Association"
"<e1>LYRM7</e1>/MZM1L is a novel disease gene, causing cIII-defective, early onset, severe <e2>mitochondrial encephalopathy</e2>.","Association"
"LYRM7/<e1>MZM1L</e1> is a novel disease gene, causing cIII-defective, early onset, severe <e2>mitochondrial encephalopathy</e2>.","Association"
"<e1>LYRM7</e1>/MZM1L is a novel disease gene, causing cIII-defective, early onset, severe <e2>mitochondrial encephalopathy</e2>.","Association"
"LYRM7/<e1>MZM1L</e1> is a novel disease gene, causing cIII-defective, early onset, severe <e2>mitochondrial encephalopathy</e2>.","Association"
"Recently, human <e1>LYRM7</e1>/MZM1L, the ortholog of yeast MZM1, has been identified as a new assembly factor for <e2>cIII</e2>.","Association"
"Recently, human LYRM7/<e1>MZM1L</e1>, the ortholog of yeast MZM1, has been identified as a new assembly factor for <e2>cIII</e2>.","Association"
"Recently, human <e1>LYRM7</e1>/MZM1L, the ortholog of yeast MZM1, has been identified as a new assembly factor for <e2>cIII</e2>.","Association"
"Recently, human LYRM7/<e1>MZM1L</e1>, the ortholog of yeast MZM1, has been identified as a new assembly factor for <e2>cIII</e2>.","Association"
"Recently, human <e1>LYRM7</e1>/MZM1L, the ortholog of yeast MZM1, has been identified as a new assembly factor for <e2>cIII</e2>.","Association"
"Recently, human LYRM7/<e1>MZM1L</e1>, the ortholog of yeast MZM1, has been identified as a new assembly factor for <e2>cIII</e2>.","Association"
"In a baby patient with early onset, severe encephalopathy, <e2>lactic acidosis</e2> and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in <e1>LYRM7</e1>/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe encephalopathy, <e2>lactic acidosis</e2> and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/<e1>MZM1L</e1>, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe encephalopathy, <e2>lactic acidosis</e2> and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in <e1>LYRM7</e1>/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe encephalopathy, <e2>lactic acidosis</e2> and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/<e1>MZM1L</e1>, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe encephalopathy, <e2>lactic acidosis</e2> and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in <e1>LYRM7</e1>/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe encephalopathy, <e2>lactic acidosis</e2> and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/<e1>MZM1L</e1>, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated <e2>cIII deficiency</e2> in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in <e1>LYRM7</e1>/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated <e2>cIII deficiency</e2> in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/<e1>MZM1L</e1>, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated <e2>cIII deficiency</e2> in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in <e1>LYRM7</e1>/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated <e2>cIII deficiency</e2> in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/<e1>MZM1L</e1>, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated <e2>cIII deficiency</e2> in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in <e1>LYRM7</e1>/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated <e2>cIII deficiency</e2> in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/<e1>MZM1L</e1>, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe <e2>encephalopathy</e2>, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in <e1>LYRM7</e1>/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe <e2>encephalopathy</e2>, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/<e1>MZM1L</e1>, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe <e2>encephalopathy</e2>, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in <e1>LYRM7</e1>/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe <e2>encephalopathy</e2>, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/<e1>MZM1L</e1>, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe <e2>encephalopathy</e2>, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in <e1>LYRM7</e1>/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"In a baby patient with early onset, severe <e2>encephalopathy</e2>, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/<e1>MZM1L</e1>, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).","Association"
"<e1>UL97 protein kinase</e1> changes responsible for resistance to <e2>ganciclovir</e2> were initially detected at residues 591 and 592, and then at position 594.","Association"
"Decreased sensitivity to <e1>foscarnet</e1> coincided with the appearance of amino acid substitution <e2>N495K</e2> in DNA polymerase, whereas cross-resistance to ganciclovir and cidofovir was due to the L501I substitution.","Negative_Correlation"
"Decreased sensitivity to <e1>foscarnet</e1> coincided with the appearance of amino acid substitution <e2>N495K</e2> in DNA polymerase, whereas cross-resistance to ganciclovir and cidofovir was due to the L501I substitution.","Negative_Correlation"
"Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase, whereas cross-resistance to ganciclovir and <e1>cidofovir</e1> was due to the <e2>L501I</e2> substitution.","Negative_Correlation"
"Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase, whereas cross-resistance to ganciclovir and <e1>cidofovir</e1> was due to the <e2>L501I</e2> substitution.","Negative_Correlation"
"Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase, whereas cross-resistance to <e1>ganciclovir</e1> and cidofovir was due to the <e2>L501I</e2> substitution.","Negative_Correlation"
"Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase, whereas cross-resistance to <e1>ganciclovir</e1> and cidofovir was due to the <e2>L501I</e2> substitution.","Negative_Correlation"
"Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase, whereas cross-resistance to <e1>ganciclovir</e1> and cidofovir was due to the <e2>L501I</e2> substitution.","Negative_Correlation"
"In parallel, we used <e1>glycoprotein B</e1> (gB) genotyping, and a- and UL10-13-sequence analysis to study <e2>CMV</e2> interstrain variability.","Association"
"In parallel, we used glycoprotein B (<e1>gB</e1>) genotyping, and a- and UL10-13-sequence analysis to study <e2>CMV</e2> interstrain variability.","Association"
"Our results suggest the importance of routine screening for the rather frequent -3170G>A mutation (in addition to <e1>c.35delG</e1>) in patients with <e2>hearing impairment</e2>.","Positive_Correlation"
"Our results suggest the importance of routine screening for the rather frequent <e1>-3170G>A</e1> mutation (in addition to c.35delG) in patients with <e2>hearing impairment</e2>.","Positive_Correlation"
"Our results suggest the importance of routine screening for the rather frequent <e1>-3170G>A</e1> mutation (in addition to c.35delG) in patients with <e2>hearing impairment</e2>.","Positive_Correlation"
"Our results suggest the importance of routine screening for the rather frequent <e1>-3170G>A</e1> mutation (in addition to c.35delG) in patients with <e2>hearing impairment</e2>.","Positive_Correlation"
"Mutations in the <e1>GJB2</e1> gene are the most common cause of hereditary prelingual <e2>sensorineural hearing impairment</e2> in Europe.","Association"
"Mutations in the <e1>GJB2</e1> gene are the most common cause of hereditary prelingual <e2>sensorineural hearing impairment</e2> in Europe.","Association"
"Mutations in the <e1>GJB2</e1> gene are the most common cause of hereditary prelingual <e2>sensorineural hearing impairment</e2> in Europe.","Association"
"Mutations in the <e1>GJB2</e1> gene are the most common cause of hereditary prelingual <e2>sensorineural hearing impairment</e2> in Europe.","Association"
"Mutations in the <e1>GJB2</e1> gene are the most common cause of hereditary prelingual <e2>sensorineural hearing impairment</e2> in Europe.","Association"
"Mutations in the <e1>GJB2</e1> gene are the most common cause of hereditary prelingual <e2>sensorineural hearing impairment</e2> in Europe.","Association"
"Mutations in the <e1>GJB2</e1> gene are the most common cause of hereditary prelingual <e2>sensorineural hearing impairment</e2> in Europe.","Association"
"Calcium sensing receptor protects high <e1>glucose</e1>-induced energy metabolism disorder via blocking <e2>gp78</e2>-ubiquitin proteasome pathway.","Positive_Correlation"
"Calcium sensing receptor protects high <e1>glucose</e1>-induced energy <e2>metabolism disorder</e2> via blocking gp78-ubiquitin proteasome pathway.","Positive_Correlation"
"<e1>Calcium sensing receptor</e1> protects high <e2>glucose</e2>-induced energy metabolism disorder via blocking gp78-ubiquitin proteasome pathway.","Negative_Correlation"
"<e1>Calcium sensing receptor</e1> protects high glucose-induced energy <e2>metabolism disorder</e2> via blocking gp78-ubiquitin proteasome pathway.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, <e2>Drp1</e2>), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, <e2>Drp1</e2>), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, <e2>Drp1</e2>), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (<e2>Fis1</e2>, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (<e2>Fis1</e2>, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (<e2>Fis1</e2>, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.","Association"
"In contrast, HG increased extracellular <e2>ATP</e2> concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.","Association"
"In contrast, HG increased extracellular <e2>ATP</e2> concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.","Association"
"In contrast, HG increased extracellular <e2>ATP</e2> concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and <e2>Cx43</e2>.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and <e2>Cx43</e2>.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and <e2>Cx43</e2>.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, <e2>Mfn2</e2> and Cx43.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, <e2>Mfn2</e2> and Cx43.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, <e2>Mfn2</e2> and Cx43.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of <e2>Mfn1</e2>, Mfn2 and Cx43.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of <e2>Mfn1</e2>, Mfn2 and Cx43.","Association"
"In contrast, HG increased extracellular ATP concentration, the expression of <e1>gp78</e1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of <e2>Mfn1</e2>, Mfn2 and Cx43.","Association"
"Taken together, these results suggest that HG induces <e2>myocardial energy metabolism disorder</e2> via decrease of CaSR expression, and activation of <e1>gp78</e1>-ubiquitin proteasome system.","Association"
"Taken together, these results suggest that HG induces <e2>myocardial energy metabolism disorder</e2> via decrease of CaSR expression, and activation of <e1>gp78</e1>-ubiquitin proteasome system.","Association"
"Taken together, these results suggest that HG induces <e2>myocardial energy metabolism disorder</e2> via decrease of CaSR expression, and activation of <e1>gp78</e1>-ubiquitin proteasome system.","Association"
"In our previous study, we found that CaSR expression, intracellular <e1>calcium</e1> levels and cardiac function were all significantly decreased in <e2>DCM</e2> rats; however, the exact mechanism are not clear yet.","Negative_Correlation"
"In our previous study, we found that CaSR expression, intracellular <e1>calcium</e1> levels and cardiac function were all significantly decreased in <e2>DCM</e2> rats; however, the exact mechanism are not clear yet.","Negative_Correlation"
"The present study revealed the protective role of CaSR in <e2>myocardial energy metabolism disorder</e2> induced by high <e1>glucose</e1> (HG) as well as the underlying mechanism.","Positive_Correlation"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular <e2>ATP</e2> concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular <e2>ATP</e2> concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular <e2>ATP</e2> concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular <e2>ATP</e2> concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular <e2>ATP</e2> concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular <e2>ATP</e2> concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular <e2>ATP</e2> concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular <e2>ATP</e2> concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (<e2>Cx43</e2>, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (<e2>Cx43</e2>, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (<e2>Cx43</e2>, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (<e2>Cx43</e2>, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (<e2>Cx43</e2>, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (<e2>Cx43</e2>, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (<e2>Cx43</e2>, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (<e2>Cx43</e2>, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, <e2>Mfn2</e2>), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, <e2>Mfn2</e2>), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, <e2>Mfn2</e2>), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, <e2>Mfn2</e2>), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, <e2>Mfn2</e2>), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, <e2>Mfn2</e2>), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, <e2>Mfn2</e2>), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (Mfn1, <e2>Mfn2</e2>), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (<e2>Mfn1</e2>, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (<e2>Mfn1</e2>, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (<e2>Mfn1</e2>, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (<e2>Mfn1</e2>, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (<e2>Mfn1</e2>, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (<e2>Mfn1</e2>, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (<e2>Mfn1</e2>, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"Here, we demonstrated that HG decreased the expression of <e1>CaSR</e1>, mitochondrial fusion proteins (<e2>Mfn1</e2>, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.","Association"
"The present study revealed the protective role of <e1>CaSR</e1> in <e2>myocardial energy metabolism disorder</e2> induced by high glucose (HG) as well as the underlying mechanism.","Association"
"The present study revealed the protective role of <e1>CaSR</e1> in <e2>myocardial energy metabolism disorder</e2> induced by high glucose (HG) as well as the underlying mechanism.","Association"
"The present study revealed the protective role of <e1>CaSR</e1> in <e2>myocardial energy metabolism disorder</e2> induced by high glucose (HG) as well as the underlying mechanism.","Association"
"The present study revealed the protective role of <e1>CaSR</e1> in <e2>myocardial energy metabolism disorder</e2> induced by high glucose (HG) as well as the underlying mechanism.","Association"
"The present study revealed the protective role of <e1>CaSR</e1> in <e2>myocardial energy metabolism disorder</e2> induced by high glucose (HG) as well as the underlying mechanism.","Association"
"The present study revealed the protective role of <e1>CaSR</e1> in <e2>myocardial energy metabolism disorder</e2> induced by high glucose (HG) as well as the underlying mechanism.","Association"
"The present study revealed the protective role of <e1>CaSR</e1> in <e2>myocardial energy metabolism disorder</e2> induced by high glucose (HG) as well as the underlying mechanism.","Association"
"The present study revealed the protective role of <e1>CaSR</e1> in <e2>myocardial energy metabolism disorder</e2> induced by high glucose (HG) as well as the underlying mechanism.","Association"
"In our previous study, we found that <e1>CaSR</e1> expression, intracellular calcium levels and cardiac function were all significantly decreased in <e2>DCM</e2> rats; however, the exact mechanism are not clear yet.","Negative_Correlation"
"In our previous study, we found that <e1>CaSR</e1> expression, intracellular calcium levels and cardiac function were all significantly decreased in <e2>DCM</e2> rats; however, the exact mechanism are not clear yet.","Negative_Correlation"
"In our previous study, we found that <e1>CaSR</e1> expression, intracellular calcium levels and cardiac function were all significantly decreased in <e2>DCM</e2> rats; however, the exact mechanism are not clear yet.","Negative_Correlation"
"In our previous study, we found that <e1>CaSR</e1> expression, intracellular calcium levels and cardiac function were all significantly decreased in <e2>DCM</e2> rats; however, the exact mechanism are not clear yet.","Negative_Correlation"
"In our previous study, we found that <e1>CaSR</e1> expression, intracellular calcium levels and cardiac function were all significantly decreased in <e2>DCM</e2> rats; however, the exact mechanism are not clear yet.","Negative_Correlation"
"In our previous study, we found that <e1>CaSR</e1> expression, intracellular calcium levels and cardiac function were all significantly decreased in <e2>DCM</e2> rats; however, the exact mechanism are not clear yet.","Negative_Correlation"
"In our previous study, we found that <e1>CaSR</e1> expression, intracellular calcium levels and cardiac function were all significantly decreased in <e2>DCM</e2> rats; however, the exact mechanism are not clear yet.","Negative_Correlation"
"In our previous study, we found that <e1>CaSR</e1> expression, intracellular calcium levels and cardiac function were all significantly decreased in <e2>DCM</e2> rats; however, the exact mechanism are not clear yet.","Negative_Correlation"
"The <e1><e2>calcium</e2> sensing receptor</e1> (CaSR) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.","Association"
"The <e2>calcium</e2> sensing receptor (<e1>CaSR</e1>) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.","Association"
"The <e2>calcium</e2> sensing receptor (CaSR) is a <e1>G protein-coupled receptor</e1>, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.","Association"
"The <e2>calcium</e2> sensing receptor (<e1>CaSR</e1>) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.","Association"
"The <e2>calcium</e2> sensing receptor (<e1>CaSR</e1>) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.","Association"
"The <e2>calcium</e2> sensing receptor (<e1>CaSR</e1>) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.","Association"
"The <e2>calcium</e2> sensing receptor (<e1>CaSR</e1>) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.","Association"
"The <e2>calcium</e2> sensing receptor (<e1>CaSR</e1>) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.","Association"
"The <e2>calcium</e2> sensing receptor (<e1>CaSR</e1>) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.","Association"
"The <e2>calcium</e2> sensing receptor (<e1>CaSR</e1>) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.","Association"
"The present study revealed the protective role of <e1>CaSR</e1> in myocardial energy metabolism disorder induced by high <e2>glucose</e2> (HG) as well as the underlying mechanism.","Negative_Correlation"
"The present study revealed the protective role of <e1>CaSR</e1> in myocardial energy metabolism disorder induced by high <e2>glucose</e2> (HG) as well as the underlying mechanism.","Negative_Correlation"
"The present study revealed the protective role of <e1>CaSR</e1> in myocardial energy metabolism disorder induced by high <e2>glucose</e2> (HG) as well as the underlying mechanism.","Negative_Correlation"
"The present study revealed the protective role of <e1>CaSR</e1> in myocardial energy metabolism disorder induced by high <e2>glucose</e2> (HG) as well as the underlying mechanism.","Negative_Correlation"
"The present study revealed the protective role of <e1>CaSR</e1> in myocardial energy metabolism disorder induced by high <e2>glucose</e2> (HG) as well as the underlying mechanism.","Negative_Correlation"
"The present study revealed the protective role of <e1>CaSR</e1> in myocardial energy metabolism disorder induced by high <e2>glucose</e2> (HG) as well as the underlying mechanism.","Negative_Correlation"
"The present study revealed the protective role of <e1>CaSR</e1> in myocardial energy metabolism disorder induced by high <e2>glucose</e2> (HG) as well as the underlying mechanism.","Negative_Correlation"
"The present study revealed the protective role of <e1>CaSR</e1> in myocardial energy metabolism disorder induced by high <e2>glucose</e2> (HG) as well as the underlying mechanism.","Negative_Correlation"
"A novel compound, <e1>maltolyl p-coumarate</e1>, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo <e2>dementia</e2> models.","Association"
"A novel compound, <e1>maltolyl p-coumarate</e1>, attenuates <e2>cognitive deficits</e2> and shows neuroprotective effects in vitro and in vivo dementia models.","Negative_Correlation"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1>maltol</e1>yl p-coumarate by the esterification of maltol and <e2>p-coumaric acid</e2>.","Association"
"In the present study, we investigated whether maltolyl p-coumarate could improve <e1>cognitive decline</e1> in <e2>scopolamine</e2>-injected rats and in amyloid beta peptide(1-42)-infused rats.","Positive_Correlation"
"In the present study, we investigated whether maltolyl p-coumarate could improve <e1>cognitive decline</e1> in scopolamine-injected rats and in <e2>amyloid beta peptide(1-42)</e2>-infused rats.","Positive_Correlation"
"Maltolyl p-coumarate was found to attenuate <e1>cognitive deficits</e1> in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the <e2>amyloid beta peptide(1-42)</e2>-infused rats.","Positive_Correlation"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1>maltolyl p-coumarate</e1> by the esterification of maltol and <e2>p-coumaric acid</e2>.","Association"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1>maltolyl p-coumarate</e1> by the esterification of maltol and <e2>p-coumaric acid</e2>.","Association"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1>maltolyl p-coumarate</e1> by the esterification of maltol and <e2>p-coumaric acid</e2>.","Association"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1>maltolyl p-coumarate</e1> by the esterification of maltol and <e2>p-coumaric acid</e2>.","Association"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1>maltolyl p-coumarate</e1> by the esterification of maltol and <e2>p-coumaric acid</e2>.","Association"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1>maltolyl p-coumarate</e1> by the esterification of maltol and <e2>p-coumaric acid</e2>.","Association"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1><e2>maltol</e2>yl p-coumarate</e1> by the esterification of maltol and p-coumaric acid.","Association"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1><e2>maltol</e2>yl p-coumarate</e1> by the esterification of maltol and p-coumaric acid.","Association"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1><e2>maltol</e2>yl p-coumarate</e1> by the esterification of maltol and p-coumaric acid.","Association"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1><e2>maltol</e2>yl p-coumarate</e1> by the esterification of maltol and p-coumaric acid.","Association"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1><e2>maltol</e2>yl p-coumarate</e1> by the esterification of maltol and p-coumaric acid.","Association"
"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <e1><e2>maltol</e2>yl p-coumarate</e1> by the esterification of maltol and p-coumaric acid.","Association"
"Taking these in vitro and in vivo results together, our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread <e2>neuronal death</e2> and progressive decline of cognitive function.","Negative_Correlation"
"Taking these in vitro and in vivo results together, our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread <e2>neuronal death</e2> and progressive decline of cognitive function.","Negative_Correlation"
"Taking these in vitro and in vivo results together, our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread <e2>neuronal death</e2> and progressive decline of cognitive function.","Negative_Correlation"
"Taking these in vitro and in vivo results together, our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread <e2>neuronal death</e2> and progressive decline of cognitive function.","Negative_Correlation"
"Taking these in vitro and in vivo results together, our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread <e2>neuronal death</e2> and progressive decline of cognitive function.","Negative_Correlation"
"Taking these in vitro and in vivo results together, our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread <e2>neuronal death</e2> and progressive decline of cognitive function.","Negative_Correlation"
"Taking these in vitro and in vivo results together, our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against <e2>Alzheimer's disease</e2> that is characterized by wide spread neuronal death and progressive decline of cognitive function.","Negative_Correlation"
"Taking these in vitro and in vivo results together, our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against <e2>Alzheimer's disease</e2> that is characterized by wide spread neuronal death and progressive decline of cognitive function.","Negative_Correlation"
"Taking these in vitro and in vivo results together, our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against <e2>Alzheimer's disease</e2> that is characterized by wide spread neuronal death and progressive decline of cognitive function.","Negative_Correlation"
"Taking these in vitro and in vivo results together, our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against <e2>Alzheimer's disease</e2> that is characterized by wide spread neuronal death and progressive decline of cognitive function.","Negative_Correlation"
"Taking these in vitro and in vivo results together, our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against <e2>Alzheimer's disease</e2> that is characterized by wide spread neuronal death and progressive decline of cognitive function.","Negative_Correlation"
"Taking these in vitro and in vivo results together, our study suggests that <e1>maltolyl p-coumarate</e1> is a potentially effective candidate against <e2>Alzheimer's disease</e2> that is characterized by wide spread neuronal death and progressive decline of cognitive function.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced reactive oxygen species, <e2>cytochrome c</e2> release, and caspase 3 activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced reactive oxygen species, <e2>cytochrome c</e2> release, and caspase 3 activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced reactive oxygen species, <e2>cytochrome c</e2> release, and caspase 3 activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced reactive oxygen species, <e2>cytochrome c</e2> release, and caspase 3 activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced reactive oxygen species, <e2>cytochrome c</e2> release, and caspase 3 activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced reactive oxygen species, <e2>cytochrome c</e2> release, and caspase 3 activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and <e2>caspase 3</e2> activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and <e2>caspase 3</e2> activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and <e2>caspase 3</e2> activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and <e2>caspase 3</e2> activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and <e2>caspase 3</e2> activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and <e2>caspase 3</e2> activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced <e2>reactive oxygen species</e2>, cytochrome c release, and caspase 3 activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced <e2>reactive oxygen species</e2>, cytochrome c release, and caspase 3 activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced <e2>reactive oxygen species</e2>, cytochrome c release, and caspase 3 activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced <e2>reactive oxygen species</e2>, cytochrome c release, and caspase 3 activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced <e2>reactive oxygen species</e2>, cytochrome c release, and caspase 3 activation.","Negative_Correlation"
"We found that <e1>maltolyl p-coumarate</e1> significantly decreased apoptotic cell death and reduced <e2>reactive oxygen species</e2>, cytochrome c release, and caspase 3 activation.","Negative_Correlation"
"In the present study, we investigated whether <e1>maltolyl p-coumarate</e1> could improve cognitive decline in scopolamine-injected rats and in <e2>amyloid beta peptide(1-42)</e2>-infused rats.","Association"
"In the present study, we investigated whether <e1>maltolyl p-coumarate</e1> could improve cognitive decline in scopolamine-injected rats and in <e2>amyloid beta peptide(1-42)</e2>-infused rats.","Association"
"<e1>Maltolyl p-coumarate</e1> was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the <e2>amyloid beta peptide(1-42)</e2>-infused rats.","Association"
"In the present study, we investigated whether <e1>maltolyl p-coumarate</e1> could improve cognitive decline in scopolamine-injected rats and in <e2>amyloid beta peptide(1-42)</e2>-infused rats.","Association"
"In the present study, we investigated whether <e1>maltolyl p-coumarate</e1> could improve cognitive decline in scopolamine-injected rats and in <e2>amyloid beta peptide(1-42)</e2>-infused rats.","Association"
"In the present study, we investigated whether <e1>maltolyl p-coumarate</e1> could improve cognitive decline in scopolamine-injected rats and in <e2>amyloid beta peptide(1-42)</e2>-infused rats.","Association"
"In the present study, we investigated whether <e1>maltolyl p-coumarate</e1> could improve cognitive decline in scopolamine-injected rats and in <e2>amyloid beta peptide(1-42)</e2>-infused rats.","Association"
"In the present study, we investigated whether <e1>maltolyl p-coumarate</e1> could improve <e2>cognitive decline</e2> in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.","Negative_Correlation"
"In the present study, we investigated whether <e1>maltolyl p-coumarate</e1> could improve <e2>cognitive decline</e2> in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.","Negative_Correlation"
"<e1>Maltolyl p-coumarate</e1> was found to attenuate <e2>cognitive deficits</e2> in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.","Negative_Correlation"
"In the present study, we investigated whether <e1>maltolyl p-coumarate</e1> could improve <e2>cognitive decline</e2> in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.","Negative_Correlation"
"In the present study, we investigated whether <e1>maltolyl p-coumarate</e1> could improve <e2>cognitive decline</e2> in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.","Negative_Correlation"
"In the present study, we investigated whether <e1>maltolyl p-coumarate</e1> could improve <e2>cognitive decline</e2> in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.","Negative_Correlation"
"In the present study, we investigated whether <e1>maltolyl p-coumarate</e1> could improve <e2>cognitive decline</e2> in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.","Negative_Correlation"
"Mono-allelic <e2>POLG</e2> expression resulting from nonsense-mediated decay and alternative splicing in a patient with <e1>Alpers syndrome</e1>.","Association"
"We studied the skin fibroblasts of a patient with <e1>Alpers syndrome</e1> having the genotype E873stop/<e2>A467T</e2>.","Association"
"We studied the skin fibroblasts of a patient with <e1>Alpers syndrome</e1> having the genotype E873stop/<e2>A467T</e2>.","Association"
"We studied the skin fibroblasts of a patient with <e1>Alpers syndrome</e1> having the genotype E873stop/<e2>A467T</e2>.","Association"
"We studied the skin fibroblasts of a patient with <e1>Alpers syndrome</e1> having the genotype <e2>E873stop</e2>/A467T.","Association"
"We studied the skin fibroblasts of a patient with <e1>Alpers syndrome</e1> having the genotype <e2>E873stop</e2>/A467T.","Association"
"We studied the skin fibroblasts of a patient with <e1>Alpers syndrome</e1> having the genotype <e2>E873stop</e2>/A467T.","Association"
"Most patients with <e1>Alpers syndrome</e1> have been found to be compound heterozygotes, carrying two pathogenic mutations in trans at the <e2>POLG</e2> locus.","Association"
"Most patients with <e1>Alpers syndrome</e1> have been found to be compound heterozygotes, carrying two pathogenic mutations in trans at the <e2>POLG</e2> locus.","Association"
"Most patients with <e1>Alpers syndrome</e1> have been found to be compound heterozygotes, carrying two pathogenic mutations in trans at the <e2>POLG</e2> locus.","Association"
"Large deletion involving exon 5 of the <e2>arylsulfatase B</e2> gene caused apparent homozygosity in a <e1>mucopolysaccharidosis type VI</e1> patient.","Association"
"Apparent homozygosity for the mutation p.R315X present on exon 5 of the <e2>arylsulfatase B</e2> (ARSB) gene in a <e1>mucopolysaccharidosis type VI</e1> patient was solved in this study by further testing for a second mutation.","Association"
"Apparent homozygosity for the mutation <e2>p.R315X</e2> present on exon 5 of the arylsulfatase B (ARSB) gene in a <e1>mucopolysaccharidosis type VI</e1> patient was solved in this study by further testing for a second mutation.","Association"
"Finally, we identified the localization of proliferating cell nuclear antigen-positive, <e1>ED-1</e1>-positive, and terminal dUTP nick-end labeled-positive cells in the <e2>hypoxic</e2> cortical area in the remnant kidney model.","Association"
"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal <e1>dUTP</e1> nick-end labeled-positive cells in the <e2>hypoxic</e2> cortical area in the remnant kidney model.","Association"
"With this model, we were able to identify diffuse cortical hypoxia in the <e1>puromycin aminonucleoside</e1>-induced <e2>nephrotic syndrome</e2> and focal and segmental hypoxia in the remnant kidney model.","Positive_Correlation"
"With this model, we were able to identify diffuse cortical hypoxia in the <e1>puromycin aminonucleoside</e1>-induced <e2>nephrotic syndrome</e2> and focal and segmental hypoxia in the remnant kidney model.","Positive_Correlation"
"In this study, we developed a new <e1>hypoxia</e1>-responsive reporter vector using a hypoxia-responsive element of the 5' <e2>vascular endothelial growth factor</e2> untranslated region and generated a novel hypoxia-sensing transgenic rat.","Association"
"In this study, we developed a new <e1>hypoxia</e1>-responsive reporter vector using a hypoxia-responsive element of the 5' <e2>vascular endothelial growth factor</e2> untranslated region and generated a novel hypoxia-sensing transgenic rat.","Association"
"In this study, we developed a new <e1>hypoxia</e1>-responsive reporter vector using a hypoxia-responsive element of the 5' <e2>vascular endothelial growth factor</e2> untranslated region and generated a novel hypoxia-sensing transgenic rat.","Association"
"In this study, we developed a new <e1>hypoxia</e1>-responsive reporter vector using a hypoxia-responsive element of the 5' <e2>vascular endothelial growth factor</e2> untranslated region and generated a novel hypoxia-sensing transgenic rat.","Association"
"In this study, we developed a new <e1>hypoxia</e1>-responsive reporter vector using a hypoxia-responsive element of the 5' <e2>vascular endothelial growth factor</e2> untranslated region and generated a novel hypoxia-sensing transgenic rat.","Association"
"In this study, we developed a new <e1>hypoxia</e1>-responsive reporter vector using a hypoxia-responsive element of the 5' <e2>vascular endothelial growth factor</e2> untranslated region and generated a novel hypoxia-sensing transgenic rat.","Association"
"In this study, we developed a new <e1>hypoxia</e1>-responsive reporter vector using a hypoxia-responsive element of the 5' <e2>vascular endothelial growth factor</e2> untranslated region and generated a novel hypoxia-sensing transgenic rat.","Association"
"In this study, we developed a new <e1>hypoxia</e1>-responsive reporter vector using a hypoxia-responsive element of the 5' <e2>vascular endothelial growth factor</e2> untranslated region and generated a novel hypoxia-sensing transgenic rat.","Association"
"In this study, we developed a new <e1>hypoxia</e1>-responsive reporter vector using a hypoxia-responsive element of the 5' <e2>vascular endothelial growth factor</e2> untranslated region and generated a novel hypoxia-sensing transgenic rat.","Association"
"With this model, we were able to identify diffuse cortical <e1>hypoxia</e1> in the <e2>puromycin aminonucleoside</e2>-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.","Association"
"With this model, we were able to identify diffuse cortical <e1>hypoxia</e1> in the <e2>puromycin aminonucleoside</e2>-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.","Association"
"With this model, we were able to identify diffuse cortical <e1>hypoxia</e1> in the <e2>puromycin aminonucleoside</e2>-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.","Association"
"With this model, we were able to identify diffuse cortical <e1>hypoxia</e1> in the <e2>puromycin aminonucleoside</e2>-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.","Association"
"With this model, we were able to identify diffuse cortical <e1>hypoxia</e1> in the <e2>puromycin aminonucleoside</e2>-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.","Association"
"With this model, we were able to identify diffuse cortical <e1>hypoxia</e1> in the <e2>puromycin aminonucleoside</e2>-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.","Association"
"With this model, we were able to identify diffuse cortical <e1>hypoxia</e1> in the <e2>puromycin aminonucleoside</e2>-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.","Association"
"With this model, we were able to identify diffuse cortical <e1>hypoxia</e1> in the <e2>puromycin aminonucleoside</e2>-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.","Association"
"With this model, we were able to identify diffuse cortical <e1>hypoxia</e1> in the <e2>puromycin aminonucleoside</e2>-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.","Association"
"Novel somatic <e1>MEN1</e1> gene alterations in sporadic <e2>primary hyperparathyroidism</e2> and correlation with clinical characteristics.","Association"
"Moreover, two polymorphisms were also found: one allele carried a R171Q polymorphism (1/39 <e2>tumors</e2>), while a <e1>D418D</e1> polymorphism (GAC/GAT) was found in 15 and 8 tumors in hetero (CT) and homozygosity (TT), respectively.","Association"
"Moreover, two polymorphisms were also found: one allele carried a R171Q polymorphism (1/39 <e2>tumors</e2>), while a D418D polymorphism (<e1>GAC/GAT</e1>) was found in 15 and 8 tumors in hetero (CT) and homozygosity (TT), respectively.","Association"
"Moreover, two polymorphisms were also found: one allele carried a <e1>R171Q</e1> polymorphism (1/39 <e2>tumors</e2>), while a D418D polymorphism (GAC/GAT) was found in 15 and 8 tumors in hetero (CT) and homozygosity (TT), respectively.","Association"
"In our study, we examined the presence of alterations in <e2>MEN1</e2> gene in a series of 39 patients who had undergone surgery for sporadic pHPT (35 with parathyroid adenoma or hyperplasia, 4 with a <e1>carcinoma</e1>).","Association"
"Somatic <e2>MEN1</e2> mutations were detected in 6 of the 35 patients with a benign parathyroid lesion examined (17.1%), whereas no alterations were found in the <e1>carcinomas</e1>.","Association"
"Somatic mutations of <e1>MEN1</e1> gene have also been described in sporadic parathyroid <e2>tumors</e2>.","Association"
"Somatic mutations of <e1>MEN1</e1> gene have also been described in sporadic parathyroid <e2>tumors</e2>.","Association"
"Somatic mutations of <e1>MEN1</e1> gene have also been described in sporadic parathyroid <e2>tumors</e2>.","Association"
"Somatic mutations of <e1>MEN1</e1> gene have also been described in sporadic parathyroid <e2>tumors</e2>.","Association"
"Somatic mutations of <e1>MEN1</e1> gene have also been described in sporadic parathyroid <e2>tumors</e2>.","Association"
"Somatic mutations of <e1>MEN1</e1> gene have also been described in sporadic parathyroid <e2>tumors</e2>.","Association"
"Somatic mutations of <e1>MEN1</e1> gene have also been described in sporadic <e2>parathyroid tumors</e2>.","Association"
"Somatic mutations of <e1>MEN1</e1> gene have also been described in sporadic <e2>parathyroid tumors</e2>.","Association"
"Somatic mutations of <e1>MEN1</e1> gene have also been described in sporadic <e2>parathyroid tumors</e2>.","Association"
"Somatic mutations of <e1>MEN1</e1> gene have also been described in sporadic <e2>parathyroid tumors</e2>.","Association"
"Somatic mutations of <e1>MEN1</e1> gene have also been described in sporadic <e2>parathyroid tumors</e2>.","Association"
"Somatic mutations of <e1>MEN1</e1> gene have also been described in sporadic <e2>parathyroid tumors</e2>.","Association"
"Somatic <e1>MEN1</e1> mutations were detected in 6 of the 35 patients with a <e2>benign parathyroid lesion</e2> examined (17.1%), whereas no alterations were found in the carcinomas.","Association"
"Somatic <e1>MEN1</e1> mutations were detected in 6 of the 35 patients with a <e2>benign parathyroid lesion</e2> examined (17.1%), whereas no alterations were found in the carcinomas.","Association"
"Somatic <e1>MEN1</e1> mutations were detected in 6 of the 35 patients with a <e2>benign parathyroid lesion</e2> examined (17.1%), whereas no alterations were found in the carcinomas.","Association"
"Somatic <e1>MEN1</e1> mutations were detected in 6 of the 35 patients with a <e2>benign parathyroid lesion</e2> examined (17.1%), whereas no alterations were found in the carcinomas.","Association"
"Somatic <e1>MEN1</e1> mutations were detected in 6 of the 35 patients with a <e2>benign parathyroid lesion</e2> examined (17.1%), whereas no alterations were found in the carcinomas.","Association"
"Somatic <e1>MEN1</e1> mutations were detected in 6 of the 35 patients with a <e2>benign parathyroid lesion</e2> examined (17.1%), whereas no alterations were found in the carcinomas.","Association"
"<e2>Primary hyperparathyroidism</e2> (pHPT) is a common endocrine disease that in more than 95% of cases is sporadic and only in some cases is caused by inherited disorders, isolated or as part of multiple endocrine neoplasia (<e1>MEN1</e1> and 2).","Association"
"<e2>Primary hyperparathyroidism</e2> (pHPT) is a common endocrine disease that in more than 95% of cases is sporadic and only in some cases is caused by inherited disorders, isolated or as part of multiple endocrine neoplasia (<e1>MEN1</e1> and 2).","Association"
"<e2>Primary hyperparathyroidism</e2> (pHPT) is a common endocrine disease that in more than 95% of cases is sporadic and only in some cases is caused by inherited disorders, isolated or as part of multiple endocrine neoplasia (<e1>MEN1</e1> and 2).","Association"
"<e2>Primary hyperparathyroidism</e2> (pHPT) is a common endocrine disease that in more than 95% of cases is sporadic and only in some cases is caused by inherited disorders, isolated or as part of multiple endocrine neoplasia (<e1>MEN1</e1> and 2).","Association"
"<e2>Primary hyperparathyroidism</e2> (pHPT) is a common endocrine disease that in more than 95% of cases is sporadic and only in some cases is caused by inherited disorders, isolated or as part of multiple endocrine neoplasia (<e1>MEN1</e1> and 2).","Association"
"<e2>Primary hyperparathyroidism</e2> (pHPT) is a common endocrine disease that in more than 95% of cases is sporadic and only in some cases is caused by inherited disorders, isolated or as part of multiple endocrine neoplasia (<e1>MEN1</e1> and 2).","Association"
"Identification of novel mutations and sequence variants in the SOX2 and <e1>CHX10</e1> genes in patients with anophthalmia/<e2>microphthalmia</e2>.","Association"
"Identification of novel mutations and sequence variants in the SOX2 and <e1>CHX10</e1> genes in patients with <e2>anophthalmia</e2>/microphthalmia.","Association"
"Identification of novel mutations and sequence variants in the <e1>SOX2</e1> and CHX10 genes in patients with anophthalmia/<e2>microphthalmia</e2>.","Association"
"Identification of novel mutations and sequence variants in the <e1>SOX2</e1> and CHX10 genes in patients with <e2>anophthalmia</e2>/microphthalmia.","Association"
"PURPOSE: Mutations in the SOX2 and <e1>CHX10</e1> genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the SOX2 and <e1>CHX10</e1> genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the SOX2 and <e1>CHX10</e1> genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the SOX2 and <e1>CHX10</e1> genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the SOX2 and <e1>CHX10</e1> genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the SOX2 and <e1>CHX10</e1> genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the SOX2 and <e1>CHX10</e1> genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"PURPOSE: Mutations in the SOX2 and <e1>CHX10</e1> genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"PURPOSE: Mutations in the SOX2 and <e1>CHX10</e1> genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"PURPOSE: Mutations in the SOX2 and <e1>CHX10</e1> genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"PURPOSE: Mutations in the SOX2 and <e1>CHX10</e1> genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"PURPOSE: Mutations in the SOX2 and <e1>CHX10</e1> genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with anophthalmia and/or <e2>microphthalmia</e2>.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"PURPOSE: Mutations in the <e1>SOX2</e1> and CHX10 genes have been reported in patients with <e2>anophthalmia</e2> and/or microphthalmia.","Association"
"Loss of <e1>SOX2</e1> function results in severe <e2>eye malformation</e2>.","Negative_Correlation"
"Loss of <e1>SOX2</e1> function results in severe <e2>eye malformation</e2>.","Negative_Correlation"
"Loss of <e1>SOX2</e1> function results in severe <e2>eye malformation</e2>.","Negative_Correlation"
"Loss of <e1>SOX2</e1> function results in severe <e2>eye malformation</e2>.","Negative_Correlation"
"Loss of <e1>SOX2</e1> function results in severe <e2>eye malformation</e2>.","Negative_Correlation"
"Loss of <e1>SOX2</e1> function results in severe <e2>eye malformation</e2>.","Negative_Correlation"
"Loss of <e1>SOX2</e1> function results in severe <e2>eye malformation</e2>.","Negative_Correlation"
"Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in <e2>Rectal Cancer</e2> Patients Treated with <e1>5-FU</e1> and Radiation.","Negative_Correlation"
"<e1>rs4073</e1> and rs1870377 may exhibit different associations with toxicity, according to the <e2>5-FU</e2> schedule.","Association"
"<e1>rs4073</e1> and rs1870377 may exhibit different associations with toxicity, according to the <e2>5-FU</e2> schedule.","Association"
"CONCLUSION: <e1>rs1695</e1> may be prognostic in patients with <e2>rectal cancer</e2> treated with adjuvant CRT.","Association"
"CONCLUSION: <e1>rs1695</e1> may be prognostic in patients with <e2>rectal cancer</e2> treated with adjuvant CRT.","Association"
"The VEGFR2 <e1>H472Q</e1> Q/Q genotype (rs1870377) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) <e2>mucositis</e2> (P = 0.04) in arm 2.","Positive_Correlation"
"The VEGFR2 H472Q Q/Q genotype (<e1>rs1870377</e1>) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) <e2>mucositis</e2> (P = 0.04) in arm 2.","Positive_Correlation"
"The VEGFR2 H472Q Q/Q genotype (<e1>rs1870377</e1>) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) <e2>mucositis</e2> (P = 0.04) in arm 2.","Positive_Correlation"
"rs4073 and <e1>rs1870377</e1> may exhibit different associations with toxicity, according to the <e2>5-FU</e2> schedule.","Association"
"rs4073 and <e1>rs1870377</e1> may exhibit different associations with toxicity, according to the <e2>5-FU</e2> schedule.","Association"
"The <e1>VEGFR2</e1> H472Q Q/Q genotype (rs1870377) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) <e2>mucositis</e2> (P = 0.04) in arm 2.","Association"
"The <e1>VEGFR2</e1> H472Q Q/Q genotype (rs1870377) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) <e2>mucositis</e2> (P = 0.04) in arm 2.","Association"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, <e1>VEGFR2</e1>, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of <e2>5-fluorouracil</e2> (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Association"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, <e1>VEGFR2</e1>, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of <e2>5-fluorouracil</e2> (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Association"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, <e1>IL8</e1>, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of <e2>5-fluorouracil</e2> (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Association"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, <e1>IL8</e1>, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of <e2>5-fluorouracil</e2> (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Association"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (<e2>GSTP1</e2>, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced <e1>rectal cancers</e1>: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Association"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (<e2>GSTP1</e2>, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced <e1>rectal cancer</e1>s: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Association"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of <e1>5-fluorouracil</e1> (5-FU)-based chemoradiation (CRT) in locally advanced <e2>rectal cancers</e2>: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Negative_Correlation"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (<e1>5-FU</e1>)-based chemoradiation (CRT) in locally advanced <e2>rectal cancers</e2>: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Negative_Correlation"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (<e1>5-FU</e1>)-based chemoradiation (CRT) in locally advanced <e2>rectal cancers</e2>: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Negative_Correlation"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (<e1>5-FU</e1>)-based chemoradiation (CRT) in locally advanced <e2>rectal cancers</e2>: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Negative_Correlation"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (<e1>5-FU</e1>)-based chemoradiation (CRT) in locally advanced <e2>rectal cancers</e2>: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Negative_Correlation"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (<e1>5-FU</e1>)-based chemoradiation (CRT) in locally advanced <e2>rectal cancers</e2>: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Negative_Correlation"
"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (<e1>5-FU</e1>)-based chemoradiation (CRT) in locally advanced <e2>rectal cancers</e2>: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.","Negative_Correlation"
"Identification of three <e1>F5</e1> gene mutations associated with <e2>inherited coagulation factor V deficiency</e2> in two Chinese pedigrees.","Association"
"Three F5 gene mutations, IVS8 -2A>G, 2238-9del AG and <e1>G6410T</e1>, have been identified in two Chinese pedigree with <e2>congenital FV deficiency</e2>, respectively.","Association"
"Three F5 gene mutations, IVS8 -2A>G, <e1>2238-9del AG</e1> and G6410T, have been identified in two Chinese pedigree with <e2>congenital FV deficiency</e2>, respectively.","Association"
"Three F5 gene mutations, IVS8 -2A>G, <e1>2238-9del AG</e1> and G6410T, have been identified in two Chinese pedigree with <e2>congenital FV deficiency</e2>, respectively.","Association"
"Three F5 gene mutations, <e1>IVS8 -2A>G</e1>, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with <e2>congenital FV deficiency</e2>, respectively.","Association"
"Three F5 gene mutations, <e1>IVS8 -2A>G</e1>, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with <e2>congenital FV deficiency</e2>, respectively.","Association"
"To investigate the molecular defects in two Chinese pedigrees with inherited factor V (<e1>FV</e1>) deficiency.","Association"
"Three <e1>F5</e1> gene mutations, IVS8 -2A>G, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with <e2>congenital FV deficiency</e2>, respectively.","Association"
"Three <e1>F5</e1> gene mutations, IVS8 -2A>G, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with <e2>congenital FV deficiency</e2>, respectively.","Association"
"To investigate the molecular defects in two Chinese pedigrees with inherited factor V (<e1>FV</e1>) deficiency.","Association"
"Three <e1>F5</e1> gene mutations, IVS8 -2A>G, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with <e2>congenital FV deficiency</e2>, respectively.","Association"
"Three <e1>F5</e1> gene mutations, IVS8 -2A>G, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with <e2>congenital FV deficiency</e2>, respectively.","Association"
"Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and <e1>streptozotocin</e1> induced <e2>hyperalgesia</e2> in chemotherapy and diabetic neuropathy rat model.","Positive_Correlation"
"Bradykinin receptors antagonists and nitric oxide synthase inhibitors in <e1>vincristine</e1> and streptozotocin induced <e2>hyperalgesia</e2> in chemotherapy and diabetic neuropathy rat model.","Positive_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of <e1>constitutive NO synthase</e1> (<e2>L-NOArg</e2>; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Negative_Correlation"
"Therefore, concomitant administration of small doses of <e1>bradykinin receptor antagonists</e1> and NO synthase inhibitors can be effective in alleviation of <e2>neuropathic pain</e2>, even in hospital care.","Negative_Correlation"
"RESULTS: The results of this paper confirm that inhibition of <e1>bradykinin</e1> receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic <e2>hyperalgesia</e2>.","Association"
"RESULTS: The results of this paper confirm that inhibition of <e1>bradykinin</e1> receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic <e2>hyperalgesia</e2>.","Association"
"RESULTS: The results of this paper confirm that inhibition of <e1>bradykinin</e1> receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic <e2>hyperalgesia</e2>.","Association"
"Moreover, <e1>L-NOArg</e1> and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in <e2>toxic neuropathy</e2>.","Association"
"Moreover, <e1>L-NOArg</e1> and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in <e2>toxic neuropathy</e2>.","Association"
"Moreover, <e1>L-NOArg</e1> and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in <e2>toxic neuropathy</e2>.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (<e1>L-NOArg</e1>; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or <e2>des Arg10 HOE 140</e2> (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Positive_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (<e1>L-NOArg</e1>; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or <e2>des Arg10 HOE 140</e2> (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Positive_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (<e1>L-NOArg</e1>; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or <e2>des Arg10 HOE 140</e2> (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Positive_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (<e1>L-NOArg</e1>; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: <e2>D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Positive_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (<e1>L-NOArg</e1>; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: <e2>D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Positive_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (<e1>L-NOArg</e1>; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: <e2>D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Positive_Correlation"
"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or <e1>des-Arg10HOE 140</e1> in <e2>toxic neuropathy</e2>.","Association"
"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of <e1>HOE 140</e1> or des-Arg10HOE 140 in <e2>toxic neuropathy</e2>.","Association"
"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of <e1>HOE 140</e1> or des-Arg10HOE 140 in <e2>toxic neuropathy</e2>.","Association"
"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of <e1>HOE 140</e1> or des-Arg10HOE 140 in <e2>toxic neuropathy</e2>.","Association"
"Moreover, L-NOArg and <e1>7-NI</e1> but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in <e2>toxic neuropathy</e2>.","Association"
"Moreover, L-NOArg and <e1>7-NI</e1> but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in <e2>toxic neuropathy</e2>.","Association"
"Moreover, L-NOArg and <e1>7-NI</e1> but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in <e2>toxic neuropathy</e2>.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (<e1>7-NI</e1>; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or <e2>des Arg10 HOE 140</e2> (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (<e1>7-NI</e1>; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or <e2>des Arg10 HOE 140</e2> (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (<e1>7-NI</e1>; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or <e2>des Arg10 HOE 140</e2> (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (<e1>7-NI</e1>; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: <e2>D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (<e1>7-NI</e1>; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: <e2>D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (<e1>7-NI</e1>; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: <e2>D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of <e1>neuronal NO synthase</e1> (<e2>7-NI</e2>; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Negative_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of <e1>neuronal NO synthase</e1> (<e2>7-NI</e2>; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Negative_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of <e1>neuronal NO synthase</e1> (<e2>7-NI</e2>; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Negative_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of <e1>neuronal NO synthase</e1> (<e2>7-NI</e2>; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Negative_Correlation"
"RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not <e1>neuronal NO synthase</e1> activity reduces diabetic <e2>hyperalgesia</e2>.","Association"
"RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not <e1>neuronal NO synthase</e1> activity reduces diabetic <e2>hyperalgesia</e2>.","Association"
"RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not <e1>neuronal NO synthase</e1> activity reduces diabetic <e2>hyperalgesia</e2>.","Association"
"RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not <e1>neuronal NO synthase</e1> activity reduces diabetic <e2>hyperalgesia</e2>.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (<e1>L-NIL</e1>; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or <e2>des Arg10 HOE 140</e2> (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Positive_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (<e1>L-NIL</e1>; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or <e2>des Arg10 HOE 140</e2> (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Positive_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (<e1>L-NIL</e1>; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or <e2>des Arg10 HOE 140</e2> (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Positive_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (<e1>L-NIL</e1>; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: <e2>D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Positive_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (<e1>L-NIL</e1>; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: <e2>D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Positive_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (<e1>L-NIL</e1>; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: <e2>D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Positive_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of <e1>inducible NO synthase</e1> (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] <e2>bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of <e1>inducible NO synthase</e1> (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] <e2>bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of <e1>inducible NO synthase</e1> (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] <e2>bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of <e1>inducible NO synthase</e1> (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] <e2>bradykinin</e2> (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Association"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of <e1>inducible NO synthase</e1> (<e2>L-NIL</e2>; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Negative_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of <e1>inducible NO synthase</e1> (<e2>L-NIL</e2>; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Negative_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of <e1>inducible NO synthase</e1> (<e2>L-NIL</e2>; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Negative_Correlation"
"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of <e1>inducible NO synthase</e1> (<e2>L-NIL</e2>; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.","Negative_Correlation"
"RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and <e1>inducible NO synthase</e1> but not neuronal NO synthase activity reduces diabetic <e2>hyperalgesia</e2>.","Association"
"RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and <e1>inducible NO synthase</e1> but not neuronal NO synthase activity reduces diabetic <e2>hyperalgesia</e2>.","Association"
"RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and <e1>inducible NO synthase</e1> but not neuronal NO synthase activity reduces diabetic <e2>hyperalgesia</e2>.","Association"
"RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and <e1>inducible NO synthase</e1> but not neuronal NO synthase activity reduces diabetic <e2>hyperalgesia</e2>.","Association"
"In <e1>streptozotocin</e1>-induced <e2>hyperalgesia</e2>, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.","Positive_Correlation"
"It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in <e2>hyperalgesia</e2> produced by <e1>vincristine</e1>.","Positive_Correlation"
"It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in <e2>hyperalgesia</e2> produced by <e1>vincristine</e1>.","Positive_Correlation"
"Association of a <e1>FGFR-4</e1> gene polymorphism with <e2>bronchopulmonary dysplasia</e2> and neonatal respiratory distress.","Association"
"Association of a <e1>FGFR-4</e1> gene polymorphism with bronchopulmonary dysplasia and <e2>neonatal respiratory distress</e2>.","Association"
"CONCLUSION: <e1>rs1966265</e1> in FGF receptor 4 is a possible genetic key variant in <e2>alveolar diseases</e2> of preterm newborns.","Positive_Correlation"
"CONCLUSION: <e1>rs1966265</e1> in FGF receptor 4 is a possible genetic key variant in <e2>alveolar diseases</e2> of preterm newborns.","Positive_Correlation"
"One of them, in FGFR-4 (<e1>rs1966265</e1>), is associated with both RDS (P = 0.003) and <e2>BPD</e2> (P = 0.023).","Positive_Correlation"
"One of them, in FGFR-4 (<e1>rs1966265</e1>), is associated with both RDS (P = 0.003) and <e2>BPD</e2> (P = 0.023).","Positive_Correlation"
"One of them, in FGFR-4 (<e1>rs1966265</e1>), is associated with both <e2>RDS</e2> (P = 0.003) and BPD (P = 0.023).","Positive_Correlation"
"One of them, in FGFR-4 (<e1>rs1966265</e1>), is associated with both <e2>RDS</e2> (P = 0.003) and BPD (P = 0.023).","Positive_Correlation"
"RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, <e1>MMP-12</e1>, FGFR-4, FGF-3, and FGF-7 are associated (P < 0.05) with <e2>RDS</e2>, defined as surfactant application within the first 24 hours after birth.","Association"
"RESULTS: Five single nucleotide polymorphisms (SNPs) in <e1>MMP-9</e1>, MMP-12, FGFR-4, FGF-3, and FGF-7 are associated (P < 0.05) with <e2>RDS</e2>, defined as surfactant application within the first 24 hours after birth.","Association"
"RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, FGFR-4, FGF-3, and <e1>FGF-7</e1> are associated (P < 0.05) with <e2>RDS</e2>, defined as surfactant application within the first 24 hours after birth.","Association"
"RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, <e2>FGFR-4</e2>, FGF-3, and <e1>FGF-7</e1> are associated (P < 0.05) with RDS, defined as surfactant application within the first 24 hours after birth.","Bind"
"RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, FGFR-4, <e1>FGF-3</e1>, and FGF-7 are associated (P < 0.05) with <e2>RDS</e2>, defined as surfactant application within the first 24 hours after birth.","Association"
"RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, <e2>FGFR-4</e2>, <e1>FGF-3</e1>, and FGF-7 are associated (P < 0.05) with RDS, defined as surfactant application within the first 24 hours after birth.","Bind"
"CONCLUSION: rs1966265 in <e1>FGF receptor 4</e1> is a possible genetic key variant in <e2>alveolar diseases</e2> of preterm newborns.","Association"
"One of them, in <e1>FGFR-4</e1> (rs1966265), is associated with both RDS (P = 0.003) and <e2>BPD</e2> (P = 0.023).","Association"
"One of them, in <e1>FGFR-4</e1> (rs1966265), is associated with both RDS (P = 0.003) and <e2>BPD</e2> (P = 0.023).","Association"
"RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, <e1>FGFR-4</e1>, FGF-3, and FGF-7 are associated (P < 0.05) with <e2>RDS</e2>, defined as surfactant application within the first 24 hours after birth.","Association"
"RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, <e1>FGFR-4</e1>, FGF-3, and FGF-7 are associated (P < 0.05) with <e2>RDS</e2>, defined as surfactant application within the first 24 hours after birth.","Association"
"Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/<e1>b-catenin</e1> signaling pathway in human <e2>colorectal adenocarcinoma</e2>.","Association"
"Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via <e1>Wnt</e1>/b-catenin signaling pathway in human <e2>colorectal adenocarcinoma</e2>.","Association"
"Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via <e1>Wnt</e1>/<e2>b-catenin</e2> signaling pathway in human colorectal adenocarcinoma.","Association"
"<e1>Pleomorphic adenoma gene like-2</e1> induces epithelial-mesenchymal transition via Wnt/b-catenin signaling pathway in human <e2>colorectal adenocarcinoma</e2>.","Association"
"<e1>Pleomorphic adenoma gene like-2</e1> induces epithelial-mesenchymal transition via Wnt/<e2>b-catenin</e2> signaling pathway in human colorectal adenocarcinoma.","Positive_Correlation"
"<e1>Pleomorphic adenoma gene like-2</e1> induces epithelial-mesenchymal transition via <e2>Wnt</e2>/b-catenin signaling pathway in human colorectal adenocarcinoma.","Association"
"We found that PLAGL2 expression was upregulated in the <e1>paraffin</e1>-embedded <e2>CRC</e2> tissues compared to borderline or benign tissues.","Association"
"Subsequently, through western blot assay, we found that PLAGL2 could activate the <e1>wnt</e1>-signaling component <e2>b-catenin</e2> in the nuclei.","Association"
"Our findings indicated that PLAGL2 might be a very upstream key molecule regulating EMT involved in <e1>Wnt</e1>/<e2>b-catenin</e2> signaling pathway.","Association"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of <e2>E-cadherin</e2>.","Negative_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of <e2>E-cadherin</e2>.","Negative_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of <e2>E-cadherin</e2>.","Negative_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of <e2>E-cadherin</e2>.","Negative_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of <e2>E-cadherin</e2>.","Negative_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of <e2>E-cadherin</e2>.","Negative_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of <e2>E-cadherin</e2>.","Negative_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of <e2>E-cadherin</e2>.","Negative_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of <e2>E-cadherin</e2>.","Negative_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of <e2>E-cadherin</e2>.","Negative_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and <e2>vimentin</e2> and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and <e2>vimentin</e2> and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and <e2>vimentin</e2> and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and <e2>vimentin</e2> and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and <e2>vimentin</e2> and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and <e2>vimentin</e2> and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and <e2>vimentin</e2> and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and <e2>vimentin</e2> and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and <e2>vimentin</e2> and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and <e2>vimentin</e2> and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, <e2>N-cadherin</e2> and vimentin and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, <e2>N-cadherin</e2> and vimentin and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, <e2>N-cadherin</e2> and vimentin and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, <e2>N-cadherin</e2> and vimentin and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, <e2>N-cadherin</e2> and vimentin and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, <e2>N-cadherin</e2> and vimentin and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, <e2>N-cadherin</e2> and vimentin and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, <e2>N-cadherin</e2> and vimentin and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, <e2>N-cadherin</e2> and vimentin and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"Experimental EMT induced by <e1>PLAGL2</e1> plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, <e2>N-cadherin</e2> and vimentin and concurrently downregulated epithelial marker of E-cadherin.","Positive_Correlation"
"We found that <e1>PLAGL2</e1> expression was upregulated in the <e2>paraffin</e2>-embedded CRC tissues compared to borderline or benign tissues.","Association"
"We found that <e1>PLAGL2</e1> expression was upregulated in the <e2>paraffin</e2>-embedded CRC tissues compared to borderline or benign tissues.","Association"
"We found that <e1>PLAGL2</e1> expression was upregulated in the <e2>paraffin</e2>-embedded CRC tissues compared to borderline or benign tissues.","Association"
"We found that <e1>PLAGL2</e1> expression was upregulated in the <e2>paraffin</e2>-embedded CRC tissues compared to borderline or benign tissues.","Association"
"We found that <e1>PLAGL2</e1> expression was upregulated in the <e2>paraffin</e2>-embedded CRC tissues compared to borderline or benign tissues.","Association"
"We found that <e1>PLAGL2</e1> expression was upregulated in the <e2>paraffin</e2>-embedded CRC tissues compared to borderline or benign tissues.","Association"
"We found that <e1>PLAGL2</e1> expression was upregulated in the <e2>paraffin</e2>-embedded CRC tissues compared to borderline or benign tissues.","Association"
"We found that <e1>PLAGL2</e1> expression was upregulated in the <e2>paraffin</e2>-embedded CRC tissues compared to borderline or benign tissues.","Association"
"We found that <e1>PLAGL2</e1> expression was upregulated in the <e2>paraffin</e2>-embedded CRC tissues compared to borderline or benign tissues.","Association"
"We found that <e1>PLAGL2</e1> expression was upregulated in the <e2>paraffin</e2>-embedded CRC tissues compared to borderline or benign tissues.","Association"
"Recent studies show that <e1>pleomorphic adenoma gene like-2</e1> (PLAGL2) could induce <e2>tumor</e2> EMT and is an independent predictive factor associated with poor prognosis in cancer.","Association"
"Recent studies show that pleomorphic adenoma gene like-2 (<e1>PLAGL2</e1>) could induce <e2>tumor</e2> EMT and is an independent predictive factor associated with poor prognosis in cancer.","Association"
"Recent studies show that pleomorphic adenoma gene like-2 (<e1>PLAGL2</e1>) could induce <e2>tumor</e2> EMT and is an independent predictive factor associated with poor prognosis in cancer.","Association"
"Recent studies show that pleomorphic adenoma gene like-2 (<e1>PLAGL2</e1>) could induce <e2>tumor</e2> EMT and is an independent predictive factor associated with poor prognosis in cancer.","Association"
"Recent studies show that pleomorphic adenoma gene like-2 (<e1>PLAGL2</e1>) could induce <e2>tumor</e2> EMT and is an independent predictive factor associated with poor prognosis in cancer.","Association"
"Recent studies show that pleomorphic adenoma gene like-2 (<e1>PLAGL2</e1>) could induce <e2>tumor</e2> EMT and is an independent predictive factor associated with poor prognosis in cancer.","Association"
"Recent studies show that pleomorphic adenoma gene like-2 (<e1>PLAGL2</e1>) could induce <e2>tumor</e2> EMT and is an independent predictive factor associated with poor prognosis in cancer.","Association"
"Recent studies show that pleomorphic adenoma gene like-2 (<e1>PLAGL2</e1>) could induce <e2>tumor</e2> EMT and is an independent predictive factor associated with poor prognosis in cancer.","Association"
"Recent studies show that pleomorphic adenoma gene like-2 (<e1>PLAGL2</e1>) could induce <e2>tumor</e2> EMT and is an independent predictive factor associated with poor prognosis in cancer.","Association"
"Recent studies show that pleomorphic adenoma gene like-2 (<e1>PLAGL2</e1>) could induce <e2>tumor</e2> EMT and is an independent predictive factor associated with poor prognosis in cancer.","Association"
"Recent studies show that pleomorphic adenoma gene like-2 (<e1>PLAGL2</e1>) could induce <e2>tumor</e2> EMT and is an independent predictive factor associated with poor prognosis in cancer.","Association"
"In the present study, we confirmed the role of <e1>PLAGL2</e1> in the prognosis of <e2>CRC</e2> patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.","Association"
"In the present study, we confirmed the role of <e1>PLAGL2</e1> in the prognosis of <e2>CRC</e2> patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.","Association"
"In the present study, we confirmed the role of <e1>PLAGL2</e1> in the prognosis of <e2>CRC</e2> patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.","Association"
"In the present study, we confirmed the role of <e1>PLAGL2</e1> in the prognosis of <e2>CRC</e2> patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.","Association"
"In the present study, we confirmed the role of <e1>PLAGL2</e1> in the prognosis of <e2>CRC</e2> patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.","Association"
"In the present study, we confirmed the role of <e1>PLAGL2</e1> in the prognosis of <e2>CRC</e2> patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.","Association"
"In the present study, we confirmed the role of <e1>PLAGL2</e1> in the prognosis of <e2>CRC</e2> patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.","Association"
"In the present study, we confirmed the role of <e1>PLAGL2</e1> in the prognosis of <e2>CRC</e2> patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.","Association"
"In the present study, we confirmed the role of <e1>PLAGL2</e1> in the prognosis of <e2>CRC</e2> patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.","Association"
"In the present study, we confirmed the role of <e1>PLAGL2</e1> in the prognosis of <e2>CRC</e2> patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.","Association"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the wnt-signaling component <e2>b-catenin</e2> in the nuclei.","Positive_Correlation"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the wnt-signaling component <e2>b-catenin</e2> in the nuclei.","Positive_Correlation"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the wnt-signaling component <e2>b-catenin</e2> in the nuclei.","Positive_Correlation"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the wnt-signaling component <e2>b-catenin</e2> in the nuclei.","Positive_Correlation"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the wnt-signaling component <e2>b-catenin</e2> in the nuclei.","Positive_Correlation"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the wnt-signaling component <e2>b-catenin</e2> in the nuclei.","Positive_Correlation"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the wnt-signaling component <e2>b-catenin</e2> in the nuclei.","Positive_Correlation"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the wnt-signaling component <e2>b-catenin</e2> in the nuclei.","Positive_Correlation"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the wnt-signaling component <e2>b-catenin</e2> in the nuclei.","Positive_Correlation"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the wnt-signaling component <e2>b-catenin</e2> in the nuclei.","Positive_Correlation"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the <e2>wnt</e2>-signaling component b-catenin in the nuclei.","Association"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the <e2>wnt</e2>-signaling component b-catenin in the nuclei.","Association"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the <e2>wnt</e2>-signaling component b-catenin in the nuclei.","Association"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the <e2>wnt</e2>-signaling component b-catenin in the nuclei.","Association"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the <e2>wnt</e2>-signaling component b-catenin in the nuclei.","Association"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the <e2>wnt</e2>-signaling component b-catenin in the nuclei.","Association"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the <e2>wnt</e2>-signaling component b-catenin in the nuclei.","Association"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the <e2>wnt</e2>-signaling component b-catenin in the nuclei.","Association"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the <e2>wnt</e2>-signaling component b-catenin in the nuclei.","Association"
"Subsequently, through western blot assay, we found that <e1>PLAGL2</e1> could activate the <e2>wnt</e2>-signaling component b-catenin in the nuclei.","Association"
"Successful therapy with <e1>argatroban</e1> for superior mesenteric <e2>vein thrombosis</e2> in a patient with congenital antithrombin deficiency.","Negative_Correlation"
"Successful therapy with <e1>argatroban</e1> for superior mesenteric vein thrombosis in a patient with <e2>congenital antithrombin deficiency</e2>.","Negative_Correlation"
"However, successful anticoagulation was achieved by administration of direct <e1>thrombin</e1> inhibitor, <e2>argatroban</e2>.","Negative_Correlation"
"Argatroban administration would be effective in the treatment of congenital <e2>antithrombin</e2> deficiency with <e1>SMV thrombosis</e1>.","Association"
"<e1>Argatroban</e1> administration would be effective in the treatment of congenital antithrombin deficiency with <e2>SMV thrombosis</e2>.","Negative_Correlation"
"<e1>Argatroban</e1> administration would be effective in the treatment of <e2>congenital antithrombin deficiency</e2> with SMV thrombosis.","Negative_Correlation"
"Family studies of <e1>antithrombin</e1> activity revealed that she had <e2>type I congenital antithrombin deficiency</e2>.","Association"
"Family studies of <e1>antithrombin</e1> activity revealed that she had <e2>type I congenital antithrombin deficiency</e2>.","Association"
"Family studies of <e1>antithrombin</e1> activity revealed that she had <e2>type I congenital antithrombin deficiency</e2>.","Association"
"Family studies of <e1>antithrombin</e1> activity revealed that she had <e2>type I congenital antithrombin deficiency</e2>.","Association"
"<e1>Amisulpride</e1> related tic-like symptoms in an adolescent <e2>schizophrenic</e2>.","Negative_Correlation"
"<e1>Tic disorders</e1> can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and <e2>ziprasidone</e2>.","Negative_Correlation"
"<e1>Tic disorders</e1> can be effectively treated by atypical antipsychotics such as risperidone, <e2>olanzapine</e2> and ziprasidone.","Negative_Correlation"
"<e1>Tic disorders</e1> can be effectively treated by atypical antipsychotics such as <e2>risperidone</e2>, olanzapine and ziprasidone.","Negative_Correlation"
"<e1>Tic disorders</e1> can be effectively treated by atypical <e2>antipsychotics</e2> such as risperidone, olanzapine and ziprasidone.","Negative_Correlation"
"We present a 15-year-old girl schizophrenic who developed frequent <e1>involuntary eye-blinking movements</e1> after 5 months of <e2>amisulpride</e2> treatment (1000 mg per day).","Positive_Correlation"
"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as <e2>quetiapine</e2>, clozapine, or <e1>amisulpride</e1>.","Cotreatment"
"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as <e2>quetiapine</e2>, clozapine, or <e1>amisulpride</e1>.","Cotreatment"
"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as <e2>quetiapine</e2>, clozapine, or <e1>amisulpride</e1>.","Cotreatment"
"We present a 15-year-old girl <e2>schizophrenic</e2> who developed frequent involuntary eye-blinking movements after 5 months of <e1>amisulpride</e1> treatment (1000 mg per day).","Negative_Correlation"
"We present a 15-year-old girl <e2>schizophrenic</e2> who developed frequent involuntary eye-blinking movements after 5 months of <e1>amisulpride</e1> treatment (1000 mg per day).","Negative_Correlation"
"We present a 15-year-old girl <e2>schizophrenic</e2> who developed frequent involuntary eye-blinking movements after 5 months of <e1>amisulpride</e1> treatment (1000 mg per day).","Negative_Correlation"
"Syncope caused by <e1>hyperkalemia</e1> during use of a combined therapy with the angiotensin-converting enzyme inhibitor and <e2>spironolactone</e2>.","Negative_Correlation"
"Syncope caused by <e1>hyperkalemia</e1> during use of a combined therapy with the <e2>angiotensin-converting enzyme inhibitor</e2> and spironolactone.","Negative_Correlation"
"Syncope caused by hyperkalemia during use of a combined therapy with the <e1>angiotensin-converting enzyme inhibitor</e1> and <e2>spironolactone</e2>.","Cotreatment"
"<e1>Syncope</e1> caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and <e2>spironolactone</e2>.","Positive_Correlation"
"<e1>Syncope</e1> caused by hyperkalemia during use of a combined therapy with the <e2>angiotensin-converting enzyme inhibitor</e2> and spironolactone.","Positive_Correlation"
"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/<e1>ARB</e1> in combination with potassium sparing agents and who have mild <e2>renal disturbance</e2>.","Association"
"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/<e1>ARB</e1> in combination with <e2>potassium</e2> sparing agents and who have mild renal disturbance.","Cotreatment"
"Clinicians should be alert to the possibility of <e2>hyperkalemia</e2>, especially in elderly patients using ACE/<e1>ARB</e1> in combination with potassium sparing agents and who have mild renal disturbance.","Association"
"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with <e1>potassium</e1> sparing agents and who have mild <e2>renal disturbance</e2>.","Association"
"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with <e1>potassium</e1> sparing agents and who have mild <e2>renal disturbance</e2>.","Association"
"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with <e1>potassium</e1> sparing agents and who have mild <e2>renal disturbance</e2>.","Association"
"Clinicians should be alert to the possibility of <e2>hyperkalemia</e2>, especially in elderly patients using ACE/ARB in combination with <e1>potassium</e1> sparing agents and who have mild renal disturbance.","Positive_Correlation"
"Clinicians should be alert to the possibility of <e2>hyperkalemia</e2>, especially in elderly patients using ACE/ARB in combination with <e1>potassium</e1> sparing agents and who have mild renal disturbance.","Positive_Correlation"
"Clinicians should be alert to the possibility of <e2>hyperkalemia</e2>, especially in elderly patients using ACE/ARB in combination with <e1>potassium</e1> sparing agents and who have mild renal disturbance.","Positive_Correlation"
"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using <e1>ACE</e1>/ARB in combination with potassium sparing agents and who have mild <e2>renal disturbance</e2>.","Association"
"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using <e1>ACE</e1>/ARB in combination with potassium sparing agents and who have mild <e2>renal disturbance</e2>.","Association"
"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using <e1>ACE</e1>/<e2>ARB</e2> in combination with potassium sparing agents and who have mild renal disturbance.","Cotreatment"
"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using <e1>ACE</e1>/<e2>ARB</e2> in combination with potassium sparing agents and who have mild renal disturbance.","Cotreatment"
"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using <e1>ACE</e1>/ARB in combination with <e2>potassium</e2> sparing agents and who have mild renal disturbance.","Cotreatment"
"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using <e1>ACE</e1>/ARB in combination with <e2>potassium</e2> sparing agents and who have mild renal disturbance.","Cotreatment"
"The cause of <e2>hyperkalemia</e2> was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an <e1>ACE</e1> inhibitor.","Association"
"The cause of <e2>hyperkalemia</e2> was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an <e1>ACE</e1> inhibitor.","Association"
"The cause of hyperkalemia was considered to be several doses of <e2>spiranolactone</e2>, an <e1>aldosterone</e1> antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.","Negative_Correlation"
"The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of <e1>ramipril</e1>, an <e2>ACE</e2> inhibitor.","Negative_Correlation"
"The cause of <e1>hyperkalemia</e1> was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of <e2>ramipril</e2>, an ACE inhibitor.","Positive_Correlation"
"The cause of <e1>hyperkalemia</e1> was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of <e2>ramipril</e2>, an ACE inhibitor.","Positive_Correlation"
"The cause of <e1>hyperkalemia</e1> was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of <e2>ramipril</e2>, an ACE inhibitor.","Positive_Correlation"
"The cause of <e1>hyperkalemia</e1> was considered to be several doses of <e2>spiranolactone</e2>, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.","Negative_Correlation"
"The cause of <e1>hyperkalemia</e1> was considered to be several doses of <e2>spiranolactone</e2>, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.","Negative_Correlation"
"The cause of <e1>hyperkalemia</e1> was considered to be several doses of <e2>spiranolactone</e2>, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.","Negative_Correlation"
"A first Taiwanese Chinese family of <e1>type 2B von Willebrand disease</e1> with <e2>R1306W</e2> mutation.","Association"
"In conclusion, a first report of <e1>type 2B VWD</e1> in a Taiwanese Chinese family who show <e2>R1306W</e2> mutation in VWF gene was described.","Association"
"In conclusion, a first report of <e1>type 2B VWD</e1> in a Taiwanese Chinese family who show R1306W mutation in <e2>VWF</e2> gene was described.","Association"
"This mutation in the <e1>glycoprotein Ib</e1> (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often <e2>thrombocytopenia</e2>.","Association"
"This mutation in the glycoprotein Ib (<e1>GPIb</e1>)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often <e2>thrombocytopenia</e2>.","Association"
"This mutation in the <e1>glycoprotein Ib</e1> (GPIb)-binding site has been found to increase the affinity of plasma <e2>VWF</e2> for platelets, and thus cause loss of HMW multimers and often thrombocytopenia.","Association"
"This mutation in the glycoprotein Ib (<e1>GPIb</e1>)-binding site has been found to increase the affinity of plasma <e2>VWF</e2> for platelets, and thus cause loss of HMW multimers and often thrombocytopenia.","Association"
"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor <e2>ristocetin</e2>-cofactor (VWF:RCo, 15%); <e1>ristocetin-induced platelet aggregation</e1> (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.","Positive_Correlation"
"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor <e2>ristocetin</e2>-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (<e1>RIPA</e1>) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.","Positive_Correlation"
"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma <e1>VWF</e1> for platelets, and thus cause loss of HMW multimers and often <e2>thrombocytopenia</e2>.","Association"
"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma <e1>VWF</e1> for platelets, and thus cause loss of HMW multimers and often <e2>thrombocytopenia</e2>.","Association"
"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma <e1>VWF</e1> for platelets, and thus cause loss of HMW multimers and often <e2>thrombocytopenia</e2>.","Association"
"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma <e1>VWF</e1> for platelets, and thus cause loss of HMW multimers and often <e2>thrombocytopenia</e2>.","Association"
"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma <e1>VWF</e1> for platelets, and thus cause loss of HMW multimers and often <e2>thrombocytopenia</e2>.","Association"
"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma <e1>VWF</e1> for platelets, and thus cause loss of HMW multimers and often <e2>thrombocytopenia</e2>.","Association"
"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, <e1>von Willebrand factor</e1> antigen (VWF:Ag), 42% and von Willerand factor <e2>ristocetin</e2>-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.","Association"
"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (<e1>VWF</e1>:Ag), 42% and von Willerand factor <e2>ristocetin</e2>-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.","Association"
"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and <e1>von Willerand factor</e1> <e2>ristocetin</e2>-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.","Association"
"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (<e1>VWF</e1>:Ag), 42% and von Willerand factor <e2>ristocetin</e2>-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.","Association"
"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, <e1>von Willebrand factor</e1> antigen (VWF:Ag), 42% and von Willerand factor <e2>ristocetin</e2>-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.","Association"
"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (<e1>VWF</e1>:Ag), 42% and von Willerand factor <e2>ristocetin</e2>-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.","Association"
"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (<e1>VWF</e1>:Ag), 42% and von Willerand factor <e2>ristocetin</e2>-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.","Association"
"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (<e1>VWF</e1>:Ag), 42% and von Willerand factor <e2>ristocetin</e2>-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.","Association"
"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (<e1>VWF</e1>:Ag), 42% and von Willerand factor <e2>ristocetin</e2>-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.","Association"
"Identification of <e1>PVT1</e1> as a candidate gene for end-stage renal disease in <e2>type 2 diabetes</e2> using a pooling-based genome-wide single nucleotide polymorphism association study.","Association"
"Identification of <e1>PVT1</e1> as a candidate gene for <e2>end-stage renal disease</e2> in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study.","Association"
"We subsequently genotyped these 11 variants and an additional 87 SNPs identified through public databases in 319-kb flanking <e1>rs2720709</e1> ( approximately 1 SNP/3.5 kb); 23 markers were associated with <e2>ESRD</e2> at P < 0.01.","Positive_Correlation"
"We subsequently genotyped these 11 variants and an additional 87 SNPs identified through public databases in 319-kb flanking <e1>rs2720709</e1> ( approximately 1 SNP/3.5 kb); 23 markers were associated with <e2>ESRD</e2> at P < 0.01.","Positive_Correlation"
"Together, these results suggest that <e1>PVT1</e1> may contribute to ESRD susceptibility in <e2>diabetes</e2>.","Association"
"Together, these results suggest that <e1>PVT1</e1> may contribute to ESRD susceptibility in <e2>diabetes</e2>.","Association"
"Together, these results suggest that <e1>PVT1</e1> may contribute to ESRD susceptibility in <e2>diabetes</e2>.","Association"
"Together, these results suggest that <e1>PVT1</e1> may contribute to ESRD susceptibility in <e2>diabetes</e2>.","Association"
"Together, these results suggest that <e1>PVT1</e1> may contribute to <e2>ESRD</e2> susceptibility in diabetes.","Association"
"Together, these results suggest that <e1>PVT1</e1> may contribute to <e2>ESRD</e2> susceptibility in diabetes.","Association"
"Together, these results suggest that <e1>PVT1</e1> may contribute to <e2>ESRD</e2> susceptibility in diabetes.","Association"
"Together, these results suggest that <e1>PVT1</e1> may contribute to <e2>ESRD</e2> susceptibility in diabetes.","Association"
"Reduced <e1>adiponectin</e1> expression after high-fat diet is associated with selective up-regulation of <e2>ALDH1A1</e2> and further retinoic acid receptor signaling in adipose tissue.","Negative_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic <e2>retinoic acid</e2> receptor (RAR)a- and RARg-selective agonists, as well as a synthetic <e1>retinoid X receptor</e1> agonist, efficiently reduced adiponectin expression, whereas ALDH1A1 expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic <e1>retinoid X receptor</e1> agonist, efficiently reduced <e2>adiponectin</e2> expression, whereas ALDH1A1 expression only increased with RAR agonists.","Negative_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic <e2>retinoic acid</e2> receptor (RAR)a- and <e1>RARg</e1>-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas ALDH1A1 expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and <e1>RARg</e1>-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced <e2>adiponectin</e2> expression, whereas ALDH1A1 expression only increased with RAR agonists.","Negative_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic <e1><e2>retinoic acid</e2> receptor (RAR)a</e1>- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas ALDH1A1 expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic <e1>retinoic acid receptor (RAR)a</e1>- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced <e2>adiponectin</e2> expression, whereas ALDH1A1 expression only increased with RAR agonists.","Negative_Correlation"
"A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <e1>retinoic acid</e1> response element signaling was selectively observed in WAT of mice fed a normal-<e2>vitamin A</e2>, high-fat diet.","Association"
"A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <e1>retinoic acid</e1> response element signaling was selectively observed in WAT of mice fed a normal-<e2>vitamin A</e2>, high-fat diet.","Association"
"A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <e1>retinoic acid</e1> response element signaling was selectively observed in WAT of mice fed a normal-<e2>vitamin A</e2>, high-fat diet.","Association"
"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic <e2>retinoid X receptor</e2> agonist, efficiently reduced adiponectin expression, whereas <e1>ALDH1A1</e1> expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic <e2>retinoid X receptor</e2> agonist, efficiently reduced adiponectin expression, whereas <e1>ALDH1A1</e1> expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic <e2>retinoid X receptor</e2> agonist, efficiently reduced adiponectin expression, whereas <e1>ALDH1A1</e1> expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic <e2>retinoid X receptor</e2> agonist, efficiently reduced adiponectin expression, whereas <e1>ALDH1A1</e1> expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and <e2>RARg</e2>-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas <e1>ALDH1A1</e1> expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and <e2>RARg</e2>-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas <e1>ALDH1A1</e1> expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and <e2>RARg</e2>-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas <e1>ALDH1A1</e1> expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and <e2>RARg</e2>-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas <e1>ALDH1A1</e1> expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic <e2>retinoic acid receptor (RAR)a</e2>- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas <e1>ALDH1A1</e1> expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic <e2>retinoic acid receptor (RAR)a</e2>- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas <e1>ALDH1A1</e1> expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic <e2>retinoic acid receptor (RAR)a</e2>- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas <e1>ALDH1A1</e1> expression only increased with RAR agonists.","Positive_Correlation"
"Adipocyte cell culture revealed that endogenous and synthetic <e2>retinoic acid receptor (RAR)a</e2>- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas <e1>ALDH1A1</e1> expression only increased with RAR agonists.","Positive_Correlation"
"A decrease of adiponectin expression in addition to an up-regulation of <e1>aldehyde dehydrogenase A1</e1> (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-<e2>vitamin A</e2>, high-fat diet.","Positive_Correlation"
"A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (<e1>ALDH1A1</e1>), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-<e2>vitamin A</e2>, high-fat diet.","Positive_Correlation"
"A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (<e1>ALDH1A1</e1>), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-<e2>vitamin A</e2>, high-fat diet.","Positive_Correlation"
"A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (<e1>ALDH1A1</e1>), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-<e2>vitamin A</e2>, high-fat diet.","Positive_Correlation"
"A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (<e1>ALDH1A1</e1>), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-<e2>vitamin A</e2>, high-fat diet.","Positive_Correlation"
"<e1>Adiponectin</e1> is an adipocyte-derived adipokine with potent antidiabetic, anti-<e2>inflammatory</e2>, and antiatherogenic activity.","Negative_Correlation"
"Adiponectin is an adipocyte-derived <e1>adipokine</e1> with potent antidiabetic, anti-<e2>inflammatory</e2>, and antiatherogenic activity.","Negative_Correlation"
"Long-term, high-fat diet results in gain of body weight, adiposity, further <e2>inflammatory</e2>-based cardiovascular diseases, and reduced <e1>adiponectin</e1> secretion.","Negative_Correlation"
"Long-term, high-fat diet results in gain of body weight, adiposity, further <e2>inflammatory</e2>-based cardiovascular diseases, and reduced <e1>adiponectin</e1> secretion.","Negative_Correlation"
"Long-term, high-fat diet results in gain of body weight, adiposity, further <e2>inflammatory</e2>-based cardiovascular diseases, and reduced <e1>adiponectin</e1> secretion.","Negative_Correlation"
"Long-term, high-fat diet results in gain of body weight, adiposity, further <e2>inflammatory</e2>-based cardiovascular diseases, and reduced <e1>adiponectin</e1> secretion.","Negative_Correlation"
"Long-term, high-fat diet results in gain of body weight, adiposity, further <e2>inflammatory</e2>-based cardiovascular diseases, and reduced <e1>adiponectin</e1> secretion.","Negative_Correlation"
"Long-term, high-fat diet results in gain of body weight, adiposity, further <e2>inflammatory</e2>-based cardiovascular diseases, and reduced <e1>adiponectin</e1> secretion.","Negative_Correlation"
"Long-term, high-fat diet results in gain of body weight, adiposity, further <e2>inflammatory</e2>-based cardiovascular diseases, and reduced <e1>adiponectin</e1> secretion.","Negative_Correlation"
"Long-term, high-fat diet results in gain of body weight, adiposity, further <e2>inflammatory</e2>-based cardiovascular diseases, and reduced <e1>adiponectin</e1> secretion.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <e2>retinoic acid</e2> response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <e2>retinoic acid</e2> response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <e2>retinoic acid</e2> response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <e2>retinoic acid</e2> response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <e2>retinoic acid</e2> response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <e2>retinoic acid</e2> response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <e2>retinoic acid</e2> response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <e2>retinoic acid</e2> response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of <e2>aldehyde dehydrogenase A1</e2> (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of <e2>aldehyde dehydrogenase A1</e2> (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of <e2>aldehyde dehydrogenase A1</e2> (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of <e2>aldehyde dehydrogenase A1</e2> (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of <e2>aldehyde dehydrogenase A1</e2> (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of <e2>aldehyde dehydrogenase A1</e2> (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of <e2>aldehyde dehydrogenase A1</e2> (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"A decrease of <e1>adiponectin</e1> expression in addition to an up-regulation of <e2>aldehyde dehydrogenase A1</e2> (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.","Negative_Correlation"
"In this study, we examined <e1>adiponectin</e1> expression as a function of dietary high-fat and high-<e2>vitamin A</e2> conditions in mice.","Negative_Correlation"
"In this study, we examined <e1>adiponectin</e1> expression as a function of dietary high-fat and high-<e2>vitamin A</e2> conditions in mice.","Negative_Correlation"
"In this study, we examined <e1>adiponectin</e1> expression as a function of dietary high-fat and high-<e2>vitamin A</e2> conditions in mice.","Negative_Correlation"
"In this study, we examined <e1>adiponectin</e1> expression as a function of dietary high-fat and high-<e2>vitamin A</e2> conditions in mice.","Negative_Correlation"
"In this study, we examined <e1>adiponectin</e1> expression as a function of dietary high-fat and high-<e2>vitamin A</e2> conditions in mice.","Negative_Correlation"
"In this study, we examined <e1>adiponectin</e1> expression as a function of dietary high-fat and high-<e2>vitamin A</e2> conditions in mice.","Negative_Correlation"
"In this study, we examined <e1>adiponectin</e1> expression as a function of dietary high-fat and high-<e2>vitamin A</e2> conditions in mice.","Negative_Correlation"
"In this study, we examined <e1>adiponectin</e1> expression as a function of dietary high-fat and high-<e2>vitamin A</e2> conditions in mice.","Negative_Correlation"
"<e1>Arginase 1</e1> deletion in myeloid cells affects the inflammatory response in allergic <e2>asthma</e2>, but not lung mechanics, in female mice.","Association"
"<e1>Arginase 1</e1> deletion in myeloid cells affects the <e2>inflammatory</e2> response in allergic asthma, but not lung mechanics, in female mice.","Association"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e1>OVA</e1>-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e2>OVA</e2>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific <e1>IgE</e1>.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e2>OVA</e2>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific <e1>IgE</e1>.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e2>OVA</e2>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific <e1>IgE</e1>.","Positive_Correlation"
"RESULTS: Arg1 ablation had no influence on the development of <e2>OVA</e2>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific <e1>IgE</e1>.","Positive_Correlation"
"BACKGROUND: (Over-)expression of <e1>arginase</e1> may limit local availability of arginine for <e2>nitric oxide</e2> synthesis.","Association"
"We investigated the significance of <e1>arginase</e1>1 (ARG1) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with <e2>ovalbumin</e2> (OVA)-induced allergic asthma.","Positive_Correlation"
"We investigated the significance of <e1>arginase1</e1> (ARG1) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with <e2>ovalbumin</e2> (OVA)-induced allergic asthma.","Positive_Correlation"
"We investigated the significance of arginase1 (<e1>ARG1</e1>) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with <e2>ovalbumin</e2> (OVA)-induced allergic asthma.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of <e2>OVA</e2>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of <e2>OVA</e2>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of <e2>OVA</e2>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of <e2>OVA</e2>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of <e2>OVA</e2>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of <e2>OVA</e2>-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific <e2>IgE</e2>.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific <e2>IgE</e2>.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific <e2>IgE</e2>.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific <e2>IgE</e2>.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific <e2>IgE</e2>.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific <e2>IgE</e2>.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <e2>Muc5ac</e2> (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <e2>Clca3</e2> and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <e2>Ifng</e2> (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <e2>Ccl11</e2> (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <e2>Ccl2</e2> and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <e2>Il13</e2> (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <e2>Il5</e2> and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <e2>Il4</e2>, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <e2>Slc7a7</e2> (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <e2>Slc7a2</e2>, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <e2>Slc7a1</e2>, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <e2>Nos2</e2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"RESULTS: <e1>Arg1</e1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of <e2>Arg2</e2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.","Positive_Correlation"
"We investigated the significance of <e1>arginase</e1>1 (ARG1) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with ovalbumin (OVA)-induced allergic <e2>asthma</e2>.","Association"
"We investigated the significance of <e1>arginase1</e1> (ARG1) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with ovalbumin (OVA)-induced allergic <e2>asthma</e2>.","Association"
"We investigated the significance of arginase1 (<e1>ARG1</e1>) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with ovalbumin (OVA)-induced allergic <e2>asthma</e2>.","Association"
"We investigated the significance of <e1>arginase</e1>1 (ARG1) for the development of airway hyperresponsiveness (AHR) and lung <e2>inflammation</e2> in female mice with ovalbumin (OVA)-induced allergic asthma.","Association"
"We investigated the significance of <e1>arginase1</e1> (ARG1) for the development of airway hyperresponsiveness (AHR) and lung <e2>inflammation</e2> in female mice with ovalbumin (OVA)-induced allergic asthma.","Association"
"We investigated the significance of arginase1 (<e1>ARG1</e1>) for the development of airway hyperresponsiveness (AHR) and lung <e2>inflammation</e2> in female mice with ovalbumin (OVA)-induced allergic asthma.","Association"
"<e1>Arg1</e1> elimination also decreased number and tightness of correlations between adaptive changes in lung function and <e2>inflammatory</e2> parameters in OVA/OVA-treated female mice.","Association"
"<e1>Arg1</e1> elimination also decreased number and tightness of correlations between adaptive changes in lung function and <e2>inflammatory</e2> parameters in OVA/OVA-treated female mice.","Association"
"<e1>Arg1</e1> elimination also decreased number and tightness of correlations between adaptive changes in lung function and <e2>inflammatory</e2> parameters in OVA/OVA-treated female mice.","Association"
"<e1>Arg1</e1> elimination also decreased number and tightness of correlations between adaptive changes in lung function and <e2>inflammatory</e2> parameters in OVA/OVA-treated female mice.","Association"
"<e1>Arg1</e1> elimination also decreased number and tightness of correlations between adaptive changes in lung function and <e2>inflammatory</e2> parameters in OVA/OVA-treated female mice.","Association"
"<e1>Arg1</e1> elimination also decreased number and tightness of correlations between adaptive changes in lung function and <e2>inflammatory</e2> parameters in OVA/OVA-treated female mice.","Association"
"Cerebrospinal fluid penetration of high-dose <e1>daptomycin</e1> in suspected Staphylococcus aureus <e2>meningitis</e2>.","Negative_Correlation"
"DISCUSSION: Daptomycin was initiated in our patient secondary to possible <e1>nafcillin</e1>-induced acute <e2>interstitial nephritis</e2> and relapsing bacteremia.","Positive_Correlation"
"DISCUSSION: Daptomycin was initiated in our patient secondary to possible <e1>nafcillin</e1>-induced acute <e2>interstitial nephritis</e2> and relapsing bacteremia.","Positive_Correlation"
"DISCUSSION: Daptomycin was initiated in our patient secondary to possible <e1>nafcillin</e1>-induced acute interstitial nephritis and relapsing <e2>bacteremia</e2>.","Positive_Correlation"
"DISCUSSION: Daptomycin was initiated in our patient secondary to possible <e1>nafcillin</e1>-induced acute interstitial nephritis and relapsing <e2>bacteremia</e2>.","Positive_Correlation"
"OBJECTIVE: To report a case of <e1>methicillin</e1>-sensitive Staphylococcus aureus (MSSA) <e2>bacteremia</e2> with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.","Association"
"DISCUSSION: <e1>Daptomycin</e1> was initiated in our patient secondary to possible nafcillin-induced acute <e2>interstitial nephritis</e2> and relapsing bacteremia.","Negative_Correlation"
"DISCUSSION: <e1>Daptomycin</e1> was initiated in our patient secondary to possible nafcillin-induced acute <e2>interstitial nephritis</e2> and relapsing bacteremia.","Negative_Correlation"
"OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) <e2>bacteremia</e2> with suspected MSSA meningitis treated with high-dose <e1>daptomycin</e1> assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.","Negative_Correlation"
"OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) <e2>bacteremia</e2> with suspected MSSA meningitis treated with high-dose <e1>daptomycin</e1> assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.","Negative_Correlation"
"DISCUSSION: <e1>Daptomycin</e1> was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing <e2>bacteremia</e2>.","Negative_Correlation"
"OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) <e2>bacteremia</e2> with suspected MSSA meningitis treated with high-dose <e1>daptomycin</e1> assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.","Negative_Correlation"
"DISCUSSION: <e1>Daptomycin</e1> was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing <e2>bacteremia</e2>.","Negative_Correlation"
"OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) <e2>bacteremia</e2> with suspected MSSA meningitis treated with high-dose <e1>daptomycin</e1> assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.","Negative_Correlation"
"OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA <e2>meningitis</e2> treated with high-dose <e1>daptomycin</e1> assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.","Negative_Correlation"
"OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA <e2>meningitis</e2> treated with high-dose <e1>daptomycin</e1> assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.","Negative_Correlation"
"OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA <e2>meningitis</e2> treated with high-dose <e1>daptomycin</e1> assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.","Negative_Correlation"
"OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA <e2>meningitis</e2> treated with high-dose <e1>daptomycin</e1> assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.","Negative_Correlation"
"On day 8, the patient developed <e1>acute renal failure</e1> (serum <e2>creatinine</e2> 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission).","Positive_Correlation"
"Treatment was empirically initiated with vancomycin, <e1>levofloxacin</e1>, and <e2>piperacillin/tazobactam</e2>.","Cotreatment"
"Treatment was empirically initiated with <e1>vancomycin</e1>, levofloxacin, and <e2>piperacillin/tazobactam</e2>.","Cotreatment"
"Treatment was empirically initiated with <e1>vancomycin</e1>, <e2>levofloxacin</e2>, and piperacillin/tazobactam.","Cotreatment"
"OBJECTIVE: <e1>C-C chemokine receptor 5</e1> (CCR5) plays an important role in <e2>inflammation</e2>.","Association"
"OBJECTIVE: C-C chemokine receptor 5 (<e1>CCR5</e1>) plays an important role in <e2>inflammation</e2>.","Association"
"OBJECTIVE: C-C chemokine receptor 5 (<e1>CCR5</e1>) plays an important role in <e2>inflammation</e2>.","Association"
"OBJECTIVE: C-C chemokine receptor 5 (<e1>CCR5</e1>) plays an important role in <e2>inflammation</e2>.","Association"
"OBJECTIVE: C-C chemokine receptor 5 (<e1>CCR5</e1>) plays an important role in <e2>inflammation</e2>.","Association"
"OBJECTIVE: C-C chemokine receptor 5 (<e1>CCR5</e1>) plays an important role in <e2>inflammation</e2>.","Association"
"OBJECTIVE: C-C chemokine receptor 5 (<e1>CCR5</e1>) plays an important role in <e2>inflammation</e2>.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD3</e2>1(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Positive_Correlation"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD3</e2>1(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Positive_Correlation"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD3</e2>1(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Positive_Correlation"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD3</e2>1(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Positive_Correlation"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD3</e2>1(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Positive_Correlation"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD3</e2>1(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Positive_Correlation"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD3</e2>1(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Positive_Correlation"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD3</e2>1(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Positive_Correlation"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD3</e2>1(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Positive_Correlation"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD3</e2>1(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Positive_Correlation"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD3</e2>1(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Positive_Correlation"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD3</e2>1(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<e2>B220</e2>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<e2>B220</e2>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<e2>B220</e2>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<e2>B220</e2>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<e2>B220</e2>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<e2>B220</e2>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<e2>B220</e2>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<e2>B220</e2>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<e2>B220</e2>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<e2>B220</e2>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<e2>B220</e2>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<e2>B220</e2>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Positive_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<e2>CD11b</e2>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Negative_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<e2>CD11b</e2>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Negative_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<e2>CD11b</e2>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Negative_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<e2>CD11b</e2>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Negative_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<e2>CD11b</e2>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Negative_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<e2>CD11b</e2>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Negative_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<e2>CD11b</e2>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Negative_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<e2>CD11b</e2>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Negative_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<e2>CD11b</e2>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Negative_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<e2>CD11b</e2>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Negative_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<e2>CD11b</e2>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Negative_Correlation"
"Besides its effects in the BM vascular niche, anti-<e1>Dll4</e1> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<e2>CD11b</e2>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.","Negative_Correlation"
"In vitro treatment of endothelial cells with anti-<e1>Dll4</e1> reduced <e2>Akt</e2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.","Association"
"In vitro treatment of endothelial cells with anti-<e1>Dll4</e1> reduced <e2>Akt</e2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.","Association"
"In vitro treatment of endothelial cells with anti-<e1>Dll4</e1> reduced <e2>Akt</e2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.","Association"
"In vitro treatment of endothelial cells with anti-<e1>Dll4</e1> reduced <e2>Akt</e2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.","Association"
"In vitro treatment of endothelial cells with anti-<e1>Dll4</e1> reduced <e2>Akt</e2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.","Association"
"In vitro treatment of endothelial cells with anti-<e1>Dll4</e1> reduced <e2>Akt</e2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.","Association"
"In vitro treatment of endothelial cells with anti-<e1>Dll4</e1> reduced <e2>Akt</e2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.","Association"
"In vitro treatment of endothelial cells with anti-<e1>Dll4</e1> reduced <e2>Akt</e2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.","Association"
"In vitro treatment of endothelial cells with anti-<e1>Dll4</e1> reduced <e2>Akt</e2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.","Association"
"In vitro treatment of endothelial cells with anti-<e1>Dll4</e1> reduced <e2>Akt</e2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.","Association"
"In vitro treatment of endothelial cells with anti-<e1>Dll4</e1> reduced <e2>Akt</e2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.","Association"
"In vitro treatment of endothelial cells with anti-<e1>Dll4</e1> reduced <e2>Akt</e2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.","Association"
"<e1>Delta-like 4</e1> (Dll4) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the Notch pathway family which has been widely studied in the context of <e2>tumor</e2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"<e1>Delta-like 4</e1> (Dll4) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"Delta-like 4 (<e1>Dll4</e1>) is a ligand of the <e2>Notch</e2> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.","Association"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and <e2>CSF2</e2> are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and <e2>CSF2</e2> are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and <e2>CSF2</e2> are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and <e2>CSF2</e2> are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and <e2>CSF2</e2> are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and <e2>CSF2</e2> are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and <e2>CSF2</e2> are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and <e2>CSF2</e2> are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and <e2>CSF2</e2> are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and <e2>CSF2</e2> are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and <e2>CSF2</e2> are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and <e2>CSF2</e2> are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while <e2>FGF1</e2> and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while <e2>FGF1</e2> and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while <e2>FGF1</e2> and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while <e2>FGF1</e2> and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while <e2>FGF1</e2> and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while <e2>FGF1</e2> and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while <e2>FGF1</e2> and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while <e2>FGF1</e2> and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while <e2>FGF1</e2> and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while <e2>FGF1</e2> and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while <e2>FGF1</e2> and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while <e2>FGF1</e2> and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and <e2>VEGF-A</e2> are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and <e2>VEGF-A</e2> are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and <e2>VEGF-A</e2> are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and <e2>VEGF-A</e2> are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and <e2>VEGF-A</e2> are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and <e2>VEGF-A</e2> are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and <e2>VEGF-A</e2> are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and <e2>VEGF-A</e2> are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and <e2>VEGF-A</e2> are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and <e2>VEGF-A</e2> are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and <e2>VEGF-A</e2> are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and <e2>VEGF-A</e2> are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, <e2>DHH</e2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, <e2>DHH</e2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, <e2>DHH</e2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, <e2>DHH</e2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, <e2>DHH</e2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, <e2>DHH</e2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, <e2>DHH</e2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, <e2>DHH</e2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, <e2>DHH</e2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, <e2>DHH</e2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, <e2>DHH</e2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, <e2>DHH</e2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <e2>Angpt2</e2>, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <e2>Angpt2</e2>, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <e2>Angpt2</e2>, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <e2>Angpt2</e2>, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <e2>Angpt2</e2>, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <e2>Angpt2</e2>, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <e2>Angpt2</e2>, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <e2>Angpt2</e2>, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <e2>Angpt2</e2>, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <e2>Angpt2</e2>, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <e2>Angpt2</e2>, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <e2>Angpt2</e2>, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, <e2>IGFbp3</e2>, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, <e2>IGFbp3</e2>, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, <e2>IGFbp3</e2>, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, <e2>IGFbp3</e2>, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, <e2>IGFbp3</e2>, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, <e2>IGFbp3</e2>, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, <e2>IGFbp3</e2>, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, <e2>IGFbp3</e2>, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, <e2>IGFbp3</e2>, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, <e2>IGFbp3</e2>, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, <e2>IGFbp3</e2>, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that IGFbp2, <e2>IGFbp3</e2>, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that <e2>IGFbp2</e2>, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that <e2>IGFbp2</e2>, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that <e2>IGFbp2</e2>, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that <e2>IGFbp2</e2>, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that <e2>IGFbp2</e2>, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that <e2>IGFbp2</e2>, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that <e2>IGFbp2</e2>, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that <e2>IGFbp2</e2>, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that <e2>IGFbp2</e2>, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that <e2>IGFbp2</e2>, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that <e2>IGFbp2</e2>, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"We investigated also the expression of angiocrine genes upon <e1>Dll4</e1> treatment in vivo, and demonstrate that <e2>IGFbp2</e2>, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.","Positive_Correlation"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <e2>c-kit</e2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <e2>c-kit</e2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <e2>c-kit</e2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <e2>c-kit</e2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <e2>c-kit</e2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <e2>c-kit</e2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <e2>c-kit</e2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <e2>c-kit</e2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <e2>c-kit</e2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <e2>c-kit</e2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <e2>c-kit</e2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <e2>c-kit</e2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <e2>VE-Cadherin</e2>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <e2>VE-Cadherin</e2>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <e2>VE-Cadherin</e2>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <e2>VE-Cadherin</e2>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <e2>VE-Cadherin</e2>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <e2>VE-Cadherin</e2>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <e2>VE-Cadherin</e2>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <e2>VE-Cadherin</e2>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <e2>VE-Cadherin</e2>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <e2>VE-Cadherin</e2>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <e2>VE-Cadherin</e2>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <e2>VE-Cadherin</e2>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD31</e2>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD31</e2>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD31</e2>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD31</e2>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD31</e2>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD31</e2>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD31</e2>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD31</e2>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD31</e2>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD31</e2>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD31</e2>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Here we show that <e1>Dll4</e1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <e2>CD31</e2>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.","Association"
"Role of <e1>angiotensin II type 1a receptor</e1> in <e2>renal injury</e2> induced by deoxycorticosterone acetate-salt hypertension.","Association"
"Role of <e2>angiotensin II type 1a receptor</e2> in renal injury induced by <e1>deoxycorticosterone acetate</e1>-salt hypertension.","Association"
"Role of angiotensin II type 1a receptor in renal injury induced by <e1>deoxycorticosterone acetate</e1>-salt <e2>hypertension</e2>.","Positive_Correlation"
"Role of angiotensin II type 1a receptor in <e1>renal injury</e1> induced by <e2>deoxycorticosterone acetate</e2>-salt hypertension.","Positive_Correlation"
"<e1>Hydralazine</e1> treatment significantly attenuated <e2>renal damage</e2> that was found in L-FABP(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.","Negative_Correlation"
"Transgenic mice that express human <e1>liver-type fatty acid binding protein</e1> (L-FABP) with or without disruption of the <e2>AT1a receptor</e2> gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.","Negative_Correlation"
"Transgenic mice that express human liver-type fatty acid binding protein (<e1>L-FABP</e1>) with or without disruption of the <e2>AT1a receptor</e2> gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.","Negative_Correlation"
"Transgenic mice that express human liver-type fatty acid binding protein (<e1>L-FABP</e1>) with or without disruption of the <e2>AT1a receptor</e2> gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.","Negative_Correlation"
"Transgenic mice that express human liver-type fatty acid binding protein (<e1>L-FABP</e1>) with or without disruption of the <e2>AT1a receptor</e2> gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.","Negative_Correlation"
"Transgenic mice that express human liver-type fatty acid binding protein (<e1>L-FABP</e1>) with or without disruption of the <e2>AT1a receptor</e2> gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.","Negative_Correlation"
"Transgenic mice that express human liver-type fatty acid binding protein (<e1>L-FABP</e1>) with or without disruption of the <e2>AT1a receptor</e2> gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.","Negative_Correlation"
"Transgenic mice that express human liver-type fatty acid binding protein (<e1>L-FABP</e1>) with or without disruption of the <e2>AT1a receptor</e2> gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.","Negative_Correlation"
"Transgenic mice that express human liver-type fatty acid binding protein (<e1>L-FABP</e1>) with or without disruption of the <e2>AT1a receptor</e2> gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.","Negative_Correlation"
"Transgenic mice that express human liver-type fatty acid binding protein (<e1>L-FABP</e1>) with or without disruption of the <e2>AT1a receptor</e2> gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.","Negative_Correlation"
"Transgenic mice that express human liver-type fatty acid binding protein (<e1>L-FABP</e1>) with or without disruption of the <e2>AT1a receptor</e2> gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.","Negative_Correlation"
"Transgenic mice that express human liver-type fatty acid binding protein (<e1>L-FABP</e1>) with or without disruption of the <e2>AT1a receptor</e2> gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.","Negative_Correlation"
"Transgenic mice that express human liver-type fatty acid binding protein (<e1>L-FABP</e1>) with or without disruption of the <e2>AT1a receptor</e2> gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.","Negative_Correlation"
"Transgenic mice that express human <e1>liver-type fatty acid binding protein</e1> (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of <e2>tubulointerstitial damage</e2>.","Association"
"Hydralazine treatment significantly attenuated <e2>renal damage</e2> that was found in <e1>L-FABP</e1>(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.","Association"
"Hydralazine treatment significantly attenuated <e2>renal damage</e2> that was found in <e1>L-FABP</e1>(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.","Association"
"Hydralazine treatment significantly attenuated <e2>renal damage</e2> that was found in <e1>L-FABP</e1>(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.","Association"
"Hydralazine treatment significantly attenuated <e2>renal damage</e2> that was found in <e1>L-FABP</e1>(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.","Association"
"Hydralazine treatment significantly attenuated <e2>renal damage</e2> that was found in <e1>L-FABP</e1>(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.","Association"
"Hydralazine treatment significantly attenuated <e2>renal damage</e2> that was found in <e1>L-FABP</e1>(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.","Association"
"Hydralazine treatment significantly attenuated <e2>renal damage</e2> that was found in <e1>L-FABP</e1>(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.","Association"
"Hydralazine treatment significantly attenuated <e2>renal damage</e2> that was found in <e1>L-FABP</e1>(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.","Association"
"Hydralazine treatment significantly attenuated <e2>renal damage</e2> that was found in <e1>L-FABP</e1>(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.","Association"
"Hydralazine treatment significantly attenuated <e2>renal damage</e2> that was found in <e1>L-FABP</e1>(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.","Association"
"Hydralazine treatment significantly attenuated <e2>renal damage</e2> that was found in <e1>L-FABP</e1>(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.","Association"
"The aim of this study was to investigate the in vivo role of <e1>angiotensin II type 1a (AT1a) receptor</e1> in <e2>renal damage</e2> as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.","Association"
"The aim of this study was to investigate the in vivo role of angiotensin II type 1a (AT1a) receptor in <e2>renal damage</e2> as a result of hypertension by using transgenic mice with <e1>AT1a receptor</e1> gene disruption.","Association"
"The aim of this study was to investigate the in vivo role of angiotensin II type 1a (AT1a) receptor in <e2>renal damage</e2> as a result of hypertension by using transgenic mice with <e1>AT1a receptor</e1> gene disruption.","Association"
"The aim of this study was to investigate the in vivo role of angiotensin II type 1a (<e1>AT1a</e1>) receptor in <e2>renal damage</e2> as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.","Association"
"The aim of this study was to investigate the in vivo role of angiotensin II type 1a (<e1>AT1a</e1>) receptor in <e2>renal damage</e2> as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.","Association"
"The aim of this study was to investigate the in vivo role of angiotensin II type 1a (<e1>AT1a</e1>) receptor in <e2>renal damage</e2> as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.","Association"
"The aim of this study was to investigate the in vivo role of angiotensin II type 1a (<e1>AT1a</e1>) receptor in <e2>renal damage</e2> as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.","Association"
"The aim of this study was to investigate the in vivo role of angiotensin II type 1a (<e1>AT1a</e1>) receptor in <e2>renal damage</e2> as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.","Association"
"The aim of this study was to investigate the in vivo role of angiotensin II type 1a (<e1>AT1a</e1>) receptor in <e2>renal damage</e2> as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.","Association"
"The aim of this study was to investigate the in vivo role of angiotensin II type 1a (<e1>AT1a</e1>) receptor in <e2>renal damage</e2> as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.","Association"
"The aim of this study was to investigate the in vivo role of angiotensin II type 1a (<e1>AT1a</e1>) receptor in <e2>renal damage</e2> as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.","Association"
"The aim of this study was to investigate the in vivo role of angiotensin II type 1a (AT1a) receptor in <e2>renal damage</e2> as a result of hypertension by using transgenic mice with <e1>AT1a receptor</e1> gene disruption.","Association"
"Role of <e1>angiotensin II type 1a receptor</e1> in <e2>renal injury</e2> induced by deoxycorticosterone acetate-salt hypertension.","Association"
"In <e2>L-FABP</e2>(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"In <e2>L-FABP</e2>(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"In <e2>L-FABP</e2>(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"In <e2>L-FABP</e2>(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"In <e2>L-FABP</e2>(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"In <e2>L-FABP</e2>(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"In <e2>L-FABP</e2>(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"Role of <e2>angiotensin II type 1a receptor</e2> in renal injury induced by <e1>deoxycorticosterone acetate</e1>-salt hypertension.","Association"
"In L-FABP(+/-) <e2>AT1a</e2>(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"In L-FABP(+/-) <e2>AT1a</e2>(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"In L-FABP(+/-) <e2>AT1a</e2>(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"In L-FABP(+/-) <e2>AT1a</e2>(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"In L-FABP(+/-) <e2>AT1a</e2>(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"In L-FABP(+/-) <e2>AT1a</e2>(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"In L-FABP(+/-) <e2>AT1a</e2>(+/+) mice that received <e1>DOCA</e1>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Association"
"Role of <e2>angiotensin II type 1a receptor</e2> in renal injury induced by <e1>deoxycorticosterone acetate</e1>-salt hypertension.","Association"
"Role of angiotensin II type 1a receptor in renal injury induced by <e1>deoxycorticosterone acetate</e1>-salt <e2>hypertension</e2>.","Positive_Correlation"
"In L-FABP(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, <e2>hypertension</e2> was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Positive_Correlation"
"In L-FABP(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, <e2>hypertension</e2> was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Positive_Correlation"
"In L-FABP(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, <e2>hypertension</e2> was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Positive_Correlation"
"In L-FABP(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, <e2>hypertension</e2> was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Positive_Correlation"
"In L-FABP(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, <e2>hypertension</e2> was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Positive_Correlation"
"In L-FABP(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, <e2>hypertension</e2> was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Positive_Correlation"
"In L-FABP(+/-) AT1a(+/+) mice that received <e1>DOCA</e1>-salt treatment, <e2>hypertension</e2> was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.","Positive_Correlation"
"Role of angiotensin II type 1a receptor in renal injury induced by <e1>deoxycorticosterone acetate</e1>-salt <e2>hypertension</e2>.","Positive_Correlation"
"Hydralazine treatment significantly attenuated <e1>renal damage</e1> that was found in L-FABP(+/-) AT1a(-/-)-<e2>DOCA</e2> mice along with a reduction in blood pressure.","Positive_Correlation"
"In L-FABP(+/-) AT1a(+/+) mice that received <e2>DOCA</e2>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and <e1>tubulointerstitial damage</e1> were observed.","Positive_Correlation"
"In L-FABP(+/-) AT1a(+/+) mice that received <e2>DOCA</e2>-salt treatment, hypertension was induced and slight expansion of glomerular area, <e1>glomerular sclerosis</e1>, and tubulointerstitial damage were observed.","Positive_Correlation"
"In L-FABP(+/-) AT1a(+/+) mice that received <e2>DOCA</e2>-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and <e1>tubulointerstitial damage</e1> were observed.","Positive_Correlation"
"In L-FABP(+/-) AT1a(-/-) mice that received <e2>DOCA</e2>-salt treatment, hypertension was similarly induced and the degree of <e1>glomerular damage</e1> was significantly more severe than in L-FABP(+/-) AT1a(+/+)-DOCA mice.","Positive_Correlation"
"Hydralazine treatment significantly attenuated <e1>renal damage</e1> that was found in L-FABP(+/-) AT1a(-/-)-<e2>DOCA</e2> mice along with a reduction in blood pressure.","Positive_Correlation"
"Role of angiotensin II type 1a receptor in <e1>renal injury</e1> induced by <e2>deoxycorticosterone acetate</e2>-salt hypertension.","Positive_Correlation"
"<e1>PTPN22</e1> Is a Critical Regulator of <e2>Fcg Receptor</e2>-Mediated Neutrophil Activation.","Association"
"In contrast, in vivo neutrophil recruitment following <e1>thioglycollate</e1>-induced <e2>peritonitis</e2> and in vitro chemotaxis were not affected by lack of PTPN22.","Positive_Correlation"
"Tyrosine phosphorylation of Lyn and <e1>Syk</e1> was altered in <e2>Ptpn22</e2>(-/-) neutrophils.","Association"
"Tyrosine phosphorylation of <e1>Lyn</e1> and Syk was altered in <e2>Ptpn22</e2>(-/-) neutrophils.","Association"
"Genome-wide association studies have established that the gene encoding the <e1>protein tyrosine phosphatase nonreceptor 22</e1> (PTPN22) makes an important contribution to susceptibility to autoimmune disease, notably <e2>rheumatoid arthritis</e2>.","Association"
"Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (<e1>PTPN22</e1>) makes an important contribution to susceptibility to autoimmune disease, notably <e2>rheumatoid arthritis</e2>.","Association"
"Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (<e1>PTPN22</e1>) makes an important contribution to susceptibility to autoimmune disease, notably <e2>rheumatoid arthritis</e2>.","Association"
"Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (<e1>PTPN22</e1>) makes an important contribution to susceptibility to autoimmune disease, notably <e2>rheumatoid arthritis</e2>.","Association"
"Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (<e1>PTPN22</e1>) makes an important contribution to susceptibility to autoimmune disease, notably <e2>rheumatoid arthritis</e2>.","Association"
"Genome-wide association studies have established that the gene encoding the <e1>protein tyrosine phosphatase nonreceptor 22</e1> (PTPN22) makes an important contribution to susceptibility to <e2>autoimmune disease</e2>, notably rheumatoid arthritis.","Association"
"Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (<e1>PTPN22</e1>) makes an important contribution to susceptibility to <e2>autoimmune disease</e2>, notably rheumatoid arthritis.","Association"
"Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (<e1>PTPN22</e1>) makes an important contribution to susceptibility to <e2>autoimmune disease</e2>, notably rheumatoid arthritis.","Association"
"Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (<e1>PTPN22</e1>) makes an important contribution to susceptibility to <e2>autoimmune disease</e2>, notably rheumatoid arthritis.","Association"
"Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (<e1>PTPN22</e1>) makes an important contribution to susceptibility to <e2>autoimmune disease</e2>, notably rheumatoid arthritis.","Association"
"Genome-wide association studies have established that the gene encoding the <e1>protein tyrosine phosphatase nonreceptor 22</e1> (PTPN22) makes an important contribution to susceptibility to autoimmune disease, notably rheumatoid <e2>arthritis</e2>.","Association"
"Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (<e1>PTPN22</e1>) makes an important contribution to susceptibility to autoimmune disease, notably rheumatoid <e2>arthritis</e2>.","Association"
"Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (<e1>PTPN22</e1>) makes an important contribution to susceptibility to autoimmune disease, notably rheumatoid <e2>arthritis</e2>.","Association"
"<e1>Ptpn22</e1>(-/-) mice were protected from immune complex-mediated <e2>arthritis</e2>, induced by the transfer of arthritogenic serum.","Association"
"<e1>Ptpn22</e1>(-/-) mice were protected from immune complex-mediated <e2>arthritis</e2>, induced by the transfer of arthritogenic serum.","Association"
"<e1>Ptpn22</e1>(-/-) mice were protected from immune complex-mediated <e2>arthritis</e2>, induced by the transfer of arthritogenic serum.","Association"
"<e1>Ptpn22</e1>(-/-) mice were protected from immune complex-mediated <e2>arthritis</e2>, induced by the transfer of arthritogenic serum.","Association"
"Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (<e1>PTPN22</e1>) makes an important contribution to susceptibility to autoimmune disease, notably rheumatoid <e2>arthritis</e2>.","Association"
"Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (<e1>PTPN22</e1>) makes an important contribution to susceptibility to autoimmune disease, notably rheumatoid <e2>arthritis</e2>.","Association"
"We show in this article that neutrophil effector functions, including adhesion, production of <e2>reactive oxygen species</e2>, and degranulation induced by immobilized immune complexes, were reduced in <e1>Ptpn22</e1>(-/-) neutrophils.","Negative_Correlation"
"We show in this article that neutrophil effector functions, including adhesion, production of <e2>reactive oxygen species</e2>, and degranulation induced by immobilized immune complexes, were reduced in <e1>Ptpn22</e1>(-/-) neutrophils.","Negative_Correlation"
"We show in this article that neutrophil effector functions, including adhesion, production of <e2>reactive oxygen species</e2>, and degranulation induced by immobilized immune complexes, were reduced in <e1>Ptpn22</e1>(-/-) neutrophils.","Negative_Correlation"
"We show in this article that neutrophil effector functions, including adhesion, production of <e2>reactive oxygen species</e2>, and degranulation induced by immobilized immune complexes, were reduced in <e1>Ptpn22</e1>(-/-) neutrophils.","Negative_Correlation"
"Our data suggest an important role for <e1>PTPN22</e1>-dependent dephosphorylation events, which are required to enable full <e2>FcgR</e2>-induced activation, pointing to an important role for this molecule in neutrophil function.","Association"
"Our data suggest an important role for <e1>PTPN22</e1>-dependent dephosphorylation events, which are required to enable full <e2>FcgR</e2>-induced activation, pointing to an important role for this molecule in neutrophil function.","Association"
"Our data suggest an important role for <e1>PTPN22</e1>-dependent dephosphorylation events, which are required to enable full <e2>FcgR</e2>-induced activation, pointing to an important role for this molecule in neutrophil function.","Association"
"Our data suggest an important role for <e1>PTPN22</e1>-dependent dephosphorylation events, which are required to enable full <e2>FcgR</e2>-induced activation, pointing to an important role for this molecule in neutrophil function.","Association"
"Four novel mutations in the <e1>thiazide</e1>-sensitive <e2>Na-Cl co-transporter</e2> gene in Japanese patients with Gitelman's syndrome.","Positive_Correlation"
"Four novel mutations in the thiazide-sensitive <e1>Na-Cl co-transporter</e1> gene in Japanese patients with <e2>Gitelman's syndrome</e2>.","Association"
"BACKGROUND: Gitelman's syndrome (GS) is an autosomal recessive disorder resulting from inactivating mutations in the <e1>thiazide</e1>-sensitive <e2>Na-Cl co-transporter</e2> (NCCT) gene.","Positive_Correlation"
"BACKGROUND: <e2>Gitelman's syndrome</e2> (GS) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive <e1>Na-Cl co-transporter</e1> (NCCT) gene.","Association"
"BACKGROUND: <e2>Gitelman's syndrome</e2> (GS) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive Na-Cl co-transporter (<e1>NCCT</e1>) gene.","Association"
"BACKGROUND: <e2>Gitelman's syndrome</e2> (GS) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive Na-Cl co-transporter (<e1>NCCT</e1>) gene.","Association"
"BACKGROUND: <e2>Gitelman's syndrome</e2> (GS) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive Na-Cl co-transporter (<e1>NCCT</e1>) gene.","Association"
"BACKGROUND: <e2>Gitelman's syndrome</e2> (GS) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive Na-Cl co-transporter (<e1>NCCT</e1>) gene.","Association"
"BACKGROUND: <e2>Gitelman's syndrome</e2> (GS) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive Na-Cl co-transporter (<e1>NCCT</e1>) gene.","Association"
"Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and <e1>c.1932delC</e1>] have been reported in Japanese patients, but not in <e2>GS</e2> patients from other ethnic groups.","Positive_Correlation"
"Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), <e1>c.2552T>A</e1> (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in <e2>GS</e2> patients from other ethnic groups.","Positive_Correlation"
"Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (<e1>Leu849His</e1>) and c.1932delC] have been reported in Japanese patients, but not in <e2>GS</e2> patients from other ethnic groups.","Positive_Correlation"
"Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), <e1>c.1930C>T</e1> (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in <e2>GS</e2> patients from other ethnic groups.","Positive_Correlation"
"Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (<e1>Arg642Cys</e1>), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in <e2>GS</e2> patients from other ethnic groups.","Positive_Correlation"
"Five of them [c.185C>T (Thr60Met), <e1>c.1712C>T</e1> (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in <e2>GS</e2> patients from other ethnic groups.","Positive_Correlation"
"Five of them [c.185C>T (Thr60Met), c.1712C>T (<e1>Ala569Val</e1>), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in <e2>GS</e2> patients from other ethnic groups.","Positive_Correlation"
"Five of them [<e1>c.185C>T</e1> (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in <e2>GS</e2> patients from other ethnic groups.","Positive_Correlation"
"Five of them [c.185C>T (<e1>Thr60Met</e1>), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in <e2>GS</e2> patients from other ethnic groups.","Positive_Correlation"
"In this context, the activation of genes such as dusp1 and <e1>nfkbia</e1> seems to counter-balance the inflammatory response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"In this context, the activation of genes such as dusp1 and <e1>nfkbia</e1> seems to counter-balance the inflammatory response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"In this context, the activation of genes such as <e1>dusp1</e1> and nfkbia seems to counter-balance the inflammatory response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"In this context, the activation of genes such as <e1>dusp1</e1> and nfkbia seems to counter-balance the inflammatory response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by <e1>PAR2</e1>-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by <e1>PAR2</e1>-deficiency.","Positive_Correlation"
"CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of <e1>PAR1</e1> in <e2>bladder inflammation</e2>, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.","Association"
"CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of <e1>PAR1</e1> in <e2>bladder inflammation</e2>, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.","Association"
"CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of <e1>PAR1</e1> in <e2>bladder inflammation</e2>, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.","Association"
"CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of <e1>PAR1</e1> in <e2>bladder inflammation</e2>, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.","Association"
"CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of <e1>PAR1</e1> in <e2>bladder inflammation</e2>, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.","Association"
"CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of <e1>PAR1</e1> in <e2>bladder inflammation</e2>, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.","Association"
"CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of <e1>PAR1</e1> in <e2>bladder inflammation</e2>, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.","Association"
"CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of <e1>PAR1</e1> in <e2>bladder inflammation</e2>, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among <e1>PAR1</e1>-dependent transcripts, the following have been implicated in the inflammatory process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by <e1>PAR1</e1>- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"In contrast, transcripts such as arf6 and <e2>dcnt1</e2> that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as arf6 and <e2>dcnt1</e2> that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as arf6 and <e2>dcnt1</e2> that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as arf6 and <e2>dcnt1</e2> that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as arf6 and <e2>dcnt1</e2> that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as arf6 and <e2>dcnt1</e2> that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as arf6 and <e2>dcnt1</e2> that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as arf6 and <e2>dcnt1</e2> that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as arf6 and <e2>dcnt1</e2> that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as <e2>arf6</e2> and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as <e2>arf6</e2> and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as <e2>arf6</e2> and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as <e2>arf6</e2> and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as <e2>arf6</e2> and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as <e2>arf6</e2> and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as <e2>arf6</e2> and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as <e2>arf6</e2> and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In contrast, transcripts such as <e2>arf6</e2> and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the <e1>inflammatory</e1> reaction in response to common pro-inflammatory stimuli.","Association"
"In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the <e1>inflammatory</e1> response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the <e1>inflammatory</e1> response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the <e1>inflammatory</e1> response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the <e1>inflammatory</e1> response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the <e1>inflammatory</e1> response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the <e1>inflammatory</e1> response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the <e1>inflammatory</e1> response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the <e1>inflammatory</e1> response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the <e1>inflammatory</e1> response to PAR activation by limiting prolonged activation of <e2>p38 MAPK</e2> and increased cytokine production.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and <e2>tnfaip2</e2>.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, <e2>sim2</e2>, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, <e2>s100a10</e2>, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, <e2>ptprcap</e2>, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, <e2>ptpn1</e2>, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, <e2>ppia</e2>, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, <e2>plaur</e2>, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, <e2>pax1</e2>, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, <e2>nfkbia</e2>, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, <e2>myo5a</e2>, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, <e2>mmp2</e2>, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, <e2>marcksl1</e2>, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, <e2>hspb1</e2>, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, <e2>fth1</e2>, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, <e2>fkbp1a</e2>, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, <e2>dusp1</e2>, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, cd63, cdbpd, <e2>cfl1</e2>, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, cd200, <e2>cd63</e2>, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, ccl7, <e2>cd200</e2>, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: b2m, <e2>ccl7</e2>, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Among PAR1-dependent transcripts, the following have been implicated in the <e1>inflammatory</e1> process: <e2>b2m</e2>, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), <e2>substance P</e2> (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli <e2>lipopolysaccharide</e2> (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.","Positive_Correlation"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by <e2>PAR2</e2>-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by <e2>PAR2</e2>-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by <e2>PAR2</e2>-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by <e2>PAR2</e2>-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by <e2>PAR2</e2>-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by <e2>PAR2</e2>-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by <e2>PAR2</e2>-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by <e2>PAR2</e2>-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by <e2>PAR2</e2>-deficiency.","Association"
"CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of <e2>PAR1</e2> in bladder <e1>inflammation</e1>, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.","Association"
"CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of <e2>PAR1</e2> in bladder <e1>inflammation</e1>, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by <e2>PAR1</e2>- and to a lesser extent by PAR2-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by <e2>PAR1</e2>- and to a lesser extent by PAR2-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by <e2>PAR1</e2>- and to a lesser extent by PAR2-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by <e2>PAR1</e2>- and to a lesser extent by PAR2-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by <e2>PAR1</e2>- and to a lesser extent by PAR2-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by <e2>PAR1</e2>- and to a lesser extent by PAR2-deficiency.","Association"
"CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of <e2>PAR1</e2> in bladder <e1>inflammation</e1>, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by <e2>PAR1</e2>- and to a lesser extent by PAR2-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by <e2>PAR1</e2>- and to a lesser extent by PAR2-deficiency.","Association"
"Moreover, the <e1>inflammatory</e1> response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by <e2>PAR1</e2>- and to a lesser extent by PAR2-deficiency.","Association"
"<e2>Caffeine</e2> challenge test in <e1>panic disorder</e1> and depression with panic attacks.","Association"
"<e2>Caffeine</e2> challenge test in panic disorder and depression with <e1>panic attacks</e1>.","Association"
"Our aim was to observe if patients with <e1>panic disorder</e1> (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (<e1>PD</e1>) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (PD) and patients with major depression with <e1>panic attacks</e1> (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (PD) and patients with major depression with <e1>panic attacks</e1> (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (<e1>PD</e1>) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (PD) and patients with major depression with <e1>panic attacks</e1> (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (<e1>PD</e1>) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (PD) and patients with major depression with <e1>panic attack</e1>s (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (<e1>PD</e1>) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (PD) and patients with major depression with <e1>panic attack</e1>s (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (PD) and patients with major depression with <e1>panic attacks</e1> (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (<e1>PD</e1>) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (PD) and patients with <e1>major depression</e1> with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (PD) and patients with <e1>major depression</e1> with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (<e1>MD</e1>P) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (<e1>MD</e1>P) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (<e1>MD</e1>P) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (<e1>MD</e1>P) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e2>caffeine</e2> challenge test.","Association"
"Upregulation of <e1>T-cell factor-4</e1> isoform-responsive target genes in <e2>hepatocellular carcinoma</e2>.","Association"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and <e1>JAG1</e1>) activated by TCF-4J isoform in <e2>HCC</e2> cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Association"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, <e1>CD24</e1> and JAG1) activated by TCF-4J isoform in <e2>HCC</e2> cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Association"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, <e1>GPR56</e1>, CD24 and JAG1) activated by TCF-4J isoform in <e2>HCC</e2> cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Association"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, <e1>ASPH</e1>, GPR56, CD24 and JAG1) activated by TCF-4J isoform in <e2>HCC</e2> cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Association"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, <e1>CAMK2N1</e1>, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in <e2>HCC</e2> cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Association"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, <e1>ANXA1</e1>, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in <e2>HCC</e2> cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Association"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, <e1>MMP7</e1>, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in <e2>HCC</e2> cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Association"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, <e1>WISP2</e1>, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in <e2>HCC</e2> cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Association"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, <e1>AXIN2</e1>, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in <e2>HCC</e2> cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Association"
"It was observed that 13 genes (CLDN2, STK17B, <e1>SPP1</e1>, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in <e2>HCC</e2> cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Association"
"It was observed that 13 genes (CLDN2, <e1>STK17B</e1>, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in <e2>HCC</e2> cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Association"
"It was observed that 13 genes (<e1>CLDN2</e1>, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in <e2>HCC</e2> cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Association"
"AIM: Here, we investigated <e1>TCF-4</e1> isoforms (TCF-4J and K)-responsive target genes that are important in hepatic oncogenesis and <e2>tumour</e2> development.","Association"
"AIM: Here, we investigated <e1>TCF-4</e1> isoforms (TCF-4J and K)-responsive target genes that are important in hepatic oncogenesis and <e2>tumour</e2> development.","Association"
"AIM: Here, we investigated TCF-4 isoforms (<e1>TCF-4J and K</e1>)-responsive target genes that are important in hepatic oncogenesis and <e2>tumour</e2> development.","Association"
"AIM: Here, we investigated TCF-4 isoforms (<e1>TCF-4J and K</e1>)-responsive target genes that are important in hepatic oncogenesis and <e2>tumour</e2> development.","Association"
"AIM: Here, we investigated <e1>TCF-4</e1> isoforms (TCF-4J and K)-responsive target genes that are important in hepatic oncogenesis and <e2>tumour</e2> development.","Association"
"AIM: Here, we investigated TCF-4 isoforms (<e1>TCF-4J</e1> and K)-responsive target genes that are important in hepatic oncogenesis and <e2>tumour</e2> development.","Association"
"AIM: Here, we investigated TCF-4 isoforms (<e1>TCF-4J</e1> and K)-responsive target genes that are important in hepatic oncogenesis and <e2>tumour</e2> development.","Association"
"AIM: Here, we investigated TCF-4 isoforms (<e1>TCF-4J</e1> and K)-responsive target genes that are important in hepatic oncogenesis and <e2>tumour</e2> development.","Association"
"AIM: Here, we investigated <e1>TCF-4</e1> isoforms (TCF-4J and K)-responsive target genes that are important in hepatic oncogenesis and <e2>tumour</e2> development.","Association"
"AIM: Here, we investigated TCF-4 isoforms (<e1>TCF-4J and K</e1>)-responsive target genes that are important in hepatic oncogenesis and <e2>tumour</e2> development.","Association"
"AIM: Here, we investigated TCF-4 isoforms (<e1>TCF-4J</e1> and K)-responsive target genes that are important in hepatic oncogenesis and <e2>tumour</e2> development.","Association"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and <e2>JAG1</e2>) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and <e2>JAG1</e2>) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and <e2>JAG1</e2>) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and <e2>JAG1</e2>) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and <e2>JAG1</e2>) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and <e2>JAG1</e2>) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and <e2>JAG1</e2>) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and <e2>JAG1</e2>) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, <e2>CD24</e2> and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, <e2>CD24</e2> and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, <e2>CD24</e2> and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, <e2>CD24</e2> and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, <e2>CD24</e2> and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, <e2>CD24</e2> and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, <e2>CD24</e2> and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, <e2>CD24</e2> and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, <e2>GPR56</e2>, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, <e2>GPR56</e2>, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, <e2>GPR56</e2>, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, <e2>GPR56</e2>, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, <e2>GPR56</e2>, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, <e2>GPR56</e2>, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, <e2>GPR56</e2>, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, <e2>GPR56</e2>, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, <e2>ASPH</e2>, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, <e2>ASPH</e2>, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, <e2>ASPH</e2>, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, <e2>ASPH</e2>, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, <e2>ASPH</e2>, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, <e2>ASPH</e2>, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, <e2>ASPH</e2>, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, <e2>ASPH</e2>, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, <e2>CAMK2N1</e2>, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, <e2>CAMK2N1</e2>, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, <e2>CAMK2N1</e2>, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, <e2>CAMK2N1</e2>, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, <e2>CAMK2N1</e2>, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, <e2>CAMK2N1</e2>, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, <e2>CAMK2N1</e2>, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, <e2>CAMK2N1</e2>, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, <e2>ANXA1</e2>, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, <e2>ANXA1</e2>, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, <e2>ANXA1</e2>, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, <e2>ANXA1</e2>, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, <e2>ANXA1</e2>, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, <e2>ANXA1</e2>, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, <e2>ANXA1</e2>, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, <e2>ANXA1</e2>, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, <e2>MMP7</e2>, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, <e2>MMP7</e2>, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, <e2>MMP7</e2>, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, <e2>MMP7</e2>, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, <e2>MMP7</e2>, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, <e2>MMP7</e2>, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, <e2>MMP7</e2>, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, <e2>MMP7</e2>, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, <e2>WISP2</e2>, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, <e2>WISP2</e2>, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, <e2>WISP2</e2>, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, <e2>WISP2</e2>, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, <e2>WISP2</e2>, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, <e2>WISP2</e2>, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, <e2>WISP2</e2>, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, <e2>WISP2</e2>, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, <e2>AXIN2</e2>, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, <e2>AXIN2</e2>, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, <e2>AXIN2</e2>, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, <e2>AXIN2</e2>, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, <e2>AXIN2</e2>, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, <e2>AXIN2</e2>, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, <e2>AXIN2</e2>, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, <e2>AXIN2</e2>, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, <e2>SPP1</e2>, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, <e2>SPP1</e2>, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, <e2>SPP1</e2>, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, <e2>SPP1</e2>, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, <e2>SPP1</e2>, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, <e2>SPP1</e2>, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, <e2>SPP1</e2>, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, <e2>SPP1</e2>, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, <e2>STK17B</e2>, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, <e2>STK17B</e2>, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, <e2>STK17B</e2>, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, <e2>STK17B</e2>, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, <e2>STK17B</e2>, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, <e2>STK17B</e2>, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, <e2>STK17B</e2>, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, <e2>STK17B</e2>, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (<e2>CLDN2</e2>, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (<e2>CLDN2</e2>, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (<e2>CLDN2</e2>, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (<e2>CLDN2</e2>, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (<e2>CLDN2</e2>, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (<e2>CLDN2</e2>, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (<e2>CLDN2</e2>, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (<e2>CLDN2</e2>, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and <e2>Notch</e2> signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and <e2>Notch</e2> signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and <e2>Notch</e2> signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and <e2>Notch</e2> signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and <e2>Notch</e2> signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and <e2>Notch</e2> signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and <e2>Notch</e2> signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and <e2>Notch</e2> signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, <e2>IRS1</e2>, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, <e2>IRS1</e2>, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, <e2>IRS1</e2>, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, <e2>IRS1</e2>, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, <e2>IRS1</e2>, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, <e2>IRS1</e2>, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, <e2>IRS1</e2>, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4</e1>J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, <e2>IRS1</e2>, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by <e1>TCF-4J</e1> isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/<e2>IGF-1</e2>/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/<e2>IGF-1</e2>/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/<e2>IGF-1</e2>/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/<e2>IGF-1</e2>/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/<e2>IGF-1</e2>/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/<e2>IGF-1</e2>/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/<e2>IGF-1</e2>/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/<e2>IGF-1</e2>/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, <e2>insulin</e2>/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, <e2>insulin</e2>/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, <e2>insulin</e2>/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, <e2>insulin</e2>/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, <e2>insulin</e2>/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, <e2>insulin</e2>/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, <e2>insulin</e2>/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, <e2>insulin</e2>/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"BACKGROUND: The Wnt/<e2>beta-catenin</e2> signalling pathway regulates genes involved in cell proliferation, survival, migration and invasion through regulation by <e1>T-cell factor (TCF)-4 transcription factor</e1> proteins.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/<e2>beta-catenin</e2>, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/<e2>beta-catenin</e2>, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/<e2>beta-catenin</e2>, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/<e2>beta-catenin</e2>, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/<e2>beta-catenin</e2>, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/<e2>beta-catenin</e2>, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite Wnt/<e2>beta-catenin</e2>, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite Wnt/<e2>beta-catenin</e2>, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"However, the role of <e1>TCF-4</e1> isoforms generated by alternative splicing events in <e2>hepatocellular carcinoma</e2> (HCC) is unknown.","Association"
"However, the role of <e1>TCF-4</e1> isoforms generated by alternative splicing events in <e2>hepatocellular carcinoma</e2> (HCC) is unknown.","Association"
"METHODS: Gene expression microarray was performed on <e2>HCC</e2> cells overexpressing <e1>TCF-4J and K</e1> isoforms.","Association"
"METHODS: Gene expression microarray was performed on <e2>HCC</e2> cells overexpressing <e1>TCF-4J and K</e1> isoforms.","Association"
"However, the role of <e1>TCF-4</e1> isoforms generated by alternative splicing events in <e2>hepatocellular carcinoma</e2> (HCC) is unknown.","Association"
"METHODS: Gene expression microarray was performed on <e2>HCC</e2> cells overexpressing <e1>TCF-4J</e1> and K isoforms.","Association"
"METHODS: Gene expression microarray was performed on <e2>HCC</e2> cells overexpressing <e1>TCF-4J</e1> and K isoforms.","Association"
"METHODS: Gene expression microarray was performed on <e2>HCC</e2> cells overexpressing <e1>TCF-4J</e1> and K isoforms.","Association"
"However, the role of <e1>TCF-4</e1> isoforms generated by alternative splicing events in <e2>hepatocellular carcinoma</e2> (HCC) is unknown.","Association"
"METHODS: Gene expression microarray was performed on <e2>HCC</e2> cells overexpressing <e1>TCF-4J and K</e1> isoforms.","Association"
"METHODS: Gene expression microarray was performed on <e2>HCC</e2> cells overexpressing <e1>TCF-4J</e1> and K isoforms.","Association"
"BACKGROUND: The <e2>Wnt</e2>/beta-catenin signalling pathway regulates genes involved in cell proliferation, survival, migration and invasion through regulation by <e1>T-cell factor (TCF)-4 transcription factor</e1> proteins.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite <e2>Wnt</e2>/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite <e2>Wnt</e2>/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite <e2>Wnt</e2>/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite <e2>Wnt</e2>/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite <e2>Wnt</e2>/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite <e2>Wnt</e2>/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4</e1>J isoform expression was upregulation of genes associated with tripartite <e2>Wnt</e2>/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"The biological consequence of <e1>TCF-4J</e1> isoform expression was upregulation of genes associated with tripartite <e2>Wnt</e2>/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.","Positive_Correlation"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/IRS1 and <e1>Notch</e1> signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/IRS1 and <e1>Notch</e1> signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/<e1>IRS1</e1> and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/<e1>IRS1</e1> and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/<e1>IRS1</e1> and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/<e1>IGF-1</e1>/<e2>IRS1</e2> and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/<e1>IGF-1</e1>/<e2>IRS1</e2> and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/<e1>IGF-1</e1>/IRS1 and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/<e1>IGF-1</e1>/IRS1 and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, <e1>insulin</e1>/IGF-1/<e2>IRS1</e2> and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, <e1>insulin</e1>/IGF-1/<e2>IRS1</e2> and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, <e1>insulin</e1>/<e2>IGF-1</e2>/IRS1 and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, <e1>insulin</e1>/<e2>IGF-1</e2>/IRS1 and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, <e1>insulin</e1>/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/beta-catenin, <e1>insulin</e1>/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/<e1>beta-catenin</e1>, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/<e1>beta-catenin</e1>, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in Wnt/<e1>beta-catenin</e1>, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"BACKGROUND: The <e1>Wnt</e1>/<e2>beta-catenin</e2> signalling pathway regulates genes involved in cell proliferation, survival, migration and invasion through regulation by T-cell factor (TCF)-4 transcription factor proteins.","Association"
"BACKGROUND: The <e1>Wnt</e1>/<e2>beta-catenin</e2> signalling pathway regulates genes involved in cell proliferation, survival, migration and invasion through regulation by T-cell factor (TCF)-4 transcription factor proteins.","Association"
"BACKGROUND: The <e1>Wnt</e1>/<e2>beta-catenin</e2> signalling pathway regulates genes involved in cell proliferation, survival, migration and invasion through regulation by T-cell factor (TCF)-4 transcription factor proteins.","Association"
"We validated expression of 18 selected target genes involved in <e1>Wnt</e1>/beta-catenin, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in <e1>Wnt</e1>/beta-catenin, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"We validated expression of 18 selected target genes involved in <e1>Wnt</e1>/beta-catenin, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human <e2>HCC</e2>s and adjacent uninvolved liver tissues.","Association"
"Nicotine antagonizes caffeine- but not <e1>pentylenetetrazole</e1>-induced <e2>anxiogenic effect</e2> in mice.","Positive_Correlation"
"Nicotine antagonizes <e1>caffeine</e1>- but not pentylenetetrazole-induced <e2>anxiogenic effect</e2> in mice.","Positive_Correlation"
"<e1>Nicotine</e1> antagonizes caffeine- but not pentylenetetrazole-induced <e2>anxiogenic effect</e2> in mice.","Negative_Correlation"
"<e1>Nicotine</e1> antagonizes <e2>caffeine</e2>- but not pentylenetetrazole-induced anxiogenic effect in mice.","Negative_Correlation"
"OBJECTIVES: The present study investigates the effects of nicotine on <e2>anxiety</e2> induced by caffeine and another anxiogenic drug, <e1>pentylenetetrazole</e1>, in mice.","Positive_Correlation"
"OBJECTIVES: The present study investigates the effects of nicotine on <e2>anxiety</e2> induced by caffeine and another anxiogenic drug, <e1>pentylenetetrazole</e1>, in mice.","Positive_Correlation"
"OBJECTIVES: The present study investigates the effects of nicotine on <e2>anxiety</e2> induced by caffeine and another anxiogenic drug, <e1>pentylenetetrazole</e1>, in mice.","Positive_Correlation"
"OBJECTIVES: The present study investigates the effects of nicotine on <e2>anxiety</e2> induced by caffeine and another anxiogenic drug, <e1>pentylenetetrazole</e1>, in mice.","Positive_Correlation"
"OBJECTIVES: The present study investigates the effects of nicotine on <e2>anxiety</e2> induced by <e1>caffeine</e1> and another anxiogenic drug, pentylenetetrazole, in mice.","Positive_Correlation"
"OBJECTIVES: The present study investigates the effects of nicotine on <e2>anxiety</e2> induced by <e1>caffeine</e1> and another anxiogenic drug, pentylenetetrazole, in mice.","Positive_Correlation"
"OBJECTIVES: The present study investigates the effects of nicotine on <e2>anxiety</e2> induced by <e1>caffeine</e1> and another anxiogenic drug, pentylenetetrazole, in mice.","Positive_Correlation"
"OBJECTIVES: The present study investigates the effects of nicotine on <e2>anxiety</e2> induced by <e1>caffeine</e1> and another anxiogenic drug, pentylenetetrazole, in mice.","Positive_Correlation"
"OBJECTIVES: The present study investigates the effects of nicotine on <e2>anxiety</e2> induced by <e1>caffeine</e1> and another anxiogenic drug, pentylenetetrazole, in mice.","Positive_Correlation"
"OBJECTIVES: The present study investigates the effects of nicotine on <e2>anxiety</e2> induced by <e1>caffeine</e1> and another anxiogenic drug, pentylenetetrazole, in mice.","Positive_Correlation"
"OBJECTIVES: The present study investigates the effects of nicotine on <e2>anxiety</e2> induced by <e1>caffeine</e1> and another anxiogenic drug, pentylenetetrazole, in mice.","Positive_Correlation"
"OBJECTIVES: The present study investigates the effects of nicotine on <e2>anxiety</e2> induced by <e1>caffeine</e1> and another anxiogenic drug, pentylenetetrazole, in mice.","Positive_Correlation"
"<e1>Nicotine</e1> (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced <e2>anxiety</e2>.","Negative_Correlation"
"OBJECTIVES: The present study investigates the effects of <e1>nicotine</e1> on <e2>anxiety</e2> induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.","Negative_Correlation"
"OBJECTIVES: The present study investigates the effects of <e1>nicotine</e1> on <e2>anxiety</e2> induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.","Negative_Correlation"
"<e1>Nicotine</e1> (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced <e2>anxiety</e2>.","Negative_Correlation"
"<e1>Nicotine</e1> (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced <e2>anxiety</e2>.","Negative_Correlation"
"OBJECTIVES: The present study investigates the effects of <e1>nicotine</e1> on <e2>anxiety</e2> induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.","Negative_Correlation"
"OBJECTIVES: The present study investigates the effects of <e1>nicotine</e1> on <e2>anxiety</e2> induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.","Negative_Correlation"
"RATIONALE: <e1>Nicotine</e1> and <e2>caffeine</e2> are widely consumed licit psychoactive drugs worldwide.","Negative_Correlation"
"OBJECTIVES: The present study investigates the effects of <e1>nicotine</e1> on anxiety induced by <e2>caffeine</e2> and another anxiogenic drug, pentylenetetrazole, in mice.","Negative_Correlation"
"OBJECTIVES: The present study investigates the effects of <e1>nicotine</e1> on anxiety induced by <e2>caffeine</e2> and another anxiogenic drug, pentylenetetrazole, in mice.","Negative_Correlation"
"RATIONALE: <e1>Nicotine</e1> and <e2>caffeine</e2> are widely consumed licit psychoactive drugs worldwide.","Negative_Correlation"
"RATIONALE: <e1>Nicotine</e1> and <e2>caffeine</e2> are widely consumed licit psychoactive drugs worldwide.","Negative_Correlation"
"OBJECTIVES: The present study investigates the effects of <e1>nicotine</e1> on anxiety induced by <e2>caffeine</e2> and another anxiogenic drug, pentylenetetrazole, in mice.","Negative_Correlation"
"OBJECTIVES: The present study investigates the effects of <e1>nicotine</e1> on anxiety induced by <e2>caffeine</e2> and another anxiogenic drug, pentylenetetrazole, in mice.","Negative_Correlation"
"The influence of the time interval between <e1>monoHER</e1> and doxorubicin administration on the protection against doxorubicin-induced <e2>cardiotoxicity</e2> in mice.","Negative_Correlation"
"The influence of the time interval between <e1>monoHER</e1> and <e2>doxorubicin</e2> administration on the protection against doxorubicin-induced cardiotoxicity in mice.","Negative_Correlation"
"The influence of the time interval between monoHER and <e1>doxorubicin</e1> administration on the protection against doxorubicin-induced <e2>cardiotoxicity</e2> in mice.","Positive_Correlation"
"The influence of the time interval between monoHER and <e1>doxorubicin</e1> administration on the protection against doxorubicin-induced <e2>cardiotoxicity</e2> in mice.","Positive_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced <e2>cardiotoxicity</e2> through its radical scavenging and <e1>iron</e1> chelating properties.","Association"
"The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against <e2>DOX</e2>-induced cardiotoxicity through its radical scavenging and <e1>iron</e1> chelating properties.","Association"
"The semisynthetic flavonoid <e1>monohydroxyethylrutoside</e1> (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and <e2>iron</e2> chelating properties.","Association"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and <e2>iron</e2> chelating properties.","Association"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and <e2>iron</e2> chelating properties.","Association"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and <e2>iron</e2> chelating properties.","Association"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and <e2>iron</e2> chelating properties.","Association"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and <e2>iron</e2> chelating properties.","Association"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and <e2>iron</e2> chelating properties.","Association"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and <e2>iron</e2> chelating properties.","Association"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and <e2>iron</e2> chelating properties.","Association"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and <e2>iron</e2> chelating properties.","Association"
"The semisynthetic flavonoid <e1>monohydroxyethylrutoside</e1> (monoHER) showed cardioprotection against DOX-induced <e2>cardiotoxicity</e2> through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced <e2>cardiotoxicity</e2> through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced <e2>cardiotoxicity</e2> through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced <e2>cardiotoxicity</e2> through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced <e2>cardiotoxicity</e2> through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced <e2>cardiotoxicity</e2> through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced <e2>cardiotoxicity</e2> through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced <e2>cardiotoxicity</e2> through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced <e2>cardiotoxicity</e2> through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against DOX-induced <e2>cardiotoxicity</e2> through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid <e1>monohydroxyethylrutoside</e1> (monoHER) showed cardioprotection against <e2>DOX</e2>-induced cardiotoxicity through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against <e2>DOX</e2>-induced cardiotoxicity through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against <e2>DOX</e2>-induced cardiotoxicity through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against <e2>DOX</e2>-induced cardiotoxicity through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against <e2>DOX</e2>-induced cardiotoxicity through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against <e2>DOX</e2>-induced cardiotoxicity through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against <e2>DOX</e2>-induced cardiotoxicity through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against <e2>DOX</e2>-induced cardiotoxicity through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against <e2>DOX</e2>-induced cardiotoxicity through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic flavonoid monohydroxyethylrutoside (<e1>monoHER</e1>) showed cardioprotection against <e2>DOX</e2>-induced cardiotoxicity through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic <e1>flavonoid</e1> monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced <e2>cardiotoxicity</e2> through its radical scavenging and iron chelating properties.","Negative_Correlation"
"The semisynthetic <e1>flavonoid</e1> monohydroxyethylrutoside (monoHER) showed cardioprotection against <e2>DOX</e2>-induced cardiotoxicity through its radical scavenging and iron chelating properties.","Negative_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"<e1>DOX</e1>-induced <e2>cardiac damage</e2> presumably results from the formation of free radicals by DOX.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin <e1>doxorubicin</e1> (DOX) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"PURPOSE: Despite its well-known <e2>cardiotoxicity</e2>, the anthracyclin doxorubicin (<e1>DOX</e1>) continues to be an effective and widely used chemotherapeutic agent.","Positive_Correlation"
"Pharmacokinetics of <e1>desipramine HCl</e1> when administered with <e2>cinacalcet HCl</e2>.","Cotreatment"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"OBJECTIVE: In vitro work has demonstrated that <e1>cinacalcet</e1> is a strong inhibitor of <e2>cytochrome P450 isoenzyme (CYP) 2D6</e2>.","Negative_Correlation"
"OBJECTIVE: In vitro work has demonstrated that <e1>cinacalcet</e1> is a strong inhibitor of <e2>cytochrome P450 isoenzyme (CYP) 2D6</e2>.","Negative_Correlation"
"OBJECTIVE: In vitro work has demonstrated that <e1>cinacalcet</e1> is a strong inhibitor of <e2>cytochrome P450 isoenzyme (CYP) 2D6</e2>.","Negative_Correlation"
"OBJECTIVE: In vitro work has demonstrated that <e1>cinacalcet</e1> is a strong inhibitor of <e2>cytochrome P450 isoenzyme (CYP) 2D6</e2>.","Negative_Correlation"
"OBJECTIVE: In vitro work has demonstrated that <e1>cinacalcet</e1> is a strong inhibitor of <e2>cytochrome P450 isoenzyme (CYP) 2D6</e2>.","Negative_Correlation"
"OBJECTIVE: In vitro work has demonstrated that <e1>cinacalcet</e1> is a strong inhibitor of <e2>cytochrome P450 isoenzyme (CYP) 2D6</e2>.","Negative_Correlation"
"OBJECTIVE: In vitro work has demonstrated that <e1>cinacalcet</e1> is a strong inhibitor of <e2>cytochrome P450 isoenzyme (CYP) 2D6</e2>.","Negative_Correlation"
"OBJECTIVE: In vitro work has demonstrated that <e1>cinacalcet</e1> is a strong inhibitor of <e2>cytochrome P450 isoenzyme (CYP) 2D6</e2>.","Negative_Correlation"
"OBJECTIVE: In vitro work has demonstrated that <e1>cinacalcet</e1> is a strong inhibitor of <e2>cytochrome P450 isoenzyme (CYP) 2D6</e2>.","Negative_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with <e1>cinacalcet</e1> (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and <e2>headache</e2>) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"Fewer subjects reported adverse events following treatment with <e1>desipramine</e1> alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (<e2>nausea</e2> and headache) have been reported for patients treated with either desipramine or cinacalcet.","Positive_Correlation"
"The purpose of this study was to evaluate the effect of <e2>cinacalcet</e2> on CYP2D6 activity, using <e1>desipramine</e1> as a probe substrate, in healthy subjects.","Cotreatment"
"The purpose of this study was to evaluate the effect of <e2>cinacalcet</e2> on CYP2D6 activity, using <e1>desipramine</e1> as a probe substrate, in healthy subjects.","Cotreatment"
"The purpose of this study was to evaluate the effect of <e2>cinacalcet</e2> on CYP2D6 activity, using <e1>desipramine</e1> as a probe substrate, in healthy subjects.","Cotreatment"
"The purpose of this study was to evaluate the effect of <e2>cinacalcet</e2> on CYP2D6 activity, using <e1>desipramine</e1> as a probe substrate, in healthy subjects.","Cotreatment"
"The purpose of this study was to evaluate the effect of <e2>cinacalcet</e2> on CYP2D6 activity, using <e1>desipramine</e1> as a probe substrate, in healthy subjects.","Cotreatment"
"The purpose of this study was to evaluate the effect of <e2>cinacalcet</e2> on CYP2D6 activity, using <e1>desipramine</e1> as a probe substrate, in healthy subjects.","Cotreatment"
"The purpose of this study was to evaluate the effect of <e2>cinacalcet</e2> on CYP2D6 activity, using <e1>desipramine</e1> as a probe substrate, in healthy subjects.","Cotreatment"
"The purpose of this study was to evaluate the effect of <e2>cinacalcet</e2> on CYP2D6 activity, using <e1>desipramine</e1> as a probe substrate, in healthy subjects.","Cotreatment"
"The purpose of this study was to evaluate the effect of <e2>cinacalcet</e2> on CYP2D6 activity, using <e1>desipramine</e1> as a probe substrate, in healthy subjects.","Cotreatment"
"Antipsychotic-like profile of <e2>thioperamide</e2>, a selective <e1>H3-receptor</e1> antagonist in mice.","Negative_Correlation"
"Findings suggest a potential for <e1>H(3)-receptor antagonists</e1> in improving the refractory cases of <e2>schizophrenia</e2>.","Negative_Correlation"
"The present study was designed to study the effect of histamine H(3)-receptor ligands on <e1>neuroleptic</e1>-induced <e2>catalepsy</e2>, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.","Positive_Correlation"
"THP exhibited an <e1>antipsychotic</e1>-like profile by potentiating haloperidol-induced <e2>catalepsy</e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"1 h prior to <e1>haloperidol</e1> resulted in a dose-dependent increase in the <e2>catalepsy</e2> times (P < 0.05).","Positive_Correlation"
"1 h prior to <e1>haloperidol</e1> resulted in a dose-dependent increase in the <e2>catalepsy</e2> times (P < 0.05).","Positive_Correlation"
"1 h prior to <e1>haloperidol</e1> resulted in a dose-dependent increase in the <e2>catalepsy</e2> times (P < 0.05).","Positive_Correlation"
"On <e1>amphetamine</e1>-induced <e2>hyperactivity</e2>, THP (3.75 and 7.5 mg/kg i.p.)","Positive_Correlation"
"On <e1>amphetamine</e1>-induced <e2>hyperactivity</e2>, THP (3.75 and 7.5 mg/kg i.p.)","Positive_Correlation"
"On <e1>amphetamine</e1>-induced <e2>hyperactivity</e2>, THP (3.75 and 7.5 mg/kg i.p.)","Positive_Correlation"
"On <e1>amphetamine</e1>-induced <e2>hyperactivity</e2>, THP (3.75 and 7.5 mg/kg i.p.)","Positive_Correlation"
"However, pretreatment with <e1>RAMH</e1> significantly reversed such an effect of <e2>THP</e2> (15 mg/kg i.p.).","Negative_Correlation"
"However, pretreatment with <e1>RAMH</e1> significantly reversed such an effect of <e2>THP</e2> (15 mg/kg i.p.).","Negative_Correlation"
"However, pretreatment with <e1>RAMH</e1> significantly reversed such an effect of <e2>THP</e2> (15 mg/kg i.p.).","Negative_Correlation"
"However, pretreatment with <e1>RAMH</e1> significantly reversed such an effect of <e2>THP</e2> (15 mg/kg i.p.).","Negative_Correlation"
"However, pretreatment with <e1>RAMH</e1> significantly reversed such an effect of <e2>THP</e2> (15 mg/kg i.p.).","Negative_Correlation"
"However, pretreatment with <e1>RAMH</e1> significantly reversed such an effect of <e2>THP</e2> (15 mg/kg i.p.).","Negative_Correlation"
"Such effects of THP were reversed by <e1>RAMH</e1> indicating the involvement of <e2>histamine H(3)-receptor</e2>s.","Association"
"Such effects of THP were reversed by <e1>RAMH</e1> indicating the involvement of <e2>histamine H(3)-receptor</e2>s.","Association"
"Such effects of THP were reversed by <e1>RAMH</e1> indicating the involvement of <e2>histamine H(3)-receptor</e2>s.","Association"
"Such effects of THP were reversed by <e1>RAMH</e1> indicating the involvement of <e2>histamine H(3)-receptor</e2>s.","Association"
"Such effects of THP were reversed by <e1>RAMH</e1> indicating the involvement of <e2>histamine H(3)-receptor</e2>s.","Association"
"Such effects of THP were reversed by <e1>RAMH</e1> indicating the involvement of <e2>histamine H(3)-receptor</e2>s.","Association"
"Climbing behavior induced by <e2>apomorphine</e2> was reduced in animals treated with <e1>THP</e1>.","Negative_Correlation"
"Climbing behavior induced by <e2>apomorphine</e2> was reduced in animals treated with <e1>THP</e1>.","Negative_Correlation"
"Climbing behavior induced by <e2>apomorphine</e2> was reduced in animals treated with <e1>THP</e1>.","Negative_Correlation"
"Climbing behavior induced by <e2>apomorphine</e2> was reduced in animals treated with <e1>THP</e1>.","Negative_Correlation"
"Climbing behavior induced by <e2>apomorphine</e2> was reduced in animals treated with <e1>THP</e1>.","Negative_Correlation"
"Climbing behavior induced by <e2>apomorphine</e2> was reduced in animals treated with <e1>THP</e1>.","Negative_Correlation"
"Climbing behavior induced by <e2>apomorphine</e2> was reduced in animals treated with <e1>THP</e1>.","Negative_Correlation"
"Climbing behavior induced by <e2>apomorphine</e2> was reduced in animals treated with <e1>THP</e1>.","Negative_Correlation"
"Climbing behavior induced by <e2>apomorphine</e2> was reduced in animals treated with <e1>THP</e1>.","Negative_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2>catalepsy</e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2>catalepsy</e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2>catalepsy</e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2>catalepsy</e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2>catalepsy</e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2>catalepsy</e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2>catalepsy</e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2>catalepsy</e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced <e2>catalepsy</e2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating <e2>haloperidol</e2>-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating <e2>haloperidol</e2>-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating <e2>haloperidol</e2>-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating <e2>haloperidol</e2>-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating <e2>haloperidol</e2>-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating <e2>haloperidol</e2>-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating <e2>haloperidol</e2>-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating <e2>haloperidol</e2>-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"<e1>THP</e1> exhibited an antipsychotic-like profile by potentiating <e2>haloperidol</e2>-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.","Positive_Correlation"
"On amphetamine-induced <e2>hyperactivity</e2>, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On amphetamine-induced <e2>hyperactivity</e2>, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On amphetamine-induced <e2>hyperactivity</e2>, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On amphetamine-induced <e2>hyperactivity</e2>, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On amphetamine-induced <e2>hyperactivity</e2>, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On amphetamine-induced <e2>hyperactivity</e2>, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On amphetamine-induced <e2>hyperactivity</e2>, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On amphetamine-induced <e2>hyperactivity</e2>, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On amphetamine-induced <e2>hyperactivity</e2>, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On <e2>amphetamine</e2>-induced hyperactivity, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On <e2>amphetamine</e2>-induced hyperactivity, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On <e2>amphetamine</e2>-induced hyperactivity, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On <e2>amphetamine</e2>-induced hyperactivity, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On <e2>amphetamine</e2>-induced hyperactivity, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On <e2>amphetamine</e2>-induced hyperactivity, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On <e2>amphetamine</e2>-induced hyperactivity, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On <e2>amphetamine</e2>-induced hyperactivity, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"On <e2>amphetamine</e2>-induced hyperactivity, <e1>THP</e1> (3.75 and 7.5 mg/kg i.p.)","Negative_Correlation"
"Such effects of <e2>THP</e2> were reversed by RAMH indicating the involvement of <e1>histamine H(3)-receptor</e1>s.","Negative_Correlation"
"Such effects of <e2>THP</e2> were reversed by RAMH indicating the involvement of <e1>histamine H(3)-receptors</e1>.","Negative_Correlation"
"Lithium was associated with a significantly higher incidence (p < 0.05) of <e1>tremor</e1> (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of <e2>lithium</e2>, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.","Positive_Correlation"
"Lithium was associated with a significantly higher incidence (p < 0.05) of <e1>tremor</e1> (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of <e2>lithium</e2>, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.","Positive_Correlation"
"Lithium was associated with a significantly higher incidence (p < 0.05) of <e1>tremor</e1> (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of <e2>lithium</e2>, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.","Positive_Correlation"
"Lithium was associated with a significantly higher incidence (p < 0.05) of <e1>tremor</e1> (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of <e2>lithium</e2>, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.","Positive_Correlation"
"<e1>Haloperidol</e1> induced a significantly higher incidence (p < 0.001) of <e2>akathisia</e2> (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.","Positive_Correlation"
"<e1>Haloperidol</e1> induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), <e2>tremor</e2> (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.","Positive_Correlation"
"Adverse events related to <e1>EPS</e1> occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with <e2>lithium</e2> (n = 98) monotherapy experienced adverse events related to EPS.","Positive_Correlation"
"Adverse events related to <e1>EPS</e1> occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with <e2>lithium</e2> (n = 98) monotherapy experienced adverse events related to EPS.","Positive_Correlation"
"Adverse events related to <e1>EPS</e1> occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with <e2>lithium</e2> (n = 98) monotherapy experienced adverse events related to EPS.","Positive_Correlation"
"Adverse events related to <e1>EPS</e1> occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with <e2>lithium</e2> (n = 98) monotherapy experienced adverse events related to EPS.","Positive_Correlation"
"Adverse events related to <e1>EPS</e1> occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with <e2>lithium</e2> (n = 98) monotherapy experienced adverse events related to EPS.","Positive_Correlation"
"Adverse events related to <e1>EPS</e1> occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with <e2>lithium</e2> (n = 98) monotherapy experienced adverse events related to EPS.","Positive_Correlation"
"Adverse events related to <e1>EPS</e1> occurred in 59.6% of patients treated with <e2>haloperidol</e2> (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.","Positive_Correlation"
"Adverse events related to <e1>EPS</e1> occurred in 59.6% of patients treated with <e2>haloperidol</e2> (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.","Positive_Correlation"
"Adverse events related to <e1>EPS</e1> occurred in 59.6% of patients treated with <e2>haloperidol</e2> (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.","Positive_Correlation"
"Adverse events related to <e1>EPS</e1> occurred in 59.6% of patients treated with <e2>haloperidol</e2> (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.","Positive_Correlation"
"Adverse events related to <e1>EPS</e1> occurred in 59.6% of patients treated with <e2>haloperidol</e2> (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.","Positive_Correlation"
"<e2>Haloperidol</e2> induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and <e1>extrapyramidal syndrome</e1> (35.4% versus 5.9%) than quetiapine.","Positive_Correlation"
"Adverse events related to <e1>EPS</e1> occurred in 59.6% of patients treated with <e2>haloperidol</e2> (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.","Positive_Correlation"
"Randomized comparison of olanzapine versus <e2>risperidone</e2> for the treatment of first-episode <e1>schizophrenia</e1>: 4-month outcomes.","Negative_Correlation"
"Randomized comparison of <e2>olanzapine</e2> versus risperidone for the treatment of first-episode <e1>schizophrenia</e1>: 4-month outcomes.","Negative_Correlation"
"Randomized comparison of <e1>olanzapine</e1> versus <e2>risperidone</e2> for the treatment of first-episode schizophrenia: 4-month outcomes.","Comparison"
"Significantly more <e1>weight gain</e1> occurred with <e2>olanzapine</e2> than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.","Positive_Correlation"
"Significantly more <e1>weight gain</e1> occurred with <e2>olanzapine</e2> than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.","Positive_Correlation"
"Significantly more <e1>weight gain</e1> occurred with <e2>olanzapine</e2> than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.","Positive_Correlation"
"<e1>Extrapyramidal symptom</e1> severity scores were 1.4 (95% CI=1.2-1.6) with <e2>risperidone</e2> and 1.2 (95% CI=1.0-1.4) with olanzapine.","Association"
"<e1>Extrapyramidal symptom</e1> severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with <e2>olanzapine</e2>.","Association"
"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), <e1>schizophreniform disorder</e1> (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or <e2>risperidone</e2> (1-6 mg/day).","Negative_Correlation"
"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or <e1>schizoaffective disorder</e1> (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or <e2>risperidone</e2> (1-6 mg/day).","Negative_Correlation"
"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), <e1>schizophreniform disorder</e1> (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with <e2>olanzapine</e2> (2.5-20 mg/day) or risperidone (1-6 mg/day).","Negative_Correlation"
"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or <e1>schizoaffective disorder</e1> (8%) were randomly assigned to treatment with <e2>olanzapine</e2> (2.5-20 mg/day) or risperidone (1-6 mg/day).","Negative_Correlation"
"OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus <e2>risperidone</e2> in patients with first-episode <e1>schizophrenia</e1> spectrum disorders.","Negative_Correlation"
"OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus <e2>risperidone</e2> in patients with first-episode <e1>schizophrenia</e1> spectrum disorders.","Negative_Correlation"
"OBJECTIVE: The authors compared 4-month treatment outcomes for <e2>olanzapine</e2> versus risperidone in patients with first-episode <e1>schizophrenia</e1> spectrum disorders.","Negative_Correlation"
"OBJECTIVE: The authors compared 4-month treatment outcomes for <e2>olanzapine</e2> versus risperidone in patients with first-episode <e1>schizophrenia</e1> spectrum disorders.","Negative_Correlation"
"Significantly more <e2>weight gain</e2> occurred with olanzapine than with <e1>risperidone</e1>: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.","Positive_Correlation"
"Significantly more <e2>weight gain</e2> occurred with olanzapine than with <e1>risperidone</e1>: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.","Positive_Correlation"
"Significantly more <e2>weight gain</e2> occurred with olanzapine than with <e1>risperidone</e1>: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.","Positive_Correlation"
"Significantly more <e2>weight gain</e2> occurred with olanzapine than with <e1>risperidone</e1>: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.","Positive_Correlation"
"Significantly more <e2>weight gain</e2> occurred with olanzapine than with <e1>risperidone</e1>: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.","Positive_Correlation"
"Significantly more <e2>weight gain</e2> occurred with olanzapine than with <e1>risperidone</e1>: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.","Positive_Correlation"
"Significantly more <e2>weight gain</e2> occurred with olanzapine than with <e1>risperidone</e1>: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.","Positive_Correlation"
"Significantly more <e2>weight gain</e2> occurred with olanzapine than with <e1>risperidone</e1>: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.","Positive_Correlation"
"Significantly more <e2>weight gain</e2> occurred with olanzapine than with <e1>risperidone</e1>: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.","Positive_Correlation"
"OBJECTIVE: The authors compared 4-month treatment outcomes for <e1>olanzapine</e1> versus <e2>risperidone</e2> in patients with first-episode schizophrenia spectrum disorders.","Comparison"
"OBJECTIVE: The authors compared 4-month treatment outcomes for <e1>olanzapine</e1> versus <e2>risperidone</e2> in patients with first-episode schizophrenia spectrum disorders.","Comparison"
"OBJECTIVE: The authors compared 4-month treatment outcomes for <e1>olanzapine</e1> versus <e2>risperidone</e2> in patients with first-episode schizophrenia spectrum disorders.","Comparison"
"OBJECTIVE: The authors compared 4-month treatment outcomes for <e1>olanzapine</e1> versus <e2>risperidone</e2> in patients with first-episode schizophrenia spectrum disorders.","Comparison"
"OBJECTIVE: The authors compared 4-month treatment outcomes for <e1>olanzapine</e1> versus <e2>risperidone</e2> in patients with first-episode schizophrenia spectrum disorders.","Comparison"
"OBJECTIVE: The authors compared 4-month treatment outcomes for <e1>olanzapine</e1> versus <e2>risperidone</e2> in patients with first-episode schizophrenia spectrum disorders.","Comparison"
"OBJECTIVE: The authors compared 4-month treatment outcomes for <e1>olanzapine</e1> versus <e2>risperidone</e2> in patients with first-episode schizophrenia spectrum disorders.","Comparison"
"OBJECTIVE: The authors compared 4-month treatment outcomes for <e1>olanzapine</e1> versus <e2>risperidone</e2> in patients with first-episode schizophrenia spectrum disorders.","Comparison"
"OBJECTIVE: The authors compared 4-month treatment outcomes for <e1>olanzapine</e1> versus <e2>risperidone</e2> in patients with first-episode schizophrenia spectrum disorders.","Comparison"
"OBJECTIVE: The authors compared 4-month treatment outcomes for <e1>olanzapine</e1> versus <e2>risperidone</e2> in patients with first-episode schizophrenia spectrum disorders.","Comparison"
"Risks and benefits of <e1>COX-2 inhibitors</e1> vs non-selective <e2>NSAIDs</e2>: does their cardiovascular risk exceed their gastrointestinal benefit?","Comparison"
"The AMI/<e1>GI toxicity</e1> of <e2>celecoxib</e2> was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.","Association"
"The AMI/<e1>GI toxicity</e1> of celecoxib was similar to that of acetaminophen and seemed to be better than those of <e2>rofecoxib</e2> and NS-NSAIDs.","Association"
"The AMI/<e1>GI toxicity</e1> of celecoxib was similar to that of <e2>acetaminophen</e2> and seemed to be better than those of rofecoxib and NS-NSAIDs.","Association"
"The AMI/<e1>GI toxicity</e1> of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-<e2>NSAIDs</e2>.","Association"
"CONCLUSION: Among non-users of aspirin, <e1>naproxen</e1> seemed to carry the highest risk for AMI/<e2>GI bleeding</e2>.","Positive_Correlation"
"CONCLUSION: Among non-users of aspirin, <e1>naproxen</e1> seemed to carry the highest risk for AMI/<e2>GI bleeding</e2>.","Positive_Correlation"
"CONCLUSION: Among non-users of aspirin, <e1>naproxen</e1> seemed to carry the highest risk for AMI/<e2>GI bleeding</e2>.","Positive_Correlation"
"CONCLUSION: Among non-users of aspirin, <e1>naproxen</e1> seemed to carry the highest risk for AMI/<e2>GI bleeding</e2>.","Positive_Correlation"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), <e1>naproxen</e1> 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Positive_Correlation"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), <e1>naproxen</e1> 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Positive_Correlation"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), <e1>naproxen</e1> 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Positive_Correlation"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), <e1>naproxen</e1> 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Positive_Correlation"
"OBJECTIVES: The risk of <e1>acute myocardial infarction</e1> (AMI) with <e2>COX-2 inhibitors</e2> may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).","Positive_Correlation"
"OBJECTIVES: The risk of acute myocardial infarction (<e1>AMI</e1>) with <e2>COX-2 inhibitors</e2> may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).","Positive_Correlation"
"OBJECTIVES: The risk of acute myocardial infarction (<e1>AMI</e1>) with <e2>COX-2 inhibitors</e2> may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).","Positive_Correlation"
"OBJECTIVES: The risk of acute myocardial infarction (<e1>AMI</e1>) with <e2>COX-2 inhibitors</e2> may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).","Positive_Correlation"
"OBJECTIVES: The risk of acute myocardial infarction (<e1>AMI</e1>) with <e2>COX-2 inhibitors</e2> may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).","Positive_Correlation"
"OBJECTIVES: The risk of acute myocardial infarction (<e1>AMI</e1>) with <e2>COX-2 inhibitors</e2> may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).","Positive_Correlation"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), <e1>celecoxib</e1> 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Association"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), <e1>celecoxib</e1> 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Association"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), <e1>celecoxib</e1> 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Association"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), <e1>celecoxib</e1> 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Association"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), <e1>celecoxib</e1> 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Association"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), <e1>celecoxib</e1> 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Association"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: <e1>rofecoxib</e1> 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Association"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: <e1>rofecoxib</e1> 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Association"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: <e1>rofecoxib</e1> 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Association"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: <e1>rofecoxib</e1> 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Association"
"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e2>AMI</e2>/GI vs the acetaminophen (with no aspirin) group were: <e1>rofecoxib</e1> 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).","Association"
"We aimed to compare the risks of hospitalization for AMI and <e2>GI bleeding</e2> among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for AMI and <e2>GI bleeding</e2> among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for AMI and <e2>GI bleeding</e2> among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for AMI and <e2>GI bleeding</e2> among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for AMI and <e2>GI bleeding</e2> among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for AMI and <e2>GI bleeding</e2> among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for AMI and <e2>GI bleeding</e2> among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for <e2>AMI</e2> and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for <e2>AMI</e2> and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for <e2>AMI</e2> and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for <e2>AMI</e2> and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for <e2>AMI</e2> and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for <e2>AMI</e2> and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"We aimed to compare the risks of hospitalization for <e2>AMI</e2> and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1>acetaminophen</e1>.","Association"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to <e2>celecoxib</e2>, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to <e2>celecoxib</e2>, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to <e2>celecoxib</e2>, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to <e2>celecoxib</e2>, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to <e2>celecoxib</e2>, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to <e2>celecoxib</e2>, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to <e2>celecoxib</e2>, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to <e2>rofecoxib</e2> 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to <e2>rofecoxib</e2> 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to <e2>rofecoxib</e2> 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to <e2>rofecoxib</e2> 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to <e2>rofecoxib</e2> 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to <e2>rofecoxib</e2> 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to <e2>rofecoxib</e2> 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to <e2>acetaminophen</e2>, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to <e2>acetaminophen</e2>, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to <e2>acetaminophen</e2>, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to <e2>acetaminophen</e2>, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to <e2>acetaminophen</e2>, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to <e2>acetaminophen</e2>, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to <e2>acetaminophen</e2>, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-<e2>NSAIDs</e2>.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-<e2>NSAIDs</e2>.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-<e2>NSAIDs</e2>.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-<e2>NSAIDs</e2>.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-<e2>NSAIDs</e2>.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-<e2>NSAIDs</e2>.","Negative_Correlation"
"RESULTS: Person-years of exposure among non-users of <e1>aspirin</e1> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-<e2>NSAIDs</e2>.","Negative_Correlation"
"OBJECTIVES: The risk of <e2>acute myocardial infarction</e2> (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) <e1>non-steroidal anti-inflammatory drugs</e1> (NSAIDs).","Association"
"OBJECTIVES: The risk of <e2>acute myocardial infarction</e2> (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (<e1>NSAIDs</e1>).","Association"
"OBJECTIVES: The risk of <e2>acute myocardial infarction</e2> (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (<e1>NSAIDs</e1>).","Association"
"OBJECTIVES: The risk of <e2>acute myocardial infarction</e2> (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (<e1>NSAID</e1>s).","Association"
"OBJECTIVES: The risk of <e2>acute myocardial infarction</e2> (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (<e1>NSAIDs</e1>).","Association"
"OBJECTIVES: The risk of <e2>acute myocardial infarction</e2> (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (<e1>NSAIDs</e1>).","Association"
"OBJECTIVES: The risk of <e2>acute myocardial infarction</e2> (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (<e1>NSAIDs</e1>).","Association"
"We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-<e1>NSAIDs</e1> and <e2>acetaminophen</e2>.","Comparison"
"We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-<e1>NSAIDs</e1> and <e2>acetaminophen</e2>.","Comparison"
"We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-<e1>NSAID</e1>s and <e2>acetaminophen</e2>.","Comparison"
"We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-<e1>NSAIDs</e1> and <e2>acetaminophen</e2>.","Comparison"
"We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-<e1>NSAIDs</e1> and <e2>acetaminophen</e2>.","Comparison"
"We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-<e1>NSAIDs</e1> and <e2>acetaminophen</e2>.","Comparison"
"We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using <e1>COX-2 inhibitors</e1>, NS-NSAIDs and <e2>acetaminophen</e2>.","Comparison"
"We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using <e1>COX-2 inhibitors</e1>, NS-NSAIDs and <e2>acetaminophen</e2>.","Comparison"
"OBJECTIVES: The risk of acute myocardial infarction (AMI) with <e1>COX-2 inhibitors</e1> may offset their gastrointestinal (GI) benefit compared with non-selective (NS) <e2>non-steroidal anti-inflammatory drugs</e2> (NSAIDs).","Comparison"
"OBJECTIVES: The risk of acute myocardial infarction (AMI) with <e1>COX-2 inhibitors</e1> may offset their gastrointestinal (GI) benefit compared with non-selective (NS) <e2>non-steroidal anti-inflammatory drugs</e2> (NSAIDs).","Comparison"
"<e1>Quinine</e1>-induced arrhythmia in a patient with <e2>severe malaria</e2>.","Negative_Correlation"
"<e1>Quinine</e1>-induced <e2>arrhythmia</e2> in a patient with severe malaria.","Positive_Correlation"
"It was reported that there was a case of severe malaria patient with <e1>jaundice</e1> who presented with arrhythmia (premature ventricular contraction) while getting <e2>quinine</e2> infusion was reported.","Negative_Correlation"
"It was reported that there was a case of severe malaria patient with <e1>jaundice</e1> who presented with arrhythmia (premature ventricular contraction) while getting <e2>quinine</e2> infusion was reported.","Negative_Correlation"
"It was reported that there was a case of severe malaria patient with <e1>jaundice</e1> who presented with arrhythmia (premature ventricular contraction) while getting <e2>quinine</e2> infusion was reported.","Negative_Correlation"
"It was reported that there was a case of <e2>severe malaria</e2> patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting <e1>quinine</e1> infusion was reported.","Negative_Correlation"
"It was reported that there was a case of <e2>severe malaria</e2> patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting <e1>quinine</e1> infusion was reported.","Negative_Correlation"
"It was reported that there was a case of <e2>severe malaria</e2> patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting <e1>quinine</e1> infusion was reported.","Negative_Correlation"
"It was reported that there was a case of <e2>severe malaria</e2> patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting <e1>quinine</e1> infusion was reported.","Negative_Correlation"
"It was reported that there was a case of <e2>severe malaria</e2> patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting <e1>quinine</e1> infusion was reported.","Negative_Correlation"
"After 30 hours of <e1>quinine</e1> infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--<e2>sinoatrial block</e2>, positive U wave.","Positive_Correlation"
"After 30 hours of <e1>quinine</e1> infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--<e2>sinoatrial block</e2>, positive U wave.","Positive_Correlation"
"After 30 hours of <e1>quinine</e1> infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--<e2>sinoatrial block</e2>, positive U wave.","Positive_Correlation"
"After 30 hours of <e1>quinine</e1> infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--<e2>sinoatrial block</e2>, positive U wave.","Positive_Correlation"
"After 30 hours of <e1>quinine</e1> infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--<e2>sinoatrial block</e2>, positive U wave.","Positive_Correlation"
"It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (<e2>premature ventricular contraction</e2>) while getting <e1>quinine</e1> infusion was reported.","Positive_Correlation"
"It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (<e2>premature ventricular contraction</e2>) while getting <e1>quinine</e1> infusion was reported.","Positive_Correlation"
"It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (<e2>premature ventricular contraction</e2>) while getting <e1>quinine</e1> infusion was reported.","Positive_Correlation"
"<e1>Quinine</e1>, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple <e2>PVC</e2>.","Positive_Correlation"
"It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (<e2>premature ventricular contraction</e2>) while getting <e1>quinine</e1> infusion was reported.","Positive_Correlation"
"<e1>Quinine</e1>, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple <e2>PVC</e2>.","Positive_Correlation"
"It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (<e2>premature ventricular contraction</e2>) while getting <e1>quinine</e1> infusion was reported.","Positive_Correlation"
"After 30 hours of <e1>quinine</e1> infusion the patient felt <e2>palpitation</e2> and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.","Positive_Correlation"
"After 30 hours of <e1>quinine</e1> infusion the patient felt <e2>palpitation</e2> and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.","Positive_Correlation"
"After 30 hours of <e1>quinine</e1> infusion the patient felt <e2>palpitation</e2> and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.","Positive_Correlation"
"After 30 hours of <e1>quinine</e1> infusion the patient felt <e2>palpitation</e2> and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.","Positive_Correlation"
"After 30 hours of <e1>quinine</e1> infusion the patient felt <e2>palpitation</e2> and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.","Positive_Correlation"
"It was reported that there was a case of severe malaria patient with jaundice who presented with <e2>arrhythmia</e2> (premature ventricular contraction) while getting <e1>quinine</e1> infusion was reported.","Positive_Correlation"
"It was reported that there was a case of severe malaria patient with jaundice who presented with <e2>arrhythmia</e2> (premature ventricular contraction) while getting <e1>quinine</e1> infusion was reported.","Positive_Correlation"
"It was reported that there was a case of severe malaria patient with jaundice who presented with <e2>arrhythmia</e2> (premature ventricular contraction) while getting <e1>quinine</e1> infusion was reported.","Positive_Correlation"
"<e1>Quinine</e1>, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various <e2>arrhythmia</e2>s, including severe arrhythmia such as multiple PVC.","Positive_Correlation"
"It was reported that there was a case of severe malaria patient with jaundice who presented with <e2>arrhythmia</e2> (premature ventricular contraction) while getting <e1>quinine</e1> infusion was reported.","Positive_Correlation"
"<e1>Quinine</e1>, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various <e2>arrhythmia</e2>s, including severe arrhythmia such as multiple PVC.","Positive_Correlation"
"It was reported that there was a case of severe malaria patient with jaundice who presented with <e2>arrhythmia</e2> (premature ventricular contraction) while getting <e1>quinine</e1> infusion was reported.","Positive_Correlation"
"Succimer chelation improves learning, attention, and arousal regulation in <e1>lead</e1>-exposed rats but produces lasting <e2>cognitive impairment</e2> in the absence of lead exposure.","Positive_Correlation"
"Succimer chelation improves learning, attention, and arousal regulation in <e1>lead</e1>-exposed rats but produces lasting <e2>cognitive impairment</e2> in the absence of lead exposure.","Positive_Correlation"
"<e1>Succimer</e1> chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting <e2>cognitive impairment</e2> in the absence of lead exposure.","Positive_Correlation"
"<e1>Succimer</e1> chelation improves learning, attention, and arousal regulation in <e2>lead</e2>-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.","Negative_Correlation"
"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate <e2>cognitive deficits</e2> due to <e1>Pb</e1> exposure.","Positive_Correlation"
"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate <e2>cognitive deficits</e2> due to <e1>Pb</e1> exposure.","Positive_Correlation"
"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate <e2>cognitive deficits</e2> due to <e1>Pb</e1> exposure.","Positive_Correlation"
"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate <e2>cognitive deficits</e2> due to <e1>Pb</e1> exposure.","Positive_Correlation"
"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate <e2>cognitive deficits</e2> due to <e1>Pb</e1> exposure.","Positive_Correlation"
"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate <e2>cognitive deficits</e2> due to <e1>Pb</e1> exposure.","Positive_Correlation"
"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate <e2>cognitive deficits</e2> due to <e1>Pb</e1> exposure.","Positive_Correlation"
"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate <e2>cognitive deficits</e2> due to <e1>Pb</e1> exposure.","Positive_Correlation"
"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate <e2>cognitive deficits</e2> due to <e1>Pb</e1> exposure.","Positive_Correlation"
"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate <e2>cognitive deficits</e2> due to <e1>Pb</e1> exposure.","Positive_Correlation"
"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate <e2>cognitive deficits</e2> due to <e1>Pb</e1> exposure.","Positive_Correlation"
"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate <e2>cognitive deficits</e2> due to <e1>Pb</e1> exposure.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e1>Pb</e1> exposure and treatment with succimer, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e1>Pb</e1> exposure and treatment with succimer, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e1>Pb</e1> exposure and treatment with succimer, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e1>Pb</e1> exposure and treatment with succimer, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e1>Pb</e1> exposure and treatment with succimer, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e1>Pb</e1> exposure and treatment with succimer, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e1>Pb</e1> exposure and treatment with succimer, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e1>Pb</e1> exposure and treatment with succimer, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e1>Pb</e1> exposure and treatment with succimer, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e1>Pb</e1> exposure and treatment with succimer, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e1>Pb</e1> exposure and treatment with succimer, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e1>Pb</e1> exposure and treatment with succimer, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Positive_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with <e1>succimer</e1>, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Negative_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with <e1>succimer</e1>, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Negative_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with <e1>succimer</e1>, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Negative_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with <e1>succimer</e1>, a widely used chelating agent for the treatment of <e2>Pb poisoning</e2>.","Negative_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e2>Pb</e2> exposure and treatment with <e1>succimer</e1>, a widely used chelating agent for the treatment of Pb poisoning.","Negative_Correlation"
"<e1>Succimer</e1> treatment of the <e2>Pb</e2>-exposed rats significantly improved learning, attention, and arousal regulation, although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit.","Negative_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e2>Pb</e2> exposure and treatment with <e1>succimer</e1>, a widely used chelating agent for the treatment of Pb poisoning.","Negative_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e2>Pb</e2> exposure and treatment with <e1>succimer</e1>, a widely used chelating agent for the treatment of Pb poisoning.","Negative_Correlation"
"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood <e2>Pb</e2> exposure and treatment with <e1>succimer</e1>, a widely used chelating agent for the treatment of Pb poisoning.","Negative_Correlation"
"Attenuation of methamphetamine-induced nigrostriatal <e1>dopaminergic</e1> <e2>neurotoxicity</e2> in mice by lipopolysaccharide pretreatment.","Positive_Correlation"
"Attenuation of methamphetamine-induced nigrostriatal dopaminergic <e2>neurotoxicity</e2> in mice by <e1>lipopolysaccharide</e1> pretreatment.","Negative_Correlation"
"Attenuation of methamphetamine-induced nigrostriatal <e2>dopaminergic</e2> neurotoxicity in mice by <e1>lipopolysaccharide</e1> pretreatment.","Association"
"Attenuation of <e2>methamphetamine</e2>-induced nigrostriatal dopaminergic neurotoxicity in mice by <e1>lipopolysaccharide</e1> pretreatment.","Negative_Correlation"
"Attenuation of <e1>methamphetamine</e1>-induced nigrostriatal dopaminergic <e2>neurotoxicity</e2> in mice by lipopolysaccharide pretreatment.","Positive_Correlation"
"Attenuation of <e1>methamphetamine</e1>-induced nigrostriatal <e2>dopaminergic</e2> neurotoxicity in mice by lipopolysaccharide pretreatment.","Association"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal <e1>dopamine</e1> <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal <e1>dopamine</e1> <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal <e1>dopamine</e1> <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal <e1>dopamine</e1> <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal <e1>dopamine</e1> <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-<e2>inflammatory</e2> and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-<e2>inflammatory</e2> and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-<e2>inflammatory</e2> and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-<e2>inflammatory</e2> and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-<e2>inflammatory</e2> and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-<e2>inflammatory</e2> and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Negative_Correlation"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Negative_Correlation"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Negative_Correlation"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Negative_Correlation"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Negative_Correlation"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Negative_Correlation"
"Such systemic <e1>lipopolysaccharide</e1> treatment mitigated methamphetamine-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic <e1>lipopolysaccharide</e1> treatment mitigated methamphetamine-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic <e1>lipopolysaccharide</e1> treatment mitigated methamphetamine-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic <e1>lipopolysaccharide</e1> treatment mitigated methamphetamine-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic <e1>lipopolysaccharide</e1> treatment mitigated methamphetamine-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic <e1>lipopolysaccharide</e1> treatment mitigated methamphetamine-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal <e2>dopamine</e2> neurotoxicity.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal <e2>dopamine</e2> neurotoxicity.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal <e2>dopamine</e2> neurotoxicity.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal <e2>dopamine</e2> neurotoxicity.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal <e2>dopamine</e2> neurotoxicity.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal <e2>dopamine</e2> neurotoxicity.","Association"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the <e2>methamphetamine</e2>-induced nigrostriatal dopamine neurotoxicity.","Negative_Correlation"
"<e1>Lipopolysaccharide</e1> pretreatment did not affect the basal body temperature or <e2>methamphetamine</e2>-elicited hyperthermia three days later.","Negative_Correlation"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the <e2>methamphetamine</e2>-induced nigrostriatal dopamine neurotoxicity.","Negative_Correlation"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the <e2>methamphetamine</e2>-induced nigrostriatal dopamine neurotoxicity.","Negative_Correlation"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the <e2>methamphetamine</e2>-induced nigrostriatal dopamine neurotoxicity.","Negative_Correlation"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the <e2>methamphetamine</e2>-induced nigrostriatal dopamine neurotoxicity.","Negative_Correlation"
"In this study, we examined the roles of <e1>lipopolysaccharide</e1>, a pro-inflammatory and inflammatory factor, treatment in modulating the <e2>methamphetamine</e2>-induced nigrostriatal dopamine neurotoxicity.","Negative_Correlation"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopaminergic terminal damage</e2>.","Positive_Correlation"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopaminergic terminal damage</e2>.","Positive_Correlation"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopaminergic terminal damage</e2>.","Positive_Correlation"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopaminergic terminal damage</e2>.","Positive_Correlation"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopaminergic terminal damage</e2>.","Positive_Correlation"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopaminergic terminal damage</e2>.","Positive_Correlation"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopaminergic terminal damage</e2>.","Positive_Correlation"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopaminergic terminal damage</e2>.","Positive_Correlation"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopaminergic terminal damage</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the <e1>methamphetamine</e1>-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the <e1>methamphetamine</e1>-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the <e1>methamphetamine</e1>-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the <e1>methamphetamine</e1>-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the <e1>methamphetamine</e1>-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the <e1>methamphetamine</e1>-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the <e1>methamphetamine</e1>-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the <e1>methamphetamine</e1>-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Positive_Correlation"
"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the <e1>methamphetamine</e1>-induced nigrostriatal dopamine <e2>neurotoxicity</e2>.","Positive_Correlation"
"Such systemic lipopolysaccharide treatment mitigated <e1>methamphetamine</e1>-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic lipopolysaccharide treatment mitigated <e1>methamphetamine</e1>-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic lipopolysaccharide treatment mitigated <e1>methamphetamine</e1>-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic lipopolysaccharide treatment mitigated <e1>methamphetamine</e1>-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic lipopolysaccharide treatment mitigated <e1>methamphetamine</e1>-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic lipopolysaccharide treatment mitigated <e1>methamphetamine</e1>-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic lipopolysaccharide treatment mitigated <e1>methamphetamine</e1>-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic lipopolysaccharide treatment mitigated <e1>methamphetamine</e1>-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Such systemic lipopolysaccharide treatment mitigated <e1>methamphetamine</e1>-induced striatal dopamine and <e2>3,4-dihydroxyphenylacetic acid</e2> depletions in a dose-dependent manner.","Association"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopamine</e2>rgic terminal damage.","Association"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopamine</e2>rgic terminal damage.","Association"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopamine</e2>rgic terminal damage.","Association"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopamine</e2>rgic terminal damage.","Association"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopamine</e2>rgic terminal damage.","Association"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopamine</e2>rgic terminal damage.","Association"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopamine</e2>rgic terminal damage.","Association"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopamine</e2>rgic terminal damage.","Association"
"Immunological activation has been proposed to play a role in <e1>methamphetamine</e1>-induced <e2>dopamine</e2>rgic terminal damage.","Association"
"Lipopolysaccharide pretreatment did not affect the basal body temperature or <e1>methamphetamine</e1>-elicited <e2>hyperthermia</e2> three days later.","Positive_Correlation"
"Lipopolysaccharide pretreatment did not affect the basal body temperature or <e1>methamphetamine</e1>-elicited <e2>hyperthermia</e2> three days later.","Positive_Correlation"
"Lipopolysaccharide pretreatment did not affect the basal body temperature or <e1>methamphetamine</e1>-elicited <e2>hyperthermia</e2> three days later.","Positive_Correlation"
"Lipopolysaccharide pretreatment did not affect the basal body temperature or <e1>methamphetamine</e1>-elicited <e2>hyperthermia</e2> three days later.","Positive_Correlation"
"Lipopolysaccharide pretreatment did not affect the basal body temperature or <e1>methamphetamine</e1>-elicited <e2>hyperthermia</e2> three days later.","Positive_Correlation"
"Lipopolysaccharide pretreatment did not affect the basal body temperature or <e1>methamphetamine</e1>-elicited <e2>hyperthermia</e2> three days later.","Positive_Correlation"
"Lipopolysaccharide pretreatment did not affect the basal body temperature or <e1>methamphetamine</e1>-elicited <e2>hyperthermia</e2> three days later.","Positive_Correlation"
"Lipopolysaccharide pretreatment did not affect the basal body temperature or <e1>methamphetamine</e1>-elicited <e2>hyperthermia</e2> three days later.","Positive_Correlation"
"Lipopolysaccharide pretreatment did not affect the basal body temperature or <e1>methamphetamine</e1>-elicited <e2>hyperthermia</e2> three days later.","Positive_Correlation"
"Hypothalamic <e2>prolactin</e2> receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on <e1>estradiol</e1>.","Positive_Correlation"
"Hypothalamic <e2>prolactin receptor</e2> messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on <e1>estradiol</e1>.","Positive_Correlation"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and <e1>CIS</e1>, which reflect the level of <e2>prolactin</e2> signaling) mRNAs in response to sulpiride and estradiol.","Association"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and <e1>CIS</e1>, which reflect the level of <e2>prolactin</e2> signaling) mRNAs in response to sulpiride and estradiol.","Association"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and <e1>CIS</e1>, which reflect the level of <e2>prolactin</e2> signaling) mRNAs in response to sulpiride and estradiol.","Association"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and <e1>CIS</e1>, which reflect the level of <e2>prolactin</e2> signaling) mRNAs in response to sulpiride and estradiol.","Association"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (<e1>SOCS-1</e1> and -3 and CIS, which reflect the level of <e2>prolactin</e2> signaling) mRNAs in response to sulpiride and estradiol.","Association"
"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to <e1>prolactin</e1>, we next demonstrated that estradiol greatly augments prolactin-induced <e2>STAT5</e2> activation.","Positive_Correlation"
"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to <e1>prolactin</e1>, we next demonstrated that estradiol greatly augments prolactin-induced <e2>STAT5</e2> activation.","Positive_Correlation"
"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to <e1>prolactin</e1>, we next demonstrated that estradiol greatly augments prolactin-induced <e2>STAT5</e2> activation.","Positive_Correlation"
"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to <e1>prolactin</e1>, we next demonstrated that estradiol greatly augments prolactin-induced <e2>STAT5</e2> activation.","Positive_Correlation"
"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to <e1>prolactin</e1>, we next demonstrated that estradiol greatly augments prolactin-induced <e2>STAT5</e2> activation.","Positive_Correlation"
"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to <e1>prolactin</e1>, we next demonstrated that estradiol greatly augments prolactin-induced <e2>STAT5</e2> activation.","Positive_Correlation"
"We first tested whether chronic hyper<e2>prolactin</e2>emia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the <e1>estrogen</e1>-induced LH surge.","Association"
"We first tested whether chronic hyper<e2>prolactin</e2>emia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the <e1>estrogen</e1>-induced LH surge.","Association"
"To test the hypothesis that <e1>estrogen</e1> increases <e2>PRL-R</e2> expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.","Positive_Correlation"
"To test the hypothesis that <e1>estrogen</e1> increases <e2>PRL-R</e2> expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.","Positive_Correlation"
"We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile <e2>LH</e2> secretion and the <e1>estrogen</e1>-induced LH surge.","Association"
"We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile <e2>LH</e2> secretion and the <e1>estrogen</e1>-induced LH surge.","Association"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and <e2>CIS</e2>, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and <e1>estradiol</e1>.","Positive_Correlation"
"<e1>Estradiol</e1> enhanced these effects on SOCS-3 and <e2>CIS</e2>.","Positive_Correlation"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and <e2>CIS</e2>, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and <e1>estradiol</e1>.","Positive_Correlation"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and <e2>CIS</e2>, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and <e1>estradiol</e1>.","Positive_Correlation"
"<e1>Estradiol</e1> enhanced these effects on SOCS-3 and <e2>CIS</e2>.","Positive_Correlation"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and <e2>CIS</e2>, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and <e1>estradiol</e1>.","Positive_Correlation"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and <e2>CIS</e2>, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and <e1>estradiol</e1>.","Positive_Correlation"
"Interestingly, <e1>estradiol</e1> also induced PRL-R, <e2>SOCS-3</e2>, and CIS mRNA levels independently.","Positive_Correlation"
"<e1>Estradiol</e1> enhanced these effects on <e2>SOCS-3</e2> and CIS.","Positive_Correlation"
"Interestingly, <e1>estradiol</e1> also induced PRL-R, <e2>SOCS-3</e2>, and CIS mRNA levels independently.","Positive_Correlation"
"Interestingly, <e1>estradiol</e1> also induced PRL-R, <e2>SOCS-3</e2>, and CIS mRNA levels independently.","Positive_Correlation"
"<e1>Estradiol</e1> enhanced these effects on <e2>SOCS-3</e2> and CIS.","Positive_Correlation"
"Interestingly, <e1>estradiol</e1> also induced PRL-R, <e2>SOCS-3</e2>, and CIS mRNA levels independently.","Positive_Correlation"
"Interestingly, <e1>estradiol</e1> also induced PRL-R, <e2>SOCS-3</e2>, and CIS mRNA levels independently.","Positive_Correlation"
"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that <e1>estradiol</e1> greatly augments prolactin-induced <e2>STAT5</e2> activation.","Positive_Correlation"
"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that <e1>estradiol</e1> greatly augments prolactin-induced <e2>STAT5</e2> activation.","Positive_Correlation"
"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that <e1>estradiol</e1> greatly augments prolactin-induced <e2>STAT5</e2> activation.","Positive_Correlation"
"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that <e1>estradiol</e1> greatly augments prolactin-induced <e2>STAT5</e2> activation.","Positive_Correlation"
"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that <e1>estradiol</e1> greatly augments prolactin-induced <e2>STAT5</e2> activation.","Positive_Correlation"
"Chronic hyper<e2>prolactin</e2>emia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of <e1>estradiol</e1>.","Positive_Correlation"
"<e1>Estradiol</e1> is known to influence expression of the long form of <e2>prolactin</e2> receptors (PRL-R) and components of prolactin's signaling pathway.","Positive_Correlation"
"Chronic hyper<e2>prolactin</e2>emia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of <e1>estradiol</e1>.","Positive_Correlation"
"Chronic hyper<e2>prolactin</e2>emia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of <e1>estradiol</e1>.","Positive_Correlation"
"<e1>Estradiol</e1> is known to influence expression of the long form of <e2>prolactin</e2> receptors (PRL-R) and components of prolactin's signaling pathway.","Positive_Correlation"
"Chronic hyper<e2>prolactin</e2>emia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of <e1>estradiol</e1>.","Positive_Correlation"
"Chronic hyper<e2>prolactin</e2>emia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of <e1>estradiol</e1>.","Positive_Correlation"
"To test the hypothesis that estrogen increases <e2>PRL-R</e2> expression and sensitivity to prolactin, we next demonstrated that <e1>estradiol</e1> greatly augments prolactin-induced STAT5 activation.","Positive_Correlation"
"<e1>Estradiol</e1> is known to influence expression of the long form of <e2>prolactin receptors</e2> (PRL-R) and components of prolactin's signaling pathway.","Positive_Correlation"
"To test the hypothesis that estrogen increases <e2>PRL-R</e2> expression and sensitivity to prolactin, we next demonstrated that <e1>estradiol</e1> greatly augments prolactin-induced STAT5 activation.","Positive_Correlation"
"To test the hypothesis that estrogen increases <e2>PRL-R</e2> expression and sensitivity to prolactin, we next demonstrated that <e1>estradiol</e1> greatly augments prolactin-induced STAT5 activation.","Positive_Correlation"
"<e1>Estradiol</e1> is known to influence expression of the long form of <e2>prolactin receptors</e2> (PRL-R) and components of prolactin's signaling pathway.","Positive_Correlation"
"To test the hypothesis that estrogen increases <e2>PRL-R</e2> expression and sensitivity to prolactin, we next demonstrated that <e1>estradiol</e1> greatly augments prolactin-induced STAT5 activation.","Positive_Correlation"
"To test the hypothesis that estrogen increases <e2>PRL-R</e2> expression and sensitivity to prolactin, we next demonstrated that <e1>estradiol</e1> greatly augments prolactin-induced STAT5 activation.","Positive_Correlation"
"Sulpiride did not affect the magnitude of a <e1>steroid</e1>-induced <e2>LH</e2> surge or the percentage of GnRH neurons activated during the surge.","Association"
"Sulpiride did not affect the magnitude of a <e1>steroid</e1>-induced <e2>LH</e2> surge or the percentage of GnRH neurons activated during the surge.","Association"
"These data show that GnRH pulse frequency is inhibited by chronic <e1>hyperprolactinemia</e1> in a <e2>steroid</e2>-dependent manner.","Association"
"These data show that GnRH pulse frequency is inhibited by chronic <e1>hyperprolactinemia</e1> in a <e2>steroid</e2>-dependent manner.","Association"
"These data show that GnRH pulse frequency is inhibited by chronic <e1>hyperprolactinemia</e1> in a <e2>steroid</e2>-dependent manner.","Association"
"Chronic <e1>hyperprolactinemia</e1> induced by the dopamine antagonist <e2>sulpiride</e2> caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.","Positive_Correlation"
"Chronic <e1>hyperprolactinemia</e1> induced by the dopamine antagonist <e2>sulpiride</e2> caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.","Positive_Correlation"
"Chronic <e1>hyperprolactinemia</e1> induced by the dopamine antagonist <e2>sulpiride</e2> caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.","Positive_Correlation"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and <e2>CIS</e2>, which reflect the level of prolactin signaling) mRNAs in response to <e1>sulpiride</e1> and estradiol.","Positive_Correlation"
"<e1>Sulpiride</e1> induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and <e2>CIS</e2> mRNA levels were also induced.","Positive_Correlation"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and <e2>CIS</e2>, which reflect the level of prolactin signaling) mRNAs in response to <e1>sulpiride</e1> and estradiol.","Positive_Correlation"
"<e1>Sulpiride</e1> induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and <e2>CIS</e2> mRNA levels were also induced.","Positive_Correlation"
"<e1>Sulpiride</e1> induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, <e2>SOCS-3</e2>, and CIS mRNA levels were also induced.","Positive_Correlation"
"<e1>Sulpiride</e1> induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, <e2>SOCS-3</e2>, and CIS mRNA levels were also induced.","Positive_Correlation"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (<e2>SOCS-1</e2> and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to <e1>sulpiride</e1> and estradiol.","Positive_Correlation"
"<e1>Sulpiride</e1> induced only <e2>SOCS-1</e2> in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.","Positive_Correlation"
"Lastly, we measured PRL-R and suppressor of cytokine signaling (<e2>SOCS-1</e2> and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to <e1>sulpiride</e1> and estradiol.","Positive_Correlation"
"<e1>Sulpiride</e1> induced only <e2>SOCS-1</e2> in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.","Positive_Correlation"
"Lastly, we measured <e2>PRL-R</e2> and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to <e1>sulpiride</e1> and estradiol.","Positive_Correlation"
"<e1>Sulpiride</e1> induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, <e2>PRL-R</e2>, SOCS-3, and CIS mRNA levels were also induced.","Positive_Correlation"
"Lastly, we measured <e2>PRL-R</e2> and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to <e1>sulpiride</e1> and estradiol.","Positive_Correlation"
"<e1>Sulpiride</e1> induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, <e2>PRL-R</e2>, SOCS-3, and CIS mRNA levels were also induced.","Positive_Correlation"
"Chronic hyperprolactinemia induced by the dopamine antagonist <e1>sulpiride</e1> caused a 40% reduction <e2>LH</e2> pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.","Negative_Correlation"
"<e1>Sulpiride</e1> did not affect the magnitude of a steroid-induced <e2>LH</e2> surge or the percentage of GnRH neurons activated during the surge.","Negative_Correlation"
"Chronic hyperprolactinemia induced by the dopamine antagonist <e1>sulpiride</e1> caused a 40% reduction <e2>LH</e2> pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.","Negative_Correlation"
"<e1>Sulpiride</e1> did not affect the magnitude of a steroid-induced <e2>LH</e2> surge or the percentage of GnRH neurons activated during the surge.","Negative_Correlation"
"Chronic hyperprolactinemia induced by the <e1>dopamine</e1> antagonist <e2>sulpiride</e2> caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.","Negative_Correlation"
"<e1>Ginsenoside Rg1</e1> restores the impairment of learning induced by chronic <e2>morphine</e2> administration in rats.","Negative_Correlation"
"<e1>Ginsenoside Rg1</e1> restores the <e2>impairment of learning</e2> induced by chronic morphine administration in rats.","Negative_Correlation"
"Ginsenoside Rg1 restores the <e1>impairment of learning</e1> induced by chronic <e2>morphine</e2> administration in rats.","Positive_Correlation"
"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by <e1>N-methyl-D-aspartate (NMDA) receptor</e1> antagonist <e2>MK801</e2>.","Negative_Correlation"
"The electrophysiological recording in vitro showed that <e1>Rg1</e1> restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by <e2>N-methyl-D-aspartate (NMDA) receptor</e2> antagonist MK801.","Association"
"The electrophysiological recording in vitro showed that <e1>Rg1</e1> restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by <e2>N-methyl-D-aspartate (NMDA) receptor</e2> antagonist MK801.","Association"
"The electrophysiological recording in vitro showed that <e1>Rg1</e1> restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by <e2>N-methyl-D-aspartate (NMDA) receptor</e2> antagonist MK801.","Association"
"The electrophysiological recording in vitro showed that <e1>Rg1</e1> restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by <e2>N-methyl-D-aspartate (NMDA) receptor</e2> antagonist MK801.","Association"
"The electrophysiological recording in vitro showed that <e1>Rg1</e1> restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by <e2>N-methyl-D-aspartate (NMDA) receptor</e2> antagonist MK801.","Association"
"The electrophysiological recording in vitro showed that <e1>Rg1</e1> restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by <e2>N-methyl-D-aspartate (NMDA) receptor</e2> antagonist MK801.","Association"
"The electrophysiological recording in vitro showed that <e1>Rg1</e1> restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by <e2>N-methyl-D-aspartate (NMDA) receptor</e2> antagonist MK801.","Association"
"The electrophysiological recording in vitro showed that <e1>Rg1</e1> restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by <e2>N-methyl-D-aspartate (NMDA) receptor</e2> antagonist MK801.","Association"
"The electrophysiological recording in vitro showed that <e1>Rg1</e1> restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by <e2>N-methyl-D-aspartate (NMDA) receptor</e2> antagonist MK801.","Association"
"Previous studies have demonstrated that <e1>Rg1</e1> might be a useful agent for the prevention and treatment of the adverse effects of <e2>morphine</e2>.","Negative_Correlation"
"Previous studies have demonstrated that <e1>Rg1</e1> might be a useful agent for the prevention and treatment of the adverse effects of <e2>morphine</e2>.","Negative_Correlation"
"Previous studies have demonstrated that <e1>Rg1</e1> might be a useful agent for the prevention and treatment of the adverse effects of <e2>morphine</e2>.","Negative_Correlation"
"Previous studies have demonstrated that <e1>Rg1</e1> might be a useful agent for the prevention and treatment of the adverse effects of <e2>morphine</e2>.","Negative_Correlation"
"Previous studies have demonstrated that <e1>Rg1</e1> might be a useful agent for the prevention and treatment of the adverse effects of <e2>morphine</e2>.","Negative_Correlation"
"Previous studies have demonstrated that <e1>Rg1</e1> might be a useful agent for the prevention and treatment of the adverse effects of <e2>morphine</e2>.","Negative_Correlation"
"Previous studies have demonstrated that <e1>Rg1</e1> might be a useful agent for the prevention and treatment of the adverse effects of <e2>morphine</e2>.","Negative_Correlation"
"Previous studies have demonstrated that <e1>Rg1</e1> might be a useful agent for the prevention and treatment of the adverse effects of <e2>morphine</e2>.","Negative_Correlation"
"Previous studies have demonstrated that <e1>Rg1</e1> might be a useful agent for the prevention and treatment of the adverse effects of <e2>morphine</e2>.","Negative_Correlation"
"<e1>Rg1</e1>, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial <e2>learning impairment</e2>.","Negative_Correlation"
"<e1>Rg1</e1>, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial <e2>learning impairment</e2>.","Negative_Correlation"
"<e1>Rg1</e1>, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial <e2>learning impairment</e2>.","Negative_Correlation"
"<e1>Rg1</e1>, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial <e2>learning impairment</e2>.","Negative_Correlation"
"<e1>Rg1</e1>, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial <e2>learning impairment</e2>.","Negative_Correlation"
"<e1>Rg1</e1>, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial <e2>learning impairment</e2>.","Negative_Correlation"
"<e1>Rg1</e1>, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial <e2>learning impairment</e2>.","Negative_Correlation"
"<e1>Rg1</e1>, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial <e2>learning impairment</e2>.","Negative_Correlation"
"<e1>Rg1</e1>, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial <e2>learning impairment</e2>.","Negative_Correlation"
"The electrophysiological recording in vitro showed that <e2>Rg1</e2> restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist <e1>MK801</e1>.","Negative_Correlation"
"The aim of this study was to investigate the effect of Rg1 on <e1>learning impairment</e1> by chronic <e2>morphine</e2> administration and the mechanism responsible for this effect.","Positive_Correlation"
"The aim of this study was to investigate the effect of Rg1 on <e1>learning impairment</e1> by chronic <e2>morphine</e2> administration and the mechanism responsible for this effect.","Positive_Correlation"
"Repetitive transcranial magnetic stimulation for <e1>levodopa</e1>-induced <e2>dyskinesias</e2> in Parkinson's disease.","Positive_Correlation"
"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and <e1>aripiprazole</e1>) antipsychotics were effective in all these models of <e2>hyperactivity</e2>.","Negative_Correlation"
"Importantly, both classical (haloperidol) and atypical (olanzapine, <e1>clozapine</e1> and aripiprazole) antipsychotics were effective in all these models of <e2>hyperactivity</e2>.","Negative_Correlation"
"Importantly, both classical (haloperidol) and atypical (<e1>olanzapine</e1>, clozapine and aripiprazole) antipsychotics were effective in all these models of <e2>hyperactivity</e2>.","Negative_Correlation"
"Importantly, both classical (<e1>haloperidol</e1>) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of <e2>hyperactivity</e2>.","Negative_Correlation"
"<e1>Schizophrenia</e1> has been initially associated with dysfunction in <e2>dopamine</e2> neurotransmission.","Association"
"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <e1>hyperactivity</e1>, involving either drug challenge (ie, <e2>amphetamine</e2> and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).","Positive_Correlation"
"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <e1>hyperactivity</e1>, involving either drug challenge (ie, <e2>amphetamine</e2> and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).","Positive_Correlation"
"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <e1>hyperactivity</e1>, involving either drug challenge (ie, <e2>amphetamine</e2> and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).","Positive_Correlation"
"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <e1>hyperactivity</e1>, involving either drug challenge (ie, <e2>amphetamine</e2> and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).","Positive_Correlation"
"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <e1>hyperactivity</e1>, involving either drug challenge (ie, <e2>amphetamine</e2> and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).","Positive_Correlation"
"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <e1>hyperactivity</e1>, involving either drug challenge (ie, amphetamine and <e2>MK-801</e2>) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).","Positive_Correlation"
"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <e1>hyperactivity</e1>, involving either drug challenge (ie, amphetamine and <e2>MK-801</e2>) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).","Positive_Correlation"
"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <e1>hyperactivity</e1>, involving either drug challenge (ie, amphetamine and <e2>MK-801</e2>) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).","Positive_Correlation"
"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <e1>hyperactivity</e1>, involving either drug challenge (ie, amphetamine and <e2>MK-801</e2>) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).","Positive_Correlation"
"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <e1>hyperactivity</e1>, involving either drug challenge (ie, amphetamine and <e2>MK-801</e2>) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).","Positive_Correlation"
"blocked <e1>hyperactivity</e1> induced by the non-competitive <e2>NMDA receptor</e2> antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.","Association"
"blocked <e1>hyperactivity</e1> induced by the non-competitive <e2>NMDA receptor</e2> antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.","Association"
"blocked <e1>hyperactivity</e1> induced by the non-competitive <e2>NMDA receptor</e2> antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.","Association"
"blocked <e1>hyperactivity</e1> induced by the non-competitive <e2>NMDA receptor</e2> antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.","Association"
"blocked <e1>hyperactivity</e1> induced by the non-competitive <e2>NMDA receptor</e2> antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.","Association"
"However, the observation that antagonists of the <e1>glutamate N-methyl-D-aspartate (NMDA) receptor</e1> produce <e2>schizophrenic</e2>-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.","Association"
"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce <e2>schizophrenic</e2>-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its <e1>NMDA receptor</e1>.","Association"
"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce <e2>schizophrenic</e2>-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its <e1>NMDA receptor</e1>.","Association"
"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce <e2>schizophrenic</e2>-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its <e1>NMDA receptor</e1>.","Association"
"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce <e2>schizophrenic</e2>-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its <e1>NMDA receptor</e1>.","Association"
"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce <e2>schizophrenic</e2>-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its <e1>NMDA receptor</e1>.","Association"
"blocked hyperactivity induced by the non-competitive <e1>NMDA receptor</e1> antagonist, <e2>MK-801</e2> and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.","Negative_Correlation"
"blocked hyperactivity induced by the non-competitive <e1>NMDA receptor</e1> antagonist, <e2>MK-801</e2> and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.","Negative_Correlation"
"blocked hyperactivity induced by the non-competitive <e1>NMDA receptor</e1> antagonist, <e2>MK-801</e2> and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.","Negative_Correlation"
"blocked hyperactivity induced by the non-competitive <e1>NMDA receptor</e1> antagonist, <e2>MK-801</e2> and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.","Negative_Correlation"
"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and <e2>MK-801</e2>) or transgenic mice (ie, <e1>NMDA Nr1</e1>(neo-/-) and DAT(-/-)).","Negative_Correlation"
"blocked hyperactivity induced by the non-competitive <e1>NMDA receptor</e1> antagonist, <e2>MK-801</e2> and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.","Negative_Correlation"
"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and <e2>MK-801</e2>) or transgenic mice (ie, <e1>NMDA Nr1</e1>(neo-/-) and DAT(-/-)).","Negative_Correlation"
"Among them are <e1>glycine</e1> transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance <e2>NMDA receptor</e2> function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.","Positive_Correlation"
"Fluoxetine improves the <e1>memory deficits</e1> caused by the chemotherapy agent <e2>5-fluorouracil</e2>.","Positive_Correlation"
"<e1>Fluoxetine</e1> improves the memory deficits caused by the chemotherapy agent <e2>5-fluorouracil</e2>.","Negative_Correlation"
"<e1>Fluoxetine</e1> improves the <e2>memory deficits</e2> caused by the chemotherapy agent 5-fluorouracil.","Negative_Correlation"
"In this investigation the behavioural effects of chronic (two week) treatment with <e2>5-FU</e2> and (three weeks) with <e1>Fluoxetine</e1> either separately or in combination with 5-FU were tested on adult Lister hooded rats.","Negative_Correlation"
"In this investigation the behavioural effects of chronic (two week) treatment with <e2>5-FU</e2> and (three weeks) with <e1>Fluoxetine</e1> either separately or in combination with 5-FU were tested on adult Lister hooded rats.","Negative_Correlation"
"In this investigation the behavioural effects of chronic (two week) treatment with <e2>5-FU</e2> and (three weeks) with <e1>Fluoxetine</e1> either separately or in combination with 5-FU were tested on adult Lister hooded rats.","Negative_Correlation"
"In this investigation the behavioural effects of chronic (two week) treatment with <e2>5-FU</e2> and (three weeks) with <e1>Fluoxetine</e1> either separately or in combination with 5-FU were tested on adult Lister hooded rats.","Negative_Correlation"
"In this investigation the behavioural effects of chronic (two week) treatment with <e2>5-FU</e2> and (three weeks) with <e1>Fluoxetine</e1> either separately or in combination with 5-FU were tested on adult Lister hooded rats.","Negative_Correlation"
"In this investigation the behavioural effects of chronic (two week) treatment with <e2>5-FU</e2> and (three weeks) with <e1>Fluoxetine</e1> either separately or in combination with 5-FU were tested on adult Lister hooded rats.","Negative_Correlation"
"Risk of <e2>nephropathy</e2> after consumption of nonionic <e1>contrast media</e1> by children undergoing cardiac angiography: a prospective study.","Positive_Correlation"
"This prospective study determined the incidence of CIN for two nonionic <e1>contrast media</e1> (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2>cyanosis</e2>.","Association"
"This prospective study determined the incidence of CIN for two nonionic <e1>contrast media</e1> (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2>cyanosis</e2>.","Association"
"This prospective study determined the incidence of CIN for two nonionic contrast media (<e1>CM</e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2>cyanosis</e2>.","Association"
"This prospective study determined the incidence of CIN for two nonionic contrast media (<e1>CM</e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2>cyanosis</e2>.","Association"
"This prospective study determined the incidence of CIN for two nonionic contrast media (<e1>CM</e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2>cyanosis</e2>.","Association"
"This prospective study determined the incidence of CIN for two nonionic contrast media (<e1>CM</e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2>cyanosis</e2>.","Association"
"This prospective study determined the incidence of CIN for two nonionic contrast media (<e1>CM</e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2>cyanosis</e2>.","Association"
"This prospective study determined the incidence of CIN for two nonionic contrast media (<e1>CM</e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2>cyanosis</e2>.","Association"
"Despite increasing reports on nonionic <e1>contrast media</e1>-induced <e2>nephropathy</e2> (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.","Positive_Correlation"
"Despite increasing reports on nonionic <e1>contrast media</e1>-induced <e2>nephropathy</e2> (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.","Positive_Correlation"
"This prospective study determined the incidence of <e2>CIN</e2> for two nonionic contrast media (<e1>CM</e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e2>CIN</e2> for two nonionic contrast media (<e1>CM</e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e2>CIN</e2> for two nonionic contrast media (<e1>CM</e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e2>CIN</e2> for two nonionic contrast media (<e1>CM</e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e2>CIN</e2> for two nonionic contrast media (<e1>CM</e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e2>CIN</e2> for two nonionic contrast media (<e1>CM</e1>), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), <e2>iopromide</e2> and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), <e2>iopromide</e2> and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), <e2>iopromide</e2> and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), <e2>iopromide</e2> and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), <e2>iopromide</e2> and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), <e2>iopromide</e2> and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), <e2>iopromide</e2> and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), <e2>iopromide</e2> and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), <e2>iopromide</e2> and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), iopromide and <e2>iohexol</e2>, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), iopromide and <e2>iohexol</e2>, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), iopromide and <e2>iohexol</e2>, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), iopromide and <e2>iohexol</e2>, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), iopromide and <e2>iohexol</e2>, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), iopromide and <e2>iohexol</e2>, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), iopromide and <e2>iohexol</e2>, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), iopromide and <e2>iohexol</e2>, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"This prospective study determined the incidence of <e1>CIN</e1> for two nonionic contrast media (CM), iopromide and <e2>iohexol</e2>, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.","Positive_Correlation"
"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features <e1>CaCl2</e1>-induced <e2>thoracic aortic aneurysm</e2> in a rat model.","Positive_Correlation"
"Elevation of ADAM10, ADAM17, MMP-2 and <e1>MMP-9</e1> expression with media degeneration features <e2>CaCl2</e2>-induced thoracic aortic aneurysm in a rat model.","Positive_Correlation"
"Elevation of ADAM10, ADAM17, MMP-2 and <e1>MMP-9</e1> expression with media degeneration features CaCl2-induced <e2>thoracic aortic aneurysm</e2> in a rat model.","Association"
"Elevation of ADAM10, ADAM17, <e1>MMP-2</e1> and MMP-9 expression with media degeneration features <e2>CaCl2</e2>-induced thoracic aortic aneurysm in a rat model.","Positive_Correlation"
"Elevation of ADAM10, ADAM17, <e1>MMP-2</e1> and MMP-9 expression with media degeneration features CaCl2-induced <e2>thoracic aortic aneurysm</e2> in a rat model.","Association"
"Elevation of ADAM10, <e1>ADAM17</e1>, MMP-2 and MMP-9 expression with media degeneration features <e2>CaCl2</e2>-induced thoracic aortic aneurysm in a rat model.","Positive_Correlation"
"Elevation of ADAM10, <e1>ADAM17</e1>, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced <e2>thoracic aortic aneurysm</e2> in a rat model.","Association"
"Elevation of <e1>ADAM10</e1>, ADAM17, MMP-2 and MMP-9 expression with media degeneration features <e2>CaCl2</e2>-induced thoracic aortic aneurysm in a rat model.","Positive_Correlation"
"Elevation of <e1>ADAM10</e1>, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced <e2>thoracic aortic aneurysm</e2> in a rat model.","Association"
"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by <e1>calcium chloride</e1> (CaCl(2))-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced <e2>arterial injury</e2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> (TAA) by <e1>calcium chloride</e1> (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"PURPOSE: This study was designed to establish a rat model of <e2>thoracic aortic aneurysm</e2> (TAA) by calcium chloride (<e1>CaCl(2)</e1>)-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.","Positive_Correlation"
"MMP-2, <e1>MMP-9</e1>, ADAM-10 and ADAM-17 mRNA levels were increased in <e2>CaCl(2)</e2>-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.","Positive_Correlation"
"MMP-2, <e1>MMP-9</e1>, ADAM-10 and ADAM-17 mRNA levels were increased in <e2>CaCl(2)</e2>-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.","Positive_Correlation"
"MMP-2, <e1>MMP-9</e1>, ADAM-10 and ADAM-17 mRNA levels were increased in <e2>CaCl(2)</e2>-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.","Positive_Correlation"
"CONCLUSION: This study establishes a <e2>TAA</e2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, <e1>MMP-9</e1>, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.","Association"
"CONCLUSION: This study establishes a <e2>TAA</e2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, <e1>MMP-9</e1>, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.","Association"
"CONCLUSION: This study establishes a <e2>TAA</e2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, <e1>MMP-9</e1>, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.","Association"
"<e1>MMP-2</e1>, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in <e2>CaCl(2)</e2>-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.","Positive_Correlation"
"<e1>MMP-2</e1>, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in <e2>CaCl(2)</e2>-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.","Positive_Correlation"
"<e1>MMP-2</e1>, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in <e2>CaCl(2)</e2>-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.","Positive_Correlation"
"CONCLUSION: This study establishes a <e2>TAA</e2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of <e1>MMP-2</e1>, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.","Association"
"CONCLUSION: This study establishes a <e2>TAA</e2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of <e1>MMP-2</e1>, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.","Association"
"CONCLUSION: This study establishes a <e2>TAA</e2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of <e1>MMP-2</e1>, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.","Association"
"MMP-2, MMP-9, ADAM-10 and <e1>ADAM-17</e1> mRNA levels were increased in <e2>CaCl(2)</e2>-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.","Positive_Correlation"
"MMP-2, MMP-9, ADAM-10 and <e1>ADAM-17</e1> mRNA levels were increased in <e2>CaCl(2)</e2>-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.","Positive_Correlation"
"CONCLUSION: This study establishes a TAA model by periarterial <e2>CaCl(2)</e2> exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and <e1>ADAM17</e1> in the pathogenesis of vascular remodeling.","Positive_Correlation"
"CONCLUSION: This study establishes a <e2>TAA</e2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and <e1>ADAM17</e1> in the pathogenesis of vascular remodeling.","Association"
"MMP-2, MMP-9, <e1>ADAM-10</e1> and ADAM-17 mRNA levels were increased in <e2>CaCl(2)</e2>-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.","Positive_Correlation"
"MMP-2, MMP-9, <e1>ADAM-10</e1> and ADAM-17 mRNA levels were increased in <e2>CaCl(2)</e2>-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.","Positive_Correlation"
"CONCLUSION: This study establishes a TAA model by periarterial <e2>CaCl(2)</e2> exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, <e1>ADAM10</e1> and ADAM17 in the pathogenesis of vascular remodeling.","Positive_Correlation"
"CONCLUSION: This study establishes a <e2>TAA</e2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, <e1>ADAM10</e1> and ADAM17 in the pathogenesis of vascular remodeling.","Association"
"Biochemical effects of <e1>Solidago virgaurea extract</e1> on experimental <e2>cardiotoxicity</e2>.","Negative_Correlation"
"<e1>Captopril</e1> (50 mg/kg/day, given orally), an inhibitor of <e2>angiotensin-converting enzyme</e2> used as a standard cardioprotective drug, was used as a positive control in this study.","Negative_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and <e2>superoxide dismutase</e2> in cardiac tissue as compared to the normal control group (P < 0.05).","Negative_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and <e2>superoxide dismutase</e2> in cardiac tissue as compared to the normal control group (P < 0.05).","Negative_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and <e2>superoxide dismutase</e2> in cardiac tissue as compared to the normal control group (P < 0.05).","Negative_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and <e2>superoxide dismutase</e2> in cardiac tissue as compared to the normal control group (P < 0.05).","Negative_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum <e2>lactate dehydrogenase</e2>, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum <e2>lactate dehydrogenase</e2>, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum <e2>lactate dehydrogenase</e2>, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum <e2>lactate dehydrogenase</e2>, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, <e2>creatine phosphokinase</e2>, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, <e2>creatine phosphokinase</e2>, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, <e2>creatine phosphokinase</e2>, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, <e2>creatine phosphokinase</e2>, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, <e2>alanine transaminase</e2>, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, <e2>alanine transaminase</e2>, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, <e2>alanine transaminase</e2>, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, <e2>alanine transaminase</e2>, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, <e2>aspartate transaminase</e2>, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, <e2>aspartate transaminase</e2>, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, <e2>aspartate transaminase</e2>, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, <e2>aspartate transaminase</e2>, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and <e2>angiotensin-converting enzyme</e2> activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and <e2>angiotensin-converting enzyme</e2> activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and <e2>angiotensin-converting enzyme</e2> activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and <e2>angiotensin-converting enzyme</e2> activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of <e2>glutathione</e2> and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Negative_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of <e2>glutathione</e2> and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Negative_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of <e2>glutathione</e2> and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Negative_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of <e2>glutathione</e2> and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Negative_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and <e2>nitric oxide</e2> levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and <e2>nitric oxide</e2> levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and <e2>nitric oxide</e2> levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and <e2>nitric oxide</e2> levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue <e2>malondialdehyde</e2> (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue <e2>malondialdehyde</e2> (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue <e2>malondialdehyde</e2> (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue <e2>malondialdehyde</e2> (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum <e2>fatty acid</e2>, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum <e2>fatty acid</e2>, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum <e2>fatty acid</e2>, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum <e2>fatty acid</e2>, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, <e2>triglycerides</e2>, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, <e2>triglycerides</e2>, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, <e2>triglycerides</e2>, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, <e2>triglycerides</e2>, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total <e2>cholesterol</e2>, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total <e2>cholesterol</e2>, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total <e2>cholesterol</e2>, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The subcutaneous injection of <e1>isoproterenol</e1> (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total <e2>cholesterol</e2>, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).","Positive_Correlation"
"The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on <e1>isoproterenol</e1>-induced <e2>cardiotoxicity</e2> in rats.","Positive_Correlation"
"The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on <e1>isoproterenol</e1>-induced <e2>cardiotoxicity</e2> in rats.","Positive_Correlation"
"The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on <e1>isoproterenol</e1>-induced <e2>cardiotoxicity</e2> in rats.","Positive_Correlation"
"The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on <e1>isoproterenol</e1>-induced <e2>cardiotoxicity</e2> in rats.","Positive_Correlation"
"The data of the present study suggest that <e1>S. virgaurea extract</e1> exerts its protective effect by decreasing <e2>MDA</e2> level and increasing the antioxidant status in isoproterenol-treated rats.","Negative_Correlation"
"The data of the present study suggest that <e1>S. virgaurea extract</e1> exerts its protective effect by decreasing <e2>MDA</e2> level and increasing the antioxidant status in isoproterenol-treated rats.","Negative_Correlation"
"The data of the present study suggest that <e1>S. virgaurea extract</e1> exerts its protective effect by decreasing <e2>MDA</e2> level and increasing the antioxidant status in isoproterenol-treated rats.","Negative_Correlation"
"The aim of the present study was to investigate the protective effect of the <e1>Solidago virgaurea extract</e1> on <e2>isoproterenol</e2>-induced cardiotoxicity in rats.","Negative_Correlation"
"Pretreatment with <e1>S. virgaurea extract</e1> for 5 weeks at a dose of 250 mg/kg followed by <e2>isoproterenol</e2> injection significantly prevented the observed alterations.","Negative_Correlation"
"Pretreatment with <e1>S. virgaurea extract</e1> for 5 weeks at a dose of 250 mg/kg followed by <e2>isoproterenol</e2> injection significantly prevented the observed alterations.","Negative_Correlation"
"Pretreatment with <e1>S. virgaurea extract</e1> for 5 weeks at a dose of 250 mg/kg followed by <e2>isoproterenol</e2> injection significantly prevented the observed alterations.","Negative_Correlation"
"The aim of the present study was to investigate the protective effect of the <e1>Solidago virgaurea extract</e1> on isoproterenol-induced <e2>cardiotoxicity</e2> in rats.","Negative_Correlation"
"Glial activation and post-synaptic <e2>neurotoxicity</e2>: the key events in <e1>Streptozotocin</e1> (ICV) induced memory impairment in rats.","Positive_Correlation"
"Glial activation and post-synaptic neurotoxicity: the key events in <e1>Streptozotocin</e1> (ICV) induced <e2>memory impairment</e2> in rats.","Positive_Correlation"
"Oral treatment with Memantine (10mg/kg) and <e1>Ibuprofen</e1> (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic <e2>neurotoxicity</e2> in rat brain.","Negative_Correlation"
"Oral treatment with <e1>Memantine</e1> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic <e2>neurotoxicity</e2> in rat brain.","Negative_Correlation"
"Oral treatment with Memantine (10mg/kg) and <e2>Ibuprofen</e2> (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with Memantine (10mg/kg) and <e2>Ibuprofen</e2> (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with Memantine (10mg/kg) and <e2>Ibuprofen</e2> (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with Memantine (10mg/kg) and <e2>Ibuprofen</e2> (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with Memantine (10mg/kg) and <e2>Ibuprofen</e2> (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with Memantine (10mg/kg) and <e2>Ibuprofen</e2> (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with Memantine (10mg/kg) and <e2>Ibuprofen</e2> (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with Memantine (10mg/kg) and <e2>Ibuprofen</e2> (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with Memantine (10mg/kg) and <e2>Ibuprofen</e2> (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic <e2>neurotoxicity</e2>.","Positive_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic <e2>neurotoxicity</e2>.","Positive_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic <e2>neurotoxicity</e2>.","Positive_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic <e2>neurotoxicity</e2>.","Positive_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic <e2>neurotoxicity</e2>.","Positive_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic <e2>neurotoxicity</e2>.","Positive_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic <e2>neurotoxicity</e2>.","Positive_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic <e2>neurotoxicity</e2>.","Positive_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic <e2>neurotoxicity</e2>.","Positive_Correlation"
"Oral treatment with <e2>Memantine</e2> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with <e2>Memantine</e2> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with <e2>Memantine</e2> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with <e2>Memantine</e2> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with <e2>Memantine</e2> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with <e2>Memantine</e2> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with <e2>Memantine</e2> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with <e2>Memantine</e2> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"Oral treatment with <e2>Memantine</e2> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated <e1>STZ</e1> induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers <e2>CaMKIIa</e2> and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers <e2>CaMKIIa</e2> and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers <e2>CaMKIIa</e2> and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers <e2>CaMKIIa</e2> and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers <e2>CaMKIIa</e2> and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers <e2>CaMKIIa</e2> and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers <e2>CaMKIIa</e2> and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers <e2>CaMKIIa</e2> and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers <e2>CaMKIIa</e2> and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and <e2>PSD-95</e2>, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and <e2>PSD-95</e2>, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and <e2>PSD-95</e2>, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and <e2>PSD-95</e2>, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and <e2>PSD-95</e2>, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and <e2>PSD-95</e2>, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and <e2>PSD-95</e2>, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and <e2>PSD-95</e2>, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"<e1>STZ</e1> treatment showed decrease expression of post synaptic markers CaMKIIa and <e2>PSD-95</e2>, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.","Negative_Correlation"
"Increased expression and activity of <e2>Caspase-3</e2> was also observed in <e1>STZ</e1> treated rat which specify apoptotic cell death in hippocampus and cortex.","Positive_Correlation"
"Increased expression and activity of <e2>Caspase-3</e2> was also observed in <e1>STZ</e1> treated rat which specify apoptotic cell death in hippocampus and cortex.","Positive_Correlation"
"Increased expression and activity of <e2>Caspase-3</e2> was also observed in <e1>STZ</e1> treated rat which specify apoptotic cell death in hippocampus and cortex.","Positive_Correlation"
"Increased expression and activity of <e2>Caspase-3</e2> was also observed in <e1>STZ</e1> treated rat which specify apoptotic cell death in hippocampus and cortex.","Positive_Correlation"
"Increased expression and activity of <e2>Caspase-3</e2> was also observed in <e1>STZ</e1> treated rat which specify apoptotic cell death in hippocampus and cortex.","Positive_Correlation"
"Increased expression and activity of <e2>Caspase-3</e2> was also observed in <e1>STZ</e1> treated rat which specify apoptotic cell death in hippocampus and cortex.","Positive_Correlation"
"Increased expression and activity of <e2>Caspase-3</e2> was also observed in <e1>STZ</e1> treated rat which specify apoptotic cell death in hippocampus and cortex.","Positive_Correlation"
"Increased expression and activity of <e2>Caspase-3</e2> was also observed in <e1>STZ</e1> treated rat which specify apoptotic cell death in hippocampus and cortex.","Positive_Correlation"
"Increased expression and activity of <e2>Caspase-3</e2> was also observed in <e1>STZ</e1> treated rat which specify apoptotic cell death in hippocampus and cortex.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, nitrite, <e2>Ca(2+)</e2> and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, nitrite, <e2>Ca(2+)</e2> and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, nitrite, <e2>Ca(2+)</e2> and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, nitrite, <e2>Ca(2+)</e2> and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, nitrite, <e2>Ca(2+)</e2> and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, nitrite, <e2>Ca(2+)</e2> and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, nitrite, <e2>Ca(2+)</e2> and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, nitrite, <e2>Ca(2+)</e2> and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, nitrite, <e2>Ca(2+)</e2> and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of <e2>ROS</e2>, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of <e2>ROS</e2>, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of <e2>ROS</e2>, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of <e2>ROS</e2>, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of <e2>ROS</e2>, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of <e2>ROS</e2>, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of <e2>ROS</e2>, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of <e2>ROS</e2>, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of <e2>ROS</e2>, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, <e2>nitrite</e2>, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, <e2>nitrite</e2>, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, <e2>nitrite</e2>, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, <e2>nitrite</e2>, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, <e2>nitrite</e2>, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, <e2>nitrite</e2>, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, <e2>nitrite</e2>, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, <e2>nitrite</e2>, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> also significantly increased the level of ROS, <e2>nitrite</e2>, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and <e2>TNF-a</e2> indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and <e2>TNF-a</e2> indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and <e2>TNF-a</e2> indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and <e2>TNF-a</e2> indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and <e2>TNF-a</e2> indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and <e2>TNF-a</e2> indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and <e2>TNF-a</e2> indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and <e2>TNF-a</e2> indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and <e2>TNF-a</e2> indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and <e2>neuroinflammation</e2>.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and <e2>neuroinflammation</e2>.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and <e2>neuroinflammation</e2>.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and <e2>neuroinflammation</e2>.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and <e2>neuroinflammation</e2>.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and <e2>neuroinflammation</e2>.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and <e2>neuroinflammation</e2>.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and <e2>neuroinflammation</e2>.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and <e2>neuroinflammation</e2>.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, <e2>CD11b</e2> and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, <e2>CD11b</e2> and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, <e2>CD11b</e2> and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, <e2>CD11b</e2> and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, <e2>CD11b</e2> and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, <e2>CD11b</e2> and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, <e2>CD11b</e2> and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, <e2>CD11b</e2> and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of GFAP, <e2>CD11b</e2> and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of <e2>GFAP</e2>, CD11b and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of <e2>GFAP</e2>, CD11b and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of <e2>GFAP</e2>, CD11b and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of <e2>GFAP</e2>, CD11b and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of <e2>GFAP</e2>, CD11b and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of <e2>GFAP</e2>, CD11b and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of <e2>GFAP</e2>, CD11b and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of <e2>GFAP</e2>, CD11b and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"<e1>STZ</e1> causes increased expression of <e2>GFAP</e2>, CD11b and TNF-a indicating glial activation and neuroinflammation.","Positive_Correlation"
"In the present study the role of glial activation and post synaptic toxicity in ICV <e1>Streptozotocin</e1> (STZ) induced <e2>memory impaired</e2> rats was explored.","Positive_Correlation"
"In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (<e1>STZ</e1>) induced <e2>memory impaired</e2> rats was explored.","Positive_Correlation"
"In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (<e1>STZ</e1>) induced <e2>memory impaired</e2> rats was explored.","Positive_Correlation"
"In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (<e1>STZ</e1>) induced <e2>memory impaired</e2> rats was explored.","Positive_Correlation"
"In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (<e1>STZ</e1>) induced <e2>memory impaired</e2> rats was explored.","Positive_Correlation"
"In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (<e1>STZ</e1>) induced <e2>memory impaired</e2> rats was explored.","Positive_Correlation"
"In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (<e1>STZ</e1>) induced <e2>memory impaired</e2> rats was explored.","Positive_Correlation"
"In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (<e1>STZ</e1>) induced <e2>memory impaired</e2> rats was explored.","Positive_Correlation"
"In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (<e1>STZ</e1>) induced <e2>memory impaired</e2> rats was explored.","Positive_Correlation"
"In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (<e1>STZ</e1>) induced <e2>memory impaired</e2> rats was explored.","Positive_Correlation"
"Pre-treatment of <e2>bupivacaine</e2>-induced cardiovascular depression using different <e1>lipid</e1> formulations of propofol.","Negative_Correlation"
"Pre-treatment of bupivacaine-induced cardiovascular depression using different <e2>lipid</e2> formulations of <e1>propofol</e1>.","Association"
"Pre-treatment of bupivacaine-induced <e2>cardiovascular depression</e2> using different lipid formulations of <e1>propofol</e1>.","Negative_Correlation"
"Pre-treatment of <e2>bupivacaine</e2>-induced cardiovascular depression using different lipid formulations of <e1>propofol</e1>.","Negative_Correlation"
"Pre-treatment of <e1>bupivacaine</e1>-induced <e2>cardiovascular depression</e2> using different lipid formulations of propofol.","Positive_Correlation"
"BACKGROUND: Pre-treatment with <e1>lipid emulsions</e1> has been shown to increase lethal doses of <e2>bupivacaine</e2>, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.","Association"
"BACKGROUND: Pre-treatment with <e1>lipid</e1> emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in intralipid or <e1>medialipid</e1> emulsions on bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in intralipid or <e1>medialipid</e1> emulsions on bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in intralipid or <e1>medialipid</e1> emulsions on bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in intralipid or <e1>medialipid</e1> emulsions on bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"BACKGROUND: Pre-treatment with <e1>lipid</e1> emulsions has been shown to increase lethal doses of <e2>bupivacaine</e2>, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in intralipid or <e1>medialipid</e1> emulsions on <e2>bupivacaine</e2>-induced cardiotoxicity.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in intralipid or <e1>medialipid</e1> emulsions on <e2>bupivacaine</e2>-induced cardiotoxicity.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in intralipid or <e1>medialipid</e1> emulsions on <e2>bupivacaine</e2>-induced cardiotoxicity.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in intralipid or <e1>medialipid</e1> emulsions on <e2>bupivacaine</e2>-induced cardiotoxicity.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in <e1>intralipid</e1> or medialipid emulsions on bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in <e1>intralipid</e1> or medialipid emulsions on bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in <e1>intralipid</e1> or medialipid emulsions on bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in <e1>intra<e2>lipid</e2></e1> or medialipid emulsions on bupivacaine-induced cardiotoxicity.","Comparison"
"The aim of this study is to investigate the effects of propofol in <e1>intra<e2>lipid</e2></e1> or medialipid emulsions on bupivacaine-induced cardiotoxicity.","Comparison"
"The aim of this study is to investigate the effects of propofol in <e1>intra<e2>lipid</e2></e1> or medialipid emulsions on bupivacaine-induced cardiotoxicity.","Comparison"
"The aim of this study is to investigate the effects of propofol in <e1>intralipid</e1> or medialipid emulsions on <e2>bupivacaine</e2>-induced cardiotoxicity.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in <e1>intralipid</e1> or medialipid emulsions on <e2>bupivacaine</e2>-induced cardiotoxicity.","Negative_Correlation"
"The aim of this study is to investigate the effects of propofol in <e1>intralipid</e1> or medialipid emulsions on <e2>bupivacaine</e2>-induced cardiotoxicity.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Negative_Correlation"
"BACKGROUND: Pre-treatment with <e2>lipid</e2> emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Association"
"BACKGROUND: Pre-treatment with <e2>lipid</e2> emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Association"
"BACKGROUND: Pre-treatment with <e2>lipid</e2> emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Association"
"BACKGROUND: Pre-treatment with <e2>lipid</e2> emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Association"
"BACKGROUND: Pre-treatment with <e2>lipid</e2> emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Association"
"BACKGROUND: Pre-treatment with <e2>lipid</e2> emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Association"
"BACKGROUND: Pre-treatment with <e2>lipid</e2> emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Association"
"The aim of this study is to investigate the effects of <e1>propofol</e1> in <e2>intralipid</e2> or medialipid emulsions on bupivacaine-induced cardiotoxicity.","Association"
"The aim of this study is to investigate the effects of <e1>propofol</e1> in <e2>intralipid</e2> or medialipid emulsions on bupivacaine-induced cardiotoxicity.","Association"
"The aim of this study is to investigate the effects of <e1>propofol</e1> in <e2>intralipid</e2> or medialipid emulsions on bupivacaine-induced cardiotoxicity.","Association"
"The aim of this study is to investigate the effects of <e1>propofol</e1> in <e2>intralipid</e2> or medialipid emulsions on bupivacaine-induced cardiotoxicity.","Association"
"The aim of this study is to investigate the effects of <e1>propofol</e1> in <e2>intralipid</e2> or medialipid emulsions on bupivacaine-induced cardiotoxicity.","Association"
"The aim of this study is to investigate the effects of <e1>propofol</e1> in <e2>intralipid</e2> or medialipid emulsions on bupivacaine-induced cardiotoxicity.","Association"
"The aim of this study is to investigate the effects of <e1>propofol</e1> in <e2>intralipid</e2> or medialipid emulsions on bupivacaine-induced cardiotoxicity.","Association"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e2>bupivacaine</e2>, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e2>bupivacaine</e2>, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e2>bupivacaine</e2>, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e2>bupivacaine</e2>, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e2>bupivacaine</e2>, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e2>bupivacaine</e2>, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e2>bupivacaine</e2>, and the lipid content of <e1>propofol</e1> may alleviate bupivacaine-induced cardiotoxicity.","Negative_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e1>bupivacaine</e1>, and the lipid content of propofol may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Positive_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e1>bupivacaine</e1>, and the lipid content of propofol may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Positive_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e1>bupivacaine</e1>, and the lipid content of propofol may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Positive_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e1>bupivacaine</e1>, and the lipid content of propofol may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Positive_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e1>bupivacaine</e1>, and the lipid content of propofol may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Positive_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e1>bupivacaine</e1>, and the lipid content of propofol may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Positive_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e1>bupivacaine</e1>, and the lipid content of propofol may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Positive_Correlation"
"The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. <e1>Bupivacaine</e1> levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced <e2>cardiotoxic</e2> effects as well as reduced plasma bupivacaine levels.","Positive_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e1>bupivacaine</e1>, and the lipid content of propofol may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Positive_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e1>bupivacaine</e1>, and the lipid content of propofol may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Positive_Correlation"
"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e1>bupivacaine</e1>, and the lipid content of propofol may alleviate bupivacaine-induced <e2>cardiotoxicity</e2>.","Positive_Correlation"
"Curcumin prevents <e1>maleate</e1>-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial <e2>oxygen</e2> consumption and activity of respiratory complex I.","Association"
"Curcumin prevents <e1>maleate</e1>-induced <e2>nephrotoxicity</e2>: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.","Positive_Correlation"
"<e1>Curcumin</e1> prevents maleate-induced <e2>nephrotoxicity</e2>: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.","Negative_Correlation"
"<e1>Curcumin</e1> prevents <e2>maleate</e2>-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.","Negative_Correlation"
"Tubular <e1>proteinuria</e1> and oxidative stress were induced by a single injection of <e2>maleate</e2> (400 mg/kg) in rats.","Positive_Correlation"
"Maleate-induced <e1>renal injury</e1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of <e2>kidney injury molecule (KIM)-1</e2>, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Positive_Correlation"
"Maleate-induced <e1>renal injury</e1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of <e2>kidney injury molecule (KIM)-1</e2>, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Positive_Correlation"
"Maleate-induced <e1>renal injury</e1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and <e2>claudin-2</e2> expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Negative_Correlation"
"Maleate-induced <e1>renal injury</e1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and <e2>claudin-2</e2> expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Negative_Correlation"
"Maleate-induced <e1>renal injury</e1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, <e2>neutrophil gelatinase-associated lipocalin</e2> (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Association"
"Maleate-induced <e1>renal injury</e1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, <e2>neutrophil gelatinase-associated lipocalin</e2> (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Association"
"Maleate-induced <e1>renal injury</e1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, <e2>sodium</e2>, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Association"
"Maleate-induced <e1>renal injury</e1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, <e2>sodium</e2>, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Association"
"Maleate-induced <e1>renal injury</e1> included increase in renal vascular resistance and in the urinary excretion of total protein, <e2>glucose</e2>, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Association"
"Maleate-induced <e1>renal injury</e1> included increase in renal vascular resistance and in the urinary excretion of total protein, <e2>glucose</e2>, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Association"
"In addition, <e1>maleate</e1> treatment reduced <e2>oxygen</e2> consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate.","Association"
"In addition, <e1>maleate</e1> treatment reduced <e2>oxygen</e2> consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate.","Association"
"<e1>Maleate</e1> induced cell damage and reactive <e2>oxygen</e2> species (ROS) production in LLC-PK1 cells in culture.","Association"
"<e1>Maleate</e1> induced cell damage and reactive <e2>oxygen</e2> species (ROS) production in LLC-PK1 cells in culture.","Association"
"In addition, <e1>maleate</e1> treatment reduced <e2>oxygen</e2> consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate.","Association"
"In addition, <e1>maleate</e1> treatment reduced <e2>oxygen</e2> consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate.","Association"
"<e1>Maleate</e1> induced cell damage and <e2>reactive oxygen species</e2> (ROS) production in LLC-PK1 cells in culture.","Positive_Correlation"
"<e1>Maleate</e1> induced cell damage and <e2>reactive oxygen species</e2> (ROS) production in LLC-PK1 cells in culture.","Positive_Correlation"
"<e1>Maleate</e1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of <e2>kidney injury molecule (KIM)-1</e2>, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Positive_Correlation"
"<e1>Maleate</e1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of <e2>kidney injury molecule (KIM)-1</e2>, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Positive_Correlation"
"<e1>Maleate</e1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and <e2>claudin-2</e2> expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Negative_Correlation"
"<e1>Maleate</e1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and <e2>claudin-2</e2> expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Negative_Correlation"
"<e1>Maleate</e1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, <e2>neutrophil gelatinase-associated lipocalin</e2> (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Association"
"<e1>Maleate</e1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, <e2>neutrophil gelatinase-associated lipocalin</e2> (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Association"
"<e1>Maleate</e1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, <e2>sodium</e2>, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Association"
"<e1>Maleate</e1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, <e2>sodium</e2>, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Association"
"<e1>Maleate</e1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, <e2>glucose</e2>, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Association"
"<e1>Maleate</e1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, <e2>glucose</e2>, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Association"
"The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the <e2>renal injury</e2> induced by <e1>maleate</e1> was evaluated.","Positive_Correlation"
"The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the <e2>renal injury</e2> induced by <e1>maleate</e1> was evaluated.","Positive_Correlation"
"<e1>Maleate</e1>-induced <e2>renal injury</e2> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Positive_Correlation"
"<e1>Maleate</e1>-induced <e2>renal injury</e2> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.","Positive_Correlation"
"The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the <e2>renal injury</e2> induced by <e1>maleate</e1> was evaluated.","Positive_Correlation"
"The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the <e2>renal injury</e2> induced by <e1>maleate</e1> was evaluated.","Positive_Correlation"
"The potential protective effect of the dietary antioxidant <e1>curcumin</e1> (120 mg/Kg/day for 6 days) against the <e2>renal injury</e2> induced by maleate was evaluated.","Negative_Correlation"
"The potential protective effect of the dietary antioxidant <e1>curcumin</e1> (120 mg/Kg/day for 6 days) against the <e2>renal injury</e2> induced by maleate was evaluated.","Negative_Correlation"
"The potential protective effect of the dietary antioxidant <e1>curcumin</e1> (120 mg/Kg/day for 6 days) against the <e2>renal injury</e2> induced by maleate was evaluated.","Negative_Correlation"
"The potential protective effect of the dietary antioxidant <e1>curcumin</e1> (120 mg/Kg/day for 6 days) against the renal injury induced by <e2>maleate</e2> was evaluated.","Negative_Correlation"
"The potential protective effect of the dietary antioxidant <e1>curcumin</e1> (120 mg/Kg/day for 6 days) against the renal injury induced by <e2>maleate</e2> was evaluated.","Negative_Correlation"
"The potential protective effect of the dietary antioxidant <e1>curcumin</e1> (120 mg/Kg/day for 6 days) against the renal injury induced by <e2>maleate</e2> was evaluated.","Negative_Correlation"
